<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Gefitinib for advanced non‐small cell lung cancer - Sim, EHA - 2018 | Cochrane Library</title> <meta content="Gefitinib for advanced non‐small cell lung cancer - Sim, EHA - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006847.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Gefitinib for advanced non‐small cell lung cancer - Sim, EHA - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006847.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD006847.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Gefitinib for advanced non‐small cell lung cancer" name="citation_title"/> <meta content="Esther HA Sim" name="citation_author"/> <meta content="GenesisCare Radiation Oncology" name="citation_author_institution"/> <meta content="esther.h.sim@gmail.com" name="citation_author_email"/> <meta content="Ian A Yang" name="citation_author"/> <meta content="Richard Wood‐Baker" name="citation_author"/> <meta content="University of Tasmania" name="citation_author_institution"/> <meta content="Rayleen V Bowman" name="citation_author"/> <meta content="The Prince Charles Hospital" name="citation_author_institution"/> <meta content="Kwun M Fong" name="citation_author"/> <meta content="The Prince Charles Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD006847.pub2" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/01/16" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006847.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006847.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006847.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antineoplastic Agents [adverse effects, *therapeutic use]; Carcinoma, Non‐Small‐Cell Lung [*drug therapy, ethnology, genetics]; Disease‐Free Survival; Gefitinib; Genes, erbB‐1; Lung Neoplasms [*drug therapy, ethnology, genetics]; Mutation; Quality of Life; Quinazolines [adverse effects, *therapeutic use]; Randomized Controlled Trials as Topic; Treatment Failure" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006847.pub2&amp;doi=10.1002/14651858.CD006847.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006847.pub2&amp;doi=10.1002/14651858.CD006847.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006847.pub2&amp;doi=10.1002/14651858.CD006847.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006847.pub2&amp;doi=10.1002/14651858.CD006847.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006847.pub2&amp;doi=10.1002/14651858.CD006847.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006847.pub2&amp;doi=10.1002/14651858.CD006847.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006847.pub2&amp;doi=10.1002/14651858.CD006847.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006847.pub2&amp;doi=10.1002/14651858.CD006847.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006847.pub2&amp;doi=10.1002/14651858.CD006847.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006847.pub2&amp;doi=10.1002/14651858.CD006847.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006847.pub2&amp;doi=10.1002/14651858.CD006847.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006847.pub2&amp;doi=10.1002/14651858.CD006847.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006847.pub2&amp;doi=10.1002/14651858.CD006847.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006847.pub2&amp;doi=10.1002/14651858.CD006847.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006847.pub2&amp;doi=10.1002/14651858.CD006847.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006847.pub2&amp;doi=10.1002/14651858.CD006847.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006847.pub2&amp;doi=10.1002/14651858.CD006847.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006847.pub2&amp;doi=10.1002/14651858.CD006847.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006847.pub2&amp;doi=10.1002/14651858.CD006847.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006847.pub2&amp;doi=10.1002/14651858.CD006847.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006847.pub2&amp;doi=10.1002/14651858.CD006847.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006847.pub2&amp;doi=10.1002/14651858.CD006847.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006847.pub2&amp;doi=10.1002/14651858.CD006847.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="jxlIh5Me";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD006847\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD006847\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006847\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006847\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ms","ja","pl","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD006847.pub2",title:"Gefitinib for advanced non\\u2010small cell lung cancer",firstPublishedDate:"Jan 16, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Lung Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jxlIh5Me&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006847.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006847.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD006847.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD006847.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006847.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD006847.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD006847.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD006847.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD006847.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD006847.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5740 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD006847.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006847.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006847.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006847.pub2/full#CD006847-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006847.pub2/full#CD006847-sec-0125"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006847.pub2/full#CD006847-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006847.pub2/full#CD006847-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006847.pub2/full#CD006847-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006847.pub2/full#CD006847-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006847.pub2/full#CD006847-sec-0056"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006847.pub2/full#CD006847-sec-0120"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006847.pub2/appendices#CD006847-sec-0130"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/table_n/CD006847StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/table_n/CD006847StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006847.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006847.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006847.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006847.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006847.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD006847.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Gefitinib for advanced non‐small cell lung cancer</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006847.pub2/information#CD006847-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Esther HA Sim</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006847.pub2/information#CD006847-cr-0003">Ian A Yang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006847.pub2/information#CD006847-cr-0004">Richard Wood‐Baker</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006847.pub2/information#CD006847-cr-0005">Rayleen V Bowman</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006847.pub2/information#CD006847-cr-0006">Kwun M Fong</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/information/en#CD006847-sec-0135">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 16 January 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD006847.pub2">https://doi.org/10.1002/14651858.CD006847.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD006847-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006847-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006847-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006847-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD006847-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD006847-abs-0001" lang="en"> <section id="CD006847-sec-0001"> <h3 class="title" id="CD006847-sec-0001">Background</h3> <p>The role of gefitinib for the treatment of advanced non‐small cell lung cancer (NSCLC) is evolving. We undertook a systematic review to evaluate the available evidence from all randomised trials. </p> </section> <section id="CD006847-sec-0002"> <h3 class="title" id="CD006847-sec-0002">Objectives</h3> <p>To determine the effectiveness and safety of gefitinib as first‐line, second‐line or maintenance treatment for advanced NSCLC. </p> </section> <section id="CD006847-sec-0003"> <h3 class="title" id="CD006847-sec-0003">Search methods</h3> <p>We performed searches in CENTRAL, MEDLINE and Embase from inception to 17 February 2017. We handsearched relevant conference proceedings, clinical trial registries and references lists of retrieved articles. </p> </section> <section id="CD006847-sec-0004"> <h3 class="title" id="CD006847-sec-0004">Selection criteria</h3> <p>We included trials assessing gefitinib, alone or in combination with other treatment, compared to placebo or other treatments in the first‐ or successive‐line treatment of patients with NSCLC, excluding compassionate use. </p> </section> <section id="CD006847-sec-0005"> <h3 class="title" id="CD006847-sec-0005">Data collection and analysis</h3> <p>We used the standard Cochrane methodology. Two authors independently assessed the search results to select those with sound methodological quality. We carried out all analyses on an intention‐to‐treat basis. We recorded the following outcome data: overall survival, progression‐free survival, toxicity, tumour response and quality of life. We also collected data for the following subgroups: Asian ethnicity and positive epidermal growth factor receptor (EGFR) mutation. </p> </section> <section id="CD006847-sec-0006"> <h3 class="title" id="CD006847-sec-0006">Main results</h3> <p>We included 35 eligible randomised controlled trials (RCTs), which examined 12,089 patients. </p> <p><b>General population</b> </p> <p>Gefitinib did not statistically improve overall survival when compared with placebo or chemotherapy in either first‐ or second‐line settings. Second‐line gefitinib prolonged time to treatment failure (TTF) (hazard ratio (HR) 0.82, 95% confidence interval (CI) 0.75 to 0.90, P &lt; 0.0001) when compared with placebo. Maintenance gefitinib improved progression‐free survival (HR 0.70, 95% CI 0.53 to 0.91, P = 0.007) after first‐line therapy. </p> <p><b>Studies in patients of Asian ethnicity or that conducted subgroup analyses</b> </p> <p>Second‐line gefitinib prolonged overall survival over placebo (HR 0.66, 95% CI 0.48 to 0.91, P = 0.01). In the first‐line setting, progression‐free survival was improved with gefitinib over chemotherapy alone (HR 0.65, 95% CI 0.43 to 0.98, P = 0.04, moderate quality of evidence). Gefitinib given in combination with a chemotherapy regimen improved progression‐free survival versus either gefitinib alone or chemotherapy alone (HR 0.69, 95% CI 0.49 to 0.96, P = 0.03; HR 0.69, 95% CI 0.62 to 0.77, P &lt; 0.00001, respectively). In the second‐line setting, progression‐free survival was superior in patients given gefitinib over placebo or chemotherapy (HR 0.69, 95% CI 0.52 to 0.91, P = 0.009; HR 0.71, 95% CI 0.57 to 0.88, P = 0.002; moderate quality of evidence, respectively). Combining gefitinib with chemotherapy in the second‐line setting was superior to gefitinib alone (HR 0.65, 95% CI 0.43 to 0.97, P = 0.04). As maintenance therapy, gefitinib improved progression‐free survival when compared with placebo (HR 0.42, 95% CI 0.33 to 0.54, P &lt; 0.00001). </p> <p><b>Patients with EGFR mutation‐positive tumours</b> </p> <p>Studies in patients with EGFR mutation‐positive tumours showed an improvement in progression‐free survival in favour of gefitinib over first‐line and second‐line chemotherapy (HR 0.47, 95% CI 0.36 to 0.61, P &lt; 0.00001; HR 0.24, 95% CI 0.12 to 0.47, P &lt; 0.0001, respectively). Gefitinib as maintenance therapy following chemotherapy improved overall and progression‐free survival (HR 0.39, 95% CI 0.15 to 0.98, P = 0.05; HR 0.17, 95% CI 0.07 to 0.41, P &lt; 0.0001, respectively) in one phase III study when compared to placebo. </p> <p>Toxicities from gefitinib included skin rash, diarrhoea and liver transaminase derangements. Toxicities from chemotherapy included anaemia, neutropenia and neurotoxicity. </p> <p>In terms of quality of life, gefitinib improved Functional Assessment of Cancer Therapy‐Lung (FACT‐L) (standardised mean difference (SMD) 10.50, 95% CI 9.55 to 11.45, P &lt; 0.000001), lung cancer subscale (SMD 3.63, 95% CI 3.08 to 4.19, P &lt; 0.00001) and Trial Outcome Index (SMD 9.87, 95% CI 1.26 to 18.48, P &lt; 0.00001) scores when compared with chemotherapy. </p> </section> <section id="CD006847-sec-0007"> <h3 class="title" id="CD006847-sec-0007">Authors' conclusions</h3> <p>This systematic review shows that gefitinib, when compared with standard first‐ or second‐line chemotherapy or maintenance therapy, probably has a beneficial effect on progression‐free survival and quality of life in selected patient populations, particularly those with tumours bearing sensitising EGFR mutations. </p> <p>Patients with EGFR mutations lived longer when given maintenance gefitinib than those given placebo. </p> <p>One study conducted subgroup analysis and showed that gefitinib improved overall survival over placebo in the second‐line setting in patients of Asian ethnicity. All other studies did not detect any benefit on overall survival. The data analysed in this review were very heterogenous. We were limited in the amount of data that could be pooled, largely due to variations in study design. The risk of bias in most studies was moderate, with some studies not adequately addressing potential selection, attrition and reporting bias. This heterogeneity may have an impact on the applicability of the results </p> <p>Combining gefitinib with chemotherapy appears to be superior in improving progression‐free survival to either gefitinib or chemotherapy alone, however further data and phase III studies in these settings are required. </p> <p>Gefitinib has a favourable toxicity profile when compared with current chemotherapy regimens. Although there is no improvement in overall survival, gefitinib compares favourably with cytotoxic chemotherapy in patients with EGFR mutations with a prolongation of progression‐free survival and a lesser side effect profile. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD006847-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006847-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006847-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006847-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ja#CD006847-abs-0007">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD006847-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD006847-abs-0008">Polski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD006847-abs-0005">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD006847-abs-0004" lang="en"> <h3>A comparison of gefitinib with no therapy or chemotherapy for non‐small cell lung cancer </h3> <p><b>Review question</b> </p> <p>Do patients with non‐small cell lung cancer live longer if they are given gefitinib?</p> <p><b>Background</b> </p> <p>Non‐small cell lung cancer (the most common type of lung cancer) is a leading cause of cancer death worldwide. People diagnosed with advanced lung cancer may be offered chemotherapy. </p> <p>Some lung cancers have been found to have a gene mutation, which is an alteration in the chromosome sequence inside the cells. This mutation affects the epidermal growth factor receptor (EGFR), which is a switch on the surface of the cell leading to uncontrolled growth and spread. Gefitinib is a drug that targets cells with mutated EGFR, thus stopping their growth. Studies have found that this mutation is more commonly found in people who are non‐smokers, female, of Asian heritage and with adenocarcinoma (a type of lung cancer). </p> <p><b>Study characteristics</b> </p> <p>We searched for relevant trials up to 17 February 2017. There were a total of 35 studies conducted between 2000 and 2017, evaluating 12,089 participants from multiple countries including North America, Europe and Asia. </p> <p><b>Key results</b> </p> <p>This review showed that patients with advanced lung cancer do not live longer when treated with gefitinib when compared with no other treatment or chemotherapy. In people whose lung cancer has worsened after initial therapy, gefitinib may prolong the time before the cancer progresses further, but only in a selected group of patients of Asian ethnicity or with EGFR mutations. Combining gefitinib with chemotherapy probably increases the time to cancer progression over either gefitinib or chemotherapy alone. For EGFR‐mutation positive patients who are stable after chemotherapy, ongoing gefitinib has been shown to improve survival when compared to placebo. </p> <p>Severe side effects, such as low red and white blood cell counts and nerve symptoms, occurred more frequently in patients given chemotherapy compared to those given gefitinib. Side effects caused by gefitinib included a skin rash, diarrhoea and liver dysfunction. </p> <p>Quality of life may be improved in favour of gefitinib when compared with chemotherapy.</p> <p><b>Quality of the evidence</b> </p> <p>When comparing gefitinib as a first‐ and second‐line treatment with chemotherapy, we downgraded the quality of the evidence to moderate for the outcomes overall survival and progression‐free survival because the results were not precise and they may not be applicable to all patients due to the inclusion of a population only over 70 years of age. However, the quality of the evidence when we compared toxicities from gefitinib with chemotherapy was high. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD006847-sec-0125" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006847-sec-0125">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006847-sec-0163">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD006847-sec-0125"></div> <h3 class="title" id="CD006847-sec-0126">Implications for practice</h3> <section id="CD006847-sec-0126"> <p> <ul id="CD006847-list-0022"> <li> <p>In patients of Asian ethnicity or who are epidermal growth factor receptor (EGFR) mutation positive, first‐line gefitinib significantly improves progression‐free survival and overall response rate but not overall survival when compared with chemotherapy. </p> </li> <li> <p>Side effects such as skin rash, diarrhoea and increased alanine aminotransferase (ALT) and aspartate transaminase (AST) are more common with gefitinib. Side effects such as nausea, vomiting, anorexia, fatigue, arthralgia, asthenia, neurotoxicity, neutropenia, leukopenia, thrombocytopaenia and anaemia are more common with chemotherapy. </p> </li> <li> <p>In patients of Asian ethnicity, first‐line gefitinib plus chemotherapy improves progression‐free survival over either gefitinib or chemotherapy alone. </p> </li> <li> <p>In the second‐line setting, gefitinib is more effective than placebo, with improvements in the one‐year survival rate, progression‐free survival and overall response rate. There was no improvement in overall survival. </p> </li> <li> <p>One study demonstrated an improvement in overall survival, time to treatment failure and overall response rate when comparing second‐line gefitinib to placebo in patients of Asian ethnicity. However, the prevalence of EGFR mutations in cancers from Asian patients means that caution needs to be exercised in interpreting these results. </p> </li> <li> <p>Second‐line gefitinib plus chemotherapy is probably more effective in improving progression‐free survival than gefitinib alone. </p> </li> <li> <p>One second‐line study selected EGFR mutation positive patients and showed that chemotherapy is more effective in improving survival than gefitinib plus chemotherapy in patients who have failed first‐line gefitinib. </p> </li> <li> <p>Maintenance treatment with gefitinib was shown to be more effective in improving overall survival and progression‐free survival than placebo in patients with EGFR mutation positive tumours. In unselected patients or those of Asian ethnicity, gefitinib improves progression‐free survival but not overall survival or overall response rate over placebo. </p> </li> <li> <p>Increasing the dose of gefitinib from 250 mg/day to 500 mg/day results in significantly more adverse side effects, without any impact on response rate, survival or reported quality of life. </p> </li> <li> <p>Quality of life is higher in patients who receive gefitinib than those who either receive placebo or chemotherapy. </p> </li> </ul> </p> </section> <h3 class="title" id="CD006847-sec-0127">Implications for research</h3> <section id="CD006847-sec-0127"> <p> <ul id="CD006847-list-0023"> <li> <p>Extended follow‐up of existing trials and the inclusion of other randomised trials will provide additional evidence on the use of gefitinib in advanced non‐small cell lung cancer. </p> </li> <li> <p>Gaining a clearer understanding of why most, but not all, patients with tumours bearing EGFR mutations respond to gefitinib, as well as identifying new predictive factors, and the mechanisms and the management of drug resistance, are high‐priority research issues. </p> </li> </ul> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD006847-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD006847-sec-0022"></div> <div class="table" id="CD006847-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Gefitinib compared to chemotherapy for first‐line treatment of advanced NSCLC</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Gefitinib compared to chemotherapy for first‐line treatment of advanced NSCLC</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> advanced NSCLC<br/> <b>Settings:</b> first‐line treatment<br/> <b>Intervention:</b> gefitinib<br/> <b>Comparison:</b> chemotherapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Chemotherapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall survival (OS)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean OS ranged across control groups from <b>3.5 to 8</b> months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean OS in the intervention group ranged from <b>2.2 to 5.9</b> months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.98</b> (0.91 to 1.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>275<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OS similar in the Asian (HR 0.94, 0.82 to 1.06) and EGFR mutation positive subgroups (HR 0.97, 0.77 to 1.21) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progression‐free survival (PFS)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The PFS ranged across control groups from <b>2 to 2.9</b> months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean PFS in the intervention group ranged from <b>1.9 to 2.7</b> months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 1.19</b> (0.86 to 1.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>275<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PFS improved with gefitinib in the Asian subgroup (HR 0.65, 0.43 to 0.98) and the EGFR mutation positive subgroup (HR 0.47, 0.36 to 0.61) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>EGFR:</b> epidermal growth factor receptor; <b>HR:</b> hazard ratio; <b>NSCLC:</b> non‐small cell lung cancer; <b>OS:</b> overall survival; <b>PFS:</b> progression‐free survival; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>We downgraded the quality of evidence by one level because of serious indirectness as one study included only elderly patients (&gt; 70 years old). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006847-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Gefitinib compared to chemotherapy for second‐line treatment of advanced NSCLC</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Gefitinib compared to chemotherapy for second‐line treatment of advanced NSCLC</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> advanced NSCLC<br/> <b>Settings:</b> second‐line therapy<br/> <b>Intervention:</b> gefitinib<br/> <b>Comparison:</b> chemotherapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Chemotherapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall survival (OS)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean OS ranged across control groups from <b>7.1 to 8</b> months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean OS in the intervention group ranged from <b>7.5 to 7.6</b> months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 1.02</b> (0.91 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1607<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OS similar in Asian patients (HR 0.94, 0.79 to 1.12) and EGFR mutation positive patients (HR 0.83, 0.41 to 1.66). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progression‐free survival (PFS)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean PFS ranged across control groups from <b>2.7 to 3.4</b> months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean PFS in the intervention group ranged from <b>2.2 to 3</b> months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 1.04</b> (0.92 to 1.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1607<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PFS significantly improved in Asian patients (HR 0.71, 0.57 to 0.88) and in patients positive for EGFR mutation (HR 0.24, 0.12 to 0.47) (ranged from 2.7 to 4.1 months versus 4.5 to 7 months). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>EGFR:</b> epidermal growth factor receptor; <b>HR:</b> hazard ratio; <b>NSCLC:</b> non‐small cell lung cancer; <b>OS:</b> overall survival; <b>PFS:</b> progression‐free survival; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>We downgraded the quality of evidence by one level because of imprecision based on the wide confidence interval. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006847-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Gefitinib compared to chemotherapy for advanced NSCLC ‐ toxicity</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Gefitinib compared to chemotherapy for advanced NSCLC</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> advanced NSCLC<br/> <b>Settings:</b> first‐line and second‐line therapy<br/> <b>Intervention:</b> gefitinib<br/> <b>Comparison:</b> chemotherapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Chemotherapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Skin rash</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.40<br/> (1.08 to 5.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1858<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000<br/> (9 to 46) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Constipation</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.41<br/> (0.17 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1719<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 1000<br/> (3 to 18) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Fatigue</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.16<br/> (0.03 to 0.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>275<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>65 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000<br/> (2 to 57) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Asthenia</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.51<br/> (0.35 to 0.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1773<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>79 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40 per 1000<br/> (28 to 60) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Neurotoxicity</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.07<br/> (0.01 to 0.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1529<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/> (0 to 10) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Neutropenia</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.04<br/> (0.02 to 0.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1857<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>505 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000<br/> (10 to 30) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Febrile neutropenia</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.12<br/> (0.06 to 0.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1768<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>92 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000<br/> (6 to 21) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>We downgraded the quality of evidence by one level because of serious indirectness as one study included only elderly patients (&gt; 70 years old). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD006847-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006847-sec-0023">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006847-sec-0144">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD006847-sec-0023"></div> <section id="CD006847-sec-0024"> <h3 class="title" id="CD006847-sec-0024">Description of the condition</h3> <p>Non‐small cell lung cancer (NSCLC) accounts for 14% of all cancer‐related deaths and is by far the leading cause of cancer death among both men and women. In the United States, it was predicted that about 234,030 new cases of NSCLC would be diagnosed, and 154,050 deaths would result from NSCLC in 2018 (<a href="./references#CD006847-bbs2-0053" title="American Cancer Society. Cancer facts and figures 2018. Available at: http://www.cancer.org/cancer/lungcancer‐non‐smallcell/ (accessed 11th Jan 2018). ">ACS 2018</a>). The survival rate for people diagnosed with NSCLC will vary according to the extent (stage) of the cancer. People with locally advanced NSCLC (stage III or more) have a five‐year survival rate of 5% to 36%, and survival estimates do vary according to stage at diagnosis (<a href="./references#CD006847-bbs2-0053" title="American Cancer Society. Cancer facts and figures 2018. Available at: http://www.cancer.org/cancer/lungcancer‐non‐smallcell/ (accessed 11th Jan 2018). ">ACS 2018</a>). Active treatment of NSCLC consists of surgery, radiotherapy and chemotherapy, given as single therapies or in combination. Although there have been major medical therapeutic advances in recent times, these have not been sufficient to significantly affect the high mortality and morbidity rates associated with lung cancer. </p> <p>The pathogenesis of lung neoplasms is multifactorial, however most can be directly attributed to tobacco smoke exposure. NSCLC arising in smokers has a different spectrum of molecular abnormalities from those in non‐smokers, suggesting differences in aetiology, pathogenesis and possibly prognosis. Mutations of tumour suppressor genes such as p53 and retinoblastoma; stimulation of proto‐oncogenes such as K‐ras, c‐myc and c‐raf; and production of autocrine growth factors are some of the potential pathogenic mechanisms so far described in the development of lung cancer. Recent research has identified two oncogenic drivers, epidermal growth factor receptor (EGFR) mutation and EML4/ALK fusion, for which targeted therapies are available. </p> </section> <section id="CD006847-sec-0025"> <h3 class="title" id="CD006847-sec-0025">Description of the intervention</h3> <p>The epidermal growth factor receptor (EGFR) family of genes encodes a widely expressed transmembrane molecule that is frequently expressed in solid tumours. Overexpression of EGFR has been associated with the pathogenesis, proliferation, invasion and metastasis of various solid tumours, including NSCLC. EGFR is overexpressed in around 40% to 80% of documented cases of primary NSCLC and around 88% of advanced cases of NSCLC (<a href="./references#CD006847-bbs2-0077" title="SmithJ . Erlotinib: small molecule targeted therapy in the treatment of non‐small‐cell lung cancer. Clinical Therapeutics2005;27(10):1513‐34. ">Smith 2005</a>). </p> <p>Tyrosine kinase inhibitors (TKIs) bind to the intracellular domain of the tyrosine kinase and may inhibit EGFR downstream signalling. Inhibition of tyrosine kinase may, therefore, block EGFR‐mediated cancer cell propagation. TKIs may be classified as reversible or irreversible, and as selective against EGFR or active against other members of the receptor family. Somatic mutations in the region of EGFR that encodes the tyrosine kinase domain of the receptor (exons 18 through 21) have been identified in lung cancer. Such mutations occur more frequently in patients with NSCLC who have the adenocarcinoma sub‐type, women, Asian people and those who have never smoked (<a href="./references#CD006847-bbs2-0069" title="KosakaT , YatabeY , EndohH , KuwanoH , TakahashiT , MitsudomiT . Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Research2004;64:8919‐23. ">Kosaka 2004</a>; <a href="./references#CD006847-bbs2-0073" title="PaezJG , JännePA , LeeJC , TracyS , GreulichH , GabrielS , et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science2004;304:1497‐500. ">Paez 2004</a>). EGFR mutations are associated with both increased growth factor signalling and increased responsiveness to tyrosine kinase inhibitors (<a href="./references#CD006847-bbs2-0070" title="MokTSK . Personalized medicine in lung cancer: what we need to know. Nature Reviews Clinical Oncology2011;8:661‐8. ">Mok 2011</a>). </p> </section> <section id="CD006847-sec-0026"> <h3 class="title" id="CD006847-sec-0026">How the intervention might work</h3> <p>Gefitinib (Iressa, ZD 1839) is an orally active anilinoquinazoline that selectively and reversibly inhibits intracellular EGFR tyrosine kinase activity. Two large, randomised phase II clinical trials assessed the efficacy and safety of gefitinib monotherapy in patients with locally advanced or metastatic NSCLC who failed previous chemotherapy regimens (<a href="./references#CD006847-bbs2-0009" title="BaelgaJ , KrisM , YanoS , NataleR , GiacconeG , BrahmerJ , et al. Phase II trials (IDEAL 1 and IDEAL 2) of ZD1839 in advanced or metastatic non‐small cell lung cancer (NSCLC) patient. Annals of Oncology2002;13(Suppl 5):131 Abs 481. DouillardJY , GiacconeG , HoraiT , NodaK , VansteenkisteJF , TakataI , et al. Improvement in disease‐related symptoms and quality of life in patients with advanced non‐small cell lung cancer (NSCLC) treated with ZD1839 ('Iressa') (IDEAL 1) [abstract]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:299a, Abs 1195. DouillardJY , SkarinA , BaselgaJ , NataleR , GiacconeG , MaddoxAM , et al. Improvement in disease‐related symptoms and quality of life (QOL) for advanced non‐small cell lung cancer (NSCLC) patients treated with ZD1839 in IDEAL 1 and IDEAL 2. Annals of Oncology2002;13 Suppl 5:131, Abs 480. FukuokaM , YanoS , GiacconeG , TamuraT , NakagawaK , DouillardJY , et al. Multi‐institutional randomized phase II trial of gefitinib for previously treated patients with advanced non‐small‐cell lung cancer. Journal of Clinical Oncology2003;21(12):2237‐46. FukuokaM , YanoS , GiacconeG , et al. [Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced non‐small cell lung cancer (IDEAL 1) [abstract]]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:298a, Abs 1188. ManegoldC , GatzemeierU , KaukelE . Results from a randomised, double blind phase II trial of ZD1839 (IRESSA) as 2nd/3rd‐line monotherapy in advanced non small cell lung cancer (NSCLC) (IDEAL 1). Journal of Cancer Research &amp; Clinical Oncology2002;128 Suppl 1:S45. NishiwakiY , YanoS , TamuraT , NakagawaK , KudohS , HoraiT , et al. Subset analysis of data in the Japanese patients with NSCLC from IDEAL I study on gefitinib. Gan to Kagaku Ryoho. Cancer &amp; Chemotherapy2004;31(4):567‐73. VansteenkisteJ , NataleR , GiacconeG , et al. Two randomised, double‐blind studies of ZD1839 in 425 patients with pretreated advanced non‐small‐call lung cancer (IDEAL 1 and IDEAL 2) [abstract]. European Respiratory Society Annual Congress. Stockholm, 2002:Abstract 2537. ">Fukuoka 2003 IDEAL I</a>; <a href="./references#CD006847-bbs2-0018" title="CellaD , HerbstRS , LynchTJ , PragerD , BelaniCP , SchillerJH , et al. Clinically meaningful improvement in symptoms and quality of life for patients with non‐small cell lung cancer receiving gefitinib in a randomized controlled trial. Journal of Clinical Oncology2005;23(13):2946‐54. KrisMG , NataleRB , HerbstRS , et al. A phase II trial of ZD1839 ('Iressa') in advanced non‐small cell lung cancer (NSCLC) patients who had failed platinum‐ and docetaxel‐based regimens (IDEAL 2) [abstract]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:292a Abstract 1166. KrisMG , NataleRB , HerbstRS , LynchTJ , PragerD , BelaniCP , et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non‐small cell lung cancer: a randomized trial. JAMA2003;290(16):2149‐58. NataleRB , SkarinA , MaddoxAM , et al. Improvement in symptoms and quality of life for advanced non‐small cell lung cancer patients receiving ZD1839 ('Iressa') in IDEAL 2 [abstract]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:292a, Abstract 1167. ">Kris 2003 IDEAL II</a>). Both showed no added benefit in terms of survival, time to progression or response rates compared with standard chemotherapy alone. However these monotherapy trials demonstrated a favourable safety profile. A phase III trial comparing gefitinib to placebo in advanced NSCLC patients who had received prior chemotherapy showed an improvement in progression‐free survival but no prolongation in overall survival (<a href="./references#CD006847-bbs2-0030" title="ChangA , ParikhP , ThongprasertS , TanEH , PerngRP , GanzonD , et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non‐small cell lung cancer: subset analysis from the ISEL study. Journal of Thoracic Oncology2006;1(8):847‐55. HirschFR , DziadziuszkoR , ThatcherN , MannH , WatkinsC , ParumsDV , et al. Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo‐controlled study in advanced non small‐cell lung cancer. Cancer2008;112(5):1114‐21. HirschFR , Varella‐GarciaM , Bunn JrPA , FranklinWA , DziadziuszkoR , ThatcherN , et al. Molecular predictors of outcome with gefitinib in a phase III placebo‐controlled study in advanced non‐small cell lung cancer. Journal of Clinical Oncology2006;24(31):5034‐42. ThatcherN , ChangA , ParikhP , Rodrigues PereiraJ , CiuleanuT , vonPawelJ , et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non‐small‐cell lung cancer: results from a randomised, placebo‐controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet2005;366(9496):1527‐37. ">Thatcher 2005 ISEL</a>). Since these early trials, a number of other randomised controlled trials (RCTs) have examined the effectiveness of gefitinib versus placebo or chemotherapy, or in combination with chemotherapy in the first‐ and second‐line settings. Several studies have also examined its role as maintenance therapy following treatment in patients with advanced NSCLC. </p> </section> <section id="CD006847-sec-0027"> <h3 class="title" id="CD006847-sec-0027">Why it is important to do this review</h3> <p>The precise clinical effectiveness of gefitinib in a range of clinical situations remains to be established. This review will bring together all the current evidence of effectiveness, in order to guide clinical management and the discussion of treatment risks and benefits in patients with NSCLC. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD006847-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006847-sec-0028">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006847-sec-0149">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD006847-sec-0028"></div> <p>To determine the effectiveness and safety of gefitinib as first‐line, second‐line or maintenance treatment for advanced NSCLC. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD006847-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006847-sec-0029">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006847-sec-0150">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD006847-sec-0029"></div> <section id="CD006847-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD006847-sec-0031"> <h4 class="title">Types of studies</h4> <p>We considered all published and unpublished randomised, controlled, phase II and phase III clinical trials of gefitinib as first‐ or second‐line or maintenance therapy in advanced NSCLC. We included any placebo‐controlled trials and trials using comparators. Trials with random allocation, double‐blinding and intention‐to‐treat analysis were preferred. We excluded cross‐over studies, studies that were quasi‐randomised and those that investigated the compassionate use of gefitinib.  </p> </section> <section id="CD006847-sec-0032"> <h4 class="title">Types of participants</h4> <p>Eligible trials included adult participants aged 18 years or older of either sex with histologically or cytologically confirmed NSCLC (stage IIIB/IV) not curable with surgery. </p> </section> <section id="CD006847-sec-0033"> <h4 class="title">Types of interventions</h4> <p>We considered any administration of gefitinib for advanced NSCLC. This included the use of any dosage of gefitinib as first‐ or second‐line therapy or maintenance therapy: </p> <p> <ol id="CD006847-list-0001"> <li> <p>Gefitinib at any dose compared with placebo or best supportive care.</p> </li> <li> <p>Gefitinib at any dose compared with chemotherapeutic agents.</p> </li> <li> <p>Gefitinib at a specific dose versus gefitinib at a different dose.</p> </li> <li> <p>Gefitinib versus gefitinib combined with a chemotherapy regimen.</p> </li> <li> <p>Gefitinib at any dose in combination with chemotherapeutic agents versus the same chemotherapy agents alone. </p> </li> <li> <p>Gefitinib at any dose in combination with chemotherapeutic agents versus a different combination of chemotherapeutic agents. </p> </li> </ol> </p> </section> <section id="CD006847-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD006847-sec-0035"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD006847-list-0002"> <li> <p>Overall survival (OS), assessed from date of randomisation to date of patient death (time to death). </p> </li> <li> <p>Progression‐free survival (PFS):</p> <ul id="CD006847-list-0003"> <li> <p>Measured from the date of randomisation to the date of objective disease progression, based on Response Evaluation Criteria in Solid Tumours (RECIST), the revised version of the International Union Against Cancer/WHO criteria (<a href="./references#CD006847-bbs2-0078" title="TherasseP , ArbuckSG , EisenhauerEA , WandersJ , KaplanRS , RubinsteinL , et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute2000;92(3):205‐16. ">Therasse 2000</a>). </p> </li> <li> <p>Time to treatment failure (TTF): measured from the date of randomisation to the date of study discontinuation (for any reason). This may be reported instead of PFS in some studies. </p> </li> </ul> </li> <li> <p>Toxicity (graded according to the National Cancer Institute Common Toxicity Criteria or the World Health Organization criteria (<a href="./references#CD006847-bbs2-0071" title="National Cancer Institute. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events. Common toxicity criteria, version 4.0. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010‐06‐14_QuickReference_5x7.pdf (accessed 17 February 2017). ">NCI CTCAE 2010</a>). </p> <ul id="CD006847-list-0004"> <li> <p>However, we accepted whatever definitions had been used in the individual trials. A risk ratio (RR) significantly greater than 1 (RR &gt; 1) is a positive response in favour of gefitinib. </p> </li> </ul> </li> </ul> </p> </section> <section id="CD006847-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD006847-list-0005"> <li> <p>Median overall survival (OS) and progression‐free survival (PFS).</p> </li> <li> <p>Survival rate at one year (1YSR).</p> </li> <li> <p>Tumour response ‐ defined according to the RECIST criteria (<a href="./references#CD006847-bbs2-0078" title="TherasseP , ArbuckSG , EisenhauerEA , WandersJ , KaplanRS , RubinsteinL , et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute2000;92(3):205‐16. ">Therasse 2000</a>): </p> <ul id="CD006847-list-0006"> <li> <p>Complete response (CR) defined as the disappearance of all target lesions.</p> </li> <li> <p>Partial response (PR) defined as at least a 30% decrease in the sum of the longest diameter of target lesions. </p> </li> <li> <p>Overall response rate (ORR) taken as the sum of complete response (CR) rate and partial response (PR) rates. </p> </li> <li> <p>Stable disease (SD) defined as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease. </p> </li> <li> <p>Disease control rate (DCR) defined as the sum of the ORR and SD rate. This represents all lesions that have either responded to the treatment or stabilised as a result of treatment. </p> </li> </ul> </li> <li> <p>Quality of life (QOL) and symptom response measured by the Functional Assessment of Cancer Therapy‐Lung (FACT‐L) quality of life instrument, the lung cancer subscale (LCS), the Trial Outcome Index (TOI) and the Pulmonary Symptom Index (PSI) (<a href="./references#CD006847-bbs2-0056" title="CellaD , BonomiAE , LloydSR , TulskyDS , KaplanE , BonomiP . Reliability and validity of the Functional Assessment of Cancer Therapy ‐ Lung (FACT‐L) quality of life instrument. Lung Cancer1995;12:199‐220. ">Cella 1995</a>). </p> </li> </ul> </p> </section> </section> </section> <section id="CD006847-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD006847-sec-0038"> <h4 class="title">Electronic searches</h4> <p>We electronically searched for eligible studies using:</p> <p> <ul id="CD006847-list-0007"> <li> <p>The Cochrane Central Register of Controlled Trials (CENTRAL 2017, Issue 2) (<a href="./appendices#CD006847-sec-0131">Appendix 1</a>); </p> </li> <li> <p>MEDLINE via PubMed (1966 to 17 February 2017) (<a href="./appendices#CD006847-sec-0132">Appendix 2</a>); </p> </li> <li> <p>Embase via OVID (1980 to Week 08, 2017) (<a href="./appendices#CD006847-sec-0133">Appendix 3</a>). </p> </li> </ul> </p> <p>We developed the search string for MEDLINE according to the Cochrane Highly Sensitive Search Strategy, sensitivity‐maximising version (2008 version) as referenced in Chapter 6.4.11.1 and detailed in box 6.4.b of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="https://archie.cochrane.org/sections/documents/view?document=z1604221013305827243969405517116%26format=REVMAN#REF-Higgins-2011" target="_blank">Higgins 2011</a>). </p> </section> <section id="CD006847-sec-0039"> <h4 class="title">Searching other resources</h4> <p>The authors (ES, IY) also screened reference lists of included and excluded studies, attempted to contact authors of relevant studies and examined registers of ongoing trials: ClinicalTrials.gov (<a href="http://clinicaltrials.gov" target="_blank">ClinicalTrials.gov</a>) and Current Controlled Trials (<a href="https://www.isrctn.com/" target="_blank">isrctn.com</a>) to locate all significant published and unpublished data. We also reviewed conference proceedings of the American Society of Clinical Oncology, the European Cancer Conference, the European Society of Medical Oncology and the International Association for the Study of Lung Cancer, from January 1990 to February 2017. When two articles or more used the same data, we only used the most updated article, unless we found some additional information in that article. </p> </section> </section> <section id="CD006847-sec-0040"> <h3 class="title" id="CD006847-sec-0040">Data collection and analysis</h3> <section id="CD006847-sec-0041"> <h4 class="title">Selection of studies</h4> <p>We assessed the eligibility of retrieved articles from the title and abstract. Two investigators (ES, IY) reviewed potential trials for inclusion and extracted data from the published manuscripts. We resolved disagreements about relevance either by consensus or by referral to a third investigator (RWB). There was no blinding of the authors as to origin or conclusions of the articles for eligibility assessment, data extraction or 'Risk of bias' assessment. We sought data for all patients randomised in all eligible randomised trials. Two review authors (ES, IY) independently carried out data extraction using a specifically designed data extraction form. We recorded study details, including year of publication, numbers of people randomised and analysed per arm, age, sex, race/ethnicity of participants, staging and histological cell type, performance status and any previous treatment. We also recorded the dose and duration of gefitinib treatment, as well as the use of any chemotherapeutic agents. We double‐checked all data for consistency, plausibility and integrity of randomisation and follow‐up. </p> </section> <section id="CD006847-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>We extracted data from included studies using the guidelines set out in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD006847-bbs2-0064" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. [www.cochrane‐handbook.org] ">Higgins 2011</a>). </p> </section> <section id="CD006847-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two authors (ES, IY) independently assessed the risk of bias of included studies according to the areas and criteria proposed in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD006847-bbs2-0064" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. [www.cochrane‐handbook.org] ">Higgins 2011</a>). We considered studies to be at low risk of bias when true randomisation occurred, when there was blinding of assessors to treatment received, when all patients were accounted for and included in the analysis on an 'intention‐to‐treat' basis and when all outcome measures were reported. We also considered studies that were terminated early to have a source of bias of interest. </p> <p>The results of these judgements are presented in the 'Risk of bias' tables (<a href="./references#CD006847-sec-0141" title="">Characteristics of included studies</a>). </p> <section id="CD006847-sec-0044"> <h5 class="title">(1) Sequence generation (checking for possible selection bias)</h5> <p>For each included study, we assessed the method used to generate the allocation sequence in sufficient detail to allow an evaluation of whether it should produce comparable groups. </p> <p>We assessed risk of bias as:</p> <p> <ul id="CD006847-list-0008"> <li> <p>Low risk: any truly random process, e.g. random number table, computer random number generator. </p> </li> <li> <p>High risk: any non‐random process, e.g. odd or even date of birth, hospital or clinic record number. </p> </li> <li> <p>Unclear risk: insufficient information about sequence generation process to permit judgement of risk. </p> </li> </ul> </p> </section> <section id="CD006847-sec-0045"> <h5 class="title">(2) Allocation concealment (checking for possible selection bias)</h5> <p>For each included study, we assessed the method used to conceal the allocation sequence to determine whether intervention allocations could have been foreseen in advance of, or during, enrolment. </p> <p>We assessed risk of bias as:</p> <p> <ul id="CD006847-list-0009"> <li> <p>Low risk: e.g. central or telephone allocation, sequentially numbered drug containers of identical appearance. </p> </li> <li> <p>High risk: e.g. open random allocation, unsealed or non‐opaque envelopes, alternation or rotation, date of birth. </p> </li> <li> <p>Unclear risk: insufficient information to permit judgement of 'low risk' or 'high risk' or the study did not address this outcome. </p> </li> </ul> </p> </section> <section id="CD006847-sec-0046"> <h5 class="title">(3) Blinding (checking for possible performance bias)</h5> <p>For each included study, we described the methods used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. </p> <p>We assessed risk of bias as:</p> <p> <ul id="CD006847-list-0010"> <li> <p>Low risk: blinding of participants and key study personnel was ensured and it was unlikely that the blinding could have been broken, or there was no blinding of outcome measurement, but outcome measurement is unlikely to be influenced by the lack of blinding. </p> </li> <li> <p>High risk: no blinding or incomplete blinding and the outcome is likely to be influenced by lack of blinding. </p> </li> <li> <p>Unclear risk: insufficient information to permit judgement of 'low risk' or 'high risk' or the study did not address this outcome. </p> </li> </ul> </p> </section> <section id="CD006847-sec-0047"> <h5 class="title">(4) Incomplete outcome data (checking for attrition bias)</h5> <p>For each included study, we reported the completeness of data including attrition and exclusions, the numbers included in the analysis at each stage and the reasons for attrition or exclusion. </p> <p>We assessed risk of bias as:</p> <p> <ul id="CD006847-list-0011"> <li> <p>Low risk: e.g. if there were any missing outcome data, the reasons for missing outcome data were unlikely to be related to true outcome. </p> </li> <li> <p>High risk: e.g. reasons for missing outcome data are likely to be related to true outcome. </p> </li> <li> <p>Unclear risk: insufficient reporting of attrition/exclusions to permit judgement of 'low risk' or 'high risk' or the study did not address this outcome. </p> </li> </ul> </p> </section> <section id="CD006847-sec-0048"> <h5 class="title">(5) Selective reporting (checking for whether the prespecified outcomes were met)</h5> <p>For each included study, we assessed if the study's protocol was available and that the study's prespecified (primary and secondary) outcomes had been reported in the prespecified way, utilising prespecified measurements and analysis methods. </p> <p>We assessed risk of bias as:</p> <p> <ul id="CD006847-list-0012"> <li> <p>Low risk: e.g. the study protocol was available and all of the study's prespecified (primary and secondary) outcomes that are of interest in the review have been reported in the prespecified way, or if the protocol was not available, that the published report included all expected outcomes. </p> </li> <li> <p>High risk: e.g. not all prespecified outcomes are reported, primary outcomes are reported using measurements or analysis methods that were not prespecified, the primary outcome reported was not prespecified, incomplete reporting of any outcomes, failure to include results for a key outcome that would be expected to have been reported. </p> </li> <li> <p>Unclear risk: insufficient information available to permit a judgement of 'low risk' or 'high risk'. </p> </li> </ul> </p> </section> <section id="CD006847-sec-0049"> <h5 class="title">(6) Other bias</h5> <p>For each included study, we assessed for bias due to problems are not covered elsewhere in the table. </p> <p>We assess risk of bias as:</p> <p> <ul id="CD006847-list-0013"> <li> <p>Low risk: e.g. study appears free of other bias.</p> </li> <li> <p>High risk: e.g. there is at least one important risk of bias, such as a potential source of bias related to study design, or the study has been claimed to have been fraudulent. </p> </li> <li> <p>Unclear risk: insufficient information or evidence that an identified problem will introduce bias. </p> </li> </ul> </p> </section> </section> <section id="CD006847-sec-0050"> <h4 class="title">Measures of treatment effect</h4> <p>Treatment effects are divided into quantitative data and patient‐reported outcomes. We analysed quantitative data such as survival and toxicity as dichotomous outcomes using the risk ratio (RR). We pooled time‐to‐event outcomes, such as hazard ratios (HR) for overall survival and progression‐free survival, provided that authors had analysed data using a Cox proportional hazards model. We summarised proportional outcomes, such as the proportion who survived, using a risk ratio (RR). We combined continuous outcomes with the inverse variance method. We combined quality of life outcomes if the same validated instrument was used, otherwise we utilised a descriptive approach. If data were combined, we presented the change from baseline as the standardised mean difference (SMD). All measures of effect included a 95% confidence interval (CI), P values and for pooled measures the I<sup>2</sup> statistic value. </p> </section> <section id="CD006847-sec-0051"> <h4 class="title">Assessment of heterogeneity</h4> <p>We performed tests for heterogeneity with Review Manager (<a href="./references#CD006847-bbs2-0074" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>) using the I<sup>2</sup> statistic and interpreting the I<sup>2</sup> value using the guidance in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD006847-bbs2-0064" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. [www.cochrane‐handbook.org] ">Higgins 2011</a>). An I<sup>2</sup> value of greater than 75% is likely to represent considerable heterogeneity, a value of 50% to 90% is likely to represent substantial heterogeneity and a value of 30% to 60% represents moderate heterogeneity. </p> </section> <section id="CD006847-sec-0052"> <h4 class="title">Data synthesis</h4> <p>We combined quantitative data using Review Manager 5.3 (<a href="./references#CD006847-bbs2-0074" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We calculated hazard ratios (HR) for data presented as survival curves using logrank expected number of events and variance. We pooled hazard ratios across trials using a fixed‐effect model. We combined continuous data, where the mean, standard deviation (SD) and number of participants in each arm were available, generating a mean difference (MD) and 95% CI. We planned to use a fixed‐effect model in the meta‐analysis if heterogeneity was deemed to be small (an I<sup>2</sup> value of less than 50%). We applied a random‐effects model to comparisons demonstrating significant heterogeneity (with an I<sup>2</sup> value of greater than 50%). </p> <section id="CD006847-sec-0053"> <h5 class="title">GRADE and 'Summary of findings' tables</h5> <p>We employed the GRADE approach to interpret findings (<a href="./references#CD006847-bbs2-0075" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011</a>). We used GRADEProGDT (<a href="./references#CD006847-bbs2-0062" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. ">GRADEpro GDT 2015</a>) to import data from Review Manager (<a href="./references#CD006847-bbs2-0074" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>) to create 'Summary of findings' tables for major comparisons in this review. These tables provide information concerning the overall quality of the evidence from the included studies, the magnitude of the effect of the interventions and the sum of available data on the primary outcome and selected secondary outcomes. We selected the most relevant comparison for presentation in the 'Summary of findings' tables and we selected the following outcomes that we considered important to clinical decision‐making for inclusion in these tables: </p> <p> <ul id="CD006847-list-0014"> <li> <p>Overall survival.</p> </li> <li> <p>Progression‐free survival.</p> </li> <li> <p>Toxicity.</p> </li> </ul> </p> </section> </section> <section id="CD006847-sec-0054"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We performed subgroup analyses for the outcomes of survival and tumour response. We categorised data from included studies into the following subgroups: </p> <p> <ul id="CD006847-list-0015"> <li> <p>Asian population: if the study presented data specifically from patients who were of Asian ethnicity. </p> </li> <li> <p>EGFR mutation positive: if the study presented data specifically from patients who were found to have EGFR activating mutations. </p> </li> </ul> </p> <p>We undertook these subgroup analyses to determine whether there are differences between treatment groups depending on these biological and genomic factors. </p> </section> <section id="CD006847-sec-0055"> <h4 class="title">Sensitivity analysis</h4> <p>Where applicable, we planned to perform a sensitivity analysis based on study quality, to assess the effect of this on the reported outcomes. We also applied a random‐effects model as part of our sensitivity analysis. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD006847-sec-0056" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD006847-sec-0056"></div> <section id="CD006847-sec-0057"> <h3 class="title">Description of studies</h3> <section id="CD006847-sec-0058"> <h4 class="title">Results of the search</h4> <p>The search strategy yielded 5703 studies or abstracts of which 127 studies were possibly eligible. Of these, we included 62 publications in this review, representing 35 primary studies and 27 publications that presented data from their respective primary studies. Fifty‐six were published in abstract form only and we found the remaining nine studies to be ineligible (<a href="#CD006847-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD006847-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram for searches 1966‐2017.(EGFR: epidermal growth factor receptor)" data-id="CD006847-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram for searches 1966‐2017.</p> <p>(EGFR: epidermal growth factor receptor)</p> </div> </div> </div> </section> <section id="CD006847-sec-0059"> <h4 class="title">Included studies</h4> <p>We included a total of 35 separate primary studies in this review and these trials randomised a total of 12,089 patients. Seventeen of the eligible studies were multicentre, phase III trials (<a href="./references#CD006847-bbs2-0010" title="GaafarR M , SurmontV , ScagliottiG , VanKlaverenR , PapamichaelD , WelchJ , et al. A double‐blind, randomized, placebo‐controlled phase III intergroup study of gefitinib (G) in patients (pts) with advanced NSCLC, non‐progressing after first‐line platinum‐based chemotherapy (EORTC 08021‐ILCP 01/03). 2010 Annual Meeting of the Americal Society of CLinical Oncology, ASCO, Chicago, IL United States. American Society of Clinical Oncology, 2010; Vol. 28. GaafarRM , SurmontVF , ScagliottiGV , VanKlaverenRJ , PapamichaelD , WelchJJ , et al. A double‐blind, randomised, placebo‐controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non‐progressing after first line platinum‐based chemotherapy (EORTC 08021/ILCP 01/03). European Journal of Cancer2011;47:2331‐40. SurmontVF , GaafarRM , ScagliottiGV , VanKlaverenRJ , PapamichaelD , HasanB , et al. A double‐blind, randomized, placebo‐controlled phase III study of gefitinib (G) versus placebo (P) in patients (pts) with advanced NSCLC, non progressing after first‐line platinum‐based chemotherapy (EORTC 08021‐ ILCP). 35th ESMO Congress Milan Italy. Oxford University Press, 2010; Vol. 21:viii124. ">Gaafar 2011 EORTC08021</a>; <a href="./references#CD006847-bbs2-0011" title="BellDW , LynchTJ , MaserlatSM , HarrisPL , OkimotoFA , BranniganBW , et al. Epidermal growth factor receptor mutations and gene amplification in non‐small‐cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. Journal of Clinical Oncology2005;23(31):8081‐92. GiacconeG , HerbstRS , ManegoldC , ScagliottiG , RosellR , MillerV , et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non‐small cell lung cancer: a phase III trial ‐ INTACT I. Journal of Clinical Oncology2004;22(5):777‐84. GiacconeG , JohnsonDH , ManegoldC , et al. A phase III clinical trial of ZD1839 ('Iressa') in combination with gemcitabine and cisplatin in chemotherapy‐naive patients with advanced non‐small cell lung cancer (INTACT 1). Annals of Oncology2002;13 Suppl 5:2, Abstract 4. ">Giaccone 2004 INTACT I</a>; <a href="./references#CD006847-bbs2-0013" title="HanJY , ParkK , KimSW , LeeDH , KimHY , KimHT , et al. First‐SIGNAL: first‐line single‐agent Iressa versus gemcitabine and cisplatin trial in never‐smokers with adenocarcinoma of the lung. Journal of Clinical Oncology2012;30:1122‐8. HanJY , YoonKA , ParkJH , LeeYJ , LeeGK , HanJH , et al. DNA repair gene polymorphisms and benefit from gefitinib in never‐smokers with lung adenocarcinoma. Cancer2011;117(14):3201‐8. ">Han 2012 First SIGNAL</a>; <a href="./references#CD006847-bbs2-0014" title="HerbstRS , GiacconeG , SchillerJH , NataleRB , MillerV , ManegoldC , et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non‐small cell lung cancer: a phase III trial ‐ INTACT 2. Journal of Clinical Oncology2004;22(5):785‐94. JohnsonDH , HerbstR , GiacconeG , et al. ZD1839 ('Iressa') in combination with paclitaxel &amp; carboplatin in chemotherapy‐naive patients with advanced non‐small cell lung cancer (NSCLC): results from a phase III clinical trial (INTACT 2). Annals of Oncology2002;13 Suppl 5:127, Abstract 468. ">Herbst 2004 INTACT II</a>; <a href="./references#CD006847-bbs2-0015" title="KellyK , ChanskyK , GasparLE , AlbainKS , JettJ , UngYC , et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non‐small‐cell lung cancer: SWOG S0023. Journal of Clinical Oncology2008;26(15):2450‐6. [SWOG S0023] KellyK , GasparLE , ChanskyK , AlbainKS , CrowleyJ , GandaraDR . Low incidence of pneumonitis on SWOG 0023: A preliminary analysis of an ongoing phase III trial of concurrent chemoradiotherapy followed by consolidation docetaxel and Iressa/placebo maintenance in patients with inoperable stage III non‐small cell lung cancer [abstract]. 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, 13‐17 May, 2005 (Abstract No. 7058). 2005; Vol. 23:634. ">Kelly 2008 SWOG S0023</a>; <a href="./references#CD006847-bbs2-0016" title="DouillardJY , ShephardFA , HirshV , MokT , SocinskiMA , GervaisR , et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non‐small‐cell lung cancer: from the randomized phase III INTEREST Trial. Journal of Clinical Oncology2010;28(5):744‐52. HorganAM , BradburyPA , AmirE , NgR , DouillardJY , KimES , et al. An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second‐/third‐line therapy in advanced non‐small‐cell lung cancer. Annals of Oncology. United Kingdom: Oxford University Press (Great Clarendon Street, Oxford OX2 6DP, United Kingdom), 2011; Vol. 22:1805‐11. HorganAM , ShepherdFA , BradburyPA , NgR , LeighlNB . Preliminary cost‐consequence analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as 2nd line therapy in advanced non‐small cell lung cancer [abstract no. 8110]. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2008;25(15 Suppl Pt 1):451. KimES , HirshV , MokT , SocinskiMA , GervaisR , WuYL , et al. Gefitinib versus docetaxel in previously treated non‐small‐cell lung cancer (INTEREST): a randomized phase III trial. Lancet2008;372:1809‐18. ">Kim 2008 INTEREST</a>; <a href="./references#CD006847-bbs2-0019" title="LeeD , KimS , ParkK , et al. A randomized open‐label study of gefitinib versus docetaxel in patients with advanced/metastatic non‐small cell lung cancer (NSCLC) who have previously received platinum‐based chemotherapy [abstract no. 8025]. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2008;26(15 Suppl Pt I):430. LeeDH , ParkK , KimJH , LeeJS , ShinSW , KangJH , et al. Randomized phase III trial of gefitinib versus docetaxel in non‐small‐cell lung cancer patients who have previously received platinum‐based chemotherapy. Clinical Cancer Research2010;16(4):1307‐14. [ISTANA] ">Lee 2010 ISTANA</a>; <a href="./references#CD006847-bbs2-0022" title="FukuharaT , MaemondoM , InoueA , KobayashiK , SugawaraS , OizumiS , et al. Factors associated with a poor response to gefitinib in the NEJ002 study: smoking and the L858R mutation. Lung Cancer2015;88:181‐6. InoueA , KobayashiK , MaemondoM , SugawaraS , OizumiS , IsobeH , et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin‐paclitaxel for chemo‐naive non‐small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Annals of Oncology. United Kingdom: Oxford University Press (Great Clarendon Street, Oxford OX2 6DP, United Kingdom), 2013; Vol. 24:54‐9. InoueA , KobayashiK , MaemondoM , et al. A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first‐line treatment of non‐small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 study. European Journal of Cancer. 2009:Abstract 9LBA. MaemondoM , InoueA , KobayashiK , SugawaraS , OizumiS , IsobeH , et al. Gefitinib or chemotherapy for non‐small‐cell lung cancer with mutated EGFR. New England Journal of Medicine2010;362(25):2380‐8. MiyauchiE , InoueA , KobayashiK , MaemondoM , SugawaraS , OizumiS , et al. Efficacy of chemotherapy after first‐line gefitinib therapy in EGFR mutation‐positive advanced non‐small cell lung cancer ‐ data from a randomized phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002). Japanese Journal of Clinical Oncology2015;45(7):670‐6. OizumiS , KobayashiK , InoueA , MaemondoM , SugawaraS , YoshizawaH , et al. Quality of life with gefitinib in patients with EGFR‐mutated non‐small cell lung cancer: quality of life analysis of North East Japan study group 002 trial. Oncologist. United States: AlphaMed Press (318 Blackwell St. Suite 260, Durham NC 27701‐2884, United States), 2012; Vol. 17:863‐70. YoshizawaH , KobayashiK , InoueA , MaemondoM , SugawaraS , OizumiS , et al. QOL analysis from NEJ 002 study comparing gefitinib to chemotherapy for non‐small cell lung cancer with mutated EGFR. 35th ESMO Congress Milan Italy. Oxford University Press, 2010; Vol. 21:viii122. ">Maemondo 2010 NEJ002</a>; <a href="./references#CD006847-bbs2-0023" title="LekiR , KawaharaM , WatanabeH , et al. The impact of response evaluation committee in a Phase III study (V‐15‐32) of gefitinib versus docetaxel in Japanese patients with non‐small cell lung cancer [Abstract No. 298P]. Annals of Oncology2009;19 Suppl 8:109‐10. MaruyamaR , NishiwakiY , TamuraT , YamamotoN , TsuboiM , NakagawaK , et al. Phase III study, V‐15‐32, of gefitinib versus docetaxel in previously treated Japanese patients with non‐small‐cell lung cancer. Journal of Clinical Oncology2008;26(26):4245‐52. SekineI , IchinoseY , NishiwakiY , YamamotoN , TsuboiM , NakagawaK , et al. Quality of life and disease‐related symptoms in previously treated Japanese patients with non‐small‐cell lung cancer: results of a randomized phase III study (V‐15‐32) of gefitinib versus docetaxel. Annals of Oncology2009;20(9):1483‐8. YamamotoN , NishiwakiY , NegoroS , JiangH , ItohY , SaijoN , et al. Disease control as a predictor of survival with gefitinib and docetaxel in a phase III study (V‐15‐32) in advanced non‐small‐cell lung cancer patients. Journal of Thoracic Oncology2010;5(7):1042‐7. ">Maruyama 2008 V‐15‐32</a>; <a href="./references#CD006847-bbs2-0024" title="MitsudomiT , MoritaS , YatabeY , NegoroS , OkamotoI , SetoT , et al. Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first‐line treatment for patients with non‐small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR). 2012 Annual Meeting of the American Society of Clinical Oncology, ASCO Chicago, IL United States. American Society of Clinical Oncology, 2012; Vol. 30. MitsudomiT , MoritaS , YatabeY , NegoroS , OkamotoI , TsurutaniJ , et al. Gefitinib versus cisplatin plus docetaxel in patients with non‐small‐cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase III trial. Lancet2010;11:121‐8. TsurutaniJ , MitsudomiT , MoriS , OkamotoI , NozakiK , TadaH , et al. A phase III, first‐line trial of gefitinib versus cisplatin plus docetaxel for patients with advanced or recurrent non‐small cell lung cancer (NSCLC) harboring activating mutation of the epidermal growth factor receptor (EGFR) gene: a preliminary results of WJTOG 3405 [abstract O‐9002]. European Journal of Cancer. 2009; Vol. 7 Suppl:505. ">Mitsudomi 2010 WJTOG3405</a>; <a href="./references#CD006847-bbs2-0025" title="FukuokaM , WuYL , ThongprasertS , SunpaweravongP , LeongSS , SriuranpongV , et al. Biomarker analyses and final overall survival results from a phase III, randomized, open‐label, first‐line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non ‐ small‐cell lung cancer in Asia (IPASS). Journal of Clinical Oncology2011;29:2866‐74. MokT , WuY‐L , ThongprasertS , et al. Phase III, randomised, open‐label, first‐line study of gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients (PTS) with advanced non‐small cell lung cancer (NSCLC) (IPASS). Annals of Oncology2008;19 Suppl 8:Viii1. MokTS , WuYL , ThongprasertS , YangCH , ChuDT , SaijoN , et al. Gefitinib or carboplatin‐paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine2009;361(10):947‐57. OheY , IchinoseY , NishiwakiY ,  etal . Phase III, randomized, open‐label, first‐line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in selected patients (pts) with advanced non‐small‐cell lung cancer (NSCLC) (IPASS): Evaluation of recruits in Japan. Journal of Clinical Oncology2009;29(15 Suppl 1):8044. ThongprasertS , DuffieldE , SaijoN , WuYL , YangJC , ChuDT , et al. Health‐related quality‐of‐life in a randomized phase III first‐line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). Journal of Thoracic Oncology2011;6:1872‐80. ThongprasertS , DuffieldE , WuY , et al. Quality of life (QOL) in a randomized phase III first‐line study of gefitinib (G) vs carboplatin/paclitaxel (CP) in clinically selected Asian patients (pts) with advanced NSCLC (IPASS). Journal of Thoracic Oncology2010;5(5 Suppl 1):S80. WuY , ChuD , HanB , LiuX , ZhangL , ZhouC , et al. Phase III, randomized, open‐label, first‐line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non‐small‐cell lung cancer: evaluation of patients recruited from mainland China. Asia‐Pacific Journal of Clinical Oncology2012;8:232‐43. WuY , FukuokaM , MokT S K , SaijoN , ThongprasertS , YangJ C H , et al. Tumour response, skin rash and health‐related quality of life (HRQOL) ‐ Post‐HOC data from the IPASS study. European Multidisciplinary Cancer Congress Stockholm Sweden. Elsevier Ltd, 2011; Vol. 47:S633‐4. WuY , MokT , ChuD , et al. Evaluation of clinically selected patients (pts) with advanced non‐small cell lung cancer (NSCLC) recruited in China in a phase III, randomized, open‐label, first‐line study in Asia of gefitinib (G) versus carboplatin/paclitaxel (C/P) (IPASS). Journal of Clinical Oncology. 2009; Vol. 27 (15 Suppl 1):8041. WuYL , FukuokaM , MokTSK , SaijoN , ThongprasertS , YangJCH , et al. Tumor response and health‐related quality of life in clinically selected patients from Asia with advanced non‐small‐cell lung cancer treated with first‐line gefitinib: post hoc analyses from the IPASS study. Lung Cancer2013;81:280‐7. YangCH , FukuokaM , MokTS , WuYL , ThongprasertS , SaijoN , et al. Final overall survival (OS) results from a phase III, randomised, open‐label, first‐line study of gefitinib (G) v carboplatin/paclitaxel (C/P) in clinically selected patients with advanced nonsmall cell lung cancer (NSCLC) in Asia (IPASS). 35th ESMO Congress Milan Italy. Oxford University Press, 2010; Vol. 21:viii1‐2. YangJ , WuY L , SaijoN , ThongprasertS , ChuD T , ChenY M , et al. Efficacy outcomes in first‐line treatment of advanced NSCLC with gefitinib (G) vs carboplatin/paclitaxel (C/P) by epidermal growth factor receptor (EGFR) gene‐copy number score and by most common EGFR mutation subtypes ‐ Exploratory data from IPASS. 2011 European Multidisciplinary Cancer Congress Stockholm Sweden. Elsevier Ltd, 2011; Vol. 47:S633. YangJ , WuY , ChanV , KurniandaJ , NakagawaK . Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan‐ASia Study (IPASS). Lung Cancer2014;83:174‐81. YangJCH , WuYL , ChanV , KurniandaJ , NakagawaK , SaijoN , et al. Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan‐ASia Study (IPASS). Lung Cancer2014;83:174‐81. ">Mok 2009 IPASS</a>; <a href="./references#CD006847-bbs2-0027" title="SoriaJC , WuYL , NakagawaK , KimSW , YangJJ , AhnMJ , et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR‐mutation‐positive non‐small‐cell lung cancer after progression on first‐line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncology2015;16:990‐8. ">Soria 2015 IMPRESS</a>; <a href="./references#CD006847-bbs2-0028" title="AhnM , SunJ , AhnJS , KimS , MinYJ , YunHJ , et al. Randomized phase III trial of gefitinib or pemetrexed as second‐line treatment in patients with non‐small cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01). ASCO Annual Meeting 2011 Chicago, IL United States. American Society of Clinical Oncology, 2011; Vol. 29. AhnMJ , SunJM , LeeKH , AhnJS , KimSW , MinYJ , et al. Randomized phase III trial of gefitinib or pemetrexed as second‐line treatment in patients with non‐small cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01). 14th World Conference on Lung Cancer Amsterdam Netherlands. International Association for the Study of Lung Cancer, 2011; Vol. 6:S317. SunJM , LeeKH , KimSW , LeeDH , MinYJ , YunHJ , et al. Gefitinib versus pemetrexed as second‐line treatment in patients with nonsmall cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01): an open‐label, phase 3 trial. Cancer2012;118:6234‐42. ">Sun 2012 KCSG‐LU08‐01</a>; <a href="./references#CD006847-bbs2-0029" title="OkamotoI , HidaT , KashiiT , et al. Randomized phase III study of platinum‐doublet chemotherapy followed by gefitinib versus continued platinum‐doublet chemotherapy in patients (pts) with advanced non‐small cell lung cancer (NSCLC): Results of West Japan Thoracic Oncology Group Trial (WJTOG0203) [Abstract No. 2 33PD]. Annals of Oncology2008;19 Suppl 8:91. TakedaK , HidaT , SatoT , AndoM , SetoT , SatouchiM , et al. Randomized phase III trial of platinum‐doublet chemotherapy followed by gefitinib comparted with continued platinum‐doublet chemotherapy in Japanese patients with advanced non‐small cell lung cancer: results of a West Japan Thoracic Oncology Group Trial (WJTOG0203). Journal of Clinical Oncology2010;28(5):753‐60. ">Takeda 2010 WJTOG0203</a>; <a href="./references#CD006847-bbs2-0030" title="ChangA , ParikhP , ThongprasertS , TanEH , PerngRP , GanzonD , et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non‐small cell lung cancer: subset analysis from the ISEL study. Journal of Thoracic Oncology2006;1(8):847‐55. HirschFR , DziadziuszkoR , ThatcherN , MannH , WatkinsC , ParumsDV , et al. Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo‐controlled study in advanced non small‐cell lung cancer. Cancer2008;112(5):1114‐21. HirschFR , Varella‐GarciaM , Bunn JrPA , FranklinWA , DziadziuszkoR , ThatcherN , et al. Molecular predictors of outcome with gefitinib in a phase III placebo‐controlled study in advanced non‐small cell lung cancer. Journal of Clinical Oncology2006;24(31):5034‐42. ThatcherN , ChangA , ParikhP , Rodrigues PereiraJ , CiuleanuT , vonPawelJ , et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non‐small‐cell lung cancer: results from a randomised, placebo‐controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet2005;366(9496):1527‐37. ">Thatcher 2005 ISEL</a>; <a href="./references#CD006847-bbs2-0033" title="BoyeM , WangX , SrimuninnimitV , KangJH , TsaiCM , OrlandoM , et al. First‐line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian never‐smoker patients with locally advanced or metastatic nonsquamous non‐small cell lung cancer: quality of life results from a randomized phase III trial. Clinical Lung Cancer2016;17(2):150‐60. KangJH , AhnM , KimD , ChoEK , KimJ , ShinSW , et al. Tolerability and outcomes of first‐line pemetrexed‐cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in Korean patients with advanced non‐squamous non‐small cell lung cancer: a post hoc descriptive subgroup analysis of a randomized, phase 3 trial. Cancer Research and Treatment2015;48(2):458‐64. YangJC , KangJH , MokT , AhnM , SrimuninnimitV , LinC , et al. First‐line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non‐squamous non‐small cell lung cancer: a randomised, phase 3 trial. European Journal of Cancer2014;50:2219‐30. YangJC , ParkK , MokTSK , KangJH , SrimuninnimitV , LinCC , et al. A randomized phase 3 study comparing first‐line pemetrexed plus cisplatin followed by gefitinib as maintenance with gefitinib monotherapy in east Asian patients with locally advanced or metastatic nonsquamous non‐small cell lung cancer (NSQNSCLC). 15th World Conference on Lung Cancer Sydney, NSW Australia. International Association for the Study of Lung Cancer, 2013; Vol. 8:S288. YangJC , SrimuninnimitV , AhnM , LinC , KimS , TsaiC , et al. A randomized phase 3 study comparing first‐line pemetrexed plus cisplatin followed by gefitinib maintenance (PC/G) with gefitinib monotherapy (G) in East Asian patients (pts) with locally advanced or metastatic nonsquamous non‐small cell lung cancer (nSqNSCLC): final survival results. Journal of Clinical Oncology2015;15 Suppl:8041. YangJC , SrimunninnimitV , AhnM , LinC , KimS , TsaiC , et al. First‐line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian never‐smoker patients with locally advanced or metastatic nonsquamous non‐small cell lung cancer: final overall survival results from a randomized phase 3 study. Journal of Thoracic Oncology2016;11(3):370‐9. ">Yang 2014</a>; <a href="./references#CD006847-bbs2-0035" title="YangY , MaY , ZhaoY , FangW , HongS , et al. QoL analyses from INFORM study, a phase III study of gefitinib versus placebo as maintenance therapy in advanced NSCLC. Scientific Reports2015;5:11934. ZhangL , MaS , SongX , HanB , ChengY , HuangC , et al. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non‐small‐cell lung cancer (INFORM; C‐TONG 0804): a multicentre, double‐blind randomised phase 3 trial. Lancet Oncology2012;13:466‐75. ZhangL , MaSL , SongXQ , ChengY , HuangC , YangSJ , et al. Pre‐planned subgroup analyses from the phase III, randomised, placebo‐controlled, parallel‐group study of gefitinib (G) as maintenance therapy in patients (pts) with locally advanced or metastatic non‐small‐cell lung cancer (NSCLC) (INFORM; C‐TONG 0804). European Multidisciplinary Cancer Congress Stockholm Sweden. Elsevier Ltd, 2011; Vol. 47:S622‐3. ZhangL , MaSL , SongXQ , HanBH , ChengY , HuangC , et al. Efficacy, tolerability and biomarker analyses from a phase III, randomized, placebo controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non‐small‐cell lung cancer (NSCLC) in China (INFORM) (C‐TONG 0804). 14th World Conference on Lung Cancer Amsterdam Netherlands. International Association for the Study of Lung Cancer, 2011; Vol. 6:S558‐9. ZhangL , ShenglinM , SongX , HanB , ChengY , HuangC , et al. Efficacy, tolerability, and biomarker analyses from a phase III, randomized, placebo‐controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non‐small cell lung cancer (NSCLC; INFORM; C‐TONG 0804). ASCO Annual Meeting 2011 Chicago, IL United States. American Society of Clinical Oncology, 2011; Vol. 29. ZhaoH , FanY , MaS , SongX , HanB , ChengY , et al. Final overall survival results from a phase III, randomized placebo‐controlled, parallel‐group study of gefitinib versus placebo as maintenance therapy in patients with advanced or metastatic non‐small‐cell lung cancer (INFORM; C‐TONG 0804). Journal of Thoracic Oncology2015;10(4):655‐64. ">Zhang 2012 INFORM</a>). The remaining 18 were phase II studies (<a href="./references#CD006847-bbs2-0001" title="AhnMJ , YangJCH , LiangJ , KangJH , XiuQ , ChenYM , et al. Randomized phase II trial of first‐line treatment with pemetrexed‐cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never‐smoker patients with advanced non‐small cell lung cancer. Lung Cancer2012;77:346‐52. ">Ahn 2012</a>; <a href="./references#CD006847-bbs2-0002" title="AnC , ZhangJ , ChuH , GuC , XiaoF , ZhuF , et al. Study of gefitinib and pemetrexed as first‐line treatment in patients with advanced non‐small cell lung cancer harboring EGFR mutation. Pathology and Oncology Research2016;22:763‐8. ">An 2016</a>; <a href="./references#CD006847-bbs2-0003" title="ChenYM , LiuJM , ChouTY , PerngRP , TsaiCM , Whang‐PengJ . Phase II randomized study of daily gefitinib treatment alone or with vinorelbine every 2 weeks in patients with adenocarcinoma of the lung who failed at least 2 regimens of chemotherapy. Cancer2007;109(9):1821‐8. ">Chen 2007</a>; <a href="./references#CD006847-bbs2-0004" title="ChenYM , FanWC , TsaiCM , LiuSH , ShihJF , ChouTY , et al. A phase II randomized trial of gefitinib alone or with Tegafur/uracil treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy. Journal of Thoracic Oncology2011;6:1110‐6. ">Chen 2011</a>; <a href="./references#CD006847-bbs2-0005" title="ChengY , MurakamiH , YangPC , HeJ , NakagawaK , KangJH , et al. Randomized phase II trial of gefitinib with and without pemetrexed as first‐line therapy in patients with advanced nonsquamous non‐small‐cell lung cancer with activating epidermal growth factor receptor mutations. Journal of Clinical Oncology2016;27(20):3258‐66. ">Cheng 2016</a>; <a href="./references#CD006847-bbs2-0006" title="CrinoL , CappuzzoF , ZatloukalP , ReckM , PesekM , ThompsonJC , et al. Gefitinib versus vinorelbine in chemotherapy‐naive elderly patients with advanced non‐small‐cell lung cancer (INVITE): a randomized, phase II study. Journal of Clinical Oncology2008;26(26):4253‐60. ">Crino 2008 INVITE</a>; <a href="./references#CD006847-bbs2-0007" title="CuferT , VrdoljakE , GaafarR , ErensoyI , PembertonK , SIGN study group. Phase II, open‐label, randomized study (SIGN) or single‐agent gefitinib (IRESSA) or docetaxel as second‐line therapy in patients with advanced (stage IIIb or IV) non‐small‐cell lung cancer. Anticancer Drugs2006;17(4):401‐9. ">Cufer 2006 SIGN</a>; <a href="./references#CD006847-bbs2-0008" title="DaiH , XuL , XiaC , ChenW . A randomized clinical study of gefitinib and pemetrexed as second line therapy for advanced non‐squamous non‐small cell lung cancer. Chinese Journal of Lung Cancer2013;16:405‐10. ">Dai 2013</a>; <a href="./references#CD006847-bbs2-0009" title="BaelgaJ , KrisM , YanoS , NataleR , GiacconeG , BrahmerJ , et al. Phase II trials (IDEAL 1 and IDEAL 2) of ZD1839 in advanced or metastatic non‐small cell lung cancer (NSCLC) patient. Annals of Oncology2002;13(Suppl 5):131 Abs 481. DouillardJY , GiacconeG , HoraiT , NodaK , VansteenkisteJF , TakataI , et al. Improvement in disease‐related symptoms and quality of life in patients with advanced non‐small cell lung cancer (NSCLC) treated with ZD1839 ('Iressa') (IDEAL 1) [abstract]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:299a, Abs 1195. DouillardJY , SkarinA , BaselgaJ , NataleR , GiacconeG , MaddoxAM , et al. Improvement in disease‐related symptoms and quality of life (QOL) for advanced non‐small cell lung cancer (NSCLC) patients treated with ZD1839 in IDEAL 1 and IDEAL 2. Annals of Oncology2002;13 Suppl 5:131, Abs 480. FukuokaM , YanoS , GiacconeG , TamuraT , NakagawaK , DouillardJY , et al. Multi‐institutional randomized phase II trial of gefitinib for previously treated patients with advanced non‐small‐cell lung cancer. Journal of Clinical Oncology2003;21(12):2237‐46. FukuokaM , YanoS , GiacconeG , et al. [Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced non‐small cell lung cancer (IDEAL 1) [abstract]]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:298a, Abs 1188. ManegoldC , GatzemeierU , KaukelE . Results from a randomised, double blind phase II trial of ZD1839 (IRESSA) as 2nd/3rd‐line monotherapy in advanced non small cell lung cancer (NSCLC) (IDEAL 1). Journal of Cancer Research &amp; Clinical Oncology2002;128 Suppl 1:S45. NishiwakiY , YanoS , TamuraT , NakagawaK , KudohS , HoraiT , et al. Subset analysis of data in the Japanese patients with NSCLC from IDEAL I study on gefitinib. Gan to Kagaku Ryoho. Cancer &amp; Chemotherapy2004;31(4):567‐73. VansteenkisteJ , NataleR , GiacconeG , et al. Two randomised, double‐blind studies of ZD1839 in 425 patients with pretreated advanced non‐small‐call lung cancer (IDEAL 1 and IDEAL 2) [abstract]. European Respiratory Society Annual Congress. Stockholm, 2002:Abstract 2537. ">Fukuoka 2003 IDEAL I</a>; <a href="./references#CD006847-bbs2-0012" title="GossG , FerryD , WierzibickiR , LaurieSA , ThompsonJ , BiesmaB , et al. Randomized phase II study of gefitinib compared with placebo in chemotherapy‐naive patients with advanced non‐small‐cell lung cancer and poor performance status. Journal of Clinical Oncology2009;27(13):2253‐60. ">Goss 2009 INSTEP</a>; <a href="./references#CD006847-bbs2-0017" title="KimYS , ChoEK , WooHS , HongJ , AhnHK , ParkI , et al. Randomized phase II study of pemetrexed versus gefitinib in previously treated patients with advanced non‐small cell lung cancer. Cancer Research and Treatment2016;48(1):80‐7. ">Kim 2016</a>; <a href="./references#CD006847-bbs2-0018" title="CellaD , HerbstRS , LynchTJ , PragerD , BelaniCP , SchillerJH , et al. Clinically meaningful improvement in symptoms and quality of life for patients with non‐small cell lung cancer receiving gefitinib in a randomized controlled trial. Journal of Clinical Oncology2005;23(13):2946‐54. KrisMG , NataleRB , HerbstRS , et al. A phase II trial of ZD1839 ('Iressa') in advanced non‐small cell lung cancer (NSCLC) patients who had failed platinum‐ and docetaxel‐based regimens (IDEAL 2) [abstract]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:292a Abstract 1166. KrisMG , NataleRB , HerbstRS , LynchTJ , PragerD , BelaniCP , et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non‐small cell lung cancer: a randomized trial. JAMA2003;290(16):2149‐58. NataleRB , SkarinA , MaddoxAM , et al. Improvement in symptoms and quality of life for advanced non‐small cell lung cancer patients receiving ZD1839 ('Iressa') in IDEAL 2 [abstract]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:292a, Abstract 1167. ">Kris 2003 IDEAL II</a>; <a href="./references#CD006847-bbs2-0020" title="LiH , WangX , HuaF . Second‐line treatment with gefitinib or docetaxel for advanced non‐small cell lung cancer. Chinese Journal of Clinical Oncology2010;37:16‐8. ">Li 2010</a>; <a href="./references#CD006847-bbs2-0021" title="LouN , YangJ , YanH , QingZ , LiaoR , XuC , et al. Efficacies of gefitinib versus paclitaxel/carboplatin for patients with advanced pulmonary adenocarcinoma. National Medical Journal of China2014;94(30):2337‐41. ">Lou 2014</a>; <a href="./references#CD006847-bbs2-0026" title="DesGuetzG , LandreT , WesteelV , MilleronB , VayletF , UrbanT , et al. Similar survival rates with first‐line gefitinib, gemcitabine or docetaxel in a randomized phase II trial in elderly patients with advanced non‐small cell lung cancer and a poor performance status (IFCT‐0301). Journal of Geriatric Oncology2015;6:233‐40. MorereJ , WesteelV , MorinF , et al. Randomized phase II trial of first‐line gefitinib,gemcitabine or docetaxel in performance status (PS) 2 or 3 non‐small‐cell lung cancer (NSCLC) patients (IFCT‐0301) [abstract no. 8086]. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2008;26(15 Suppl Pt I):445. MorereJF , BrechotJM , WesteelV , GounantV , LebeauB , VayletF , et al. Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non‐small‐cell lung cancer and a performance status of  2 or 3 (IFCT‐0301 study). Lung Cancer2010;70(1):301‐7. ">Morere 2010 IFCT‐0301</a>; <a href="./references#CD006847-bbs2-0031" title="XuYH , MeiJS , ZhouJ . Randomized study of gefitinib versus pemetrexed as maintenance treatment in patients with advanced glandular non‐small cell lung cancer. International Journal of Clinical and Experimental Medicine2015;8(4):6242‐6. ">Xu 2015</a>; <a href="./references#CD006847-bbs2-0032" title="XueC , HongS , LiN , FengW , JiaJ , PengJ , et al. Randomized, multicenter study of gefitinib dose‐escalation in advanced non‐small‐cell lung cancer patients achieved stable disease after one‐month gefitinib treatment. Scientific Reports2015;5:10648. ZhangL , XueC , LiN , FengW , JiaJ , PengJ , et al. Randomized, open‐label, multi‐center study of gefitinib dose‐escalation (500mg/d versus 250mg/d) in advanced NSCLC patient achieved stable disease (SD) after one‐month gefitinib treatment. 15th World Conference on Lung Cancer Sydney, NSW Australia. International Association for the Study of Lung Cancer, 2013; Vol. 8:S1185. ">Xue 2015</a>; <a href="./references#CD006847-bbs2-0034" title="YuH , ZhangJ , WuX , LuoZ , WangH , SunS , et al. A phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non‐squamous non‐small cell lung cancer. Cancer Biology and Therapy2014;15(7):832‐9. ">Yu 2014</a>). A summary of the 35 included primary studies is presented in <a href="#CD006847-tbl-0004">Table 1</a>. An additional 14 publications analysed data from their respective primary studies (<a href="./references#CD006847-bbs2-0054" title="BellDW , LynchTJ , MaserlatSM , HarrisPL , OkimotoFA , BranniganBW , et al. Epidermal growth factor receptor mutations and gene amplification in non‐small‐cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. Journal of Clinical Oncology2005;23(31):8081‐92. ">Bell 2005</a>; <a href="./references#CD006847-bbs2-0055" title="BoyeM , WangX , SrimuninnimitV , KangJH , TsaiCM , OrlandoM , et al. First‐line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in east Asian never‐smoker patients with locally advanced or metastatic nonsquamous non‐small cell lung cancer: quality of life results from a randomized phase III trial. Clinical Lung Cancer2016;17(2):150‐60. ">Boye 2016</a>; <a href="./references#CD006847-bbs2-0058" title="CellaD , HerbstRS , LynchTJ , PragerD , BelaniCP , SchillerJH , et al. Clinically meaningful improvement in symptoms and quality of life for patients with non‐small cell lung cancer receiving gefitinib in a randomized controlled trial. Journal of Clinical Oncology2005;23(13):2946‐54. ">Cella 2005</a>; <a href="./references#CD006847-bbs2-0059" title="ChangA , ParikhP , ThongprasertS , TanEH , PerngRP , GanzonD , et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non‐small‐cell lung cancer: Subset analysis from the ISEL study. Journal of Thoracic Oncology2006;1(8):847‐55. ">Chang 2006</a>; <a href="./references#CD006847-bbs2-0060" title="DouillardJY , ShephardFA , HirshV , MokT , SocinskiMA , GervaisR , et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non‐small‐cell lung cancer: from the randomized phase III INTEREST trial. Journal of Clinical Oncology2010;28(5):744‐52. ">Douillard 2010</a>; <a href="./references#CD006847-bbs2-0061" title="FukuokaM , WuYL , ThongprasertS , SunpaweravongP , LeongSS , SriuranpongV , et al. Biomarker analyses and final overall survival results from a phase III, randomized, open‐label, first‐line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non ‐ small‐cell lung cancer in Asia (IPASS). Journal of Clinical Oncology. United States: American Society of Clinical Oncology (330 John Carlyle Street, Suite 300, Alexandria VA 22314, United States), 2011; Vol. 29:2866‐74. ">Fukuoka 2011</a>; <a href="./references#CD006847-bbs2-0065" title="HirschFR , Varella‐GarciaM , Bunn JrPA , FranklinWA , DziadziuszkoR , ThatcherN , et al. Molecular predictors of outcome with gefitinib in a phase III placebo‐controlled study in advanced non‐small cell lung cancer. Journal of Clinical Oncology2006;24(31):5034‐42. ">Hirsch 2006</a>; <a href="./references#CD006847-bbs2-0063" title="HerbstRS , PragerD , HermannR , FenrenbacherL , JohnsonBE , SandlerA , et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI‐774) combined with carboplatin and paclitaxel chemotherapy in advanced non‐small‐cell lung cancer. Journal of Clinical Oncology2005;23(25):5892‐9. ">Herbst 2005</a>; <a href="./references#CD006847-bbs2-0067" title="InoueA , KobayashiK , MaemondoM , SugawaraS , OizumiS , IsobeH , et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin‐paclitaxel for chemo‐naive non‐small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Annals of Oncology2013;24:54‐9. ">Inoue 2013</a>; <a href="./references#CD006847-bbs2-0072" title="OizumiS , KobayashiK , InoueA , MaemondoM , SugawaraS , YoshizawaH , et al. Quality of life with gefitinib in patients with EGFR‐mutated non‐small cell lung cancer: quality of life analysis of north east Japan study group 002 trial. Oncologist. United States: AlphaMed Press (318 Blackwell St. Suite 260, Durham NC 27701‐2884, United States), 2012; Vol. 17:863‐70. ">Oizumi 2012</a>; <a href="./references#CD006847-bbs2-0076" title="SekineI , IchinoseY , NishiwakiY , YamamotoN , TsuboiM , NakagawaK , et al. Quality of life and disease‐related symptoms in previously treated Japanese patients with non‐small‐cell lung cancer: results of a randomized phase III study (V‐15‐32) of gefitinib versus docetaxel. Annals of Oncology2009;20(9):1483‐8. ">Sekine 2009</a>; <a href="./references#CD006847-bbs2-0079" title="ThongprasertS , DuffieldE , SaijoN , WuYL , YangJC , ChuDT , et al. Health‐related quality‐of‐life in a randomized phase III first‐line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). Journal of Thoracic Oncology2011;6:1872‐80. ">Thongprasert 2011</a>; <a href="./references#CD006847-bbs2-0080" title="YamamotoN , NishiwakiY , NegoroS , JiangH , ItohY , SaijoN , et al. Disease control as a predictor of survival with gefitinib and docetaxel in a phase III study (V‐15‐32) in advanced non‐small‐cell lung cancer patients. Journal of Thoracic Oncology2010;5(7):1042‐7. ">Yamamoto 2010</a>; <a href="./references#CD006847-bbs2-0081" title="YangYP , MaYX , HuangY , ZhaoYY , FangWF , HongSD , et al. QoL analyses from INFORM study, a phase III study of gefitinib versus placebo as maintenance therapy in advanced NSCLC. Scientific Reports2015;5:11934. ">Yang 2015</a>). If we used data from these secondary studies, we did not duplicate with data from the respective primary studies and vice versa. </p> <div class="table" id="CD006847-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Included studies</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Author/Year</b> </p> <p><b>(Study name)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Journal</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparison</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inclusion criteria</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Phase</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Asian</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>EGFR mutation</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Line?</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p><b>1. Gefitinib versus placebo</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Goss 2009 (INSTEP)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JCO 27(13):2253‐2260</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>201</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Poor PS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subgroup</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1st line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thatcher 2005 (ISEL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lancet 366:1527‐37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1692</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subset (Chang)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subgroup (Hirsch)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2nd line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gaafar 2011 (EORTC08021)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eur J Cancer (47):2331‐2340</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>173</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maintenance</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maintenance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kelly 2008 (SWOGS0023)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JCO 26(15):2450‐2456</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>243</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Consolidation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maintenance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zhang 2012 (INFORM)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lancet Oncology 13:466‐475</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>296</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maintenance</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subgroup</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maintenance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p><b>2. Gefitinib versus chemotherapy</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Crino 2008 (INVITE)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JCO 26(26):4253‐4260</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>196</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vinorelbine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Elderly patients</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subgroup</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1st line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lou 2014</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Natl Med J China 94(30): 2337‐2341</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin + paclitaxel</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asian</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1st line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Morere 2010 (IFCT0301)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lung Cancer 70:301‐307</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Docetaxel</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Poor PS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1st line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Han 2013 (First‐SIGNAL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JCO 30(10): 1122‐1128</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>313</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gemcitabine + cisplatin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Planned Subgroup</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1st line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mok 2009 (IPASS)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NEJM 361(10):947‐957</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1217</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin + paclitaxel</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asian, adenocarcinomas</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subgroup</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1st line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maemondo 2010 (NEJ002)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NEJM 362(25):2580‐2588</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>230</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin + paclitaxel</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asian, EGFR mutation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1st line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mitsudomi 2010 (WJTOG3405)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lancet Oncol 11:121‐128</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>177</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cisplatin + docetaxel</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asian, EGFR mutation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1st line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yang 2014</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eur J Cancer 50:2219‐2230</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>236</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pemetrexed + cisplatin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asian</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subgroup</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1st line + maintenance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cufer 2006 (SIGN)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐cancer Drugs 14:401‐409</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Docetaxel</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open‐label</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2nd line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dai 2013</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chin J Lung Cancer 16(8):405‐410</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pemetrexed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asian</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2nd line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kim 2016</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cancer Res Treat 48(1):80‐87</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pemetrexed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asian</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2nd/3rd line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Li 2010</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chinese J Clin Onc 37:16‐18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Docetaxel</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asian</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2nd line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kim 2008 (INTEREST)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lancet 372:1809‐1818</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1466</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Docetaxel</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subgroup (Doulliard)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2nd line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lee 2010 (ISTANA)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clin Cancer Res 16(4):1307‐1314</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>161</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Docetaxel</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asian</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2nd/3rd line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maruyama 2008 (V‐15‐32)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JCO 26(26):4244‐4252</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>489</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Docetaxel</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asian</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subgroup</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2nd/3rd line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sun 2012 (KSCG‐LU08‐01)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cancer 118:6234‐6242</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pemetrexed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adenocarcinoma, non‐smoker</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subgroup</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2nd line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ahn 2012</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lung Cancer 77:346‐352</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pemetrexed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asian, never‐smokers</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maintenance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xu 2015</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Int J Clin Exp Med 8(4):6242‐6246</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>188</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pemetrexed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asian</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maintenance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p><b>3. Gefitinib 250 mg versus gefitinib 500 mg</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fukuoka 2003 (IDEAL I)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JCO 21(12):2237‐2246</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>210</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G250 versus G500</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2rd/3rd line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kris 2003 (IDEAL II)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JAMA 290(16):2149‐2158</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>216</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G250 versus G500</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3rd line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xue 2015</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Int J Clin Exp Med 8(4):6242‐6246</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>188</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G250 versus G500</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asian</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maintenance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p><b>4. Gefitinib versus gefitinib + chemotherapy</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An 2016</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pathol Oncol Res 22:763‐768</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gefitinib + Pemetrexed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asian, EGFR mutation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1st line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cheng 2016</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JCO 34(27): 3258‐3266</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>191</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gefitinib + Pemetrexed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asian, EGFR mutation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1st line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chen 2007</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cancer 109:1821‐8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gefitinib + Vinorelbine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adenocarcinoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subgroup</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3rd line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chen 2011</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>J Thor Oncol 6:1110‐1116</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gefitinib + Tegafur</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adenocarcinoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subgroup</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2nd/3rd line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p><b>5. Gefitinib + chemotherapy versus chemotherapy</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Giaccone 2004 (INTACT I)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JCO 22(5):777‐784</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1093</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gemcitabine + Cisplatin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1st line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Herbst 2004</p> <p>(INTACT II)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JCO 22(5):785‐794</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1037</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin + paclitaxel</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1st line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Takeda 2010 (WTOG0203)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JCO 28(5):753‐760</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>604</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Platinum doublet</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1st line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yu 2014</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cancer Biology &amp; Therapy 15:832‐839</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pemetrexed + platinum</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asian</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1st line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Soria 2015 (IMPRESS)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lancet Oncology 16:990‐98</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>265</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pemetrexed + cisplatin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EGFR mutation positive</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2nd line</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>EGFR: epidermal growth factor receptor<br/> N: number of patients included<br/> PS: performance status </p> <p>Journals:</p> <p>Cancer Res Treat: <i>Cancer Research and Treatment</i> <br/> Chin J Lung Cancer: <i>Chinese Journal of Lung Cancer</i> <br/> Chinese J Clin Onc: <i>Chinese Journal of Clinical Oncology</i> <br/> Clin Cancer Res: <i>Clinical Cancer Research</i> <br/> Eur J Cancer: <i>European Journal of Cancer</i> <br/> Int J Clin Exp Med: <i>International Journal of Clinical and Experimental Medicine</i> <br/> J Thor Oncol: <i>Journal of Thoracic Oncology</i> <br/> JCO: <i>Journal of Clinical Oncology</i> <br/> Natl Med J China: <i>National Medical Journal of China</i> <br/> NMEJ: <i>New England Journal of Medicine</i> <br/> Pathol Oncol Res: <i>Pathology and Oncology Research</i> </p> </div> </div> <p>The duration of gefitinib therapy varied between studies. Most studies continued therapy until there was disease progression, unacceptable toxicity or withdrawal. Two studies administered gefitinib for six or eight weeks (<a href="./references#CD006847-bbs2-0003" title="ChenYM , LiuJM , ChouTY , PerngRP , TsaiCM , Whang‐PengJ . Phase II randomized study of daily gefitinib treatment alone or with vinorelbine every 2 weeks in patients with adenocarcinoma of the lung who failed at least 2 regimens of chemotherapy. Cancer2007;109(9):1821‐8. ">Chen 2007</a>; <a href="./references#CD006847-bbs2-0026" title="DesGuetzG , LandreT , WesteelV , MilleronB , VayletF , UrbanT , et al. Similar survival rates with first‐line gefitinib, gemcitabine or docetaxel in a randomized phase II trial in elderly patients with advanced non‐small cell lung cancer and a poor performance status (IFCT‐0301). Journal of Geriatric Oncology2015;6:233‐40. MorereJ , WesteelV , MorinF , et al. Randomized phase II trial of first‐line gefitinib,gemcitabine or docetaxel in performance status (PS) 2 or 3 non‐small‐cell lung cancer (NSCLC) patients (IFCT‐0301) [abstract no. 8086]. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2008;26(15 Suppl Pt I):445. MorereJF , BrechotJM , WesteelV , GounantV , LebeauB , VayletF , et al. Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non‐small‐cell lung cancer and a performance status of  2 or 3 (IFCT‐0301 study). Lung Cancer2010;70(1):301‐7. ">Morere 2010 IFCT‐0301</a>). The shortest reported median duration of treatment was 50 days (<a href="./references#CD006847-bbs2-0012" title="GossG , FerryD , WierzibickiR , LaurieSA , ThompsonJ , BiesmaB , et al. Randomized phase II study of gefitinib compared with placebo in chemotherapy‐naive patients with advanced non‐small‐cell lung cancer and poor performance status. Journal of Clinical Oncology2009;27(13):2253‐60. ">Goss 2009 INSTEP</a>) and the longest 308 days (<a href="./references#CD006847-bbs2-0022" title="FukuharaT , MaemondoM , InoueA , KobayashiK , SugawaraS , OizumiS , et al. Factors associated with a poor response to gefitinib in the NEJ002 study: smoking and the L858R mutation. Lung Cancer2015;88:181‐6. InoueA , KobayashiK , MaemondoM , SugawaraS , OizumiS , IsobeH , et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin‐paclitaxel for chemo‐naive non‐small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Annals of Oncology. United Kingdom: Oxford University Press (Great Clarendon Street, Oxford OX2 6DP, United Kingdom), 2013; Vol. 24:54‐9. InoueA , KobayashiK , MaemondoM , et al. A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first‐line treatment of non‐small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 study. European Journal of Cancer. 2009:Abstract 9LBA. MaemondoM , InoueA , KobayashiK , SugawaraS , OizumiS , IsobeH , et al. Gefitinib or chemotherapy for non‐small‐cell lung cancer with mutated EGFR. New England Journal of Medicine2010;362(25):2380‐8. MiyauchiE , InoueA , KobayashiK , MaemondoM , SugawaraS , OizumiS , et al. Efficacy of chemotherapy after first‐line gefitinib therapy in EGFR mutation‐positive advanced non‐small cell lung cancer ‐ data from a randomized phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002). Japanese Journal of Clinical Oncology2015;45(7):670‐6. OizumiS , KobayashiK , InoueA , MaemondoM , SugawaraS , YoshizawaH , et al. Quality of life with gefitinib in patients with EGFR‐mutated non‐small cell lung cancer: quality of life analysis of North East Japan study group 002 trial. Oncologist. United States: AlphaMed Press (318 Blackwell St. Suite 260, Durham NC 27701‐2884, United States), 2012; Vol. 17:863‐70. YoshizawaH , KobayashiK , InoueA , MaemondoM , SugawaraS , OizumiS , et al. QOL analysis from NEJ 002 study comparing gefitinib to chemotherapy for non‐small cell lung cancer with mutated EGFR. 35th ESMO Congress Milan Italy. Oxford University Press, 2010; Vol. 21:viii122. ">Maemondo 2010 NEJ002</a>). </p> <p>Please refer to the <a href="./references#CD006847-sec-0141" title="">Characteristics of included studies</a> for full details of included studies. Study characteristics have also been summarised in <a href="#CD006847-tbl-0004">Table 1</a>. </p> <p>The various comparisons can be seen in the <a href="./references#CD006847-sec-0129" title="">Data and analyses</a> section. </p> <section id="CD006847-sec-0060"> <h5 class="title">1. Gefitinib at any dose compared with placebo or best supportive care for NSCLC</h5> <p> <ul id="CD006847-list-0016"> <li> <p><i>General population (Comparison 1)</i> </p> </li> </ul> </p> <p>Three phase III studies (<a href="./references#CD006847-bbs2-0010" title="GaafarR M , SurmontV , ScagliottiG , VanKlaverenR , PapamichaelD , WelchJ , et al. A double‐blind, randomized, placebo‐controlled phase III intergroup study of gefitinib (G) in patients (pts) with advanced NSCLC, non‐progressing after first‐line platinum‐based chemotherapy (EORTC 08021‐ILCP 01/03). 2010 Annual Meeting of the Americal Society of CLinical Oncology, ASCO, Chicago, IL United States. American Society of Clinical Oncology, 2010; Vol. 28. GaafarRM , SurmontVF , ScagliottiGV , VanKlaverenRJ , PapamichaelD , WelchJJ , et al. A double‐blind, randomised, placebo‐controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non‐progressing after first line platinum‐based chemotherapy (EORTC 08021/ILCP 01/03). European Journal of Cancer2011;47:2331‐40. SurmontVF , GaafarRM , ScagliottiGV , VanKlaverenRJ , PapamichaelD , HasanB , et al. A double‐blind, randomized, placebo‐controlled phase III study of gefitinib (G) versus placebo (P) in patients (pts) with advanced NSCLC, non progressing after first‐line platinum‐based chemotherapy (EORTC 08021‐ ILCP). 35th ESMO Congress Milan Italy. Oxford University Press, 2010; Vol. 21:viii124. ">Gaafar 2011 EORTC08021</a>; <a href="./references#CD006847-bbs2-0015" title="KellyK , ChanskyK , GasparLE , AlbainKS , JettJ , UngYC , et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non‐small‐cell lung cancer: SWOG S0023. Journal of Clinical Oncology2008;26(15):2450‐6. [SWOG S0023] KellyK , GasparLE , ChanskyK , AlbainKS , CrowleyJ , GandaraDR . Low incidence of pneumonitis on SWOG 0023: A preliminary analysis of an ongoing phase III trial of concurrent chemoradiotherapy followed by consolidation docetaxel and Iressa/placebo maintenance in patients with inoperable stage III non‐small cell lung cancer [abstract]. 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, 13‐17 May, 2005 (Abstract No. 7058). 2005; Vol. 23:634. ">Kelly 2008 SWOG S0023</a>; <a href="./references#CD006847-bbs2-0030" title="ChangA , ParikhP , ThongprasertS , TanEH , PerngRP , GanzonD , et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non‐small cell lung cancer: subset analysis from the ISEL study. Journal of Thoracic Oncology2006;1(8):847‐55. HirschFR , DziadziuszkoR , ThatcherN , MannH , WatkinsC , ParumsDV , et al. Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo‐controlled study in advanced non small‐cell lung cancer. Cancer2008;112(5):1114‐21. HirschFR , Varella‐GarciaM , Bunn JrPA , FranklinWA , DziadziuszkoR , ThatcherN , et al. Molecular predictors of outcome with gefitinib in a phase III placebo‐controlled study in advanced non‐small cell lung cancer. Journal of Clinical Oncology2006;24(31):5034‐42. ThatcherN , ChangA , ParikhP , Rodrigues PereiraJ , CiuleanuT , vonPawelJ , et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non‐small‐cell lung cancer: results from a randomised, placebo‐controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet2005;366(9496):1527‐37. ">Thatcher 2005 ISEL</a>) and a single phase II study (<a href="./references#CD006847-bbs2-0012" title="GossG , FerryD , WierzibickiR , LaurieSA , ThompsonJ , BiesmaB , et al. Randomized phase II study of gefitinib compared with placebo in chemotherapy‐naive patients with advanced non‐small‐cell lung cancer and poor performance status. Journal of Clinical Oncology2009;27(13):2253‐60. ">Goss 2009 INSTEP</a>) compared gefitinib with placebo. The ISEL (<a href="./references#CD006847-bbs2-0030" title="ChangA , ParikhP , ThongprasertS , TanEH , PerngRP , GanzonD , et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non‐small cell lung cancer: subset analysis from the ISEL study. Journal of Thoracic Oncology2006;1(8):847‐55. HirschFR , DziadziuszkoR , ThatcherN , MannH , WatkinsC , ParumsDV , et al. Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo‐controlled study in advanced non small‐cell lung cancer. Cancer2008;112(5):1114‐21. HirschFR , Varella‐GarciaM , Bunn JrPA , FranklinWA , DziadziuszkoR , ThatcherN , et al. Molecular predictors of outcome with gefitinib in a phase III placebo‐controlled study in advanced non‐small cell lung cancer. Journal of Clinical Oncology2006;24(31):5034‐42. ThatcherN , ChangA , ParikhP , Rodrigues PereiraJ , CiuleanuT , vonPawelJ , et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non‐small‐cell lung cancer: results from a randomised, placebo‐controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet2005;366(9496):1527‐37. ">Thatcher 2005 ISEL</a>), INSTEP (<a href="./references#CD006847-bbs2-0012" title="GossG , FerryD , WierzibickiR , LaurieSA , ThompsonJ , BiesmaB , et al. Randomized phase II study of gefitinib compared with placebo in chemotherapy‐naive patients with advanced non‐small‐cell lung cancer and poor performance status. Journal of Clinical Oncology2009;27(13):2253‐60. ">Goss 2009 INSTEP</a>), EORTC 08021 (<a href="./references#CD006847-bbs2-0010" title="GaafarR M , SurmontV , ScagliottiG , VanKlaverenR , PapamichaelD , WelchJ , et al. A double‐blind, randomized, placebo‐controlled phase III intergroup study of gefitinib (G) in patients (pts) with advanced NSCLC, non‐progressing after first‐line platinum‐based chemotherapy (EORTC 08021‐ILCP 01/03). 2010 Annual Meeting of the Americal Society of CLinical Oncology, ASCO, Chicago, IL United States. American Society of Clinical Oncology, 2010; Vol. 28. GaafarRM , SurmontVF , ScagliottiGV , VanKlaverenRJ , PapamichaelD , WelchJJ , et al. A double‐blind, randomised, placebo‐controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non‐progressing after first line platinum‐based chemotherapy (EORTC 08021/ILCP 01/03). European Journal of Cancer2011;47:2331‐40. SurmontVF , GaafarRM , ScagliottiGV , VanKlaverenRJ , PapamichaelD , HasanB , et al. A double‐blind, randomized, placebo‐controlled phase III study of gefitinib (G) versus placebo (P) in patients (pts) with advanced NSCLC, non progressing after first‐line platinum‐based chemotherapy (EORTC 08021‐ ILCP). 35th ESMO Congress Milan Italy. Oxford University Press, 2010; Vol. 21:viii124. ">Gaafar 2011 EORTC08021</a>) and SWOGS0023 (<a href="./references#CD006847-bbs2-0015" title="KellyK , ChanskyK , GasparLE , AlbainKS , JettJ , UngYC , et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non‐small‐cell lung cancer: SWOG S0023. Journal of Clinical Oncology2008;26(15):2450‐6. [SWOG S0023] KellyK , GasparLE , ChanskyK , AlbainKS , CrowleyJ , GandaraDR . Low incidence of pneumonitis on SWOG 0023: A preliminary analysis of an ongoing phase III trial of concurrent chemoradiotherapy followed by consolidation docetaxel and Iressa/placebo maintenance in patients with inoperable stage III non‐small cell lung cancer [abstract]. 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, 13‐17 May, 2005 (Abstract No. 7058). 2005; Vol. 23:634. ">Kelly 2008 SWOG S0023</a>) trials examined survival outcomes, objective response rates and toxicity in the general population. The INSTEP study randomised chemotherapy‐naive patients to 250 mg of gefitinib or placebo as first‐line therapy. The ISEL study studied its effects as second‐line therapy in advanced NSCLC. Detailed subgroup analysis was conducted in the ISEL population and subsequently published. These two studies are also presented below as subgroup analyses (<a href="./references#CD006847-bbs2-0059" title="ChangA , ParikhP , ThongprasertS , TanEH , PerngRP , GanzonD , et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non‐small‐cell lung cancer: Subset analysis from the ISEL study. Journal of Thoracic Oncology2006;1(8):847‐55. ">Chang 2006</a>; <a href="./references#CD006847-bbs2-0065" title="HirschFR , Varella‐GarciaM , Bunn JrPA , FranklinWA , DziadziuszkoR , ThatcherN , et al. Molecular predictors of outcome with gefitinib in a phase III placebo‐controlled study in advanced non‐small cell lung cancer. Journal of Clinical Oncology2006;24(31):5034‐42. ">Hirsch 2006</a>). Subgroups were assessed for evidence by subgroup interactions, thus ensuring that outcomes were indeed different. Pre‐planned subgroup analysis of patients of Asian ethnicity was presented in <a href="./references#CD006847-bbs2-0059" title="ChangA , ParikhP , ThongprasertS , TanEH , PerngRP , GanzonD , et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non‐small‐cell lung cancer: Subset analysis from the ISEL study. Journal of Thoracic Oncology2006;1(8):847‐55. ">Chang 2006</a> and analysis of molecular predictors of outcome was presented in <a href="./references#CD006847-bbs2-0065" title="HirschFR , Varella‐GarciaM , Bunn JrPA , FranklinWA , DziadziuszkoR , ThatcherN , et al. Molecular predictors of outcome with gefitinib in a phase III placebo‐controlled study in advanced non‐small cell lung cancer. Journal of Clinical Oncology2006;24(31):5034‐42. ">Hirsch 2006</a>. The SWOGS0023 and EORTC08021 studies assessed the effect of gefitinib versus placebo as maintenance therapy after initial treatment. In the SWOG study, patients were included after receiving concurrent cisplatin/etoposide chemotherapy with thoracic radiation (45 Gy, 1.8 Gy per fraction). The EORTC08021 trial included patients not progressing after first‐line platinum doublet chemotherapy. We studied a total of 2605 patients in this group. </p> <p> <ul id="CD006847-list-0017"> <li> <p><i>Asian population (Comparison 2)</i> </p> </li> </ul> </p> <p>The INFORM study assessed the use of gefitinib as maintenance therapy in an East Asian patient group (<a href="./references#CD006847-bbs2-0035" title="YangY , MaY , ZhaoY , FangW , HongS , et al. QoL analyses from INFORM study, a phase III study of gefitinib versus placebo as maintenance therapy in advanced NSCLC. Scientific Reports2015;5:11934. ZhangL , MaS , SongX , HanB , ChengY , HuangC , et al. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non‐small‐cell lung cancer (INFORM; C‐TONG 0804): a multicentre, double‐blind randomised phase 3 trial. Lancet Oncology2012;13:466‐75. ZhangL , MaSL , SongXQ , ChengY , HuangC , YangSJ , et al. Pre‐planned subgroup analyses from the phase III, randomised, placebo‐controlled, parallel‐group study of gefitinib (G) as maintenance therapy in patients (pts) with locally advanced or metastatic non‐small‐cell lung cancer (NSCLC) (INFORM; C‐TONG 0804). European Multidisciplinary Cancer Congress Stockholm Sweden. Elsevier Ltd, 2011; Vol. 47:S622‐3. ZhangL , MaSL , SongXQ , HanBH , ChengY , HuangC , et al. Efficacy, tolerability and biomarker analyses from a phase III, randomized, placebo controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non‐small‐cell lung cancer (NSCLC) in China (INFORM) (C‐TONG 0804). 14th World Conference on Lung Cancer Amsterdam Netherlands. International Association for the Study of Lung Cancer, 2011; Vol. 6:S558‐9. ZhangL , ShenglinM , SongX , HanB , ChengY , HuangC , et al. Efficacy, tolerability, and biomarker analyses from a phase III, randomized, placebo‐controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non‐small cell lung cancer (NSCLC; INFORM; C‐TONG 0804). ASCO Annual Meeting 2011 Chicago, IL United States. American Society of Clinical Oncology, 2011; Vol. 29. ZhaoH , FanY , MaS , SongX , HanB , ChengY , et al. Final overall survival results from a phase III, randomized placebo‐controlled, parallel‐group study of gefitinib versus placebo as maintenance therapy in patients with advanced or metastatic non‐small‐cell lung cancer (INFORM; C‐TONG 0804). Journal of Thoracic Oncology2015;10(4):655‐64. ">Zhang 2012 INFORM</a>). These patients had achieved disease control after first‐line platinum‐based chemotherapy. <a href="./references#CD006847-bbs2-0059" title="ChangA , ParikhP , ThongprasertS , TanEH , PerngRP , GanzonD , et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non‐small‐cell lung cancer: Subset analysis from the ISEL study. Journal of Thoracic Oncology2006;1(8):847‐55. ">Chang 2006</a> selected only ISEL patients who were of Asian ethnicity. This subgroup represented 20% of the original ISEL population, a total of 342 patients. We included a total of 638 patients in this group. </p> <p> <ul id="CD006847-list-0018"> <li> <p><i>EGFR mutation positive population (Comparison 3)</i> </p> </li> </ul> </p> <p><a href="./references#CD006847-bbs2-0035" title="YangY , MaY , ZhaoY , FangW , HongS , et al. QoL analyses from INFORM study, a phase III study of gefitinib versus placebo as maintenance therapy in advanced NSCLC. Scientific Reports2015;5:11934. ZhangL , MaS , SongX , HanB , ChengY , HuangC , et al. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non‐small‐cell lung cancer (INFORM; C‐TONG 0804): a multicentre, double‐blind randomised phase 3 trial. Lancet Oncology2012;13:466‐75. ZhangL , MaSL , SongXQ , ChengY , HuangC , YangSJ , et al. Pre‐planned subgroup analyses from the phase III, randomised, placebo‐controlled, parallel‐group study of gefitinib (G) as maintenance therapy in patients (pts) with locally advanced or metastatic non‐small‐cell lung cancer (NSCLC) (INFORM; C‐TONG 0804). European Multidisciplinary Cancer Congress Stockholm Sweden. Elsevier Ltd, 2011; Vol. 47:S622‐3. ZhangL , MaSL , SongXQ , HanBH , ChengY , HuangC , et al. Efficacy, tolerability and biomarker analyses from a phase III, randomized, placebo controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non‐small‐cell lung cancer (NSCLC) in China (INFORM) (C‐TONG 0804). 14th World Conference on Lung Cancer Amsterdam Netherlands. International Association for the Study of Lung Cancer, 2011; Vol. 6:S558‐9. ZhangL , ShenglinM , SongX , HanB , ChengY , HuangC , et al. Efficacy, tolerability, and biomarker analyses from a phase III, randomized, placebo‐controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non‐small cell lung cancer (NSCLC; INFORM; C‐TONG 0804). ASCO Annual Meeting 2011 Chicago, IL United States. American Society of Clinical Oncology, 2011; Vol. 29. ZhaoH , FanY , MaS , SongX , HanB , ChengY , et al. Final overall survival results from a phase III, randomized placebo‐controlled, parallel‐group study of gefitinib versus placebo as maintenance therapy in patients with advanced or metastatic non‐small‐cell lung cancer (INFORM; C‐TONG 0804). Journal of Thoracic Oncology2015;10(4):655‐64. ">Zhang 2012 INFORM</a> performed planned subgroup analysis on EGFR mutation positive patients and 30 of 79 (38%) tissue tumour samples were positive for EGFR mutations. <a href="./references#CD006847-bbs2-0065" title="HirschFR , Varella‐GarciaM , Bunn JrPA , FranklinWA , DziadziuszkoR , ThatcherN , et al. Molecular predictors of outcome with gefitinib in a phase III placebo‐controlled study in advanced non‐small cell lung cancer. Journal of Clinical Oncology2006;24(31):5034‐42. ">Hirsch 2006</a> analysed ISEL tumour biopsy samples to examine the relationships between biomarkers and clinical outcome after gefitinib administration. Two‐hundred and fifteen of 1692 patients (12.7%) in the ISEL trial were assessable for mutation detection. Of these, 26 (12.1%) patients were positive for EGFR mutations. Other biomarkers examined included EGFR gene copy number, EGFR and p‐Akt protein expression and KRAS and BRAF mutations. Data from these other biomarkers are beyond the scope of this review. </p> </section> <section id="CD006847-sec-0061"> <h5 class="title">2. Gefitinib at any dose compared with other chemotherapeutic agents</h5> <p>We included 18 primary studies in this analysis (<a href="./references#CD006847-bbs2-0001" title="AhnMJ , YangJCH , LiangJ , KangJH , XiuQ , ChenYM , et al. Randomized phase II trial of first‐line treatment with pemetrexed‐cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never‐smoker patients with advanced non‐small cell lung cancer. Lung Cancer2012;77:346‐52. ">Ahn 2012</a>; <a href="./references#CD006847-bbs2-0006" title="CrinoL , CappuzzoF , ZatloukalP , ReckM , PesekM , ThompsonJC , et al. Gefitinib versus vinorelbine in chemotherapy‐naive elderly patients with advanced non‐small‐cell lung cancer (INVITE): a randomized, phase II study. Journal of Clinical Oncology2008;26(26):4253‐60. ">Crino 2008 INVITE</a>; <a href="./references#CD006847-bbs2-0007" title="CuferT , VrdoljakE , GaafarR , ErensoyI , PembertonK , SIGN study group. Phase II, open‐label, randomized study (SIGN) or single‐agent gefitinib (IRESSA) or docetaxel as second‐line therapy in patients with advanced (stage IIIb or IV) non‐small‐cell lung cancer. Anticancer Drugs2006;17(4):401‐9. ">Cufer 2006 SIGN</a>; <a href="./references#CD006847-bbs2-0008" title="DaiH , XuL , XiaC , ChenW . A randomized clinical study of gefitinib and pemetrexed as second line therapy for advanced non‐squamous non‐small cell lung cancer. Chinese Journal of Lung Cancer2013;16:405‐10. ">Dai 2013</a>; <a href="./references#CD006847-bbs2-0013" title="HanJY , ParkK , KimSW , LeeDH , KimHY , KimHT , et al. First‐SIGNAL: first‐line single‐agent Iressa versus gemcitabine and cisplatin trial in never‐smokers with adenocarcinoma of the lung. Journal of Clinical Oncology2012;30:1122‐8. HanJY , YoonKA , ParkJH , LeeYJ , LeeGK , HanJH , et al. DNA repair gene polymorphisms and benefit from gefitinib in never‐smokers with lung adenocarcinoma. Cancer2011;117(14):3201‐8. ">Han 2012 First SIGNAL</a>; <a href="./references#CD006847-bbs2-0016" title="DouillardJY , ShephardFA , HirshV , MokT , SocinskiMA , GervaisR , et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non‐small‐cell lung cancer: from the randomized phase III INTEREST Trial. Journal of Clinical Oncology2010;28(5):744‐52. HorganAM , BradburyPA , AmirE , NgR , DouillardJY , KimES , et al. An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second‐/third‐line therapy in advanced non‐small‐cell lung cancer. Annals of Oncology. United Kingdom: Oxford University Press (Great Clarendon Street, Oxford OX2 6DP, United Kingdom), 2011; Vol. 22:1805‐11. HorganAM , ShepherdFA , BradburyPA , NgR , LeighlNB . Preliminary cost‐consequence analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as 2nd line therapy in advanced non‐small cell lung cancer [abstract no. 8110]. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2008;25(15 Suppl Pt 1):451. KimES , HirshV , MokT , SocinskiMA , GervaisR , WuYL , et al. Gefitinib versus docetaxel in previously treated non‐small‐cell lung cancer (INTEREST): a randomized phase III trial. Lancet2008;372:1809‐18. ">Kim 2008 INTEREST</a>; <a href="./references#CD006847-bbs2-0017" title="KimYS , ChoEK , WooHS , HongJ , AhnHK , ParkI , et al. Randomized phase II study of pemetrexed versus gefitinib in previously treated patients with advanced non‐small cell lung cancer. Cancer Research and Treatment2016;48(1):80‐7. ">Kim 2016</a>; <a href="./references#CD006847-bbs2-0019" title="LeeD , KimS , ParkK , et al. A randomized open‐label study of gefitinib versus docetaxel in patients with advanced/metastatic non‐small cell lung cancer (NSCLC) who have previously received platinum‐based chemotherapy [abstract no. 8025]. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2008;26(15 Suppl Pt I):430. LeeDH , ParkK , KimJH , LeeJS , ShinSW , KangJH , et al. Randomized phase III trial of gefitinib versus docetaxel in non‐small‐cell lung cancer patients who have previously received platinum‐based chemotherapy. Clinical Cancer Research2010;16(4):1307‐14. [ISTANA] ">Lee 2010 ISTANA</a>; <a href="./references#CD006847-bbs2-0020" title="LiH , WangX , HuaF . Second‐line treatment with gefitinib or docetaxel for advanced non‐small cell lung cancer. Chinese Journal of Clinical Oncology2010;37:16‐8. ">Li 2010</a>; <a href="./references#CD006847-bbs2-0021" title="LouN , YangJ , YanH , QingZ , LiaoR , XuC , et al. Efficacies of gefitinib versus paclitaxel/carboplatin for patients with advanced pulmonary adenocarcinoma. National Medical Journal of China2014;94(30):2337‐41. ">Lou 2014</a>; <a href="./references#CD006847-bbs2-0022" title="FukuharaT , MaemondoM , InoueA , KobayashiK , SugawaraS , OizumiS , et al. Factors associated with a poor response to gefitinib in the NEJ002 study: smoking and the L858R mutation. Lung Cancer2015;88:181‐6. InoueA , KobayashiK , MaemondoM , SugawaraS , OizumiS , IsobeH , et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin‐paclitaxel for chemo‐naive non‐small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Annals of Oncology. United Kingdom: Oxford University Press (Great Clarendon Street, Oxford OX2 6DP, United Kingdom), 2013; Vol. 24:54‐9. InoueA , KobayashiK , MaemondoM , et al. A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first‐line treatment of non‐small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 study. European Journal of Cancer. 2009:Abstract 9LBA. MaemondoM , InoueA , KobayashiK , SugawaraS , OizumiS , IsobeH , et al. Gefitinib or chemotherapy for non‐small‐cell lung cancer with mutated EGFR. New England Journal of Medicine2010;362(25):2380‐8. MiyauchiE , InoueA , KobayashiK , MaemondoM , SugawaraS , OizumiS , et al. Efficacy of chemotherapy after first‐line gefitinib therapy in EGFR mutation‐positive advanced non‐small cell lung cancer ‐ data from a randomized phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002). Japanese Journal of Clinical Oncology2015;45(7):670‐6. OizumiS , KobayashiK , InoueA , MaemondoM , SugawaraS , YoshizawaH , et al. Quality of life with gefitinib in patients with EGFR‐mutated non‐small cell lung cancer: quality of life analysis of North East Japan study group 002 trial. Oncologist. United States: AlphaMed Press (318 Blackwell St. Suite 260, Durham NC 27701‐2884, United States), 2012; Vol. 17:863‐70. YoshizawaH , KobayashiK , InoueA , MaemondoM , SugawaraS , OizumiS , et al. QOL analysis from NEJ 002 study comparing gefitinib to chemotherapy for non‐small cell lung cancer with mutated EGFR. 35th ESMO Congress Milan Italy. Oxford University Press, 2010; Vol. 21:viii122. ">Maemondo 2010 NEJ002</a>; <a href="./references#CD006847-bbs2-0023" title="LekiR , KawaharaM , WatanabeH , et al. The impact of response evaluation committee in a Phase III study (V‐15‐32) of gefitinib versus docetaxel in Japanese patients with non‐small cell lung cancer [Abstract No. 298P]. Annals of Oncology2009;19 Suppl 8:109‐10. MaruyamaR , NishiwakiY , TamuraT , YamamotoN , TsuboiM , NakagawaK , et al. Phase III study, V‐15‐32, of gefitinib versus docetaxel in previously treated Japanese patients with non‐small‐cell lung cancer. Journal of Clinical Oncology2008;26(26):4245‐52. SekineI , IchinoseY , NishiwakiY , YamamotoN , TsuboiM , NakagawaK , et al. Quality of life and disease‐related symptoms in previously treated Japanese patients with non‐small‐cell lung cancer: results of a randomized phase III study (V‐15‐32) of gefitinib versus docetaxel. Annals of Oncology2009;20(9):1483‐8. YamamotoN , NishiwakiY , NegoroS , JiangH , ItohY , SaijoN , et al. Disease control as a predictor of survival with gefitinib and docetaxel in a phase III study (V‐15‐32) in advanced non‐small‐cell lung cancer patients. Journal of Thoracic Oncology2010;5(7):1042‐7. ">Maruyama 2008 V‐15‐32</a>; <a href="./references#CD006847-bbs2-0024" title="MitsudomiT , MoritaS , YatabeY , NegoroS , OkamotoI , SetoT , et al. Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first‐line treatment for patients with non‐small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR). 2012 Annual Meeting of the American Society of Clinical Oncology, ASCO Chicago, IL United States. American Society of Clinical Oncology, 2012; Vol. 30. MitsudomiT , MoritaS , YatabeY , NegoroS , OkamotoI , TsurutaniJ , et al. Gefitinib versus cisplatin plus docetaxel in patients with non‐small‐cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase III trial. Lancet2010;11:121‐8. TsurutaniJ , MitsudomiT , MoriS , OkamotoI , NozakiK , TadaH , et al. A phase III, first‐line trial of gefitinib versus cisplatin plus docetaxel for patients with advanced or recurrent non‐small cell lung cancer (NSCLC) harboring activating mutation of the epidermal growth factor receptor (EGFR) gene: a preliminary results of WJTOG 3405 [abstract O‐9002]. European Journal of Cancer. 2009; Vol. 7 Suppl:505. ">Mitsudomi 2010 WJTOG3405</a>; <a href="./references#CD006847-bbs2-0025" title="FukuokaM , WuYL , ThongprasertS , SunpaweravongP , LeongSS , SriuranpongV , et al. Biomarker analyses and final overall survival results from a phase III, randomized, open‐label, first‐line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non ‐ small‐cell lung cancer in Asia (IPASS). Journal of Clinical Oncology2011;29:2866‐74. MokT , WuY‐L , ThongprasertS , et al. Phase III, randomised, open‐label, first‐line study of gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients (PTS) with advanced non‐small cell lung cancer (NSCLC) (IPASS). Annals of Oncology2008;19 Suppl 8:Viii1. MokTS , WuYL , ThongprasertS , YangCH , ChuDT , SaijoN , et al. Gefitinib or carboplatin‐paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine2009;361(10):947‐57. OheY , IchinoseY , NishiwakiY ,  etal . Phase III, randomized, open‐label, first‐line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in selected patients (pts) with advanced non‐small‐cell lung cancer (NSCLC) (IPASS): Evaluation of recruits in Japan. Journal of Clinical Oncology2009;29(15 Suppl 1):8044. ThongprasertS , DuffieldE , SaijoN , WuYL , YangJC , ChuDT , et al. Health‐related quality‐of‐life in a randomized phase III first‐line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). Journal of Thoracic Oncology2011;6:1872‐80. ThongprasertS , DuffieldE , WuY , et al. Quality of life (QOL) in a randomized phase III first‐line study of gefitinib (G) vs carboplatin/paclitaxel (CP) in clinically selected Asian patients (pts) with advanced NSCLC (IPASS). Journal of Thoracic Oncology2010;5(5 Suppl 1):S80. WuY , ChuD , HanB , LiuX , ZhangL , ZhouC , et al. Phase III, randomized, open‐label, first‐line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non‐small‐cell lung cancer: evaluation of patients recruited from mainland China. Asia‐Pacific Journal of Clinical Oncology2012;8:232‐43. WuY , FukuokaM , MokT S K , SaijoN , ThongprasertS , YangJ C H , et al. Tumour response, skin rash and health‐related quality of life (HRQOL) ‐ Post‐HOC data from the IPASS study. European Multidisciplinary Cancer Congress Stockholm Sweden. Elsevier Ltd, 2011; Vol. 47:S633‐4. WuY , MokT , ChuD , et al. Evaluation of clinically selected patients (pts) with advanced non‐small cell lung cancer (NSCLC) recruited in China in a phase III, randomized, open‐label, first‐line study in Asia of gefitinib (G) versus carboplatin/paclitaxel (C/P) (IPASS). Journal of Clinical Oncology. 2009; Vol. 27 (15 Suppl 1):8041. WuYL , FukuokaM , MokTSK , SaijoN , ThongprasertS , YangJCH , et al. Tumor response and health‐related quality of life in clinically selected patients from Asia with advanced non‐small‐cell lung cancer treated with first‐line gefitinib: post hoc analyses from the IPASS study. Lung Cancer2013;81:280‐7. YangCH , FukuokaM , MokTS , WuYL , ThongprasertS , SaijoN , et al. Final overall survival (OS) results from a phase III, randomised, open‐label, first‐line study of gefitinib (G) v carboplatin/paclitaxel (C/P) in clinically selected patients with advanced nonsmall cell lung cancer (NSCLC) in Asia (IPASS). 35th ESMO Congress Milan Italy. Oxford University Press, 2010; Vol. 21:viii1‐2. YangJ , WuY L , SaijoN , ThongprasertS , ChuD T , ChenY M , et al. Efficacy outcomes in first‐line treatment of advanced NSCLC with gefitinib (G) vs carboplatin/paclitaxel (C/P) by epidermal growth factor receptor (EGFR) gene‐copy number score and by most common EGFR mutation subtypes ‐ Exploratory data from IPASS. 2011 European Multidisciplinary Cancer Congress Stockholm Sweden. Elsevier Ltd, 2011; Vol. 47:S633. YangJ , WuY , ChanV , KurniandaJ , NakagawaK . Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan‐ASia Study (IPASS). Lung Cancer2014;83:174‐81. YangJCH , WuYL , ChanV , KurniandaJ , NakagawaK , SaijoN , et al. Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan‐ASia Study (IPASS). Lung Cancer2014;83:174‐81. ">Mok 2009 IPASS</a>; <a href="./references#CD006847-bbs2-0026" title="DesGuetzG , LandreT , WesteelV , MilleronB , VayletF , UrbanT , et al. Similar survival rates with first‐line gefitinib, gemcitabine or docetaxel in a randomized phase II trial in elderly patients with advanced non‐small cell lung cancer and a poor performance status (IFCT‐0301). Journal of Geriatric Oncology2015;6:233‐40. MorereJ , WesteelV , MorinF , et al. Randomized phase II trial of first‐line gefitinib,gemcitabine or docetaxel in performance status (PS) 2 or 3 non‐small‐cell lung cancer (NSCLC) patients (IFCT‐0301) [abstract no. 8086]. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2008;26(15 Suppl Pt I):445. MorereJF , BrechotJM , WesteelV , GounantV , LebeauB , VayletF , et al. Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non‐small‐cell lung cancer and a performance status of  2 or 3 (IFCT‐0301 study). Lung Cancer2010;70(1):301‐7. ">Morere 2010 IFCT‐0301</a>; <a href="./references#CD006847-bbs2-0028" title="AhnM , SunJ , AhnJS , KimS , MinYJ , YunHJ , et al. Randomized phase III trial of gefitinib or pemetrexed as second‐line treatment in patients with non‐small cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01). ASCO Annual Meeting 2011 Chicago, IL United States. American Society of Clinical Oncology, 2011; Vol. 29. AhnMJ , SunJM , LeeKH , AhnJS , KimSW , MinYJ , et al. Randomized phase III trial of gefitinib or pemetrexed as second‐line treatment in patients with non‐small cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01). 14th World Conference on Lung Cancer Amsterdam Netherlands. International Association for the Study of Lung Cancer, 2011; Vol. 6:S317. SunJM , LeeKH , KimSW , LeeDH , MinYJ , YunHJ , et al. Gefitinib versus pemetrexed as second‐line treatment in patients with nonsmall cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01): an open‐label, phase 3 trial. Cancer2012;118:6234‐42. ">Sun 2012 KCSG‐LU08‐01</a>; <a href="./references#CD006847-bbs2-0031" title="XuYH , MeiJS , ZhouJ . Randomized study of gefitinib versus pemetrexed as maintenance treatment in patients with advanced glandular non‐small cell lung cancer. International Journal of Clinical and Experimental Medicine2015;8(4):6242‐6. ">Xu 2015</a>; <a href="./references#CD006847-bbs2-0033" title="BoyeM , WangX , SrimuninnimitV , KangJH , TsaiCM , OrlandoM , et al. First‐line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian never‐smoker patients with locally advanced or metastatic nonsquamous non‐small cell lung cancer: quality of life results from a randomized phase III trial. Clinical Lung Cancer2016;17(2):150‐60. KangJH , AhnM , KimD , ChoEK , KimJ , ShinSW , et al. Tolerability and outcomes of first‐line pemetrexed‐cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in Korean patients with advanced non‐squamous non‐small cell lung cancer: a post hoc descriptive subgroup analysis of a randomized, phase 3 trial. Cancer Research and Treatment2015;48(2):458‐64. YangJC , KangJH , MokT , AhnM , SrimuninnimitV , LinC , et al. First‐line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non‐squamous non‐small cell lung cancer: a randomised, phase 3 trial. European Journal of Cancer2014;50:2219‐30. YangJC , ParkK , MokTSK , KangJH , SrimuninnimitV , LinCC , et al. A randomized phase 3 study comparing first‐line pemetrexed plus cisplatin followed by gefitinib as maintenance with gefitinib monotherapy in east Asian patients with locally advanced or metastatic nonsquamous non‐small cell lung cancer (NSQNSCLC). 15th World Conference on Lung Cancer Sydney, NSW Australia. International Association for the Study of Lung Cancer, 2013; Vol. 8:S288. YangJC , SrimuninnimitV , AhnM , LinC , KimS , TsaiC , et al. A randomized phase 3 study comparing first‐line pemetrexed plus cisplatin followed by gefitinib maintenance (PC/G) with gefitinib monotherapy (G) in East Asian patients (pts) with locally advanced or metastatic nonsquamous non‐small cell lung cancer (nSqNSCLC): final survival results. Journal of Clinical Oncology2015;15 Suppl:8041. YangJC , SrimunninnimitV , AhnM , LinC , KimS , TsaiC , et al. First‐line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian never‐smoker patients with locally advanced or metastatic nonsquamous non‐small cell lung cancer: final overall survival results from a randomized phase 3 study. Journal of Thoracic Oncology2016;11(3):370‐9. ">Yang 2014</a>). Nine of these studies were multicentre, randomised, phase III trials. </p> <p>These 18 primary studies randomised a total of 5400 patients.</p> <p> <ul id="CD006847-list-0019"> <li> <p><i>General population (Comparison 4)</i> </p> </li> </ul> </p> <p>Four studies, SIGN (<a href="./references#CD006847-bbs2-0007" title="CuferT , VrdoljakE , GaafarR , ErensoyI , PembertonK , SIGN study group. Phase II, open‐label, randomized study (SIGN) or single‐agent gefitinib (IRESSA) or docetaxel as second‐line therapy in patients with advanced (stage IIIb or IV) non‐small‐cell lung cancer. Anticancer Drugs2006;17(4):401‐9. ">Cufer 2006 SIGN</a>), INTEREST (<a href="./references#CD006847-bbs2-0016" title="DouillardJY , ShephardFA , HirshV , MokT , SocinskiMA , GervaisR , et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non‐small‐cell lung cancer: from the randomized phase III INTEREST Trial. Journal of Clinical Oncology2010;28(5):744‐52. HorganAM , BradburyPA , AmirE , NgR , DouillardJY , KimES , et al. An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second‐/third‐line therapy in advanced non‐small‐cell lung cancer. Annals of Oncology. United Kingdom: Oxford University Press (Great Clarendon Street, Oxford OX2 6DP, United Kingdom), 2011; Vol. 22:1805‐11. HorganAM , ShepherdFA , BradburyPA , NgR , LeighlNB . Preliminary cost‐consequence analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as 2nd line therapy in advanced non‐small cell lung cancer [abstract no. 8110]. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2008;25(15 Suppl Pt 1):451. KimES , HirshV , MokT , SocinskiMA , GervaisR , WuYL , et al. Gefitinib versus docetaxel in previously treated non‐small‐cell lung cancer (INTEREST): a randomized phase III trial. Lancet2008;372:1809‐18. ">Kim 2008 INTEREST</a>), INVITE (<a href="./references#CD006847-bbs2-0006" title="CrinoL , CappuzzoF , ZatloukalP , ReckM , PesekM , ThompsonJC , et al. Gefitinib versus vinorelbine in chemotherapy‐naive elderly patients with advanced non‐small‐cell lung cancer (INVITE): a randomized, phase II study. Journal of Clinical Oncology2008;26(26):4253‐60. ">Crino 2008 INVITE</a>) and IFCT‐0301 (<a href="./references#CD006847-bbs2-0026" title="DesGuetzG , LandreT , WesteelV , MilleronB , VayletF , UrbanT , et al. Similar survival rates with first‐line gefitinib, gemcitabine or docetaxel in a randomized phase II trial in elderly patients with advanced non‐small cell lung cancer and a poor performance status (IFCT‐0301). Journal of Geriatric Oncology2015;6:233‐40. MorereJ , WesteelV , MorinF , et al. Randomized phase II trial of first‐line gefitinib,gemcitabine or docetaxel in performance status (PS) 2 or 3 non‐small‐cell lung cancer (NSCLC) patients (IFCT‐0301) [abstract no. 8086]. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2008;26(15 Suppl Pt I):445. MorereJF , BrechotJM , WesteelV , GounantV , LebeauB , VayletF , et al. Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non‐small‐cell lung cancer and a performance status of  2 or 3 (IFCT‐0301 study). Lung Cancer2010;70(1):301‐7. ">Morere 2010 IFCT‐0301</a>), compared gefitinib with chemotherapy in 1888 patients and data from these are presented in Comparison 4. Two studies compared gefitinib with first‐line chemotherapy (<a href="./references#CD006847-bbs2-0006" title="CrinoL , CappuzzoF , ZatloukalP , ReckM , PesekM , ThompsonJC , et al. Gefitinib versus vinorelbine in chemotherapy‐naive elderly patients with advanced non‐small‐cell lung cancer (INVITE): a randomized, phase II study. Journal of Clinical Oncology2008;26(26):4253‐60. ">Crino 2008 INVITE</a>; <a href="./references#CD006847-bbs2-0026" title="DesGuetzG , LandreT , WesteelV , MilleronB , VayletF , UrbanT , et al. Similar survival rates with first‐line gefitinib, gemcitabine or docetaxel in a randomized phase II trial in elderly patients with advanced non‐small cell lung cancer and a poor performance status (IFCT‐0301). Journal of Geriatric Oncology2015;6:233‐40. MorereJ , WesteelV , MorinF , et al. Randomized phase II trial of first‐line gefitinib,gemcitabine or docetaxel in performance status (PS) 2 or 3 non‐small‐cell lung cancer (NSCLC) patients (IFCT‐0301) [abstract no. 8086]. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2008;26(15 Suppl Pt I):445. MorereJF , BrechotJM , WesteelV , GounantV , LebeauB , VayletF , et al. Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non‐small‐cell lung cancer and a performance status of  2 or 3 (IFCT‐0301 study). Lung Cancer2010;70(1):301‐7. ">Morere 2010 IFCT‐0301</a>) and the other two studies compared it with second‐line chemotherapy (<a href="./references#CD006847-bbs2-0007" title="CuferT , VrdoljakE , GaafarR , ErensoyI , PembertonK , SIGN study group. Phase II, open‐label, randomized study (SIGN) or single‐agent gefitinib (IRESSA) or docetaxel as second‐line therapy in patients with advanced (stage IIIb or IV) non‐small‐cell lung cancer. Anticancer Drugs2006;17(4):401‐9. ">Cufer 2006 SIGN</a>; <a href="./references#CD006847-bbs2-0016" title="DouillardJY , ShephardFA , HirshV , MokT , SocinskiMA , GervaisR , et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non‐small‐cell lung cancer: from the randomized phase III INTEREST Trial. Journal of Clinical Oncology2010;28(5):744‐52. HorganAM , BradburyPA , AmirE , NgR , DouillardJY , KimES , et al. An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second‐/third‐line therapy in advanced non‐small‐cell lung cancer. Annals of Oncology. United Kingdom: Oxford University Press (Great Clarendon Street, Oxford OX2 6DP, United Kingdom), 2011; Vol. 22:1805‐11. HorganAM , ShepherdFA , BradburyPA , NgR , LeighlNB . Preliminary cost‐consequence analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as 2nd line therapy in advanced non‐small cell lung cancer [abstract no. 8110]. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2008;25(15 Suppl Pt 1):451. KimES , HirshV , MokT , SocinskiMA , GervaisR , WuYL , et al. Gefitinib versus docetaxel in previously treated non‐small‐cell lung cancer (INTEREST): a randomized phase III trial. Lancet2008;372:1809‐18. ">Kim 2008 INTEREST</a>). 'Iressa in NSCLC versus Vinorelbine Investigation in the Elderly' (INVITE) was a randomised, multicentre, phase II trial that compared gefitinib with vinorelbine as first‐line therapy in elderly patients (<a href="./references#CD006847-bbs2-0006" title="CrinoL , CappuzzoF , ZatloukalP , ReckM , PesekM , ThompsonJC , et al. Gefitinib versus vinorelbine in chemotherapy‐naive elderly patients with advanced non‐small‐cell lung cancer (INVITE): a randomized, phase II study. Journal of Clinical Oncology2008;26(26):4253‐60. ">Crino 2008 INVITE</a>). IFCT‐0301 compared gefitinib, gemcitabine and docetaxel in chemotherapy‐naive patients with a performance status of 2 or 3 (<a href="./references#CD006847-bbs2-0026" title="DesGuetzG , LandreT , WesteelV , MilleronB , VayletF , UrbanT , et al. Similar survival rates with first‐line gefitinib, gemcitabine or docetaxel in a randomized phase II trial in elderly patients with advanced non‐small cell lung cancer and a poor performance status (IFCT‐0301). Journal of Geriatric Oncology2015;6:233‐40. MorereJ , WesteelV , MorinF , et al. Randomized phase II trial of first‐line gefitinib,gemcitabine or docetaxel in performance status (PS) 2 or 3 non‐small‐cell lung cancer (NSCLC) patients (IFCT‐0301) [abstract no. 8086]. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2008;26(15 Suppl Pt I):445. MorereJF , BrechotJM , WesteelV , GounantV , LebeauB , VayletF , et al. Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non‐small‐cell lung cancer and a performance status of  2 or 3 (IFCT‐0301 study). Lung Cancer2010;70(1):301‐7. ">Morere 2010 IFCT‐0301</a>). SIGN (Second‐line Indication of Gefitinib in NSCLC) was a phase II, randomised study comparing gefitinib with docetaxel as second‐line therapy (<a href="./references#CD006847-bbs2-0007" title="CuferT , VrdoljakE , GaafarR , ErensoyI , PembertonK , SIGN study group. Phase II, open‐label, randomized study (SIGN) or single‐agent gefitinib (IRESSA) or docetaxel as second‐line therapy in patients with advanced (stage IIIb or IV) non‐small‐cell lung cancer. Anticancer Drugs2006;17(4):401‐9. ">Cufer 2006 SIGN</a>). INTEREST (Iressa NSCLC Trial Evaluating Response and Survival again Taxotere) was a phase III trial, which assessed the non‐inferiority of gefitinib to docetaxel as second‐line therapy (<a href="./references#CD006847-bbs2-0016" title="DouillardJY , ShephardFA , HirshV , MokT , SocinskiMA , GervaisR , et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non‐small‐cell lung cancer: from the randomized phase III INTEREST Trial. Journal of Clinical Oncology2010;28(5):744‐52. HorganAM , BradburyPA , AmirE , NgR , DouillardJY , KimES , et al. An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second‐/third‐line therapy in advanced non‐small‐cell lung cancer. Annals of Oncology. United Kingdom: Oxford University Press (Great Clarendon Street, Oxford OX2 6DP, United Kingdom), 2011; Vol. 22:1805‐11. HorganAM , ShepherdFA , BradburyPA , NgR , LeighlNB . Preliminary cost‐consequence analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as 2nd line therapy in advanced non‐small cell lung cancer [abstract no. 8110]. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2008;25(15 Suppl Pt 1):451. KimES , HirshV , MokT , SocinskiMA , GervaisR , WuYL , et al. Gefitinib versus docetaxel in previously treated non‐small‐cell lung cancer (INTEREST): a randomized phase III trial. Lancet2008;372:1809‐18. ">Kim 2008 INTEREST</a>). <a href="./references#CD006847-bbs2-0060" title="DouillardJY , ShephardFA , HirshV , MokT , SocinskiMA , GervaisR , et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non‐small‐cell lung cancer: from the randomized phase III INTEREST trial. Journal of Clinical Oncology2010;28(5):744‐52. ">Douillard 2010</a> performed a preplanned secondary analysis to investigate the relationship between biomarkers and clinical outcomes in the INTEREST population. We included a total of 1888 patients in this group. </p> <p> <ul id="CD006847-list-0020"> <li> <p><i>Asian population (Comparison 5)</i> </p> </li> </ul> </p> <p>Fourteen studies selected Asian patients only (<a href="./references#CD006847-bbs2-0001" title="AhnMJ , YangJCH , LiangJ , KangJH , XiuQ , ChenYM , et al. Randomized phase II trial of first‐line treatment with pemetrexed‐cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never‐smoker patients with advanced non‐small cell lung cancer. Lung Cancer2012;77:346‐52. ">Ahn 2012</a>; <a href="./references#CD006847-bbs2-0008" title="DaiH , XuL , XiaC , ChenW . A randomized clinical study of gefitinib and pemetrexed as second line therapy for advanced non‐squamous non‐small cell lung cancer. Chinese Journal of Lung Cancer2013;16:405‐10. ">Dai 2013</a>; <a href="./references#CD006847-bbs2-0013" title="HanJY , ParkK , KimSW , LeeDH , KimHY , KimHT , et al. First‐SIGNAL: first‐line single‐agent Iressa versus gemcitabine and cisplatin trial in never‐smokers with adenocarcinoma of the lung. Journal of Clinical Oncology2012;30:1122‐8. HanJY , YoonKA , ParkJH , LeeYJ , LeeGK , HanJH , et al. DNA repair gene polymorphisms and benefit from gefitinib in never‐smokers with lung adenocarcinoma. Cancer2011;117(14):3201‐8. ">Han 2012 First SIGNAL</a>; <a href="./references#CD006847-bbs2-0017" title="KimYS , ChoEK , WooHS , HongJ , AhnHK , ParkI , et al. Randomized phase II study of pemetrexed versus gefitinib in previously treated patients with advanced non‐small cell lung cancer. Cancer Research and Treatment2016;48(1):80‐7. ">Kim 2016</a>; <a href="./references#CD006847-bbs2-0019" title="LeeD , KimS , ParkK , et al. A randomized open‐label study of gefitinib versus docetaxel in patients with advanced/metastatic non‐small cell lung cancer (NSCLC) who have previously received platinum‐based chemotherapy [abstract no. 8025]. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2008;26(15 Suppl Pt I):430. LeeDH , ParkK , KimJH , LeeJS , ShinSW , KangJH , et al. Randomized phase III trial of gefitinib versus docetaxel in non‐small‐cell lung cancer patients who have previously received platinum‐based chemotherapy. Clinical Cancer Research2010;16(4):1307‐14. [ISTANA] ">Lee 2010 ISTANA</a>; <a href="./references#CD006847-bbs2-0020" title="LiH , WangX , HuaF . Second‐line treatment with gefitinib or docetaxel for advanced non‐small cell lung cancer. Chinese Journal of Clinical Oncology2010;37:16‐8. ">Li 2010</a>; <a href="./references#CD006847-bbs2-0021" title="LouN , YangJ , YanH , QingZ , LiaoR , XuC , et al. Efficacies of gefitinib versus paclitaxel/carboplatin for patients with advanced pulmonary adenocarcinoma. National Medical Journal of China2014;94(30):2337‐41. ">Lou 2014</a>; <a href="./references#CD006847-bbs2-0023" title="LekiR , KawaharaM , WatanabeH , et al. The impact of response evaluation committee in a Phase III study (V‐15‐32) of gefitinib versus docetaxel in Japanese patients with non‐small cell lung cancer [Abstract No. 298P]. Annals of Oncology2009;19 Suppl 8:109‐10. MaruyamaR , NishiwakiY , TamuraT , YamamotoN , TsuboiM , NakagawaK , et al. Phase III study, V‐15‐32, of gefitinib versus docetaxel in previously treated Japanese patients with non‐small‐cell lung cancer. Journal of Clinical Oncology2008;26(26):4245‐52. SekineI , IchinoseY , NishiwakiY , YamamotoN , TsuboiM , NakagawaK , et al. Quality of life and disease‐related symptoms in previously treated Japanese patients with non‐small‐cell lung cancer: results of a randomized phase III study (V‐15‐32) of gefitinib versus docetaxel. Annals of Oncology2009;20(9):1483‐8. YamamotoN , NishiwakiY , NegoroS , JiangH , ItohY , SaijoN , et al. Disease control as a predictor of survival with gefitinib and docetaxel in a phase III study (V‐15‐32) in advanced non‐small‐cell lung cancer patients. Journal of Thoracic Oncology2010;5(7):1042‐7. ">Maruyama 2008 V‐15‐32</a>; <a href="./references#CD006847-bbs2-0025" title="FukuokaM , WuYL , ThongprasertS , SunpaweravongP , LeongSS , SriuranpongV , et al. Biomarker analyses and final overall survival results from a phase III, randomized, open‐label, first‐line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non ‐ small‐cell lung cancer in Asia (IPASS). Journal of Clinical Oncology2011;29:2866‐74. MokT , WuY‐L , ThongprasertS , et al. Phase III, randomised, open‐label, first‐line study of gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients (PTS) with advanced non‐small cell lung cancer (NSCLC) (IPASS). Annals of Oncology2008;19 Suppl 8:Viii1. MokTS , WuYL , ThongprasertS , YangCH , ChuDT , SaijoN , et al. Gefitinib or carboplatin‐paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine2009;361(10):947‐57. OheY , IchinoseY , NishiwakiY ,  etal . Phase III, randomized, open‐label, first‐line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in selected patients (pts) with advanced non‐small‐cell lung cancer (NSCLC) (IPASS): Evaluation of recruits in Japan. Journal of Clinical Oncology2009;29(15 Suppl 1):8044. ThongprasertS , DuffieldE , SaijoN , WuYL , YangJC , ChuDT , et al. Health‐related quality‐of‐life in a randomized phase III first‐line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). Journal of Thoracic Oncology2011;6:1872‐80. ThongprasertS , DuffieldE , WuY , et al. Quality of life (QOL) in a randomized phase III first‐line study of gefitinib (G) vs carboplatin/paclitaxel (CP) in clinically selected Asian patients (pts) with advanced NSCLC (IPASS). Journal of Thoracic Oncology2010;5(5 Suppl 1):S80. WuY , ChuD , HanB , LiuX , ZhangL , ZhouC , et al. Phase III, randomized, open‐label, first‐line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non‐small‐cell lung cancer: evaluation of patients recruited from mainland China. Asia‐Pacific Journal of Clinical Oncology2012;8:232‐43. WuY , FukuokaM , MokT S K , SaijoN , ThongprasertS , YangJ C H , et al. Tumour response, skin rash and health‐related quality of life (HRQOL) ‐ Post‐HOC data from the IPASS study. European Multidisciplinary Cancer Congress Stockholm Sweden. Elsevier Ltd, 2011; Vol. 47:S633‐4. WuY , MokT , ChuD , et al. Evaluation of clinically selected patients (pts) with advanced non‐small cell lung cancer (NSCLC) recruited in China in a phase III, randomized, open‐label, first‐line study in Asia of gefitinib (G) versus carboplatin/paclitaxel (C/P) (IPASS). Journal of Clinical Oncology. 2009; Vol. 27 (15 Suppl 1):8041. WuYL , FukuokaM , MokTSK , SaijoN , ThongprasertS , YangJCH , et al. Tumor response and health‐related quality of life in clinically selected patients from Asia with advanced non‐small‐cell lung cancer treated with first‐line gefitinib: post hoc analyses from the IPASS study. Lung Cancer2013;81:280‐7. YangCH , FukuokaM , MokTS , WuYL , ThongprasertS , SaijoN , et al. Final overall survival (OS) results from a phase III, randomised, open‐label, first‐line study of gefitinib (G) v carboplatin/paclitaxel (C/P) in clinically selected patients with advanced nonsmall cell lung cancer (NSCLC) in Asia (IPASS). 35th ESMO Congress Milan Italy. Oxford University Press, 2010; Vol. 21:viii1‐2. YangJ , WuY L , SaijoN , ThongprasertS , ChuD T , ChenY M , et al. Efficacy outcomes in first‐line treatment of advanced NSCLC with gefitinib (G) vs carboplatin/paclitaxel (C/P) by epidermal growth factor receptor (EGFR) gene‐copy number score and by most common EGFR mutation subtypes ‐ Exploratory data from IPASS. 2011 European Multidisciplinary Cancer Congress Stockholm Sweden. Elsevier Ltd, 2011; Vol. 47:S633. YangJ , WuY , ChanV , KurniandaJ , NakagawaK . Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan‐ASia Study (IPASS). Lung Cancer2014;83:174‐81. YangJCH , WuYL , ChanV , KurniandaJ , NakagawaK , SaijoN , et al. Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan‐ASia Study (IPASS). Lung Cancer2014;83:174‐81. ">Mok 2009 IPASS</a>; <a href="./references#CD006847-bbs2-0024" title="MitsudomiT , MoritaS , YatabeY , NegoroS , OkamotoI , SetoT , et al. Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first‐line treatment for patients with non‐small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR). 2012 Annual Meeting of the American Society of Clinical Oncology, ASCO Chicago, IL United States. American Society of Clinical Oncology, 2012; Vol. 30. MitsudomiT , MoritaS , YatabeY , NegoroS , OkamotoI , TsurutaniJ , et al. Gefitinib versus cisplatin plus docetaxel in patients with non‐small‐cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase III trial. Lancet2010;11:121‐8. TsurutaniJ , MitsudomiT , MoriS , OkamotoI , NozakiK , TadaH , et al. A phase III, first‐line trial of gefitinib versus cisplatin plus docetaxel for patients with advanced or recurrent non‐small cell lung cancer (NSCLC) harboring activating mutation of the epidermal growth factor receptor (EGFR) gene: a preliminary results of WJTOG 3405 [abstract O‐9002]. European Journal of Cancer. 2009; Vol. 7 Suppl:505. ">Mitsudomi 2010 WJTOG3405</a>; <a href="./references#CD006847-bbs2-0022" title="FukuharaT , MaemondoM , InoueA , KobayashiK , SugawaraS , OizumiS , et al. Factors associated with a poor response to gefitinib in the NEJ002 study: smoking and the L858R mutation. Lung Cancer2015;88:181‐6. InoueA , KobayashiK , MaemondoM , SugawaraS , OizumiS , IsobeH , et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin‐paclitaxel for chemo‐naive non‐small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Annals of Oncology. United Kingdom: Oxford University Press (Great Clarendon Street, Oxford OX2 6DP, United Kingdom), 2013; Vol. 24:54‐9. InoueA , KobayashiK , MaemondoM , et al. A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first‐line treatment of non‐small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 study. European Journal of Cancer. 2009:Abstract 9LBA. MaemondoM , InoueA , KobayashiK , SugawaraS , OizumiS , IsobeH , et al. Gefitinib or chemotherapy for non‐small‐cell lung cancer with mutated EGFR. New England Journal of Medicine2010;362(25):2380‐8. MiyauchiE , InoueA , KobayashiK , MaemondoM , SugawaraS , OizumiS , et al. Efficacy of chemotherapy after first‐line gefitinib therapy in EGFR mutation‐positive advanced non‐small cell lung cancer ‐ data from a randomized phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002). Japanese Journal of Clinical Oncology2015;45(7):670‐6. OizumiS , KobayashiK , InoueA , MaemondoM , SugawaraS , YoshizawaH , et al. Quality of life with gefitinib in patients with EGFR‐mutated non‐small cell lung cancer: quality of life analysis of North East Japan study group 002 trial. Oncologist. United States: AlphaMed Press (318 Blackwell St. Suite 260, Durham NC 27701‐2884, United States), 2012; Vol. 17:863‐70. YoshizawaH , KobayashiK , InoueA , MaemondoM , SugawaraS , OizumiS , et al. QOL analysis from NEJ 002 study comparing gefitinib to chemotherapy for non‐small cell lung cancer with mutated EGFR. 35th ESMO Congress Milan Italy. Oxford University Press, 2010; Vol. 21:viii122. ">Maemondo 2010 NEJ002</a>; <a href="./references#CD006847-bbs2-0028" title="AhnM , SunJ , AhnJS , KimS , MinYJ , YunHJ , et al. Randomized phase III trial of gefitinib or pemetrexed as second‐line treatment in patients with non‐small cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01). ASCO Annual Meeting 2011 Chicago, IL United States. American Society of Clinical Oncology, 2011; Vol. 29. AhnMJ , SunJM , LeeKH , AhnJS , KimSW , MinYJ , et al. Randomized phase III trial of gefitinib or pemetrexed as second‐line treatment in patients with non‐small cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01). 14th World Conference on Lung Cancer Amsterdam Netherlands. International Association for the Study of Lung Cancer, 2011; Vol. 6:S317. SunJM , LeeKH , KimSW , LeeDH , MinYJ , YunHJ , et al. Gefitinib versus pemetrexed as second‐line treatment in patients with nonsmall cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01): an open‐label, phase 3 trial. Cancer2012;118:6234‐42. ">Sun 2012 KCSG‐LU08‐01</a>; <a href="./references#CD006847-bbs2-0031" title="XuYH , MeiJS , ZhouJ . Randomized study of gefitinib versus pemetrexed as maintenance treatment in patients with advanced glandular non‐small cell lung cancer. International Journal of Clinical and Experimental Medicine2015;8(4):6242‐6. ">Xu 2015</a>; <a href="./references#CD006847-bbs2-0033" title="BoyeM , WangX , SrimuninnimitV , KangJH , TsaiCM , OrlandoM , et al. First‐line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian never‐smoker patients with locally advanced or metastatic nonsquamous non‐small cell lung cancer: quality of life results from a randomized phase III trial. Clinical Lung Cancer2016;17(2):150‐60. KangJH , AhnM , KimD , ChoEK , KimJ , ShinSW , et al. Tolerability and outcomes of first‐line pemetrexed‐cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in Korean patients with advanced non‐squamous non‐small cell lung cancer: a post hoc descriptive subgroup analysis of a randomized, phase 3 trial. Cancer Research and Treatment2015;48(2):458‐64. YangJC , KangJH , MokT , AhnM , SrimuninnimitV , LinC , et al. First‐line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non‐squamous non‐small cell lung cancer: a randomised, phase 3 trial. European Journal of Cancer2014;50:2219‐30. YangJC , ParkK , MokTSK , KangJH , SrimuninnimitV , LinCC , et al. A randomized phase 3 study comparing first‐line pemetrexed plus cisplatin followed by gefitinib as maintenance with gefitinib monotherapy in east Asian patients with locally advanced or metastatic nonsquamous non‐small cell lung cancer (NSQNSCLC). 15th World Conference on Lung Cancer Sydney, NSW Australia. International Association for the Study of Lung Cancer, 2013; Vol. 8:S288. YangJC , SrimuninnimitV , AhnM , LinC , KimS , TsaiC , et al. A randomized phase 3 study comparing first‐line pemetrexed plus cisplatin followed by gefitinib maintenance (PC/G) with gefitinib monotherapy (G) in East Asian patients (pts) with locally advanced or metastatic nonsquamous non‐small cell lung cancer (nSqNSCLC): final survival results. Journal of Clinical Oncology2015;15 Suppl:8041. YangJC , SrimunninnimitV , AhnM , LinC , KimS , TsaiC , et al. First‐line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian never‐smoker patients with locally advanced or metastatic nonsquamous non‐small cell lung cancer: final overall survival results from a randomized phase 3 study. Journal of Thoracic Oncology2016;11(3):370‐9. ">Yang 2014</a>), of which all except six (<a href="./references#CD006847-bbs2-0001" title="AhnMJ , YangJCH , LiangJ , KangJH , XiuQ , ChenYM , et al. Randomized phase II trial of first‐line treatment with pemetrexed‐cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never‐smoker patients with advanced non‐small cell lung cancer. Lung Cancer2012;77:346‐52. ">Ahn 2012</a>; <a href="./references#CD006847-bbs2-0008" title="DaiH , XuL , XiaC , ChenW . A randomized clinical study of gefitinib and pemetrexed as second line therapy for advanced non‐squamous non‐small cell lung cancer. Chinese Journal of Lung Cancer2013;16:405‐10. ">Dai 2013</a>; <a href="./references#CD006847-bbs2-0017" title="KimYS , ChoEK , WooHS , HongJ , AhnHK , ParkI , et al. Randomized phase II study of pemetrexed versus gefitinib in previously treated patients with advanced non‐small cell lung cancer. Cancer Research and Treatment2016;48(1):80‐7. ">Kim 2016</a>; <a href="./references#CD006847-bbs2-0020" title="LiH , WangX , HuaF . Second‐line treatment with gefitinib or docetaxel for advanced non‐small cell lung cancer. Chinese Journal of Clinical Oncology2010;37:16‐8. ">Li 2010</a>; <a href="./references#CD006847-bbs2-0021" title="LouN , YangJ , YanH , QingZ , LiaoR , XuC , et al. Efficacies of gefitinib versus paclitaxel/carboplatin for patients with advanced pulmonary adenocarcinoma. National Medical Journal of China2014;94(30):2337‐41. ">Lou 2014</a>; <a href="./references#CD006847-bbs2-0031" title="XuYH , MeiJS , ZhouJ . Randomized study of gefitinib versus pemetrexed as maintenance treatment in patients with advanced glandular non‐small cell lung cancer. International Journal of Clinical and Experimental Medicine2015;8(4):6242‐6. ">Xu 2015</a>) were phase III studies. We included a total of 3512 patients in this group. </p> <p><i>First‐line studies</i> </p> <p>Five phase III studies (<a href="./references#CD006847-bbs2-0013" title="HanJY , ParkK , KimSW , LeeDH , KimHY , KimHT , et al. First‐SIGNAL: first‐line single‐agent Iressa versus gemcitabine and cisplatin trial in never‐smokers with adenocarcinoma of the lung. Journal of Clinical Oncology2012;30:1122‐8. HanJY , YoonKA , ParkJH , LeeYJ , LeeGK , HanJH , et al. DNA repair gene polymorphisms and benefit from gefitinib in never‐smokers with lung adenocarcinoma. Cancer2011;117(14):3201‐8. ">Han 2012 First SIGNAL</a>; <a href="./references#CD006847-bbs2-0022" title="FukuharaT , MaemondoM , InoueA , KobayashiK , SugawaraS , OizumiS , et al. Factors associated with a poor response to gefitinib in the NEJ002 study: smoking and the L858R mutation. Lung Cancer2015;88:181‐6. InoueA , KobayashiK , MaemondoM , SugawaraS , OizumiS , IsobeH , et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin‐paclitaxel for chemo‐naive non‐small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Annals of Oncology. United Kingdom: Oxford University Press (Great Clarendon Street, Oxford OX2 6DP, United Kingdom), 2013; Vol. 24:54‐9. InoueA , KobayashiK , MaemondoM , et al. A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first‐line treatment of non‐small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 study. European Journal of Cancer. 2009:Abstract 9LBA. MaemondoM , InoueA , KobayashiK , SugawaraS , OizumiS , IsobeH , et al. Gefitinib or chemotherapy for non‐small‐cell lung cancer with mutated EGFR. New England Journal of Medicine2010;362(25):2380‐8. MiyauchiE , InoueA , KobayashiK , MaemondoM , SugawaraS , OizumiS , et al. Efficacy of chemotherapy after first‐line gefitinib therapy in EGFR mutation‐positive advanced non‐small cell lung cancer ‐ data from a randomized phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002). Japanese Journal of Clinical Oncology2015;45(7):670‐6. OizumiS , KobayashiK , InoueA , MaemondoM , SugawaraS , YoshizawaH , et al. Quality of life with gefitinib in patients with EGFR‐mutated non‐small cell lung cancer: quality of life analysis of North East Japan study group 002 trial. Oncologist. United States: AlphaMed Press (318 Blackwell St. Suite 260, Durham NC 27701‐2884, United States), 2012; Vol. 17:863‐70. YoshizawaH , KobayashiK , InoueA , MaemondoM , SugawaraS , OizumiS , et al. QOL analysis from NEJ 002 study comparing gefitinib to chemotherapy for non‐small cell lung cancer with mutated EGFR. 35th ESMO Congress Milan Italy. Oxford University Press, 2010; Vol. 21:viii122. ">Maemondo 2010 NEJ002</a>; <a href="./references#CD006847-bbs2-0024" title="MitsudomiT , MoritaS , YatabeY , NegoroS , OkamotoI , SetoT , et al. Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first‐line treatment for patients with non‐small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR). 2012 Annual Meeting of the American Society of Clinical Oncology, ASCO Chicago, IL United States. American Society of Clinical Oncology, 2012; Vol. 30. MitsudomiT , MoritaS , YatabeY , NegoroS , OkamotoI , TsurutaniJ , et al. Gefitinib versus cisplatin plus docetaxel in patients with non‐small‐cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase III trial. Lancet2010;11:121‐8. TsurutaniJ , MitsudomiT , MoriS , OkamotoI , NozakiK , TadaH , et al. A phase III, first‐line trial of gefitinib versus cisplatin plus docetaxel for patients with advanced or recurrent non‐small cell lung cancer (NSCLC) harboring activating mutation of the epidermal growth factor receptor (EGFR) gene: a preliminary results of WJTOG 3405 [abstract O‐9002]. European Journal of Cancer. 2009; Vol. 7 Suppl:505. ">Mitsudomi 2010 WJTOG3405</a>; <a href="./references#CD006847-bbs2-0025" title="FukuokaM , WuYL , ThongprasertS , SunpaweravongP , LeongSS , SriuranpongV , et al. Biomarker analyses and final overall survival results from a phase III, randomized, open‐label, first‐line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non ‐ small‐cell lung cancer in Asia (IPASS). Journal of Clinical Oncology2011;29:2866‐74. MokT , WuY‐L , ThongprasertS , et al. Phase III, randomised, open‐label, first‐line study of gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients (PTS) with advanced non‐small cell lung cancer (NSCLC) (IPASS). Annals of Oncology2008;19 Suppl 8:Viii1. MokTS , WuYL , ThongprasertS , YangCH , ChuDT , SaijoN , et al. Gefitinib or carboplatin‐paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine2009;361(10):947‐57. OheY , IchinoseY , NishiwakiY ,  etal . Phase III, randomized, open‐label, first‐line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in selected patients (pts) with advanced non‐small‐cell lung cancer (NSCLC) (IPASS): Evaluation of recruits in Japan. Journal of Clinical Oncology2009;29(15 Suppl 1):8044. ThongprasertS , DuffieldE , SaijoN , WuYL , YangJC , ChuDT , et al. Health‐related quality‐of‐life in a randomized phase III first‐line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). Journal of Thoracic Oncology2011;6:1872‐80. ThongprasertS , DuffieldE , WuY , et al. Quality of life (QOL) in a randomized phase III first‐line study of gefitinib (G) vs carboplatin/paclitaxel (CP) in clinically selected Asian patients (pts) with advanced NSCLC (IPASS). Journal of Thoracic Oncology2010;5(5 Suppl 1):S80. WuY , ChuD , HanB , LiuX , ZhangL , ZhouC , et al. Phase III, randomized, open‐label, first‐line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non‐small‐cell lung cancer: evaluation of patients recruited from mainland China. Asia‐Pacific Journal of Clinical Oncology2012;8:232‐43. WuY , FukuokaM , MokT S K , SaijoN , ThongprasertS , YangJ C H , et al. Tumour response, skin rash and health‐related quality of life (HRQOL) ‐ Post‐HOC data from the IPASS study. European Multidisciplinary Cancer Congress Stockholm Sweden. Elsevier Ltd, 2011; Vol. 47:S633‐4. WuY , MokT , ChuD , et al. Evaluation of clinically selected patients (pts) with advanced non‐small cell lung cancer (NSCLC) recruited in China in a phase III, randomized, open‐label, first‐line study in Asia of gefitinib (G) versus carboplatin/paclitaxel (C/P) (IPASS). Journal of Clinical Oncology. 2009; Vol. 27 (15 Suppl 1):8041. WuYL , FukuokaM , MokTSK , SaijoN , ThongprasertS , YangJCH , et al. Tumor response and health‐related quality of life in clinically selected patients from Asia with advanced non‐small‐cell lung cancer treated with first‐line gefitinib: post hoc analyses from the IPASS study. Lung Cancer2013;81:280‐7. YangCH , FukuokaM , MokTS , WuYL , ThongprasertS , SaijoN , et al. Final overall survival (OS) results from a phase III, randomised, open‐label, first‐line study of gefitinib (G) v carboplatin/paclitaxel (C/P) in clinically selected patients with advanced nonsmall cell lung cancer (NSCLC) in Asia (IPASS). 35th ESMO Congress Milan Italy. Oxford University Press, 2010; Vol. 21:viii1‐2. YangJ , WuY L , SaijoN , ThongprasertS , ChuD T , ChenY M , et al. Efficacy outcomes in first‐line treatment of advanced NSCLC with gefitinib (G) vs carboplatin/paclitaxel (C/P) by epidermal growth factor receptor (EGFR) gene‐copy number score and by most common EGFR mutation subtypes ‐ Exploratory data from IPASS. 2011 European Multidisciplinary Cancer Congress Stockholm Sweden. Elsevier Ltd, 2011; Vol. 47:S633. YangJ , WuY , ChanV , KurniandaJ , NakagawaK . Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan‐ASia Study (IPASS). Lung Cancer2014;83:174‐81. YangJCH , WuYL , ChanV , KurniandaJ , NakagawaK , SaijoN , et al. Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan‐ASia Study (IPASS). Lung Cancer2014;83:174‐81. ">Mok 2009 IPASS</a>; <a href="./references#CD006847-bbs2-0033" title="BoyeM , WangX , SrimuninnimitV , KangJH , TsaiCM , OrlandoM , et al. First‐line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian never‐smoker patients with locally advanced or metastatic nonsquamous non‐small cell lung cancer: quality of life results from a randomized phase III trial. Clinical Lung Cancer2016;17(2):150‐60. KangJH , AhnM , KimD , ChoEK , KimJ , ShinSW , et al. Tolerability and outcomes of first‐line pemetrexed‐cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in Korean patients with advanced non‐squamous non‐small cell lung cancer: a post hoc descriptive subgroup analysis of a randomized, phase 3 trial. Cancer Research and Treatment2015;48(2):458‐64. YangJC , KangJH , MokT , AhnM , SrimuninnimitV , LinC , et al. First‐line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non‐squamous non‐small cell lung cancer: a randomised, phase 3 trial. European Journal of Cancer2014;50:2219‐30. YangJC , ParkK , MokTSK , KangJH , SrimuninnimitV , LinCC , et al. A randomized phase 3 study comparing first‐line pemetrexed plus cisplatin followed by gefitinib as maintenance with gefitinib monotherapy in east Asian patients with locally advanced or metastatic nonsquamous non‐small cell lung cancer (NSQNSCLC). 15th World Conference on Lung Cancer Sydney, NSW Australia. International Association for the Study of Lung Cancer, 2013; Vol. 8:S288. YangJC , SrimuninnimitV , AhnM , LinC , KimS , TsaiC , et al. A randomized phase 3 study comparing first‐line pemetrexed plus cisplatin followed by gefitinib maintenance (PC/G) with gefitinib monotherapy (G) in East Asian patients (pts) with locally advanced or metastatic nonsquamous non‐small cell lung cancer (nSqNSCLC): final survival results. Journal of Clinical Oncology2015;15 Suppl:8041. YangJC , SrimunninnimitV , AhnM , LinC , KimS , TsaiC , et al. First‐line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian never‐smoker patients with locally advanced or metastatic nonsquamous non‐small cell lung cancer: final overall survival results from a randomized phase 3 study. Journal of Thoracic Oncology2016;11(3):370‐9. ">Yang 2014</a>) and one phase II study (<a href="./references#CD006847-bbs2-0021" title="LouN , YangJ , YanH , QingZ , LiaoR , XuC , et al. Efficacies of gefitinib versus paclitaxel/carboplatin for patients with advanced pulmonary adenocarcinoma. National Medical Journal of China2014;94(30):2337‐41. ">Lou 2014</a>) compared gefitinib with first‐line chemotherapy. IPASS compared gefitinib with carboplatin‐paclitaxel, but in Asian patients with adenocarcinoma who were light or never‐smokers (<a href="./references#CD006847-bbs2-0025" title="FukuokaM , WuYL , ThongprasertS , SunpaweravongP , LeongSS , SriuranpongV , et al. Biomarker analyses and final overall survival results from a phase III, randomized, open‐label, first‐line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non ‐ small‐cell lung cancer in Asia (IPASS). Journal of Clinical Oncology2011;29:2866‐74. MokT , WuY‐L , ThongprasertS , et al. Phase III, randomised, open‐label, first‐line study of gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients (PTS) with advanced non‐small cell lung cancer (NSCLC) (IPASS). Annals of Oncology2008;19 Suppl 8:Viii1. MokTS , WuYL , ThongprasertS , YangCH , ChuDT , SaijoN , et al. Gefitinib or carboplatin‐paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine2009;361(10):947‐57. OheY , IchinoseY , NishiwakiY ,  etal . Phase III, randomized, open‐label, first‐line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in selected patients (pts) with advanced non‐small‐cell lung cancer (NSCLC) (IPASS): Evaluation of recruits in Japan. Journal of Clinical Oncology2009;29(15 Suppl 1):8044. ThongprasertS , DuffieldE , SaijoN , WuYL , YangJC , ChuDT , et al. Health‐related quality‐of‐life in a randomized phase III first‐line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). Journal of Thoracic Oncology2011;6:1872‐80. ThongprasertS , DuffieldE , WuY , et al. Quality of life (QOL) in a randomized phase III first‐line study of gefitinib (G) vs carboplatin/paclitaxel (CP) in clinically selected Asian patients (pts) with advanced NSCLC (IPASS). Journal of Thoracic Oncology2010;5(5 Suppl 1):S80. WuY , ChuD , HanB , LiuX , ZhangL , ZhouC , et al. Phase III, randomized, open‐label, first‐line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non‐small‐cell lung cancer: evaluation of patients recruited from mainland China. Asia‐Pacific Journal of Clinical Oncology2012;8:232‐43. WuY , FukuokaM , MokT S K , SaijoN , ThongprasertS , YangJ C H , et al. Tumour response, skin rash and health‐related quality of life (HRQOL) ‐ Post‐HOC data from the IPASS study. European Multidisciplinary Cancer Congress Stockholm Sweden. Elsevier Ltd, 2011; Vol. 47:S633‐4. WuY , MokT , ChuD , et al. Evaluation of clinically selected patients (pts) with advanced non‐small cell lung cancer (NSCLC) recruited in China in a phase III, randomized, open‐label, first‐line study in Asia of gefitinib (G) versus carboplatin/paclitaxel (C/P) (IPASS). Journal of Clinical Oncology. 2009; Vol. 27 (15 Suppl 1):8041. WuYL , FukuokaM , MokTSK , SaijoN , ThongprasertS , YangJCH , et al. Tumor response and health‐related quality of life in clinically selected patients from Asia with advanced non‐small‐cell lung cancer treated with first‐line gefitinib: post hoc analyses from the IPASS study. Lung Cancer2013;81:280‐7. YangCH , FukuokaM , MokTS , WuYL , ThongprasertS , SaijoN , et al. Final overall survival (OS) results from a phase III, randomised, open‐label, first‐line study of gefitinib (G) v carboplatin/paclitaxel (C/P) in clinically selected patients with advanced nonsmall cell lung cancer (NSCLC) in Asia (IPASS). 35th ESMO Congress Milan Italy. Oxford University Press, 2010; Vol. 21:viii1‐2. YangJ , WuY L , SaijoN , ThongprasertS , ChuD T , ChenY M , et al. Efficacy outcomes in first‐line treatment of advanced NSCLC with gefitinib (G) vs carboplatin/paclitaxel (C/P) by epidermal growth factor receptor (EGFR) gene‐copy number score and by most common EGFR mutation subtypes ‐ Exploratory data from IPASS. 2011 European Multidisciplinary Cancer Congress Stockholm Sweden. Elsevier Ltd, 2011; Vol. 47:S633. YangJ , WuY , ChanV , KurniandaJ , NakagawaK . Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan‐ASia Study (IPASS). Lung Cancer2014;83:174‐81. YangJCH , WuYL , ChanV , KurniandaJ , NakagawaK , SaijoN , et al. Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan‐ASia Study (IPASS). Lung Cancer2014;83:174‐81. ">Mok 2009 IPASS</a>). <a href="./references#CD006847-bbs2-0022" title="FukuharaT , MaemondoM , InoueA , KobayashiK , SugawaraS , OizumiS , et al. Factors associated with a poor response to gefitinib in the NEJ002 study: smoking and the L858R mutation. Lung Cancer2015;88:181‐6. InoueA , KobayashiK , MaemondoM , SugawaraS , OizumiS , IsobeH , et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin‐paclitaxel for chemo‐naive non‐small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Annals of Oncology. United Kingdom: Oxford University Press (Great Clarendon Street, Oxford OX2 6DP, United Kingdom), 2013; Vol. 24:54‐9. InoueA , KobayashiK , MaemondoM , et al. A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first‐line treatment of non‐small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 study. European Journal of Cancer. 2009:Abstract 9LBA. MaemondoM , InoueA , KobayashiK , SugawaraS , OizumiS , IsobeH , et al. Gefitinib or chemotherapy for non‐small‐cell lung cancer with mutated EGFR. New England Journal of Medicine2010;362(25):2380‐8. MiyauchiE , InoueA , KobayashiK , MaemondoM , SugawaraS , OizumiS , et al. Efficacy of chemotherapy after first‐line gefitinib therapy in EGFR mutation‐positive advanced non‐small cell lung cancer ‐ data from a randomized phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002). Japanese Journal of Clinical Oncology2015;45(7):670‐6. OizumiS , KobayashiK , InoueA , MaemondoM , SugawaraS , YoshizawaH , et al. Quality of life with gefitinib in patients with EGFR‐mutated non‐small cell lung cancer: quality of life analysis of North East Japan study group 002 trial. Oncologist. United States: AlphaMed Press (318 Blackwell St. Suite 260, Durham NC 27701‐2884, United States), 2012; Vol. 17:863‐70. YoshizawaH , KobayashiK , InoueA , MaemondoM , SugawaraS , OizumiS , et al. QOL analysis from NEJ 002 study comparing gefitinib to chemotherapy for non‐small cell lung cancer with mutated EGFR. 35th ESMO Congress Milan Italy. Oxford University Press, 2010; Vol. 21:viii122. ">Maemondo 2010 NEJ002</a> randomised Asian chemotherapy‐naive patients with EGFR mutations to receive gefitinib or carboplatin‐paclitaxel. WJTOG3405 compared gefitinib with cisplatin plus docetaxel in Asian patients with EGFR mutations (<a href="./references#CD006847-bbs2-0024" title="MitsudomiT , MoritaS , YatabeY , NegoroS , OkamotoI , SetoT , et al. Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first‐line treatment for patients with non‐small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR). 2012 Annual Meeting of the American Society of Clinical Oncology, ASCO Chicago, IL United States. American Society of Clinical Oncology, 2012; Vol. 30. MitsudomiT , MoritaS , YatabeY , NegoroS , OkamotoI , TsurutaniJ , et al. Gefitinib versus cisplatin plus docetaxel in patients with non‐small‐cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase III trial. Lancet2010;11:121‐8. TsurutaniJ , MitsudomiT , MoriS , OkamotoI , NozakiK , TadaH , et al. A phase III, first‐line trial of gefitinib versus cisplatin plus docetaxel for patients with advanced or recurrent non‐small cell lung cancer (NSCLC) harboring activating mutation of the epidermal growth factor receptor (EGFR) gene: a preliminary results of WJTOG 3405 [abstract O‐9002]. European Journal of Cancer. 2009; Vol. 7 Suppl:505. ">Mitsudomi 2010 WJTOG3405</a>). First‐SIGNAL compared first‐line gefitinib with gemcitabine plus cisplatin in Asian never‐smokers with lung adenocarcinoma (<a href="./references#CD006847-bbs2-0013" title="HanJY , ParkK , KimSW , LeeDH , KimHY , KimHT , et al. First‐SIGNAL: first‐line single‐agent Iressa versus gemcitabine and cisplatin trial in never‐smokers with adenocarcinoma of the lung. Journal of Clinical Oncology2012;30:1122‐8. HanJY , YoonKA , ParkJH , LeeYJ , LeeGK , HanJH , et al. DNA repair gene polymorphisms and benefit from gefitinib in never‐smokers with lung adenocarcinoma. Cancer2011;117(14):3201‐8. ">Han 2012 First SIGNAL</a>). The phase III study by <a href="./references#CD006847-bbs2-0033" title="BoyeM , WangX , SrimuninnimitV , KangJH , TsaiCM , OrlandoM , et al. First‐line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian never‐smoker patients with locally advanced or metastatic nonsquamous non‐small cell lung cancer: quality of life results from a randomized phase III trial. Clinical Lung Cancer2016;17(2):150‐60. KangJH , AhnM , KimD , ChoEK , KimJ , ShinSW , et al. Tolerability and outcomes of first‐line pemetrexed‐cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in Korean patients with advanced non‐squamous non‐small cell lung cancer: a post hoc descriptive subgroup analysis of a randomized, phase 3 trial. Cancer Research and Treatment2015;48(2):458‐64. YangJC , KangJH , MokT , AhnM , SrimuninnimitV , LinC , et al. First‐line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non‐squamous non‐small cell lung cancer: a randomised, phase 3 trial. European Journal of Cancer2014;50:2219‐30. YangJC , ParkK , MokTSK , KangJH , SrimuninnimitV , LinCC , et al. A randomized phase 3 study comparing first‐line pemetrexed plus cisplatin followed by gefitinib as maintenance with gefitinib monotherapy in east Asian patients with locally advanced or metastatic nonsquamous non‐small cell lung cancer (NSQNSCLC). 15th World Conference on Lung Cancer Sydney, NSW Australia. International Association for the Study of Lung Cancer, 2013; Vol. 8:S288. YangJC , SrimuninnimitV , AhnM , LinC , KimS , TsaiC , et al. A randomized phase 3 study comparing first‐line pemetrexed plus cisplatin followed by gefitinib maintenance (PC/G) with gefitinib monotherapy (G) in East Asian patients (pts) with locally advanced or metastatic nonsquamous non‐small cell lung cancer (nSqNSCLC): final survival results. Journal of Clinical Oncology2015;15 Suppl:8041. YangJC , SrimunninnimitV , AhnM , LinC , KimS , TsaiC , et al. First‐line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian never‐smoker patients with locally advanced or metastatic nonsquamous non‐small cell lung cancer: final overall survival results from a randomized phase 3 study. Journal of Thoracic Oncology2016;11(3):370‐9. ">Yang 2014</a> compared first‐line pemetrexed and cisplatin followed by gefitinib maintenance therapy with gefitinib monotherapy alone in Asian non‐smoking patients. Patients were randomised at trial entry to either gefitinib or pemetrexed plus cisplatin chemotherapy. Patients in both arms then continued with maintenance gefitinib. Data were analysed in the intention‐to‐treat population and only data from the first phase of the study were included in this analysis. In the phase II study by <a href="./references#CD006847-bbs2-0021" title="LouN , YangJ , YanH , QingZ , LiaoR , XuC , et al. Efficacies of gefitinib versus paclitaxel/carboplatin for patients with advanced pulmonary adenocarcinoma. National Medical Journal of China2014;94(30):2337‐41. ">Lou 2014</a>, gefitinib was compared with carboplatin and paclitaxel in Asian patients who were either non‐smokers or light ex‐smokers. </p> <p>We analysed a total of 2224 patients from the six studies in this group.</p> <p><i>Second‐line studies</i> </p> <p>Three phase III studies (<a href="./references#CD006847-bbs2-0019" title="LeeD , KimS , ParkK , et al. A randomized open‐label study of gefitinib versus docetaxel in patients with advanced/metastatic non‐small cell lung cancer (NSCLC) who have previously received platinum‐based chemotherapy [abstract no. 8025]. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2008;26(15 Suppl Pt I):430. LeeDH , ParkK , KimJH , LeeJS , ShinSW , KangJH , et al. Randomized phase III trial of gefitinib versus docetaxel in non‐small‐cell lung cancer patients who have previously received platinum‐based chemotherapy. Clinical Cancer Research2010;16(4):1307‐14. [ISTANA] ">Lee 2010 ISTANA</a>; <a href="./references#CD006847-bbs2-0023" title="LekiR , KawaharaM , WatanabeH , et al. The impact of response evaluation committee in a Phase III study (V‐15‐32) of gefitinib versus docetaxel in Japanese patients with non‐small cell lung cancer [Abstract No. 298P]. Annals of Oncology2009;19 Suppl 8:109‐10. MaruyamaR , NishiwakiY , TamuraT , YamamotoN , TsuboiM , NakagawaK , et al. Phase III study, V‐15‐32, of gefitinib versus docetaxel in previously treated Japanese patients with non‐small‐cell lung cancer. Journal of Clinical Oncology2008;26(26):4245‐52. SekineI , IchinoseY , NishiwakiY , YamamotoN , TsuboiM , NakagawaK , et al. Quality of life and disease‐related symptoms in previously treated Japanese patients with non‐small‐cell lung cancer: results of a randomized phase III study (V‐15‐32) of gefitinib versus docetaxel. Annals of Oncology2009;20(9):1483‐8. YamamotoN , NishiwakiY , NegoroS , JiangH , ItohY , SaijoN , et al. Disease control as a predictor of survival with gefitinib and docetaxel in a phase III study (V‐15‐32) in advanced non‐small‐cell lung cancer patients. Journal of Thoracic Oncology2010;5(7):1042‐7. ">Maruyama 2008 V‐15‐32</a>; <a href="./references#CD006847-bbs2-0028" title="AhnM , SunJ , AhnJS , KimS , MinYJ , YunHJ , et al. Randomized phase III trial of gefitinib or pemetrexed as second‐line treatment in patients with non‐small cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01). ASCO Annual Meeting 2011 Chicago, IL United States. American Society of Clinical Oncology, 2011; Vol. 29. AhnMJ , SunJM , LeeKH , AhnJS , KimSW , MinYJ , et al. Randomized phase III trial of gefitinib or pemetrexed as second‐line treatment in patients with non‐small cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01). 14th World Conference on Lung Cancer Amsterdam Netherlands. International Association for the Study of Lung Cancer, 2011; Vol. 6:S317. SunJM , LeeKH , KimSW , LeeDH , MinYJ , YunHJ , et al. Gefitinib versus pemetrexed as second‐line treatment in patients with nonsmall cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01): an open‐label, phase 3 trial. Cancer2012;118:6234‐42. ">Sun 2012 KCSG‐LU08‐01</a>) and three phase II studies (<a href="./references#CD006847-bbs2-0008" title="DaiH , XuL , XiaC , ChenW . A randomized clinical study of gefitinib and pemetrexed as second line therapy for advanced non‐squamous non‐small cell lung cancer. Chinese Journal of Lung Cancer2013;16:405‐10. ">Dai 2013</a>; <a href="./references#CD006847-bbs2-0017" title="KimYS , ChoEK , WooHS , HongJ , AhnHK , ParkI , et al. Randomized phase II study of pemetrexed versus gefitinib in previously treated patients with advanced non‐small cell lung cancer. Cancer Research and Treatment2016;48(1):80‐7. ">Kim 2016</a>; <a href="./references#CD006847-bbs2-0020" title="LiH , WangX , HuaF . Second‐line treatment with gefitinib or docetaxel for advanced non‐small cell lung cancer. Chinese Journal of Clinical Oncology2010;37:16‐8. ">Li 2010</a>) compared gefitinib with second‐line chemotherapy. ISTANA (<a href="./references#CD006847-bbs2-0019" title="LeeD , KimS , ParkK , et al. A randomized open‐label study of gefitinib versus docetaxel in patients with advanced/metastatic non‐small cell lung cancer (NSCLC) who have previously received platinum‐based chemotherapy [abstract no. 8025]. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2008;26(15 Suppl Pt I):430. LeeDH , ParkK , KimJH , LeeJS , ShinSW , KangJH , et al. Randomized phase III trial of gefitinib versus docetaxel in non‐small‐cell lung cancer patients who have previously received platinum‐based chemotherapy. Clinical Cancer Research2010;16(4):1307‐14. [ISTANA] ">Lee 2010 ISTANA</a>), V‐15‐32 (<a href="./references#CD006847-bbs2-0023" title="LekiR , KawaharaM , WatanabeH , et al. The impact of response evaluation committee in a Phase III study (V‐15‐32) of gefitinib versus docetaxel in Japanese patients with non‐small cell lung cancer [Abstract No. 298P]. Annals of Oncology2009;19 Suppl 8:109‐10. MaruyamaR , NishiwakiY , TamuraT , YamamotoN , TsuboiM , NakagawaK , et al. Phase III study, V‐15‐32, of gefitinib versus docetaxel in previously treated Japanese patients with non‐small‐cell lung cancer. Journal of Clinical Oncology2008;26(26):4245‐52. SekineI , IchinoseY , NishiwakiY , YamamotoN , TsuboiM , NakagawaK , et al. Quality of life and disease‐related symptoms in previously treated Japanese patients with non‐small‐cell lung cancer: results of a randomized phase III study (V‐15‐32) of gefitinib versus docetaxel. Annals of Oncology2009;20(9):1483‐8. YamamotoN , NishiwakiY , NegoroS , JiangH , ItohY , SaijoN , et al. Disease control as a predictor of survival with gefitinib and docetaxel in a phase III study (V‐15‐32) in advanced non‐small‐cell lung cancer patients. Journal of Thoracic Oncology2010;5(7):1042‐7. ">Maruyama 2008 V‐15‐32</a>) and the phase II study by <a href="./references#CD006847-bbs2-0020" title="LiH , WangX , HuaF . Second‐line treatment with gefitinib or docetaxel for advanced non‐small cell lung cancer. Chinese Journal of Clinical Oncology2010;37:16‐8. ">Li 2010</a> included patients of Asian ethnicity but where mutation status was not always known, and compared gefitinib with docetaxel. KCSG‐LU08‐01 (<a href="./references#CD006847-bbs2-0028" title="AhnM , SunJ , AhnJS , KimS , MinYJ , YunHJ , et al. Randomized phase III trial of gefitinib or pemetrexed as second‐line treatment in patients with non‐small cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01). ASCO Annual Meeting 2011 Chicago, IL United States. American Society of Clinical Oncology, 2011; Vol. 29. AhnMJ , SunJM , LeeKH , AhnJS , KimSW , MinYJ , et al. Randomized phase III trial of gefitinib or pemetrexed as second‐line treatment in patients with non‐small cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01). 14th World Conference on Lung Cancer Amsterdam Netherlands. International Association for the Study of Lung Cancer, 2011; Vol. 6:S317. SunJM , LeeKH , KimSW , LeeDH , MinYJ , YunHJ , et al. Gefitinib versus pemetrexed as second‐line treatment in patients with nonsmall cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01): an open‐label, phase 3 trial. Cancer2012;118:6234‐42. ">Sun 2012 KCSG‐LU08‐01</a>), <a href="./references#CD006847-bbs2-0008" title="DaiH , XuL , XiaC , ChenW . A randomized clinical study of gefitinib and pemetrexed as second line therapy for advanced non‐squamous non‐small cell lung cancer. Chinese Journal of Lung Cancer2013;16:405‐10. ">Dai 2013</a> and <a href="./references#CD006847-bbs2-0017" title="KimYS , ChoEK , WooHS , HongJ , AhnHK , ParkI , et al. Randomized phase II study of pemetrexed versus gefitinib in previously treated patients with advanced non‐small cell lung cancer. Cancer Research and Treatment2016;48(1):80‐7. ">Kim 2016</a> selected Asian patients with unknown EGFR status and compared gefitinib with second‐line pemetrexed. Secondary studies published by <a href="./references#CD006847-bbs2-0076" title="SekineI , IchinoseY , NishiwakiY , YamamotoN , TsuboiM , NakagawaK , et al. Quality of life and disease‐related symptoms in previously treated Japanese patients with non‐small‐cell lung cancer: results of a randomized phase III study (V‐15‐32) of gefitinib versus docetaxel. Annals of Oncology2009;20(9):1483‐8. ">Sekine 2009</a> and <a href="./references#CD006847-bbs2-0080" title="YamamotoN , NishiwakiY , NegoroS , JiangH , ItohY , SaijoN , et al. Disease control as a predictor of survival with gefitinib and docetaxel in a phase III study (V‐15‐32) in advanced non‐small‐cell lung cancer patients. Journal of Thoracic Oncology2010;5(7):1042‐7. ">Yamamoto 2010</a> conducted analyses on quality of life and disease control respectively in the V‐15‐32 trial. </p> <p>We analysed a total of 1030 patients from the six studies in this group.</p> <p><i>Maintenance studies</i> </p> <p>Two phase II studies compared the role of gefitinib as maintenance to chemotherapy. <a href="./references#CD006847-bbs2-0001" title="AhnMJ , YangJCH , LiangJ , KangJH , XiuQ , ChenYM , et al. Randomized phase II trial of first‐line treatment with pemetrexed‐cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never‐smoker patients with advanced non‐small cell lung cancer. Lung Cancer2012;77:346‐52. ">Ahn 2012</a> randomised Asian non‐smokers not progressing after first‐line pemetrexed‐cisplatin, to receive either gefitinib or pemetrexed ± cisplatin, in a two‐staged study design. <a href="./references#CD006847-bbs2-0031" title="XuYH , MeiJS , ZhouJ . Randomized study of gefitinib versus pemetrexed as maintenance treatment in patients with advanced glandular non‐small cell lung cancer. International Journal of Clinical and Experimental Medicine2015;8(4):6242‐6. ">Xu 2015</a> compared single‐agent pemetrexed with gefitinib in Asian patients not progressing after four to eight cycles of first‐line chemotherapy. </p> <p>We analysed 258 patients in this group.</p> <p> <ul id="CD006847-list-0021"> <li> <p><i>EGFR mutation positive population (Comparison 6)</i> </p> </li> </ul> </p> <p>Nine studies were included in this group, six of which were first‐line studies (<a href="./references#CD006847-bbs2-0006" title="CrinoL , CappuzzoF , ZatloukalP , ReckM , PesekM , ThompsonJC , et al. Gefitinib versus vinorelbine in chemotherapy‐naive elderly patients with advanced non‐small‐cell lung cancer (INVITE): a randomized, phase II study. Journal of Clinical Oncology2008;26(26):4253‐60. ">Crino 2008 INVITE</a>; <a href="./references#CD006847-bbs2-0013" title="HanJY , ParkK , KimSW , LeeDH , KimHY , KimHT , et al. First‐SIGNAL: first‐line single‐agent Iressa versus gemcitabine and cisplatin trial in never‐smokers with adenocarcinoma of the lung. Journal of Clinical Oncology2012;30:1122‐8. HanJY , YoonKA , ParkJH , LeeYJ , LeeGK , HanJH , et al. DNA repair gene polymorphisms and benefit from gefitinib in never‐smokers with lung adenocarcinoma. Cancer2011;117(14):3201‐8. ">Han 2012 First SIGNAL</a>; <a href="./references#CD006847-bbs2-0022" title="FukuharaT , MaemondoM , InoueA , KobayashiK , SugawaraS , OizumiS , et al. Factors associated with a poor response to gefitinib in the NEJ002 study: smoking and the L858R mutation. Lung Cancer2015;88:181‐6. InoueA , KobayashiK , MaemondoM , SugawaraS , OizumiS , IsobeH , et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin‐paclitaxel for chemo‐naive non‐small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Annals of Oncology. United Kingdom: Oxford University Press (Great Clarendon Street, Oxford OX2 6DP, United Kingdom), 2013; Vol. 24:54‐9. InoueA , KobayashiK , MaemondoM , et al. A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first‐line treatment of non‐small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 study. European Journal of Cancer. 2009:Abstract 9LBA. MaemondoM , InoueA , KobayashiK , SugawaraS , OizumiS , IsobeH , et al. Gefitinib or chemotherapy for non‐small‐cell lung cancer with mutated EGFR. New England Journal of Medicine2010;362(25):2380‐8. MiyauchiE , InoueA , KobayashiK , MaemondoM , SugawaraS , OizumiS , et al. Efficacy of chemotherapy after first‐line gefitinib therapy in EGFR mutation‐positive advanced non‐small cell lung cancer ‐ data from a randomized phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002). Japanese Journal of Clinical Oncology2015;45(7):670‐6. OizumiS , KobayashiK , InoueA , MaemondoM , SugawaraS , YoshizawaH , et al. Quality of life with gefitinib in patients with EGFR‐mutated non‐small cell lung cancer: quality of life analysis of North East Japan study group 002 trial. Oncologist. United States: AlphaMed Press (318 Blackwell St. Suite 260, Durham NC 27701‐2884, United States), 2012; Vol. 17:863‐70. YoshizawaH , KobayashiK , InoueA , MaemondoM , SugawaraS , OizumiS , et al. QOL analysis from NEJ 002 study comparing gefitinib to chemotherapy for non‐small cell lung cancer with mutated EGFR. 35th ESMO Congress Milan Italy. Oxford University Press, 2010; Vol. 21:viii122. ">Maemondo 2010 NEJ002</a>; <a href="./references#CD006847-bbs2-0024" title="MitsudomiT , MoritaS , YatabeY , NegoroS , OkamotoI , SetoT , et al. Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first‐line treatment for patients with non‐small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR). 2012 Annual Meeting of the American Society of Clinical Oncology, ASCO Chicago, IL United States. American Society of Clinical Oncology, 2012; Vol. 30. MitsudomiT , MoritaS , YatabeY , NegoroS , OkamotoI , TsurutaniJ , et al. Gefitinib versus cisplatin plus docetaxel in patients with non‐small‐cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase III trial. Lancet2010;11:121‐8. TsurutaniJ , MitsudomiT , MoriS , OkamotoI , NozakiK , TadaH , et al. A phase III, first‐line trial of gefitinib versus cisplatin plus docetaxel for patients with advanced or recurrent non‐small cell lung cancer (NSCLC) harboring activating mutation of the epidermal growth factor receptor (EGFR) gene: a preliminary results of WJTOG 3405 [abstract O‐9002]. European Journal of Cancer. 2009; Vol. 7 Suppl:505. ">Mitsudomi 2010 WJTOG3405</a>; <a href="./references#CD006847-bbs2-0025" title="FukuokaM , WuYL , ThongprasertS , SunpaweravongP , LeongSS , SriuranpongV , et al. Biomarker analyses and final overall survival results from a phase III, randomized, open‐label, first‐line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non ‐ small‐cell lung cancer in Asia (IPASS). Journal of Clinical Oncology2011;29:2866‐74. MokT , WuY‐L , ThongprasertS , et al. Phase III, randomised, open‐label, first‐line study of gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients (PTS) with advanced non‐small cell lung cancer (NSCLC) (IPASS). Annals of Oncology2008;19 Suppl 8:Viii1. MokTS , WuYL , ThongprasertS , YangCH , ChuDT , SaijoN , et al. Gefitinib or carboplatin‐paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine2009;361(10):947‐57. OheY , IchinoseY , NishiwakiY ,  etal . Phase III, randomized, open‐label, first‐line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in selected patients (pts) with advanced non‐small‐cell lung cancer (NSCLC) (IPASS): Evaluation of recruits in Japan. Journal of Clinical Oncology2009;29(15 Suppl 1):8044. ThongprasertS , DuffieldE , SaijoN , WuYL , YangJC , ChuDT , et al. Health‐related quality‐of‐life in a randomized phase III first‐line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). Journal of Thoracic Oncology2011;6:1872‐80. ThongprasertS , DuffieldE , WuY , et al. Quality of life (QOL) in a randomized phase III first‐line study of gefitinib (G) vs carboplatin/paclitaxel (CP) in clinically selected Asian patients (pts) with advanced NSCLC (IPASS). Journal of Thoracic Oncology2010;5(5 Suppl 1):S80. WuY , ChuD , HanB , LiuX , ZhangL , ZhouC , et al. Phase III, randomized, open‐label, first‐line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non‐small‐cell lung cancer: evaluation of patients recruited from mainland China. Asia‐Pacific Journal of Clinical Oncology2012;8:232‐43. WuY , FukuokaM , MokT S K , SaijoN , ThongprasertS , YangJ C H , et al. Tumour response, skin rash and health‐related quality of life (HRQOL) ‐ Post‐HOC data from the IPASS study. European Multidisciplinary Cancer Congress Stockholm Sweden. Elsevier Ltd, 2011; Vol. 47:S633‐4. WuY , MokT , ChuD , et al. Evaluation of clinically selected patients (pts) with advanced non‐small cell lung cancer (NSCLC) recruited in China in a phase III, randomized, open‐label, first‐line study in Asia of gefitinib (G) versus carboplatin/paclitaxel (C/P) (IPASS). Journal of Clinical Oncology. 2009; Vol. 27 (15 Suppl 1):8041. WuYL , FukuokaM , MokTSK , SaijoN , ThongprasertS , YangJCH , et al. Tumor response and health‐related quality of life in clinically selected patients from Asia with advanced non‐small‐cell lung cancer treated with first‐line gefitinib: post hoc analyses from the IPASS study. Lung Cancer2013;81:280‐7. YangCH , FukuokaM , MokTS , WuYL , ThongprasertS , SaijoN , et al. Final overall survival (OS) results from a phase III, randomised, open‐label, first‐line study of gefitinib (G) v carboplatin/paclitaxel (C/P) in clinically selected patients with advanced nonsmall cell lung cancer (NSCLC) in Asia (IPASS). 35th ESMO Congress Milan Italy. Oxford University Press, 2010; Vol. 21:viii1‐2. YangJ , WuY L , SaijoN , ThongprasertS , ChuD T , ChenY M , et al. Efficacy outcomes in first‐line treatment of advanced NSCLC with gefitinib (G) vs carboplatin/paclitaxel (C/P) by epidermal growth factor receptor (EGFR) gene‐copy number score and by most common EGFR mutation subtypes ‐ Exploratory data from IPASS. 2011 European Multidisciplinary Cancer Congress Stockholm Sweden. Elsevier Ltd, 2011; Vol. 47:S633. YangJ , WuY , ChanV , KurniandaJ , NakagawaK . Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan‐ASia Study (IPASS). Lung Cancer2014;83:174‐81. YangJCH , WuYL , ChanV , KurniandaJ , NakagawaK , SaijoN , et al. Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan‐ASia Study (IPASS). Lung Cancer2014;83:174‐81. ">Mok 2009 IPASS</a>; <a href="./references#CD006847-bbs2-0033" title="BoyeM , WangX , SrimuninnimitV , KangJH , TsaiCM , OrlandoM , et al. First‐line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian never‐smoker patients with locally advanced or metastatic nonsquamous non‐small cell lung cancer: quality of life results from a randomized phase III trial. Clinical Lung Cancer2016;17(2):150‐60. KangJH , AhnM , KimD , ChoEK , KimJ , ShinSW , et al. Tolerability and outcomes of first‐line pemetrexed‐cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in Korean patients with advanced non‐squamous non‐small cell lung cancer: a post hoc descriptive subgroup analysis of a randomized, phase 3 trial. Cancer Research and Treatment2015;48(2):458‐64. YangJC , KangJH , MokT , AhnM , SrimuninnimitV , LinC , et al. First‐line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non‐squamous non‐small cell lung cancer: a randomised, phase 3 trial. European Journal of Cancer2014;50:2219‐30. YangJC , ParkK , MokTSK , KangJH , SrimuninnimitV , LinCC , et al. A randomized phase 3 study comparing first‐line pemetrexed plus cisplatin followed by gefitinib as maintenance with gefitinib monotherapy in east Asian patients with locally advanced or metastatic nonsquamous non‐small cell lung cancer (NSQNSCLC). 15th World Conference on Lung Cancer Sydney, NSW Australia. International Association for the Study of Lung Cancer, 2013; Vol. 8:S288. YangJC , SrimuninnimitV , AhnM , LinC , KimS , TsaiC , et al. A randomized phase 3 study comparing first‐line pemetrexed plus cisplatin followed by gefitinib maintenance (PC/G) with gefitinib monotherapy (G) in East Asian patients (pts) with locally advanced or metastatic nonsquamous non‐small cell lung cancer (nSqNSCLC): final survival results. Journal of Clinical Oncology2015;15 Suppl:8041. YangJC , SrimunninnimitV , AhnM , LinC , KimS , TsaiC , et al. First‐line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian never‐smoker patients with locally advanced or metastatic nonsquamous non‐small cell lung cancer: final overall survival results from a randomized phase 3 study. Journal of Thoracic Oncology2016;11(3):370‐9. ">Yang 2014</a>) and three of which were second‐line studies (<a href="./references#CD006847-bbs2-0016" title="DouillardJY , ShephardFA , HirshV , MokT , SocinskiMA , GervaisR , et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non‐small‐cell lung cancer: from the randomized phase III INTEREST Trial. Journal of Clinical Oncology2010;28(5):744‐52. HorganAM , BradburyPA , AmirE , NgR , DouillardJY , KimES , et al. An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second‐/third‐line therapy in advanced non‐small‐cell lung cancer. Annals of Oncology. United Kingdom: Oxford University Press (Great Clarendon Street, Oxford OX2 6DP, United Kingdom), 2011; Vol. 22:1805‐11. HorganAM , ShepherdFA , BradburyPA , NgR , LeighlNB . Preliminary cost‐consequence analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as 2nd line therapy in advanced non‐small cell lung cancer [abstract no. 8110]. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2008;25(15 Suppl Pt 1):451. KimES , HirshV , MokT , SocinskiMA , GervaisR , WuYL , et al. Gefitinib versus docetaxel in previously treated non‐small‐cell lung cancer (INTEREST): a randomized phase III trial. Lancet2008;372:1809‐18. ">Kim 2008 INTEREST</a>; <a href="./references#CD006847-bbs2-0023" title="LekiR , KawaharaM , WatanabeH , et al. The impact of response evaluation committee in a Phase III study (V‐15‐32) of gefitinib versus docetaxel in Japanese patients with non‐small cell lung cancer [Abstract No. 298P]. Annals of Oncology2009;19 Suppl 8:109‐10. MaruyamaR , NishiwakiY , TamuraT , YamamotoN , TsuboiM , NakagawaK , et al. Phase III study, V‐15‐32, of gefitinib versus docetaxel in previously treated Japanese patients with non‐small‐cell lung cancer. Journal of Clinical Oncology2008;26(26):4245‐52. SekineI , IchinoseY , NishiwakiY , YamamotoN , TsuboiM , NakagawaK , et al. Quality of life and disease‐related symptoms in previously treated Japanese patients with non‐small‐cell lung cancer: results of a randomized phase III study (V‐15‐32) of gefitinib versus docetaxel. Annals of Oncology2009;20(9):1483‐8. YamamotoN , NishiwakiY , NegoroS , JiangH , ItohY , SaijoN , et al. Disease control as a predictor of survival with gefitinib and docetaxel in a phase III study (V‐15‐32) in advanced non‐small‐cell lung cancer patients. Journal of Thoracic Oncology2010;5(7):1042‐7. ">Maruyama 2008 V‐15‐32</a>; <a href="./references#CD006847-bbs2-0028" title="AhnM , SunJ , AhnJS , KimS , MinYJ , YunHJ , et al. Randomized phase III trial of gefitinib or pemetrexed as second‐line treatment in patients with non‐small cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01). ASCO Annual Meeting 2011 Chicago, IL United States. American Society of Clinical Oncology, 2011; Vol. 29. AhnMJ , SunJM , LeeKH , AhnJS , KimSW , MinYJ , et al. Randomized phase III trial of gefitinib or pemetrexed as second‐line treatment in patients with non‐small cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01). 14th World Conference on Lung Cancer Amsterdam Netherlands. International Association for the Study of Lung Cancer, 2011; Vol. 6:S317. SunJM , LeeKH , KimSW , LeeDH , MinYJ , YunHJ , et al. Gefitinib versus pemetrexed as second‐line treatment in patients with nonsmall cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01): an open‐label, phase 3 trial. Cancer2012;118:6234‐42. ">Sun 2012 KCSG‐LU08‐01</a>). </p> <p>We included a total of 879 patients in this group.</p> <p>Two phase III studies selected patients of Asian ethnicity who were also positive for EGFR mutations and compared gefitinib with first‐line carboplatin and paclitaxel or cisplatin and docetaxel respectively (<a href="./references#CD006847-bbs2-0022" title="FukuharaT , MaemondoM , InoueA , KobayashiK , SugawaraS , OizumiS , et al. Factors associated with a poor response to gefitinib in the NEJ002 study: smoking and the L858R mutation. Lung Cancer2015;88:181‐6. InoueA , KobayashiK , MaemondoM , SugawaraS , OizumiS , IsobeH , et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin‐paclitaxel for chemo‐naive non‐small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Annals of Oncology. United Kingdom: Oxford University Press (Great Clarendon Street, Oxford OX2 6DP, United Kingdom), 2013; Vol. 24:54‐9. InoueA , KobayashiK , MaemondoM , et al. A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first‐line treatment of non‐small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 study. European Journal of Cancer. 2009:Abstract 9LBA. MaemondoM , InoueA , KobayashiK , SugawaraS , OizumiS , IsobeH , et al. Gefitinib or chemotherapy for non‐small‐cell lung cancer with mutated EGFR. New England Journal of Medicine2010;362(25):2380‐8. MiyauchiE , InoueA , KobayashiK , MaemondoM , SugawaraS , OizumiS , et al. Efficacy of chemotherapy after first‐line gefitinib therapy in EGFR mutation‐positive advanced non‐small cell lung cancer ‐ data from a randomized phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002). Japanese Journal of Clinical Oncology2015;45(7):670‐6. OizumiS , KobayashiK , InoueA , MaemondoM , SugawaraS , YoshizawaH , et al. Quality of life with gefitinib in patients with EGFR‐mutated non‐small cell lung cancer: quality of life analysis of North East Japan study group 002 trial. Oncologist. United States: AlphaMed Press (318 Blackwell St. Suite 260, Durham NC 27701‐2884, United States), 2012; Vol. 17:863‐70. YoshizawaH , KobayashiK , InoueA , MaemondoM , SugawaraS , OizumiS , et al. QOL analysis from NEJ 002 study comparing gefitinib to chemotherapy for non‐small cell lung cancer with mutated EGFR. 35th ESMO Congress Milan Italy. Oxford University Press, 2010; Vol. 21:viii122. ">Maemondo 2010 NEJ002</a>; <a href="./references#CD006847-bbs2-0024" title="MitsudomiT , MoritaS , YatabeY , NegoroS , OkamotoI , SetoT , et al. Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first‐line treatment for patients with non‐small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR). 2012 Annual Meeting of the American Society of Clinical Oncology, ASCO Chicago, IL United States. American Society of Clinical Oncology, 2012; Vol. 30. MitsudomiT , MoritaS , YatabeY , NegoroS , OkamotoI , TsurutaniJ , et al. Gefitinib versus cisplatin plus docetaxel in patients with non‐small‐cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase III trial. Lancet2010;11:121‐8. TsurutaniJ , MitsudomiT , MoriS , OkamotoI , NozakiK , TadaH , et al. A phase III, first‐line trial of gefitinib versus cisplatin plus docetaxel for patients with advanced or recurrent non‐small cell lung cancer (NSCLC) harboring activating mutation of the epidermal growth factor receptor (EGFR) gene: a preliminary results of WJTOG 3405 [abstract O‐9002]. European Journal of Cancer. 2009; Vol. 7 Suppl:505. ">Mitsudomi 2010 WJTOG3405</a>). In contrast, the IPASS (<a href="./references#CD006847-bbs2-0025" title="FukuokaM , WuYL , ThongprasertS , SunpaweravongP , LeongSS , SriuranpongV , et al. Biomarker analyses and final overall survival results from a phase III, randomized, open‐label, first‐line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non ‐ small‐cell lung cancer in Asia (IPASS). Journal of Clinical Oncology2011;29:2866‐74. MokT , WuY‐L , ThongprasertS , et al. Phase III, randomised, open‐label, first‐line study of gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients (PTS) with advanced non‐small cell lung cancer (NSCLC) (IPASS). Annals of Oncology2008;19 Suppl 8:Viii1. MokTS , WuYL , ThongprasertS , YangCH , ChuDT , SaijoN , et al. Gefitinib or carboplatin‐paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine2009;361(10):947‐57. OheY , IchinoseY , NishiwakiY ,  etal . Phase III, randomized, open‐label, first‐line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in selected patients (pts) with advanced non‐small‐cell lung cancer (NSCLC) (IPASS): Evaluation of recruits in Japan. Journal of Clinical Oncology2009;29(15 Suppl 1):8044. ThongprasertS , DuffieldE , SaijoN , WuYL , YangJC , ChuDT , et al. Health‐related quality‐of‐life in a randomized phase III first‐line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). Journal of Thoracic Oncology2011;6:1872‐80. ThongprasertS , DuffieldE , WuY , et al. Quality of life (QOL) in a randomized phase III first‐line study of gefitinib (G) vs carboplatin/paclitaxel (CP) in clinically selected Asian patients (pts) with advanced NSCLC (IPASS). Journal of Thoracic Oncology2010;5(5 Suppl 1):S80. WuY , ChuD , HanB , LiuX , ZhangL , ZhouC , et al. Phase III, randomized, open‐label, first‐line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non‐small‐cell lung cancer: evaluation of patients recruited from mainland China. Asia‐Pacific Journal of Clinical Oncology2012;8:232‐43. WuY , FukuokaM , MokT S K , SaijoN , ThongprasertS , YangJ C H , et al. Tumour response, skin rash and health‐related quality of life (HRQOL) ‐ Post‐HOC data from the IPASS study. European Multidisciplinary Cancer Congress Stockholm Sweden. Elsevier Ltd, 2011; Vol. 47:S633‐4. WuY , MokT , ChuD , et al. Evaluation of clinically selected patients (pts) with advanced non‐small cell lung cancer (NSCLC) recruited in China in a phase III, randomized, open‐label, first‐line study in Asia of gefitinib (G) versus carboplatin/paclitaxel (C/P) (IPASS). Journal of Clinical Oncology. 2009; Vol. 27 (15 Suppl 1):8041. WuYL , FukuokaM , MokTSK , SaijoN , ThongprasertS , YangJCH , et al. Tumor response and health‐related quality of life in clinically selected patients from Asia with advanced non‐small‐cell lung cancer treated with first‐line gefitinib: post hoc analyses from the IPASS study. Lung Cancer2013;81:280‐7. YangCH , FukuokaM , MokTS , WuYL , ThongprasertS , SaijoN , et al. Final overall survival (OS) results from a phase III, randomised, open‐label, first‐line study of gefitinib (G) v carboplatin/paclitaxel (C/P) in clinically selected patients with advanced nonsmall cell lung cancer (NSCLC) in Asia (IPASS). 35th ESMO Congress Milan Italy. Oxford University Press, 2010; Vol. 21:viii1‐2. YangJ , WuY L , SaijoN , ThongprasertS , ChuD T , ChenY M , et al. Efficacy outcomes in first‐line treatment of advanced NSCLC with gefitinib (G) vs carboplatin/paclitaxel (C/P) by epidermal growth factor receptor (EGFR) gene‐copy number score and by most common EGFR mutation subtypes ‐ Exploratory data from IPASS. 2011 European Multidisciplinary Cancer Congress Stockholm Sweden. Elsevier Ltd, 2011; Vol. 47:S633. YangJ , WuY , ChanV , KurniandaJ , NakagawaK . Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan‐ASia Study (IPASS). Lung Cancer2014;83:174‐81. YangJCH , WuYL , ChanV , KurniandaJ , NakagawaK , SaijoN , et al. Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan‐ASia Study (IPASS). Lung Cancer2014;83:174‐81. ">Mok 2009 IPASS</a>) and First‐SIGNAL (<a href="./references#CD006847-bbs2-0013" title="HanJY , ParkK , KimSW , LeeDH , KimHY , KimHT , et al. First‐SIGNAL: first‐line single‐agent Iressa versus gemcitabine and cisplatin trial in never‐smokers with adenocarcinoma of the lung. Journal of Clinical Oncology2012;30:1122‐8. HanJY , YoonKA , ParkJH , LeeYJ , LeeGK , HanJH , et al. DNA repair gene polymorphisms and benefit from gefitinib in never‐smokers with lung adenocarcinoma. Cancer2011;117(14):3201‐8. ">Han 2012 First SIGNAL</a>) studies selected Asian patients with adenocarcinomas, and conducted planned subgroup analyses on the EGFR mutation positive patients. IPASS compared first‐line gefitinib with carboplatin and paclitaxel and First‐SIGNAL compared gefitinib with gemcitabine and cisplatin. <a href="./references#CD006847-bbs2-0033" title="BoyeM , WangX , SrimuninnimitV , KangJH , TsaiCM , OrlandoM , et al. First‐line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian never‐smoker patients with locally advanced or metastatic nonsquamous non‐small cell lung cancer: quality of life results from a randomized phase III trial. Clinical Lung Cancer2016;17(2):150‐60. KangJH , AhnM , KimD , ChoEK , KimJ , ShinSW , et al. Tolerability and outcomes of first‐line pemetrexed‐cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in Korean patients with advanced non‐squamous non‐small cell lung cancer: a post hoc descriptive subgroup analysis of a randomized, phase 3 trial. Cancer Research and Treatment2015;48(2):458‐64. YangJC , KangJH , MokT , AhnM , SrimuninnimitV , LinC , et al. First‐line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non‐squamous non‐small cell lung cancer: a randomised, phase 3 trial. European Journal of Cancer2014;50:2219‐30. YangJC , ParkK , MokTSK , KangJH , SrimuninnimitV , LinCC , et al. A randomized phase 3 study comparing first‐line pemetrexed plus cisplatin followed by gefitinib as maintenance with gefitinib monotherapy in east Asian patients with locally advanced or metastatic nonsquamous non‐small cell lung cancer (NSQNSCLC). 15th World Conference on Lung Cancer Sydney, NSW Australia. International Association for the Study of Lung Cancer, 2013; Vol. 8:S288. YangJC , SrimuninnimitV , AhnM , LinC , KimS , TsaiC , et al. A randomized phase 3 study comparing first‐line pemetrexed plus cisplatin followed by gefitinib maintenance (PC/G) with gefitinib monotherapy (G) in East Asian patients (pts) with locally advanced or metastatic nonsquamous non‐small cell lung cancer (nSqNSCLC): final survival results. Journal of Clinical Oncology2015;15 Suppl:8041. YangJC , SrimunninnimitV , AhnM , LinC , KimS , TsaiC , et al. First‐line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian never‐smoker patients with locally advanced or metastatic nonsquamous non‐small cell lung cancer: final overall survival results from a randomized phase 3 study. Journal of Thoracic Oncology2016;11(3):370‐9. ">Yang 2014</a> conducted a post‐hoc analysis of EGFR mutation positive patients and compared first‐line pemetrexed and cisplatin followed by gefitinib maintenance with gefitinib alone. The INVITE phase II study in elderly patients that compared first‐line gefitinib with vinorelbine also conducted analysis of EGFR mutation positive patients but this study did not include any data that could be pooled (<a href="./references#CD006847-bbs2-0006" title="CrinoL , CappuzzoF , ZatloukalP , ReckM , PesekM , ThompsonJC , et al. Gefitinib versus vinorelbine in chemotherapy‐naive elderly patients with advanced non‐small‐cell lung cancer (INVITE): a randomized, phase II study. Journal of Clinical Oncology2008;26(26):4253‐60. ">Crino 2008 INVITE</a>). </p> <p>We analysed a total of 802 patients in this group.</p> <p>A further three phase III studies compared second‐line gefitinib with chemotherapy and conducted subgroup analyses in the EGFR mutation positive patients (<a href="./references#CD006847-bbs2-0016" title="DouillardJY , ShephardFA , HirshV , MokT , SocinskiMA , GervaisR , et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non‐small‐cell lung cancer: from the randomized phase III INTEREST Trial. Journal of Clinical Oncology2010;28(5):744‐52. HorganAM , BradburyPA , AmirE , NgR , DouillardJY , KimES , et al. An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second‐/third‐line therapy in advanced non‐small‐cell lung cancer. Annals of Oncology. United Kingdom: Oxford University Press (Great Clarendon Street, Oxford OX2 6DP, United Kingdom), 2011; Vol. 22:1805‐11. HorganAM , ShepherdFA , BradburyPA , NgR , LeighlNB . Preliminary cost‐consequence analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as 2nd line therapy in advanced non‐small cell lung cancer [abstract no. 8110]. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2008;25(15 Suppl Pt 1):451. KimES , HirshV , MokT , SocinskiMA , GervaisR , WuYL , et al. Gefitinib versus docetaxel in previously treated non‐small‐cell lung cancer (INTEREST): a randomized phase III trial. Lancet2008;372:1809‐18. ">Kim 2008 INTEREST</a>; <a href="./references#CD006847-bbs2-0023" title="LekiR , KawaharaM , WatanabeH , et al. The impact of response evaluation committee in a Phase III study (V‐15‐32) of gefitinib versus docetaxel in Japanese patients with non‐small cell lung cancer [Abstract No. 298P]. Annals of Oncology2009;19 Suppl 8:109‐10. MaruyamaR , NishiwakiY , TamuraT , YamamotoN , TsuboiM , NakagawaK , et al. Phase III study, V‐15‐32, of gefitinib versus docetaxel in previously treated Japanese patients with non‐small‐cell lung cancer. Journal of Clinical Oncology2008;26(26):4245‐52. SekineI , IchinoseY , NishiwakiY , YamamotoN , TsuboiM , NakagawaK , et al. Quality of life and disease‐related symptoms in previously treated Japanese patients with non‐small‐cell lung cancer: results of a randomized phase III study (V‐15‐32) of gefitinib versus docetaxel. Annals of Oncology2009;20(9):1483‐8. YamamotoN , NishiwakiY , NegoroS , JiangH , ItohY , SaijoN , et al. Disease control as a predictor of survival with gefitinib and docetaxel in a phase III study (V‐15‐32) in advanced non‐small‐cell lung cancer patients. Journal of Thoracic Oncology2010;5(7):1042‐7. ">Maruyama 2008 V‐15‐32</a>; <a href="./references#CD006847-bbs2-0028" title="AhnM , SunJ , AhnJS , KimS , MinYJ , YunHJ , et al. Randomized phase III trial of gefitinib or pemetrexed as second‐line treatment in patients with non‐small cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01). ASCO Annual Meeting 2011 Chicago, IL United States. American Society of Clinical Oncology, 2011; Vol. 29. AhnMJ , SunJM , LeeKH , AhnJS , KimSW , MinYJ , et al. Randomized phase III trial of gefitinib or pemetrexed as second‐line treatment in patients with non‐small cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01). 14th World Conference on Lung Cancer Amsterdam Netherlands. International Association for the Study of Lung Cancer, 2011; Vol. 6:S317. SunJM , LeeKH , KimSW , LeeDH , MinYJ , YunHJ , et al. Gefitinib versus pemetrexed as second‐line treatment in patients with nonsmall cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01): an open‐label, phase 3 trial. Cancer2012;118:6234‐42. ">Sun 2012 KCSG‐LU08‐01</a>). INTEREST and V‐15‐32 compared gefitinib with docetaxel and KCSG‐LU08‐01 compared gefitinib with pemetrexed in this second‐line setting. The INTEREST study also analysed other biomarkers, such as EGFR gene copy number, EGFR protein expression and KRAS mutations, in addition to EGFR mutations. One study did not publish data that could be pooled (<a href="./references#CD006847-bbs2-0023" title="LekiR , KawaharaM , WatanabeH , et al. The impact of response evaluation committee in a Phase III study (V‐15‐32) of gefitinib versus docetaxel in Japanese patients with non‐small cell lung cancer [Abstract No. 298P]. Annals of Oncology2009;19 Suppl 8:109‐10. MaruyamaR , NishiwakiY , TamuraT , YamamotoN , TsuboiM , NakagawaK , et al. Phase III study, V‐15‐32, of gefitinib versus docetaxel in previously treated Japanese patients with non‐small‐cell lung cancer. Journal of Clinical Oncology2008;26(26):4245‐52. SekineI , IchinoseY , NishiwakiY , YamamotoN , TsuboiM , NakagawaK , et al. Quality of life and disease‐related symptoms in previously treated Japanese patients with non‐small‐cell lung cancer: results of a randomized phase III study (V‐15‐32) of gefitinib versus docetaxel. Annals of Oncology2009;20(9):1483‐8. YamamotoN , NishiwakiY , NegoroS , JiangH , ItohY , SaijoN , et al. Disease control as a predictor of survival with gefitinib and docetaxel in a phase III study (V‐15‐32) in advanced non‐small‐cell lung cancer patients. Journal of Thoracic Oncology2010;5(7):1042‐7. ">Maruyama 2008 V‐15‐32</a>) and thus we included a total of 77 patients in this group. </p> </section> <section id="CD006847-sec-0062"> <h5 class="title">3. Gefitinib at a specific dose versus a different dose (Comparison 7)</h5> <p>Three phase II studies compared the effect of two different doses of gefitinib, 250 mg and 500 mg in 527 patients (<a href="./references#CD006847-bbs2-0009" title="BaelgaJ , KrisM , YanoS , NataleR , GiacconeG , BrahmerJ , et al. Phase II trials (IDEAL 1 and IDEAL 2) of ZD1839 in advanced or metastatic non‐small cell lung cancer (NSCLC) patient. Annals of Oncology2002;13(Suppl 5):131 Abs 481. DouillardJY , GiacconeG , HoraiT , NodaK , VansteenkisteJF , TakataI , et al. Improvement in disease‐related symptoms and quality of life in patients with advanced non‐small cell lung cancer (NSCLC) treated with ZD1839 ('Iressa') (IDEAL 1) [abstract]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:299a, Abs 1195. DouillardJY , SkarinA , BaselgaJ , NataleR , GiacconeG , MaddoxAM , et al. Improvement in disease‐related symptoms and quality of life (QOL) for advanced non‐small cell lung cancer (NSCLC) patients treated with ZD1839 in IDEAL 1 and IDEAL 2. Annals of Oncology2002;13 Suppl 5:131, Abs 480. FukuokaM , YanoS , GiacconeG , TamuraT , NakagawaK , DouillardJY , et al. Multi‐institutional randomized phase II trial of gefitinib for previously treated patients with advanced non‐small‐cell lung cancer. Journal of Clinical Oncology2003;21(12):2237‐46. FukuokaM , YanoS , GiacconeG , et al. [Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced non‐small cell lung cancer (IDEAL 1) [abstract]]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:298a, Abs 1188. ManegoldC , GatzemeierU , KaukelE . Results from a randomised, double blind phase II trial of ZD1839 (IRESSA) as 2nd/3rd‐line monotherapy in advanced non small cell lung cancer (NSCLC) (IDEAL 1). Journal of Cancer Research &amp; Clinical Oncology2002;128 Suppl 1:S45. NishiwakiY , YanoS , TamuraT , NakagawaK , KudohS , HoraiT , et al. Subset analysis of data in the Japanese patients with NSCLC from IDEAL I study on gefitinib. Gan to Kagaku Ryoho. Cancer &amp; Chemotherapy2004;31(4):567‐73. VansteenkisteJ , NataleR , GiacconeG , et al. Two randomised, double‐blind studies of ZD1839 in 425 patients with pretreated advanced non‐small‐call lung cancer (IDEAL 1 and IDEAL 2) [abstract]. European Respiratory Society Annual Congress. Stockholm, 2002:Abstract 2537. ">Fukuoka 2003 IDEAL I</a>; <a href="./references#CD006847-bbs2-0018" title="CellaD , HerbstRS , LynchTJ , PragerD , BelaniCP , SchillerJH , et al. Clinically meaningful improvement in symptoms and quality of life for patients with non‐small cell lung cancer receiving gefitinib in a randomized controlled trial. Journal of Clinical Oncology2005;23(13):2946‐54. KrisMG , NataleRB , HerbstRS , et al. A phase II trial of ZD1839 ('Iressa') in advanced non‐small cell lung cancer (NSCLC) patients who had failed platinum‐ and docetaxel‐based regimens (IDEAL 2) [abstract]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:292a Abstract 1166. KrisMG , NataleRB , HerbstRS , LynchTJ , PragerD , BelaniCP , et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non‐small cell lung cancer: a randomized trial. JAMA2003;290(16):2149‐58. NataleRB , SkarinA , MaddoxAM , et al. Improvement in symptoms and quality of life for advanced non‐small cell lung cancer patients receiving ZD1839 ('Iressa') in IDEAL 2 [abstract]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:292a, Abstract 1167. ">Kris 2003 IDEAL II</a>; <a href="./references#CD006847-bbs2-0032" title="XueC , HongS , LiN , FengW , JiaJ , PengJ , et al. Randomized, multicenter study of gefitinib dose‐escalation in advanced non‐small‐cell lung cancer patients achieved stable disease after one‐month gefitinib treatment. Scientific Reports2015;5:10648. ZhangL , XueC , LiN , FengW , JiaJ , PengJ , et al. Randomized, open‐label, multi‐center study of gefitinib dose‐escalation (500mg/d versus 250mg/d) in advanced NSCLC patient achieved stable disease (SD) after one‐month gefitinib treatment. 15th World Conference on Lung Cancer Sydney, NSW Australia. International Association for the Study of Lung Cancer, 2013; Vol. 8:S1185. ">Xue 2015</a>). IDEAL I (<a href="./references#CD006847-bbs2-0009" title="BaelgaJ , KrisM , YanoS , NataleR , GiacconeG , BrahmerJ , et al. Phase II trials (IDEAL 1 and IDEAL 2) of ZD1839 in advanced or metastatic non‐small cell lung cancer (NSCLC) patient. Annals of Oncology2002;13(Suppl 5):131 Abs 481. DouillardJY , GiacconeG , HoraiT , NodaK , VansteenkisteJF , TakataI , et al. Improvement in disease‐related symptoms and quality of life in patients with advanced non‐small cell lung cancer (NSCLC) treated with ZD1839 ('Iressa') (IDEAL 1) [abstract]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:299a, Abs 1195. DouillardJY , SkarinA , BaselgaJ , NataleR , GiacconeG , MaddoxAM , et al. Improvement in disease‐related symptoms and quality of life (QOL) for advanced non‐small cell lung cancer (NSCLC) patients treated with ZD1839 in IDEAL 1 and IDEAL 2. Annals of Oncology2002;13 Suppl 5:131, Abs 480. FukuokaM , YanoS , GiacconeG , TamuraT , NakagawaK , DouillardJY , et al. Multi‐institutional randomized phase II trial of gefitinib for previously treated patients with advanced non‐small‐cell lung cancer. Journal of Clinical Oncology2003;21(12):2237‐46. FukuokaM , YanoS , GiacconeG , et al. [Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced non‐small cell lung cancer (IDEAL 1) [abstract]]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:298a, Abs 1188. ManegoldC , GatzemeierU , KaukelE . Results from a randomised, double blind phase II trial of ZD1839 (IRESSA) as 2nd/3rd‐line monotherapy in advanced non small cell lung cancer (NSCLC) (IDEAL 1). Journal of Cancer Research &amp; Clinical Oncology2002;128 Suppl 1:S45. NishiwakiY , YanoS , TamuraT , NakagawaK , KudohS , HoraiT , et al. Subset analysis of data in the Japanese patients with NSCLC from IDEAL I study on gefitinib. Gan to Kagaku Ryoho. Cancer &amp; Chemotherapy2004;31(4):567‐73. VansteenkisteJ , NataleR , GiacconeG , et al. Two randomised, double‐blind studies of ZD1839 in 425 patients with pretreated advanced non‐small‐call lung cancer (IDEAL 1 and IDEAL 2) [abstract]. European Respiratory Society Annual Congress. Stockholm, 2002:Abstract 2537. ">Fukuoka 2003 IDEAL I</a>) and IDEAL II (<a href="./references#CD006847-bbs2-0018" title="CellaD , HerbstRS , LynchTJ , PragerD , BelaniCP , SchillerJH , et al. Clinically meaningful improvement in symptoms and quality of life for patients with non‐small cell lung cancer receiving gefitinib in a randomized controlled trial. Journal of Clinical Oncology2005;23(13):2946‐54. KrisMG , NataleRB , HerbstRS , et al. A phase II trial of ZD1839 ('Iressa') in advanced non‐small cell lung cancer (NSCLC) patients who had failed platinum‐ and docetaxel‐based regimens (IDEAL 2) [abstract]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:292a Abstract 1166. KrisMG , NataleRB , HerbstRS , LynchTJ , PragerD , BelaniCP , et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non‐small cell lung cancer: a randomized trial. JAMA2003;290(16):2149‐58. NataleRB , SkarinA , MaddoxAM , et al. Improvement in symptoms and quality of life for advanced non‐small cell lung cancer patients receiving ZD1839 ('Iressa') in IDEAL 2 [abstract]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:292a, Abstract 1167. ">Kris 2003 IDEAL II</a>) were multicentre, randomised, double‐blind, phase II studies that evaluated two doses of gefitinib (250 mg/day and 500 mg/day) as second‐ or third‐line therapy. </p> <p>We analysed 431 patients in this group.</p> <p>The third study randomised 96 patients who were stable after one month of gefitinib (250 mg/day) to either 250 mg/day or 500 mg/day as maintenance therapy (<a href="./references#CD006847-bbs2-0032" title="XueC , HongS , LiN , FengW , JiaJ , PengJ , et al. Randomized, multicenter study of gefitinib dose‐escalation in advanced non‐small‐cell lung cancer patients achieved stable disease after one‐month gefitinib treatment. Scientific Reports2015;5:10648. ZhangL , XueC , LiN , FengW , JiaJ , PengJ , et al. Randomized, open‐label, multi‐center study of gefitinib dose‐escalation (500mg/d versus 250mg/d) in advanced NSCLC patient achieved stable disease (SD) after one‐month gefitinib treatment. 15th World Conference on Lung Cancer Sydney, NSW Australia. International Association for the Study of Lung Cancer, 2013; Vol. 8:S1185. ">Xue 2015</a>). </p> </section> <section id="CD006847-sec-0063"> <h5 class="title">4. Gefitinib versus gefitinib combined with a chemotherapy regimen (Comparison 8)</h5> <p>Four studies compared gefitinib alone or in combination with chemotherapy. Two recently published studies examined the addition of chemotherapy to gefitinib versus gefitinib alone in the first‐line setting. A small study by <a href="./references#CD006847-bbs2-0002" title="AnC , ZhangJ , ChuH , GuC , XiaoF , ZhuF , et al. Study of gefitinib and pemetrexed as first‐line treatment in patients with advanced non‐small cell lung cancer harboring EGFR mutation. Pathology and Oncology Research2016;22:763‐8. ">An 2016</a> recruited 90 East Asian patients with an EGFR mutation and randomised them to receive gefitinib or gefitinib plus pemetrexed (500 mg/m<sup>2</sup>). In this study, pemetrexed or placebo was administered via intravenous infusion on day 1 of a 21‐day cycle. Gefitinib 250 mg was administered on days 2 to 16. A multicentre, phase II study by <a href="./references#CD006847-bbs2-0005" title="ChengY , MurakamiH , YangPC , HeJ , NakagawaK , KangJH , et al. Randomized phase II trial of gefitinib with and without pemetrexed as first‐line therapy in patients with advanced nonsquamous non‐small‐cell lung cancer with activating epidermal growth factor receptor mutations. Journal of Clinical Oncology2016;27(20):3258‐66. ">Cheng 2016</a> also compared gefitinib with and without pemetrexed as first‐line therapy. This study recruited 191 East Asian patients from China, Japan, Korea and Taiwan with advanced non‐squamous NSCLC with an activating EGFR mutation. Patients either received gefitinib 250 mg per day or gefitinib plus pemetrexed (500 mg/m<sup>2</sup>) infusion on day 1 of a 21‐day cycle. </p> <p>We included a total of 281 patients in this group.</p> <p><a href="./references#CD006847-bbs2-0003" title="ChenYM , LiuJM , ChouTY , PerngRP , TsaiCM , Whang‐PengJ . Phase II randomized study of daily gefitinib treatment alone or with vinorelbine every 2 weeks in patients with adenocarcinoma of the lung who failed at least 2 regimens of chemotherapy. Cancer2007;109(9):1821‐8. ">Chen 2007</a> compared 250 mg of daily oral gefitinib with gefitinib plus vinorelbine (15 mg/m<sup>2</sup>) every two weeks in 48 patients of Asian ethnicity with stage IV adenocarcinoma who had failed at least two lines of chemotherapy. <a href="./references#CD006847-bbs2-0004" title="ChenYM , FanWC , TsaiCM , LiuSH , ShihJF , ChouTY , et al. A phase II randomized trial of gefitinib alone or with Tegafur/uracil treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy. Journal of Thoracic Oncology2011;6:1110‐6. ">Chen 2011</a> compared gefitinib alone with the combination of gefitinib plus tegafur (100 mg)/uracil (224 mg) in 115 Taiwanese patients with stage IIIB or IV adenocarcinoma who had failed first‐line chemotherapy. </p> <p>We included a total of 163 patients in this group.</p> </section> <section id="CD006847-sec-0064"> <h5 class="title">5. Gefitinib at any dose in combination with other chemotherapeutic agents versus the same chemotherapy agents alone (Comparison 9) </h5> <p>Five studies examined survival outcomes, objective response rates and toxicity (<a href="./references#CD006847-bbs2-0011" title="BellDW , LynchTJ , MaserlatSM , HarrisPL , OkimotoFA , BranniganBW , et al. Epidermal growth factor receptor mutations and gene amplification in non‐small‐cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. Journal of Clinical Oncology2005;23(31):8081‐92. GiacconeG , HerbstRS , ManegoldC , ScagliottiG , RosellR , MillerV , et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non‐small cell lung cancer: a phase III trial ‐ INTACT I. Journal of Clinical Oncology2004;22(5):777‐84. GiacconeG , JohnsonDH , ManegoldC , et al. A phase III clinical trial of ZD1839 ('Iressa') in combination with gemcitabine and cisplatin in chemotherapy‐naive patients with advanced non‐small cell lung cancer (INTACT 1). Annals of Oncology2002;13 Suppl 5:2, Abstract 4. ">Giaccone 2004 INTACT I</a>; <a href="./references#CD006847-bbs2-0014" title="HerbstRS , GiacconeG , SchillerJH , NataleRB , MillerV , ManegoldC , et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non‐small cell lung cancer: a phase III trial ‐ INTACT 2. Journal of Clinical Oncology2004;22(5):785‐94. JohnsonDH , HerbstR , GiacconeG , et al. ZD1839 ('Iressa') in combination with paclitaxel &amp; carboplatin in chemotherapy‐naive patients with advanced non‐small cell lung cancer (NSCLC): results from a phase III clinical trial (INTACT 2). Annals of Oncology2002;13 Suppl 5:127, Abstract 468. ">Herbst 2004 INTACT II</a>; <a href="./references#CD006847-bbs2-0027" title="SoriaJC , WuYL , NakagawaK , KimSW , YangJJ , AhnMJ , et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR‐mutation‐positive non‐small‐cell lung cancer after progression on first‐line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncology2015;16:990‐8. ">Soria 2015 IMPRESS</a>; <a href="./references#CD006847-bbs2-0029" title="OkamotoI , HidaT , KashiiT , et al. Randomized phase III study of platinum‐doublet chemotherapy followed by gefitinib versus continued platinum‐doublet chemotherapy in patients (pts) with advanced non‐small cell lung cancer (NSCLC): Results of West Japan Thoracic Oncology Group Trial (WJTOG0203) [Abstract No. 2 33PD]. Annals of Oncology2008;19 Suppl 8:91. TakedaK , HidaT , SatoT , AndoM , SetoT , SatouchiM , et al. Randomized phase III trial of platinum‐doublet chemotherapy followed by gefitinib comparted with continued platinum‐doublet chemotherapy in Japanese patients with advanced non‐small cell lung cancer: results of a West Japan Thoracic Oncology Group Trial (WJTOG0203). Journal of Clinical Oncology2010;28(5):753‐60. ">Takeda 2010 WJTOG0203</a>; <a href="./references#CD006847-bbs2-0034" title="YuH , ZhangJ , WuX , LuoZ , WangH , SunS , et al. A phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non‐squamous non‐small cell lung cancer. Cancer Biology and Therapy2014;15(7):832‐9. ">Yu 2014</a>). Overall, we included a total of 3110 patients. </p> <p>INTACT I (<a href="./references#CD006847-bbs2-0011" title="BellDW , LynchTJ , MaserlatSM , HarrisPL , OkimotoFA , BranniganBW , et al. Epidermal growth factor receptor mutations and gene amplification in non‐small‐cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. Journal of Clinical Oncology2005;23(31):8081‐92. GiacconeG , HerbstRS , ManegoldC , ScagliottiG , RosellR , MillerV , et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non‐small cell lung cancer: a phase III trial ‐ INTACT I. Journal of Clinical Oncology2004;22(5):777‐84. GiacconeG , JohnsonDH , ManegoldC , et al. A phase III clinical trial of ZD1839 ('Iressa') in combination with gemcitabine and cisplatin in chemotherapy‐naive patients with advanced non‐small cell lung cancer (INTACT 1). Annals of Oncology2002;13 Suppl 5:2, Abstract 4. ">Giaccone 2004 INTACT I</a>) and INTACT II (<a href="./references#CD006847-bbs2-0014" title="HerbstRS , GiacconeG , SchillerJH , NataleRB , MillerV , ManegoldC , et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non‐small cell lung cancer: a phase III trial ‐ INTACT 2. Journal of Clinical Oncology2004;22(5):785‐94. JohnsonDH , HerbstR , GiacconeG , et al. ZD1839 ('Iressa') in combination with paclitaxel &amp; carboplatin in chemotherapy‐naive patients with advanced non‐small cell lung cancer (NSCLC): results from a phase III clinical trial (INTACT 2). Annals of Oncology2002;13 Suppl 5:127, Abstract 468. ">Herbst 2004 INTACT II</a>) were large, multicentre trials that examined the effect of the addition of two different doses of gefitinib to a chemotherapy regimen with the chemotherapy alone in chemotherapy‐naive patients. INTACT I compared the effect of the addition of gefitinib to a chemotherapy regimen that included gemcitabine and cisplatin and INTACT II a paclitaxel and carboplatin regime. WJTOG0203 compared the addition of 250 mg of gefitinib to platinum‐doublet chemotherapy in chemotherapy‐naive Japanese patients (<a href="./references#CD006847-bbs2-0029" title="OkamotoI , HidaT , KashiiT , et al. Randomized phase III study of platinum‐doublet chemotherapy followed by gefitinib versus continued platinum‐doublet chemotherapy in patients (pts) with advanced non‐small cell lung cancer (NSCLC): Results of West Japan Thoracic Oncology Group Trial (WJTOG0203) [Abstract No. 2 33PD]. Annals of Oncology2008;19 Suppl 8:91. TakedaK , HidaT , SatoT , AndoM , SetoT , SatouchiM , et al. Randomized phase III trial of platinum‐doublet chemotherapy followed by gefitinib comparted with continued platinum‐doublet chemotherapy in Japanese patients with advanced non‐small cell lung cancer: results of a West Japan Thoracic Oncology Group Trial (WJTOG0203). Journal of Clinical Oncology2010;28(5):753‐60. ">Takeda 2010 WJTOG0203</a>). In this study, patients were randomised to receive platinum doublet chemotherapy (Arm A) or platinum‐doublet chemotherapy for three cycles followed by gefitinib until disease progression (Arm B). The phase II study by <a href="./references#CD006847-bbs2-0034" title="YuH , ZhangJ , WuX , LuoZ , WangH , SunS , et al. A phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non‐squamous non‐small cell lung cancer. Cancer Biology and Therapy2014;15(7):832‐9. ">Yu 2014</a> examined the addition of gefitinib to a first‐line pemetrexed and cisplatin chemotherapy schedule in Asian patients who were non‐smokers or light ex‐smokers. </p> <p>In this group, we included 2845 patients.</p> <p>The IMPRESS study was a phase III, multicentre study conducted across Europe and the Asia‐Pacific region (<a href="./references#CD006847-bbs2-0027" title="SoriaJC , WuYL , NakagawaK , KimSW , YangJJ , AhnMJ , et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR‐mutation‐positive non‐small‐cell lung cancer after progression on first‐line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncology2015;16:990‐8. ">Soria 2015 IMPRESS</a>). This study selected patients with EGFR mutation positive advanced NSCLC who had failed first‐line therapy with gefitinib. This study compared second‐line gefitinib plus chemotherapy (cisplatin and pemetrexed) with placebo plus the same chemotherapy regimen (cisplatin and pemetrexed). Two hundred and sixty‐five patients were included in this trial. </p> </section> <section id="CD006847-sec-0065"> <h5 class="title">6. Gefitinib at any dose in combination with other chemotherapeutic agents versus a different combination of chemotherapeutic agent (Comparison 10) </h5> <p>No studies compared gefitinib in combination with a chemotherapeutic regime with a different regime of agents. </p> <p>Data for all endpoints were not available in all published reports. A summary of efficacy and survival data is presented in <a href="#CD006847-tbl-0005">Table 2</a>. </p> <div class="table" id="CD006847-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Efficacy and survival data</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>ORR (%)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>PFS (months)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>OS (months)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1. Gefitinib versus placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p><b>1st line</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Goss 2009</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.43</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p><b>2nd line</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thatcher 2005 ISEL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0006</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.087</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p><b>Maintenance therapy</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kelly 2008 SWOGS0023</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.013</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gaafar 2011 EORTC08021</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.004</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0015</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2. Gefitinib versus placebo (Asian population)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chang 2006 ISEL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.008</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zhang 2012 INFORM</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.0001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3. Gefitinib versus placebo (EGFR mutation positive)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zhang 2012 INFORM</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0063</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.87</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.97</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.036</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p><b>Gefitinib vs chemotherapy</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4. General population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chemo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chemo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chemo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p><b>versus 1st line chemotherapy</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Crino 2008 INVITE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Morere 2010 IFCT0301</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.078</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.088</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Morere 2010 IFCT0301 (Adenocarcinoma)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.272</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p><b>versus 2nd line chemotherapy</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cufer 2006 SIGN</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kim 2008 INTEREST</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kim 2008 INTEREST</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5. Asian population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chemo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chemo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chemo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p><b>versus 1st line chemotherapy</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lou 2014</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maemondo 2010 (EGFR mutation positive)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mitsudomi 2010 WJTOG (EGFR mutation positive)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.0001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.0001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mok 2009 IPASS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Han 2012 First‐SIGNAL (adenocarcinoma)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yang 2014 (Asian)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.63</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.38</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>versus 2nd line chemotherapy</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dai 2013</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kim 2016</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Li 2010</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kim 2008 INTEREST (subgroup)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lee 2010 ISTANA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0007</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maruyama 2008 V‐15‐32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.009</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sun 2012 KCSG‐LU08‐01 (adenocarcinoma, subgroup)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0006</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p><b>versus maintenance therapy</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ahn 2012 (Asian)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.95</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.83</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xu 2015 (Asian)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>6. EGFR mutation positive</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chemo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chemo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chemo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p><b>versus 1st line chemotherapy</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maemondo 2010 (EGFR mutation positive)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mitsudomi 2010 WJTOG (EGFR mutation positive)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.0001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.0001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mok 2009 IPASS (subgroup)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Han 2012 First‐SIGNAL (subgroup)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.002</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yang 2014 (subgroup)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.62</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.91</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.255</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p><b>versus 2nd line chemotherapy</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>INTEREST Doulliard 2010 (subgroup)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.04</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maruyama 2008 (subgroup)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sun 2012 KCSG‐LU08‐01 (subgroup)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.005</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>7. Gefitinib 250 mg versus gefitinib 500 mg</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>250 mg</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>500 mg</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>250 mg</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>500 mg</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>250 mg</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>500 mg</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p><b>2nd+ line</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fukuoka 2003</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kris 2004</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p><b>Maintenance therapy</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xue 2015 (Asian)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>8. Gefitinib versus gefitinib + chemotherapy</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>G + Chemo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>G + Chemo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>G + Chemo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p><b>1st line</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An 2016</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73.33</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.05</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cheng 2016</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.014</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p><b>2nd+ line</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chen 2007(Asian, adenocarcinoma)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chen 2011(Asian, adenocarcinoma)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.04</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chen 2011 (EGFR mutation positive subgroup)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0061</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>9. Gefitinib + chemotherapy versus chemotherapy</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>250 mg + Chemo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chemo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>250 mg + Chemo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chemo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>250 mg + Chemo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chemo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1st line</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Giaccone 2004</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Herbst 2004</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Takeda 2010 (Asian)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yu 2014 (Asian)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2nd line</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Soria 2015 IMPRESS (EGFR mutation positive)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Chemo: chemotherapy<br/> G: gefitinib<br/> NS: non‐significant<br/> ORR: overall response rate<br/> OS: overall survival<br/> PFS: progression‐free survival </p> </div> </div> </section> </section> </section> <section id="CD006847-sec-0066"> <h3 class="title">Risk of bias in included studies</h3> <p>We included trials that met our inclusion criteria. We checked all data extracted for accuracy and final database entries. We resolved any discrepancies through discussion. Overall, the risk of bias in the 35 included studies was moderate. The results of the 'Risk of bias' assessment are depicted graphically in <a href="#CD006847-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD006847-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD006847-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD006847-sec-0067"> <h4 class="title">Allocation</h4> <section id="CD006847-sec-0068"> <h5 class="title">Sequence generation</h5> <p>Seventeen of the 35 included studies reported adequate sequence generation (<a href="./references#CD006847-bbs2-0001" title="AhnMJ , YangJCH , LiangJ , KangJH , XiuQ , ChenYM , et al. Randomized phase II trial of first‐line treatment with pemetrexed‐cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never‐smoker patients with advanced non‐small cell lung cancer. Lung Cancer2012;77:346‐52. ">Ahn 2012</a>; <a href="./references#CD006847-bbs2-0005" title="ChengY , MurakamiH , YangPC , HeJ , NakagawaK , KangJH , et al. Randomized phase II trial of gefitinib with and without pemetrexed as first‐line therapy in patients with advanced nonsquamous non‐small‐cell lung cancer with activating epidermal growth factor receptor mutations. Journal of Clinical Oncology2016;27(20):3258‐66. ">Cheng 2016</a>; <a href="./references#CD006847-bbs2-0006" title="CrinoL , CappuzzoF , ZatloukalP , ReckM , PesekM , ThompsonJC , et al. Gefitinib versus vinorelbine in chemotherapy‐naive elderly patients with advanced non‐small‐cell lung cancer (INVITE): a randomized, phase II study. Journal of Clinical Oncology2008;26(26):4253‐60. ">Crino 2008 INVITE</a>; <a href="./references#CD006847-bbs2-0007" title="CuferT , VrdoljakE , GaafarR , ErensoyI , PembertonK , SIGN study group. Phase II, open‐label, randomized study (SIGN) or single‐agent gefitinib (IRESSA) or docetaxel as second‐line therapy in patients with advanced (stage IIIb or IV) non‐small‐cell lung cancer. Anticancer Drugs2006;17(4):401‐9. ">Cufer 2006 SIGN</a>; <a href="./references#CD006847-bbs2-0010" title="GaafarR M , SurmontV , ScagliottiG , VanKlaverenR , PapamichaelD , WelchJ , et al. A double‐blind, randomized, placebo‐controlled phase III intergroup study of gefitinib (G) in patients (pts) with advanced NSCLC, non‐progressing after first‐line platinum‐based chemotherapy (EORTC 08021‐ILCP 01/03). 2010 Annual Meeting of the Americal Society of CLinical Oncology, ASCO, Chicago, IL United States. American Society of Clinical Oncology, 2010; Vol. 28. GaafarRM , SurmontVF , ScagliottiGV , VanKlaverenRJ , PapamichaelD , WelchJJ , et al. A double‐blind, randomised, placebo‐controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non‐progressing after first line platinum‐based chemotherapy (EORTC 08021/ILCP 01/03). European Journal of Cancer2011;47:2331‐40. SurmontVF , GaafarRM , ScagliottiGV , VanKlaverenRJ , PapamichaelD , HasanB , et al. A double‐blind, randomized, placebo‐controlled phase III study of gefitinib (G) versus placebo (P) in patients (pts) with advanced NSCLC, non progressing after first‐line platinum‐based chemotherapy (EORTC 08021‐ ILCP). 35th ESMO Congress Milan Italy. Oxford University Press, 2010; Vol. 21:viii124. ">Gaafar 2011 EORTC08021</a>; <a href="./references#CD006847-bbs2-0011" title="BellDW , LynchTJ , MaserlatSM , HarrisPL , OkimotoFA , BranniganBW , et al. Epidermal growth factor receptor mutations and gene amplification in non‐small‐cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. Journal of Clinical Oncology2005;23(31):8081‐92. GiacconeG , HerbstRS , ManegoldC , ScagliottiG , RosellR , MillerV , et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non‐small cell lung cancer: a phase III trial ‐ INTACT I. Journal of Clinical Oncology2004;22(5):777‐84. GiacconeG , JohnsonDH , ManegoldC , et al. A phase III clinical trial of ZD1839 ('Iressa') in combination with gemcitabine and cisplatin in chemotherapy‐naive patients with advanced non‐small cell lung cancer (INTACT 1). Annals of Oncology2002;13 Suppl 5:2, Abstract 4. ">Giaccone 2004 INTACT I</a>; <a href="./references#CD006847-bbs2-0012" title="GossG , FerryD , WierzibickiR , LaurieSA , ThompsonJ , BiesmaB , et al. Randomized phase II study of gefitinib compared with placebo in chemotherapy‐naive patients with advanced non‐small‐cell lung cancer and poor performance status. Journal of Clinical Oncology2009;27(13):2253‐60. ">Goss 2009 INSTEP</a>; <a href="./references#CD006847-bbs2-0016" title="DouillardJY , ShephardFA , HirshV , MokT , SocinskiMA , GervaisR , et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non‐small‐cell lung cancer: from the randomized phase III INTEREST Trial. Journal of Clinical Oncology2010;28(5):744‐52. HorganAM , BradburyPA , AmirE , NgR , DouillardJY , KimES , et al. An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second‐/third‐line therapy in advanced non‐small‐cell lung cancer. Annals of Oncology. United Kingdom: Oxford University Press (Great Clarendon Street, Oxford OX2 6DP, United Kingdom), 2011; Vol. 22:1805‐11. HorganAM , ShepherdFA , BradburyPA , NgR , LeighlNB . Preliminary cost‐consequence analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as 2nd line therapy in advanced non‐small cell lung cancer [abstract no. 8110]. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2008;25(15 Suppl Pt 1):451. KimES , HirshV , MokT , SocinskiMA , GervaisR , WuYL , et al. Gefitinib versus docetaxel in previously treated non‐small‐cell lung cancer (INTEREST): a randomized phase III trial. Lancet2008;372:1809‐18. ">Kim 2008 INTEREST</a>; <a href="./references#CD006847-bbs2-0023" title="LekiR , KawaharaM , WatanabeH , et al. The impact of response evaluation committee in a Phase III study (V‐15‐32) of gefitinib versus docetaxel in Japanese patients with non‐small cell lung cancer [Abstract No. 298P]. Annals of Oncology2009;19 Suppl 8:109‐10. MaruyamaR , NishiwakiY , TamuraT , YamamotoN , TsuboiM , NakagawaK , et al. Phase III study, V‐15‐32, of gefitinib versus docetaxel in previously treated Japanese patients with non‐small‐cell lung cancer. Journal of Clinical Oncology2008;26(26):4245‐52. SekineI , IchinoseY , NishiwakiY , YamamotoN , TsuboiM , NakagawaK , et al. Quality of life and disease‐related symptoms in previously treated Japanese patients with non‐small‐cell lung cancer: results of a randomized phase III study (V‐15‐32) of gefitinib versus docetaxel. Annals of Oncology2009;20(9):1483‐8. YamamotoN , NishiwakiY , NegoroS , JiangH , ItohY , SaijoN , et al. Disease control as a predictor of survival with gefitinib and docetaxel in a phase III study (V‐15‐32) in advanced non‐small‐cell lung cancer patients. Journal of Thoracic Oncology2010;5(7):1042‐7. ">Maruyama 2008 V‐15‐32</a>; <a href="./references#CD006847-bbs2-0024" title="MitsudomiT , MoritaS , YatabeY , NegoroS , OkamotoI , SetoT , et al. Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first‐line treatment for patients with non‐small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR). 2012 Annual Meeting of the American Society of Clinical Oncology, ASCO Chicago, IL United States. American Society of Clinical Oncology, 2012; Vol. 30. MitsudomiT , MoritaS , YatabeY , NegoroS , OkamotoI , TsurutaniJ , et al. Gefitinib versus cisplatin plus docetaxel in patients with non‐small‐cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase III trial. Lancet2010;11:121‐8. TsurutaniJ , MitsudomiT , MoriS , OkamotoI , NozakiK , TadaH , et al. A phase III, first‐line trial of gefitinib versus cisplatin plus docetaxel for patients with advanced or recurrent non‐small cell lung cancer (NSCLC) harboring activating mutation of the epidermal growth factor receptor (EGFR) gene: a preliminary results of WJTOG 3405 [abstract O‐9002]. European Journal of Cancer. 2009; Vol. 7 Suppl:505. ">Mitsudomi 2010 WJTOG3405</a>; <a href="./references#CD006847-bbs2-0025" title="FukuokaM , WuYL , ThongprasertS , SunpaweravongP , LeongSS , SriuranpongV , et al. Biomarker analyses and final overall survival results from a phase III, randomized, open‐label, first‐line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non ‐ small‐cell lung cancer in Asia (IPASS). Journal of Clinical Oncology2011;29:2866‐74. MokT , WuY‐L , ThongprasertS , et al. Phase III, randomised, open‐label, first‐line study of gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients (PTS) with advanced non‐small cell lung cancer (NSCLC) (IPASS). Annals of Oncology2008;19 Suppl 8:Viii1. MokTS , WuYL , ThongprasertS , YangCH , ChuDT , SaijoN , et al. Gefitinib or carboplatin‐paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine2009;361(10):947‐57. OheY , IchinoseY , NishiwakiY ,  etal . Phase III, randomized, open‐label, first‐line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in selected patients (pts) with advanced non‐small‐cell lung cancer (NSCLC) (IPASS): Evaluation of recruits in Japan. Journal of Clinical Oncology2009;29(15 Suppl 1):8044. ThongprasertS , DuffieldE , SaijoN , WuYL , YangJC , ChuDT , et al. Health‐related quality‐of‐life in a randomized phase III first‐line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). Journal of Thoracic Oncology2011;6:1872‐80. ThongprasertS , DuffieldE , WuY , et al. Quality of life (QOL) in a randomized phase III first‐line study of gefitinib (G) vs carboplatin/paclitaxel (CP) in clinically selected Asian patients (pts) with advanced NSCLC (IPASS). Journal of Thoracic Oncology2010;5(5 Suppl 1):S80. WuY , ChuD , HanB , LiuX , ZhangL , ZhouC , et al. Phase III, randomized, open‐label, first‐line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non‐small‐cell lung cancer: evaluation of patients recruited from mainland China. Asia‐Pacific Journal of Clinical Oncology2012;8:232‐43. WuY , FukuokaM , MokT S K , SaijoN , ThongprasertS , YangJ C H , et al. Tumour response, skin rash and health‐related quality of life (HRQOL) ‐ Post‐HOC data from the IPASS study. European Multidisciplinary Cancer Congress Stockholm Sweden. Elsevier Ltd, 2011; Vol. 47:S633‐4. WuY , MokT , ChuD , et al. Evaluation of clinically selected patients (pts) with advanced non‐small cell lung cancer (NSCLC) recruited in China in a phase III, randomized, open‐label, first‐line study in Asia of gefitinib (G) versus carboplatin/paclitaxel (C/P) (IPASS). Journal of Clinical Oncology. 2009; Vol. 27 (15 Suppl 1):8041. WuYL , FukuokaM , MokTSK , SaijoN , ThongprasertS , YangJCH , et al. Tumor response and health‐related quality of life in clinically selected patients from Asia with advanced non‐small‐cell lung cancer treated with first‐line gefitinib: post hoc analyses from the IPASS study. Lung Cancer2013;81:280‐7. YangCH , FukuokaM , MokTS , WuYL , ThongprasertS , SaijoN , et al. Final overall survival (OS) results from a phase III, randomised, open‐label, first‐line study of gefitinib (G) v carboplatin/paclitaxel (C/P) in clinically selected patients with advanced nonsmall cell lung cancer (NSCLC) in Asia (IPASS). 35th ESMO Congress Milan Italy. Oxford University Press, 2010; Vol. 21:viii1‐2. YangJ , WuY L , SaijoN , ThongprasertS , ChuD T , ChenY M , et al. Efficacy outcomes in first‐line treatment of advanced NSCLC with gefitinib (G) vs carboplatin/paclitaxel (C/P) by epidermal growth factor receptor (EGFR) gene‐copy number score and by most common EGFR mutation subtypes ‐ Exploratory data from IPASS. 2011 European Multidisciplinary Cancer Congress Stockholm Sweden. Elsevier Ltd, 2011; Vol. 47:S633. YangJ , WuY , ChanV , KurniandaJ , NakagawaK . Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan‐ASia Study (IPASS). Lung Cancer2014;83:174‐81. YangJCH , WuYL , ChanV , KurniandaJ , NakagawaK , SaijoN , et al. Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan‐ASia Study (IPASS). Lung Cancer2014;83:174‐81. ">Mok 2009 IPASS</a>; <a href="./references#CD006847-bbs2-0026" title="DesGuetzG , LandreT , WesteelV , MilleronB , VayletF , UrbanT , et al. Similar survival rates with first‐line gefitinib, gemcitabine or docetaxel in a randomized phase II trial in elderly patients with advanced non‐small cell lung cancer and a poor performance status (IFCT‐0301). Journal of Geriatric Oncology2015;6:233‐40. MorereJ , WesteelV , MorinF , et al. Randomized phase II trial of first‐line gefitinib,gemcitabine or docetaxel in performance status (PS) 2 or 3 non‐small‐cell lung cancer (NSCLC) patients (IFCT‐0301) [abstract no. 8086]. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2008;26(15 Suppl Pt I):445. MorereJF , BrechotJM , WesteelV , GounantV , LebeauB , VayletF , et al. Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non‐small‐cell lung cancer and a performance status of  2 or 3 (IFCT‐0301 study). Lung Cancer2010;70(1):301‐7. ">Morere 2010 IFCT‐0301</a>; <a href="./references#CD006847-bbs2-0027" title="SoriaJC , WuYL , NakagawaK , KimSW , YangJJ , AhnMJ , et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR‐mutation‐positive non‐small‐cell lung cancer after progression on first‐line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncology2015;16:990‐8. ">Soria 2015 IMPRESS</a>; <a href="./references#CD006847-bbs2-0028" title="AhnM , SunJ , AhnJS , KimS , MinYJ , YunHJ , et al. Randomized phase III trial of gefitinib or pemetrexed as second‐line treatment in patients with non‐small cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01). ASCO Annual Meeting 2011 Chicago, IL United States. American Society of Clinical Oncology, 2011; Vol. 29. AhnMJ , SunJM , LeeKH , AhnJS , KimSW , MinYJ , et al. Randomized phase III trial of gefitinib or pemetrexed as second‐line treatment in patients with non‐small cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01). 14th World Conference on Lung Cancer Amsterdam Netherlands. International Association for the Study of Lung Cancer, 2011; Vol. 6:S317. SunJM , LeeKH , KimSW , LeeDH , MinYJ , YunHJ , et al. Gefitinib versus pemetrexed as second‐line treatment in patients with nonsmall cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01): an open‐label, phase 3 trial. Cancer2012;118:6234‐42. ">Sun 2012 KCSG‐LU08‐01</a>; <a href="./references#CD006847-bbs2-0030" title="ChangA , ParikhP , ThongprasertS , TanEH , PerngRP , GanzonD , et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non‐small cell lung cancer: subset analysis from the ISEL study. Journal of Thoracic Oncology2006;1(8):847‐55. HirschFR , DziadziuszkoR , ThatcherN , MannH , WatkinsC , ParumsDV , et al. Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo‐controlled study in advanced non small‐cell lung cancer. Cancer2008;112(5):1114‐21. HirschFR , Varella‐GarciaM , Bunn JrPA , FranklinWA , DziadziuszkoR , ThatcherN , et al. Molecular predictors of outcome with gefitinib in a phase III placebo‐controlled study in advanced non‐small cell lung cancer. Journal of Clinical Oncology2006;24(31):5034‐42. ThatcherN , ChangA , ParikhP , Rodrigues PereiraJ , CiuleanuT , vonPawelJ , et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non‐small‐cell lung cancer: results from a randomised, placebo‐controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet2005;366(9496):1527‐37. ">Thatcher 2005 ISEL</a>; <a href="./references#CD006847-bbs2-0033" title="BoyeM , WangX , SrimuninnimitV , KangJH , TsaiCM , OrlandoM , et al. First‐line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian never‐smoker patients with locally advanced or metastatic nonsquamous non‐small cell lung cancer: quality of life results from a randomized phase III trial. Clinical Lung Cancer2016;17(2):150‐60. KangJH , AhnM , KimD , ChoEK , KimJ , ShinSW , et al. Tolerability and outcomes of first‐line pemetrexed‐cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in Korean patients with advanced non‐squamous non‐small cell lung cancer: a post hoc descriptive subgroup analysis of a randomized, phase 3 trial. Cancer Research and Treatment2015;48(2):458‐64. YangJC , KangJH , MokT , AhnM , SrimuninnimitV , LinC , et al. First‐line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non‐squamous non‐small cell lung cancer: a randomised, phase 3 trial. European Journal of Cancer2014;50:2219‐30. YangJC , ParkK , MokTSK , KangJH , SrimuninnimitV , LinCC , et al. A randomized phase 3 study comparing first‐line pemetrexed plus cisplatin followed by gefitinib as maintenance with gefitinib monotherapy in east Asian patients with locally advanced or metastatic nonsquamous non‐small cell lung cancer (NSQNSCLC). 15th World Conference on Lung Cancer Sydney, NSW Australia. International Association for the Study of Lung Cancer, 2013; Vol. 8:S288. YangJC , SrimuninnimitV , AhnM , LinC , KimS , TsaiC , et al. A randomized phase 3 study comparing first‐line pemetrexed plus cisplatin followed by gefitinib maintenance (PC/G) with gefitinib monotherapy (G) in East Asian patients (pts) with locally advanced or metastatic nonsquamous non‐small cell lung cancer (nSqNSCLC): final survival results. Journal of Clinical Oncology2015;15 Suppl:8041. YangJC , SrimunninnimitV , AhnM , LinC , KimS , TsaiC , et al. First‐line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian never‐smoker patients with locally advanced or metastatic nonsquamous non‐small cell lung cancer: final overall survival results from a randomized phase 3 study. Journal of Thoracic Oncology2016;11(3):370‐9. ">Yang 2014</a>; <a href="./references#CD006847-bbs2-0035" title="YangY , MaY , ZhaoY , FangW , HongS , et al. QoL analyses from INFORM study, a phase III study of gefitinib versus placebo as maintenance therapy in advanced NSCLC. Scientific Reports2015;5:11934. ZhangL , MaS , SongX , HanB , ChengY , HuangC , et al. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non‐small‐cell lung cancer (INFORM; C‐TONG 0804): a multicentre, double‐blind randomised phase 3 trial. Lancet Oncology2012;13:466‐75. ZhangL , MaSL , SongXQ , ChengY , HuangC , YangSJ , et al. Pre‐planned subgroup analyses from the phase III, randomised, placebo‐controlled, parallel‐group study of gefitinib (G) as maintenance therapy in patients (pts) with locally advanced or metastatic non‐small‐cell lung cancer (NSCLC) (INFORM; C‐TONG 0804). European Multidisciplinary Cancer Congress Stockholm Sweden. Elsevier Ltd, 2011; Vol. 47:S622‐3. ZhangL , MaSL , SongXQ , HanBH , ChengY , HuangC , et al. Efficacy, tolerability and biomarker analyses from a phase III, randomized, placebo controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non‐small‐cell lung cancer (NSCLC) in China (INFORM) (C‐TONG 0804). 14th World Conference on Lung Cancer Amsterdam Netherlands. International Association for the Study of Lung Cancer, 2011; Vol. 6:S558‐9. ZhangL , ShenglinM , SongX , HanB , ChengY , HuangC , et al. Efficacy, tolerability, and biomarker analyses from a phase III, randomized, placebo‐controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non‐small cell lung cancer (NSCLC; INFORM; C‐TONG 0804). ASCO Annual Meeting 2011 Chicago, IL United States. American Society of Clinical Oncology, 2011; Vol. 29. ZhaoH , FanY , MaS , SongX , HanB , ChengY , et al. Final overall survival results from a phase III, randomized placebo‐controlled, parallel‐group study of gefitinib versus placebo as maintenance therapy in patients with advanced or metastatic non‐small‐cell lung cancer (INFORM; C‐TONG 0804). Journal of Thoracic Oncology2015;10(4):655‐64. ">Zhang 2012 INFORM</a>). The remaining 18 studies were all described as randomised, but none provided any further information and so we classified them as having an uncertain risk of bias (<a href="./references#CD006847-bbs2-0002" title="AnC , ZhangJ , ChuH , GuC , XiaoF , ZhuF , et al. Study of gefitinib and pemetrexed as first‐line treatment in patients with advanced non‐small cell lung cancer harboring EGFR mutation. Pathology and Oncology Research2016;22:763‐8. ">An 2016</a>; <a href="./references#CD006847-bbs2-0003" title="ChenYM , LiuJM , ChouTY , PerngRP , TsaiCM , Whang‐PengJ . Phase II randomized study of daily gefitinib treatment alone or with vinorelbine every 2 weeks in patients with adenocarcinoma of the lung who failed at least 2 regimens of chemotherapy. Cancer2007;109(9):1821‐8. ">Chen 2007</a>; <a href="./references#CD006847-bbs2-0004" title="ChenYM , FanWC , TsaiCM , LiuSH , ShihJF , ChouTY , et al. A phase II randomized trial of gefitinib alone or with Tegafur/uracil treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy. Journal of Thoracic Oncology2011;6:1110‐6. ">Chen 2011</a>; <a href="./references#CD006847-bbs2-0008" title="DaiH , XuL , XiaC , ChenW . A randomized clinical study of gefitinib and pemetrexed as second line therapy for advanced non‐squamous non‐small cell lung cancer. Chinese Journal of Lung Cancer2013;16:405‐10. ">Dai 2013</a>; <a href="./references#CD006847-bbs2-0009" title="BaelgaJ , KrisM , YanoS , NataleR , GiacconeG , BrahmerJ , et al. Phase II trials (IDEAL 1 and IDEAL 2) of ZD1839 in advanced or metastatic non‐small cell lung cancer (NSCLC) patient. Annals of Oncology2002;13(Suppl 5):131 Abs 481. DouillardJY , GiacconeG , HoraiT , NodaK , VansteenkisteJF , TakataI , et al. Improvement in disease‐related symptoms and quality of life in patients with advanced non‐small cell lung cancer (NSCLC) treated with ZD1839 ('Iressa') (IDEAL 1) [abstract]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:299a, Abs 1195. DouillardJY , SkarinA , BaselgaJ , NataleR , GiacconeG , MaddoxAM , et al. Improvement in disease‐related symptoms and quality of life (QOL) for advanced non‐small cell lung cancer (NSCLC) patients treated with ZD1839 in IDEAL 1 and IDEAL 2. Annals of Oncology2002;13 Suppl 5:131, Abs 480. FukuokaM , YanoS , GiacconeG , TamuraT , NakagawaK , DouillardJY , et al. Multi‐institutional randomized phase II trial of gefitinib for previously treated patients with advanced non‐small‐cell lung cancer. Journal of Clinical Oncology2003;21(12):2237‐46. FukuokaM , YanoS , GiacconeG , et al. [Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced non‐small cell lung cancer (IDEAL 1) [abstract]]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:298a, Abs 1188. ManegoldC , GatzemeierU , KaukelE . Results from a randomised, double blind phase II trial of ZD1839 (IRESSA) as 2nd/3rd‐line monotherapy in advanced non small cell lung cancer (NSCLC) (IDEAL 1). Journal of Cancer Research &amp; Clinical Oncology2002;128 Suppl 1:S45. NishiwakiY , YanoS , TamuraT , NakagawaK , KudohS , HoraiT , et al. Subset analysis of data in the Japanese patients with NSCLC from IDEAL I study on gefitinib. Gan to Kagaku Ryoho. Cancer &amp; Chemotherapy2004;31(4):567‐73. VansteenkisteJ , NataleR , GiacconeG , et al. Two randomised, double‐blind studies of ZD1839 in 425 patients with pretreated advanced non‐small‐call lung cancer (IDEAL 1 and IDEAL 2) [abstract]. European Respiratory Society Annual Congress. Stockholm, 2002:Abstract 2537. ">Fukuoka 2003 IDEAL I</a>; <a href="./references#CD006847-bbs2-0013" title="HanJY , ParkK , KimSW , LeeDH , KimHY , KimHT , et al. First‐SIGNAL: first‐line single‐agent Iressa versus gemcitabine and cisplatin trial in never‐smokers with adenocarcinoma of the lung. Journal of Clinical Oncology2012;30:1122‐8. HanJY , YoonKA , ParkJH , LeeYJ , LeeGK , HanJH , et al. DNA repair gene polymorphisms and benefit from gefitinib in never‐smokers with lung adenocarcinoma. Cancer2011;117(14):3201‐8. ">Han 2012 First SIGNAL</a>; <a href="./references#CD006847-bbs2-0014" title="HerbstRS , GiacconeG , SchillerJH , NataleRB , MillerV , ManegoldC , et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non‐small cell lung cancer: a phase III trial ‐ INTACT 2. Journal of Clinical Oncology2004;22(5):785‐94. JohnsonDH , HerbstR , GiacconeG , et al. ZD1839 ('Iressa') in combination with paclitaxel &amp; carboplatin in chemotherapy‐naive patients with advanced non‐small cell lung cancer (NSCLC): results from a phase III clinical trial (INTACT 2). Annals of Oncology2002;13 Suppl 5:127, Abstract 468. ">Herbst 2004 INTACT II</a>; <a href="./references#CD006847-bbs2-0015" title="KellyK , ChanskyK , GasparLE , AlbainKS , JettJ , UngYC , et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non‐small‐cell lung cancer: SWOG S0023. Journal of Clinical Oncology2008;26(15):2450‐6. [SWOG S0023] KellyK , GasparLE , ChanskyK , AlbainKS , CrowleyJ , GandaraDR . Low incidence of pneumonitis on SWOG 0023: A preliminary analysis of an ongoing phase III trial of concurrent chemoradiotherapy followed by consolidation docetaxel and Iressa/placebo maintenance in patients with inoperable stage III non‐small cell lung cancer [abstract]. 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, 13‐17 May, 2005 (Abstract No. 7058). 2005; Vol. 23:634. ">Kelly 2008 SWOG S0023</a>; <a href="./references#CD006847-bbs2-0017" title="KimYS , ChoEK , WooHS , HongJ , AhnHK , ParkI , et al. Randomized phase II study of pemetrexed versus gefitinib in previously treated patients with advanced non‐small cell lung cancer. Cancer Research and Treatment2016;48(1):80‐7. ">Kim 2016</a>; <a href="./references#CD006847-bbs2-0018" title="CellaD , HerbstRS , LynchTJ , PragerD , BelaniCP , SchillerJH , et al. Clinically meaningful improvement in symptoms and quality of life for patients with non‐small cell lung cancer receiving gefitinib in a randomized controlled trial. Journal of Clinical Oncology2005;23(13):2946‐54. KrisMG , NataleRB , HerbstRS , et al. A phase II trial of ZD1839 ('Iressa') in advanced non‐small cell lung cancer (NSCLC) patients who had failed platinum‐ and docetaxel‐based regimens (IDEAL 2) [abstract]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:292a Abstract 1166. KrisMG , NataleRB , HerbstRS , LynchTJ , PragerD , BelaniCP , et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non‐small cell lung cancer: a randomized trial. JAMA2003;290(16):2149‐58. NataleRB , SkarinA , MaddoxAM , et al. Improvement in symptoms and quality of life for advanced non‐small cell lung cancer patients receiving ZD1839 ('Iressa') in IDEAL 2 [abstract]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:292a, Abstract 1167. ">Kris 2003 IDEAL II</a>; <a href="./references#CD006847-bbs2-0019" title="LeeD , KimS , ParkK , et al. A randomized open‐label study of gefitinib versus docetaxel in patients with advanced/metastatic non‐small cell lung cancer (NSCLC) who have previously received platinum‐based chemotherapy [abstract no. 8025]. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2008;26(15 Suppl Pt I):430. LeeDH , ParkK , KimJH , LeeJS , ShinSW , KangJH , et al. Randomized phase III trial of gefitinib versus docetaxel in non‐small‐cell lung cancer patients who have previously received platinum‐based chemotherapy. Clinical Cancer Research2010;16(4):1307‐14. [ISTANA] ">Lee 2010 ISTANA</a>; <a href="./references#CD006847-bbs2-0020" title="LiH , WangX , HuaF . Second‐line treatment with gefitinib or docetaxel for advanced non‐small cell lung cancer. Chinese Journal of Clinical Oncology2010;37:16‐8. ">Li 2010</a>; <a href="./references#CD006847-bbs2-0021" title="LouN , YangJ , YanH , QingZ , LiaoR , XuC , et al. Efficacies of gefitinib versus paclitaxel/carboplatin for patients with advanced pulmonary adenocarcinoma. National Medical Journal of China2014;94(30):2337‐41. ">Lou 2014</a>; <a href="./references#CD006847-bbs2-0022" title="FukuharaT , MaemondoM , InoueA , KobayashiK , SugawaraS , OizumiS , et al. Factors associated with a poor response to gefitinib in the NEJ002 study: smoking and the L858R mutation. Lung Cancer2015;88:181‐6. InoueA , KobayashiK , MaemondoM , SugawaraS , OizumiS , IsobeH , et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin‐paclitaxel for chemo‐naive non‐small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Annals of Oncology. United Kingdom: Oxford University Press (Great Clarendon Street, Oxford OX2 6DP, United Kingdom), 2013; Vol. 24:54‐9. InoueA , KobayashiK , MaemondoM , et al. A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first‐line treatment of non‐small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 study. European Journal of Cancer. 2009:Abstract 9LBA. MaemondoM , InoueA , KobayashiK , SugawaraS , OizumiS , IsobeH , et al. Gefitinib or chemotherapy for non‐small‐cell lung cancer with mutated EGFR. New England Journal of Medicine2010;362(25):2380‐8. MiyauchiE , InoueA , KobayashiK , MaemondoM , SugawaraS , OizumiS , et al. Efficacy of chemotherapy after first‐line gefitinib therapy in EGFR mutation‐positive advanced non‐small cell lung cancer ‐ data from a randomized phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002). Japanese Journal of Clinical Oncology2015;45(7):670‐6. OizumiS , KobayashiK , InoueA , MaemondoM , SugawaraS , YoshizawaH , et al. Quality of life with gefitinib in patients with EGFR‐mutated non‐small cell lung cancer: quality of life analysis of North East Japan study group 002 trial. Oncologist. United States: AlphaMed Press (318 Blackwell St. Suite 260, Durham NC 27701‐2884, United States), 2012; Vol. 17:863‐70. YoshizawaH , KobayashiK , InoueA , MaemondoM , SugawaraS , OizumiS , et al. QOL analysis from NEJ 002 study comparing gefitinib to chemotherapy for non‐small cell lung cancer with mutated EGFR. 35th ESMO Congress Milan Italy. Oxford University Press, 2010; Vol. 21:viii122. ">Maemondo 2010 NEJ002</a>; <a href="./references#CD006847-bbs2-0029" title="OkamotoI , HidaT , KashiiT , et al. Randomized phase III study of platinum‐doublet chemotherapy followed by gefitinib versus continued platinum‐doublet chemotherapy in patients (pts) with advanced non‐small cell lung cancer (NSCLC): Results of West Japan Thoracic Oncology Group Trial (WJTOG0203) [Abstract No. 2 33PD]. Annals of Oncology2008;19 Suppl 8:91. TakedaK , HidaT , SatoT , AndoM , SetoT , SatouchiM , et al. Randomized phase III trial of platinum‐doublet chemotherapy followed by gefitinib comparted with continued platinum‐doublet chemotherapy in Japanese patients with advanced non‐small cell lung cancer: results of a West Japan Thoracic Oncology Group Trial (WJTOG0203). Journal of Clinical Oncology2010;28(5):753‐60. ">Takeda 2010 WJTOG0203</a>; <a href="./references#CD006847-bbs2-0031" title="XuYH , MeiJS , ZhouJ . Randomized study of gefitinib versus pemetrexed as maintenance treatment in patients with advanced glandular non‐small cell lung cancer. International Journal of Clinical and Experimental Medicine2015;8(4):6242‐6. ">Xu 2015</a>; <a href="./references#CD006847-bbs2-0032" title="XueC , HongS , LiN , FengW , JiaJ , PengJ , et al. Randomized, multicenter study of gefitinib dose‐escalation in advanced non‐small‐cell lung cancer patients achieved stable disease after one‐month gefitinib treatment. Scientific Reports2015;5:10648. ZhangL , XueC , LiN , FengW , JiaJ , PengJ , et al. Randomized, open‐label, multi‐center study of gefitinib dose‐escalation (500mg/d versus 250mg/d) in advanced NSCLC patient achieved stable disease (SD) after one‐month gefitinib treatment. 15th World Conference on Lung Cancer Sydney, NSW Australia. International Association for the Study of Lung Cancer, 2013; Vol. 8:S1185. ">Xue 2015</a>; <a href="./references#CD006847-bbs2-0034" title="YuH , ZhangJ , WuX , LuoZ , WangH , SunS , et al. A phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non‐squamous non‐small cell lung cancer. Cancer Biology and Therapy2014;15(7):832‐9. ">Yu 2014</a>). </p> </section> <section id="CD006847-sec-0069"> <h5 class="title">Allocation concealment</h5> <p>Allocation concealment was adequate in 11 of the included studies (<a href="./references#CD006847-bbs2-0001" title="AhnMJ , YangJCH , LiangJ , KangJH , XiuQ , ChenYM , et al. Randomized phase II trial of first‐line treatment with pemetrexed‐cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never‐smoker patients with advanced non‐small cell lung cancer. Lung Cancer2012;77:346‐52. ">Ahn 2012</a>; <a href="./references#CD006847-bbs2-0007" title="CuferT , VrdoljakE , GaafarR , ErensoyI , PembertonK , SIGN study group. Phase II, open‐label, randomized study (SIGN) or single‐agent gefitinib (IRESSA) or docetaxel as second‐line therapy in patients with advanced (stage IIIb or IV) non‐small‐cell lung cancer. Anticancer Drugs2006;17(4):401‐9. ">Cufer 2006 SIGN</a>; <a href="./references#CD006847-bbs2-0010" title="GaafarR M , SurmontV , ScagliottiG , VanKlaverenR , PapamichaelD , WelchJ , et al. A double‐blind, randomized, placebo‐controlled phase III intergroup study of gefitinib (G) in patients (pts) with advanced NSCLC, non‐progressing after first‐line platinum‐based chemotherapy (EORTC 08021‐ILCP 01/03). 2010 Annual Meeting of the Americal Society of CLinical Oncology, ASCO, Chicago, IL United States. American Society of Clinical Oncology, 2010; Vol. 28. GaafarRM , SurmontVF , ScagliottiGV , VanKlaverenRJ , PapamichaelD , WelchJJ , et al. A double‐blind, randomised, placebo‐controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non‐progressing after first line platinum‐based chemotherapy (EORTC 08021/ILCP 01/03). European Journal of Cancer2011;47:2331‐40. SurmontVF , GaafarRM , ScagliottiGV , VanKlaverenRJ , PapamichaelD , HasanB , et al. A double‐blind, randomized, placebo‐controlled phase III study of gefitinib (G) versus placebo (P) in patients (pts) with advanced NSCLC, non progressing after first‐line platinum‐based chemotherapy (EORTC 08021‐ ILCP). 35th ESMO Congress Milan Italy. Oxford University Press, 2010; Vol. 21:viii124. ">Gaafar 2011 EORTC08021</a>; <a href="./references#CD006847-bbs2-0012" title="GossG , FerryD , WierzibickiR , LaurieSA , ThompsonJ , BiesmaB , et al. Randomized phase II study of gefitinib compared with placebo in chemotherapy‐naive patients with advanced non‐small‐cell lung cancer and poor performance status. Journal of Clinical Oncology2009;27(13):2253‐60. ">Goss 2009 INSTEP</a>; <a href="./references#CD006847-bbs2-0016" title="DouillardJY , ShephardFA , HirshV , MokT , SocinskiMA , GervaisR , et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non‐small‐cell lung cancer: from the randomized phase III INTEREST Trial. Journal of Clinical Oncology2010;28(5):744‐52. HorganAM , BradburyPA , AmirE , NgR , DouillardJY , KimES , et al. An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second‐/third‐line therapy in advanced non‐small‐cell lung cancer. Annals of Oncology. United Kingdom: Oxford University Press (Great Clarendon Street, Oxford OX2 6DP, United Kingdom), 2011; Vol. 22:1805‐11. HorganAM , ShepherdFA , BradburyPA , NgR , LeighlNB . Preliminary cost‐consequence analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as 2nd line therapy in advanced non‐small cell lung cancer [abstract no. 8110]. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2008;25(15 Suppl Pt 1):451. KimES , HirshV , MokT , SocinskiMA , GervaisR , WuYL , et al. Gefitinib versus docetaxel in previously treated non‐small‐cell lung cancer (INTEREST): a randomized phase III trial. Lancet2008;372:1809‐18. ">Kim 2008 INTEREST</a>; <a href="./references#CD006847-bbs2-0024" title="MitsudomiT , MoritaS , YatabeY , NegoroS , OkamotoI , SetoT , et al. Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first‐line treatment for patients with non‐small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR). 2012 Annual Meeting of the American Society of Clinical Oncology, ASCO Chicago, IL United States. American Society of Clinical Oncology, 2012; Vol. 30. MitsudomiT , MoritaS , YatabeY , NegoroS , OkamotoI , TsurutaniJ , et al. Gefitinib versus cisplatin plus docetaxel in patients with non‐small‐cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase III trial. Lancet2010;11:121‐8. TsurutaniJ , MitsudomiT , MoriS , OkamotoI , NozakiK , TadaH , et al. A phase III, first‐line trial of gefitinib versus cisplatin plus docetaxel for patients with advanced or recurrent non‐small cell lung cancer (NSCLC) harboring activating mutation of the epidermal growth factor receptor (EGFR) gene: a preliminary results of WJTOG 3405 [abstract O‐9002]. European Journal of Cancer. 2009; Vol. 7 Suppl:505. ">Mitsudomi 2010 WJTOG3405</a>; <a href="./references#CD006847-bbs2-0027" title="SoriaJC , WuYL , NakagawaK , KimSW , YangJJ , AhnMJ , et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR‐mutation‐positive non‐small‐cell lung cancer after progression on first‐line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncology2015;16:990‐8. ">Soria 2015 IMPRESS</a>; <a href="./references#CD006847-bbs2-0028" title="AhnM , SunJ , AhnJS , KimS , MinYJ , YunHJ , et al. Randomized phase III trial of gefitinib or pemetrexed as second‐line treatment in patients with non‐small cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01). ASCO Annual Meeting 2011 Chicago, IL United States. American Society of Clinical Oncology, 2011; Vol. 29. AhnMJ , SunJM , LeeKH , AhnJS , KimSW , MinYJ , et al. Randomized phase III trial of gefitinib or pemetrexed as second‐line treatment in patients with non‐small cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01). 14th World Conference on Lung Cancer Amsterdam Netherlands. International Association for the Study of Lung Cancer, 2011; Vol. 6:S317. SunJM , LeeKH , KimSW , LeeDH , MinYJ , YunHJ , et al. Gefitinib versus pemetrexed as second‐line treatment in patients with nonsmall cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01): an open‐label, phase 3 trial. Cancer2012;118:6234‐42. ">Sun 2012 KCSG‐LU08‐01</a>; <a href="./references#CD006847-bbs2-0030" title="ChangA , ParikhP , ThongprasertS , TanEH , PerngRP , GanzonD , et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non‐small cell lung cancer: subset analysis from the ISEL study. Journal of Thoracic Oncology2006;1(8):847‐55. HirschFR , DziadziuszkoR , ThatcherN , MannH , WatkinsC , ParumsDV , et al. Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo‐controlled study in advanced non small‐cell lung cancer. Cancer2008;112(5):1114‐21. HirschFR , Varella‐GarciaM , Bunn JrPA , FranklinWA , DziadziuszkoR , ThatcherN , et al. Molecular predictors of outcome with gefitinib in a phase III placebo‐controlled study in advanced non‐small cell lung cancer. Journal of Clinical Oncology2006;24(31):5034‐42. ThatcherN , ChangA , ParikhP , Rodrigues PereiraJ , CiuleanuT , vonPawelJ , et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non‐small‐cell lung cancer: results from a randomised, placebo‐controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet2005;366(9496):1527‐37. ">Thatcher 2005 ISEL</a>; <a href="./references#CD006847-bbs2-0033" title="BoyeM , WangX , SrimuninnimitV , KangJH , TsaiCM , OrlandoM , et al. First‐line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian never‐smoker patients with locally advanced or metastatic nonsquamous non‐small cell lung cancer: quality of life results from a randomized phase III trial. Clinical Lung Cancer2016;17(2):150‐60. KangJH , AhnM , KimD , ChoEK , KimJ , ShinSW , et al. Tolerability and outcomes of first‐line pemetrexed‐cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in Korean patients with advanced non‐squamous non‐small cell lung cancer: a post hoc descriptive subgroup analysis of a randomized, phase 3 trial. Cancer Research and Treatment2015;48(2):458‐64. YangJC , KangJH , MokT , AhnM , SrimuninnimitV , LinC , et al. First‐line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non‐squamous non‐small cell lung cancer: a randomised, phase 3 trial. European Journal of Cancer2014;50:2219‐30. YangJC , ParkK , MokTSK , KangJH , SrimuninnimitV , LinCC , et al. A randomized phase 3 study comparing first‐line pemetrexed plus cisplatin followed by gefitinib as maintenance with gefitinib monotherapy in east Asian patients with locally advanced or metastatic nonsquamous non‐small cell lung cancer (NSQNSCLC). 15th World Conference on Lung Cancer Sydney, NSW Australia. International Association for the Study of Lung Cancer, 2013; Vol. 8:S288. YangJC , SrimuninnimitV , AhnM , LinC , KimS , TsaiC , et al. A randomized phase 3 study comparing first‐line pemetrexed plus cisplatin followed by gefitinib maintenance (PC/G) with gefitinib monotherapy (G) in East Asian patients (pts) with locally advanced or metastatic nonsquamous non‐small cell lung cancer (nSqNSCLC): final survival results. Journal of Clinical Oncology2015;15 Suppl:8041. YangJC , SrimunninnimitV , AhnM , LinC , KimS , TsaiC , et al. First‐line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian never‐smoker patients with locally advanced or metastatic nonsquamous non‐small cell lung cancer: final overall survival results from a randomized phase 3 study. Journal of Thoracic Oncology2016;11(3):370‐9. ">Yang 2014</a>; <a href="./references#CD006847-bbs2-0035" title="YangY , MaY , ZhaoY , FangW , HongS , et al. QoL analyses from INFORM study, a phase III study of gefitinib versus placebo as maintenance therapy in advanced NSCLC. Scientific Reports2015;5:11934. ZhangL , MaS , SongX , HanB , ChengY , HuangC , et al. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non‐small‐cell lung cancer (INFORM; C‐TONG 0804): a multicentre, double‐blind randomised phase 3 trial. Lancet Oncology2012;13:466‐75. ZhangL , MaSL , SongXQ , ChengY , HuangC , YangSJ , et al. Pre‐planned subgroup analyses from the phase III, randomised, placebo‐controlled, parallel‐group study of gefitinib (G) as maintenance therapy in patients (pts) with locally advanced or metastatic non‐small‐cell lung cancer (NSCLC) (INFORM; C‐TONG 0804). European Multidisciplinary Cancer Congress Stockholm Sweden. Elsevier Ltd, 2011; Vol. 47:S622‐3. ZhangL , MaSL , SongXQ , HanBH , ChengY , HuangC , et al. Efficacy, tolerability and biomarker analyses from a phase III, randomized, placebo controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non‐small‐cell lung cancer (NSCLC) in China (INFORM) (C‐TONG 0804). 14th World Conference on Lung Cancer Amsterdam Netherlands. International Association for the Study of Lung Cancer, 2011; Vol. 6:S558‐9. ZhangL , ShenglinM , SongX , HanB , ChengY , HuangC , et al. Efficacy, tolerability, and biomarker analyses from a phase III, randomized, placebo‐controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non‐small cell lung cancer (NSCLC; INFORM; C‐TONG 0804). ASCO Annual Meeting 2011 Chicago, IL United States. American Society of Clinical Oncology, 2011; Vol. 29. ZhaoH , FanY , MaS , SongX , HanB , ChengY , et al. Final overall survival results from a phase III, randomized placebo‐controlled, parallel‐group study of gefitinib versus placebo as maintenance therapy in patients with advanced or metastatic non‐small‐cell lung cancer (INFORM; C‐TONG 0804). Journal of Thoracic Oncology2015;10(4):655‐64. ">Zhang 2012 INFORM</a>). Most of these studies used a minimisation method or centralised allocation procedure. The remaining studies did not report whether allocation was concealed and so are possibly at risk of bias. </p> </section> </section> <section id="CD006847-sec-0070"> <h4 class="title">Blinding</h4> <p>Of the 35 included trials, we judged blinding to be adequate in all studies. Eight studies blinded participants and investigators using an identical placebo (<a href="./references#CD006847-bbs2-0009" title="BaelgaJ , KrisM , YanoS , NataleR , GiacconeG , BrahmerJ , et al. Phase II trials (IDEAL 1 and IDEAL 2) of ZD1839 in advanced or metastatic non‐small cell lung cancer (NSCLC) patient. Annals of Oncology2002;13(Suppl 5):131 Abs 481. DouillardJY , GiacconeG , HoraiT , NodaK , VansteenkisteJF , TakataI , et al. Improvement in disease‐related symptoms and quality of life in patients with advanced non‐small cell lung cancer (NSCLC) treated with ZD1839 ('Iressa') (IDEAL 1) [abstract]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:299a, Abs 1195. DouillardJY , SkarinA , BaselgaJ , NataleR , GiacconeG , MaddoxAM , et al. Improvement in disease‐related symptoms and quality of life (QOL) for advanced non‐small cell lung cancer (NSCLC) patients treated with ZD1839 in IDEAL 1 and IDEAL 2. Annals of Oncology2002;13 Suppl 5:131, Abs 480. FukuokaM , YanoS , GiacconeG , TamuraT , NakagawaK , DouillardJY , et al. Multi‐institutional randomized phase II trial of gefitinib for previously treated patients with advanced non‐small‐cell lung cancer. Journal of Clinical Oncology2003;21(12):2237‐46. FukuokaM , YanoS , GiacconeG , et al. [Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced non‐small cell lung cancer (IDEAL 1) [abstract]]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:298a, Abs 1188. ManegoldC , GatzemeierU , KaukelE . Results from a randomised, double blind phase II trial of ZD1839 (IRESSA) as 2nd/3rd‐line monotherapy in advanced non small cell lung cancer (NSCLC) (IDEAL 1). Journal of Cancer Research &amp; Clinical Oncology2002;128 Suppl 1:S45. NishiwakiY , YanoS , TamuraT , NakagawaK , KudohS , HoraiT , et al. Subset analysis of data in the Japanese patients with NSCLC from IDEAL I study on gefitinib. Gan to Kagaku Ryoho. Cancer &amp; Chemotherapy2004;31(4):567‐73. VansteenkisteJ , NataleR , GiacconeG , et al. Two randomised, double‐blind studies of ZD1839 in 425 patients with pretreated advanced non‐small‐call lung cancer (IDEAL 1 and IDEAL 2) [abstract]. European Respiratory Society Annual Congress. Stockholm, 2002:Abstract 2537. ">Fukuoka 2003 IDEAL I</a>; <a href="./references#CD006847-bbs2-0010" title="GaafarR M , SurmontV , ScagliottiG , VanKlaverenR , PapamichaelD , WelchJ , et al. A double‐blind, randomized, placebo‐controlled phase III intergroup study of gefitinib (G) in patients (pts) with advanced NSCLC, non‐progressing after first‐line platinum‐based chemotherapy (EORTC 08021‐ILCP 01/03). 2010 Annual Meeting of the Americal Society of CLinical Oncology, ASCO, Chicago, IL United States. American Society of Clinical Oncology, 2010; Vol. 28. GaafarRM , SurmontVF , ScagliottiGV , VanKlaverenRJ , PapamichaelD , WelchJJ , et al. A double‐blind, randomised, placebo‐controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non‐progressing after first line platinum‐based chemotherapy (EORTC 08021/ILCP 01/03). European Journal of Cancer2011;47:2331‐40. SurmontVF , GaafarRM , ScagliottiGV , VanKlaverenRJ , PapamichaelD , HasanB , et al. A double‐blind, randomized, placebo‐controlled phase III study of gefitinib (G) versus placebo (P) in patients (pts) with advanced NSCLC, non progressing after first‐line platinum‐based chemotherapy (EORTC 08021‐ ILCP). 35th ESMO Congress Milan Italy. Oxford University Press, 2010; Vol. 21:viii124. ">Gaafar 2011 EORTC08021</a>; <a href="./references#CD006847-bbs2-0011" title="BellDW , LynchTJ , MaserlatSM , HarrisPL , OkimotoFA , BranniganBW , et al. Epidermal growth factor receptor mutations and gene amplification in non‐small‐cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. Journal of Clinical Oncology2005;23(31):8081‐92. GiacconeG , HerbstRS , ManegoldC , ScagliottiG , RosellR , MillerV , et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non‐small cell lung cancer: a phase III trial ‐ INTACT I. Journal of Clinical Oncology2004;22(5):777‐84. GiacconeG , JohnsonDH , ManegoldC , et al. A phase III clinical trial of ZD1839 ('Iressa') in combination with gemcitabine and cisplatin in chemotherapy‐naive patients with advanced non‐small cell lung cancer (INTACT 1). Annals of Oncology2002;13 Suppl 5:2, Abstract 4. ">Giaccone 2004 INTACT I</a>; <a href="./references#CD006847-bbs2-0012" title="GossG , FerryD , WierzibickiR , LaurieSA , ThompsonJ , BiesmaB , et al. Randomized phase II study of gefitinib compared with placebo in chemotherapy‐naive patients with advanced non‐small‐cell lung cancer and poor performance status. Journal of Clinical Oncology2009;27(13):2253‐60. ">Goss 2009 INSTEP</a>; <a href="./references#CD006847-bbs2-0027" title="SoriaJC , WuYL , NakagawaK , KimSW , YangJJ , AhnMJ , et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR‐mutation‐positive non‐small‐cell lung cancer after progression on first‐line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncology2015;16:990‐8. ">Soria 2015 IMPRESS</a>; <a href="./references#CD006847-bbs2-0030" title="ChangA , ParikhP , ThongprasertS , TanEH , PerngRP , GanzonD , et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non‐small cell lung cancer: subset analysis from the ISEL study. Journal of Thoracic Oncology2006;1(8):847‐55. HirschFR , DziadziuszkoR , ThatcherN , MannH , WatkinsC , ParumsDV , et al. Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo‐controlled study in advanced non small‐cell lung cancer. Cancer2008;112(5):1114‐21. HirschFR , Varella‐GarciaM , Bunn JrPA , FranklinWA , DziadziuszkoR , ThatcherN , et al. Molecular predictors of outcome with gefitinib in a phase III placebo‐controlled study in advanced non‐small cell lung cancer. Journal of Clinical Oncology2006;24(31):5034‐42. ThatcherN , ChangA , ParikhP , Rodrigues PereiraJ , CiuleanuT , vonPawelJ , et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non‐small‐cell lung cancer: results from a randomised, placebo‐controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet2005;366(9496):1527‐37. ">Thatcher 2005 ISEL</a>; <a href="./references#CD006847-bbs2-0033" title="BoyeM , WangX , SrimuninnimitV , KangJH , TsaiCM , OrlandoM , et al. First‐line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian never‐smoker patients with locally advanced or metastatic nonsquamous non‐small cell lung cancer: quality of life results from a randomized phase III trial. Clinical Lung Cancer2016;17(2):150‐60. KangJH , AhnM , KimD , ChoEK , KimJ , ShinSW , et al. Tolerability and outcomes of first‐line pemetrexed‐cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in Korean patients with advanced non‐squamous non‐small cell lung cancer: a post hoc descriptive subgroup analysis of a randomized, phase 3 trial. Cancer Research and Treatment2015;48(2):458‐64. YangJC , KangJH , MokT , AhnM , SrimuninnimitV , LinC , et al. First‐line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non‐squamous non‐small cell lung cancer: a randomised, phase 3 trial. European Journal of Cancer2014;50:2219‐30. YangJC , ParkK , MokTSK , KangJH , SrimuninnimitV , LinCC , et al. A randomized phase 3 study comparing first‐line pemetrexed plus cisplatin followed by gefitinib as maintenance with gefitinib monotherapy in east Asian patients with locally advanced or metastatic nonsquamous non‐small cell lung cancer (NSQNSCLC). 15th World Conference on Lung Cancer Sydney, NSW Australia. International Association for the Study of Lung Cancer, 2013; Vol. 8:S288. YangJC , SrimuninnimitV , AhnM , LinC , KimS , TsaiC , et al. A randomized phase 3 study comparing first‐line pemetrexed plus cisplatin followed by gefitinib maintenance (PC/G) with gefitinib monotherapy (G) in East Asian patients (pts) with locally advanced or metastatic nonsquamous non‐small cell lung cancer (nSqNSCLC): final survival results. Journal of Clinical Oncology2015;15 Suppl:8041. YangJC , SrimunninnimitV , AhnM , LinC , KimS , TsaiC , et al. First‐line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian never‐smoker patients with locally advanced or metastatic nonsquamous non‐small cell lung cancer: final overall survival results from a randomized phase 3 study. Journal of Thoracic Oncology2016;11(3):370‐9. ">Yang 2014</a>; <a href="./references#CD006847-bbs2-0035" title="YangY , MaY , ZhaoY , FangW , HongS , et al. QoL analyses from INFORM study, a phase III study of gefitinib versus placebo as maintenance therapy in advanced NSCLC. Scientific Reports2015;5:11934. ZhangL , MaS , SongX , HanB , ChengY , HuangC , et al. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non‐small‐cell lung cancer (INFORM; C‐TONG 0804): a multicentre, double‐blind randomised phase 3 trial. Lancet Oncology2012;13:466‐75. ZhangL , MaSL , SongXQ , ChengY , HuangC , YangSJ , et al. Pre‐planned subgroup analyses from the phase III, randomised, placebo‐controlled, parallel‐group study of gefitinib (G) as maintenance therapy in patients (pts) with locally advanced or metastatic non‐small‐cell lung cancer (NSCLC) (INFORM; C‐TONG 0804). European Multidisciplinary Cancer Congress Stockholm Sweden. Elsevier Ltd, 2011; Vol. 47:S622‐3. ZhangL , MaSL , SongXQ , HanBH , ChengY , HuangC , et al. Efficacy, tolerability and biomarker analyses from a phase III, randomized, placebo controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non‐small‐cell lung cancer (NSCLC) in China (INFORM) (C‐TONG 0804). 14th World Conference on Lung Cancer Amsterdam Netherlands. International Association for the Study of Lung Cancer, 2011; Vol. 6:S558‐9. ZhangL , ShenglinM , SongX , HanB , ChengY , HuangC , et al. Efficacy, tolerability, and biomarker analyses from a phase III, randomized, placebo‐controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non‐small cell lung cancer (NSCLC; INFORM; C‐TONG 0804). ASCO Annual Meeting 2011 Chicago, IL United States. American Society of Clinical Oncology, 2011; Vol. 29. ZhaoH , FanY , MaS , SongX , HanB , ChengY , et al. Final overall survival results from a phase III, randomized placebo‐controlled, parallel‐group study of gefitinib versus placebo as maintenance therapy in patients with advanced or metastatic non‐small‐cell lung cancer (INFORM; C‐TONG 0804). Journal of Thoracic Oncology2015;10(4):655‐64. ">Zhang 2012 INFORM</a>). The remaining 27 studies were unblinded or open‐label (for example comparing gefitinib with intravenous chemotherapy), but we judged that this would not affect the measured outcomes. </p> </section> <section id="CD006847-sec-0071"> <h4 class="title">Incomplete outcome data</h4> <p>The majority of studies adequately addressed incomplete outcome data. Of the 35 included trials, 28 had a low risk of bias from incomplete outcome data. Studies cited reasons such as death, disease progression and drug toxicity for dropouts. Five phase II studies did not address withdrawals or patients lost to follow‐up and thus are potentially at high risk of bias (<a href="./references#CD006847-bbs2-0003" title="ChenYM , LiuJM , ChouTY , PerngRP , TsaiCM , Whang‐PengJ . Phase II randomized study of daily gefitinib treatment alone or with vinorelbine every 2 weeks in patients with adenocarcinoma of the lung who failed at least 2 regimens of chemotherapy. Cancer2007;109(9):1821‐8. ">Chen 2007</a>; <a href="./references#CD006847-bbs2-0004" title="ChenYM , FanWC , TsaiCM , LiuSH , ShihJF , ChouTY , et al. A phase II randomized trial of gefitinib alone or with Tegafur/uracil treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy. Journal of Thoracic Oncology2011;6:1110‐6. ">Chen 2011</a>; <a href="./references#CD006847-bbs2-0011" title="BellDW , LynchTJ , MaserlatSM , HarrisPL , OkimotoFA , BranniganBW , et al. Epidermal growth factor receptor mutations and gene amplification in non‐small‐cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. Journal of Clinical Oncology2005;23(31):8081‐92. GiacconeG , HerbstRS , ManegoldC , ScagliottiG , RosellR , MillerV , et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non‐small cell lung cancer: a phase III trial ‐ INTACT I. Journal of Clinical Oncology2004;22(5):777‐84. GiacconeG , JohnsonDH , ManegoldC , et al. A phase III clinical trial of ZD1839 ('Iressa') in combination with gemcitabine and cisplatin in chemotherapy‐naive patients with advanced non‐small cell lung cancer (INTACT 1). Annals of Oncology2002;13 Suppl 5:2, Abstract 4. ">Giaccone 2004 INTACT I</a>; <a href="./references#CD006847-bbs2-0017" title="KimYS , ChoEK , WooHS , HongJ , AhnHK , ParkI , et al. Randomized phase II study of pemetrexed versus gefitinib in previously treated patients with advanced non‐small cell lung cancer. Cancer Research and Treatment2016;48(1):80‐7. ">Kim 2016</a>; <a href="./references#CD006847-bbs2-0031" title="XuYH , MeiJS , ZhouJ . Randomized study of gefitinib versus pemetrexed as maintenance treatment in patients with advanced glandular non‐small cell lung cancer. International Journal of Clinical and Experimental Medicine2015;8(4):6242‐6. ">Xu 2015</a>). Two studies did not provide adequate outcome data and so are at a risk of bias from incomplete outcome data analysis (<a href="./references#CD006847-bbs2-0002" title="AnC , ZhangJ , ChuH , GuC , XiaoF , ZhuF , et al. Study of gefitinib and pemetrexed as first‐line treatment in patients with advanced non‐small cell lung cancer harboring EGFR mutation. Pathology and Oncology Research2016;22:763‐8. ">An 2016</a>;<a href="./references#CD006847-bbs2-0014" title="HerbstRS , GiacconeG , SchillerJH , NataleRB , MillerV , ManegoldC , et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non‐small cell lung cancer: a phase III trial ‐ INTACT 2. Journal of Clinical Oncology2004;22(5):785‐94. JohnsonDH , HerbstR , GiacconeG , et al. ZD1839 ('Iressa') in combination with paclitaxel &amp; carboplatin in chemotherapy‐naive patients with advanced non‐small cell lung cancer (NSCLC): results from a phase III clinical trial (INTACT 2). Annals of Oncology2002;13 Suppl 5:127, Abstract 468. ">Herbst 2004 INTACT II</a>). </p> </section> <section id="CD006847-sec-0072"> <h4 class="title">Selective reporting</h4> <p>We judged 33 of the 35 included studies as at low risk of reporting bias. One study reported an outcome (progression‐free survival) that was not pre‐specified (<a href="./references#CD006847-bbs2-0007" title="CuferT , VrdoljakE , GaafarR , ErensoyI , PembertonK , SIGN study group. Phase II, open‐label, randomized study (SIGN) or single‐agent gefitinib (IRESSA) or docetaxel as second‐line therapy in patients with advanced (stage IIIb or IV) non‐small‐cell lung cancer. Anticancer Drugs2006;17(4):401‐9. ">Cufer 2006 SIGN</a>). We judged this as an unclear risk of bias. Another study did not report an outcome that was prespecified in the methods ("survival time"), with no reason provided for this in the paper (<a href="./references#CD006847-bbs2-0031" title="XuYH , MeiJS , ZhouJ . Randomized study of gefitinib versus pemetrexed as maintenance treatment in patients with advanced glandular non‐small cell lung cancer. International Journal of Clinical and Experimental Medicine2015;8(4):6242‐6. ">Xu 2015</a>). We judged this as a high risk of bias </p> </section> <section id="CD006847-sec-0073"> <h4 class="title">Other potential sources of bias</h4> <p>Three trials were stopped early (<a href="./references#CD006847-bbs2-0015" title="KellyK , ChanskyK , GasparLE , AlbainKS , JettJ , UngYC , et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non‐small‐cell lung cancer: SWOG S0023. Journal of Clinical Oncology2008;26(15):2450‐6. [SWOG S0023] KellyK , GasparLE , ChanskyK , AlbainKS , CrowleyJ , GandaraDR . Low incidence of pneumonitis on SWOG 0023: A preliminary analysis of an ongoing phase III trial of concurrent chemoradiotherapy followed by consolidation docetaxel and Iressa/placebo maintenance in patients with inoperable stage III non‐small cell lung cancer [abstract]. 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, 13‐17 May, 2005 (Abstract No. 7058). 2005; Vol. 23:634. ">Kelly 2008 SWOG S0023</a>; <a href="./references#CD006847-bbs2-0022" title="FukuharaT , MaemondoM , InoueA , KobayashiK , SugawaraS , OizumiS , et al. Factors associated with a poor response to gefitinib in the NEJ002 study: smoking and the L858R mutation. Lung Cancer2015;88:181‐6. InoueA , KobayashiK , MaemondoM , SugawaraS , OizumiS , IsobeH , et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin‐paclitaxel for chemo‐naive non‐small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Annals of Oncology. United Kingdom: Oxford University Press (Great Clarendon Street, Oxford OX2 6DP, United Kingdom), 2013; Vol. 24:54‐9. InoueA , KobayashiK , MaemondoM , et al. A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first‐line treatment of non‐small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 study. European Journal of Cancer. 2009:Abstract 9LBA. MaemondoM , InoueA , KobayashiK , SugawaraS , OizumiS , IsobeH , et al. Gefitinib or chemotherapy for non‐small‐cell lung cancer with mutated EGFR. New England Journal of Medicine2010;362(25):2380‐8. MiyauchiE , InoueA , KobayashiK , MaemondoM , SugawaraS , OizumiS , et al. Efficacy of chemotherapy after first‐line gefitinib therapy in EGFR mutation‐positive advanced non‐small cell lung cancer ‐ data from a randomized phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002). Japanese Journal of Clinical Oncology2015;45(7):670‐6. OizumiS , KobayashiK , InoueA , MaemondoM , SugawaraS , YoshizawaH , et al. Quality of life with gefitinib in patients with EGFR‐mutated non‐small cell lung cancer: quality of life analysis of North East Japan study group 002 trial. Oncologist. United States: AlphaMed Press (318 Blackwell St. Suite 260, Durham NC 27701‐2884, United States), 2012; Vol. 17:863‐70. YoshizawaH , KobayashiK , InoueA , MaemondoM , SugawaraS , OizumiS , et al. QOL analysis from NEJ 002 study comparing gefitinib to chemotherapy for non‐small cell lung cancer with mutated EGFR. 35th ESMO Congress Milan Italy. Oxford University Press, 2010; Vol. 21:viii122. ">Maemondo 2010 NEJ002</a>; <a href="./references#CD006847-bbs2-0024" title="MitsudomiT , MoritaS , YatabeY , NegoroS , OkamotoI , SetoT , et al. Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first‐line treatment for patients with non‐small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR). 2012 Annual Meeting of the American Society of Clinical Oncology, ASCO Chicago, IL United States. American Society of Clinical Oncology, 2012; Vol. 30. MitsudomiT , MoritaS , YatabeY , NegoroS , OkamotoI , TsurutaniJ , et al. Gefitinib versus cisplatin plus docetaxel in patients with non‐small‐cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase III trial. Lancet2010;11:121‐8. TsurutaniJ , MitsudomiT , MoriS , OkamotoI , NozakiK , TadaH , et al. A phase III, first‐line trial of gefitinib versus cisplatin plus docetaxel for patients with advanced or recurrent non‐small cell lung cancer (NSCLC) harboring activating mutation of the epidermal growth factor receptor (EGFR) gene: a preliminary results of WJTOG 3405 [abstract O‐9002]. European Journal of Cancer. 2009; Vol. 7 Suppl:505. ">Mitsudomi 2010 WJTOG3405</a>), which may be another source of bias. The SWOGS0023 study was stopped because an unplanned interim analysis concluded that the alternate hypothesis of improved survival would not be met. The NEJ002 and WJTOG3405 studies were concluded early following the presentation of contemporary data showing a progression‐free survival benefit in EGFR mutated patients. These studies were then closed to accrual. </p> <p>We judged the remaining studies as having an unclear risk of bias listed due to conflicts of interest, in particular pharmaceutical funding or significant affiliations, or because they did not adequately declare any conflicts of interest (<a href="./references#CD006847-bbs2-0001" title="AhnMJ , YangJCH , LiangJ , KangJH , XiuQ , ChenYM , et al. Randomized phase II trial of first‐line treatment with pemetrexed‐cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never‐smoker patients with advanced non‐small cell lung cancer. Lung Cancer2012;77:346‐52. ">Ahn 2012</a>; <a href="./references#CD006847-bbs2-0002" title="AnC , ZhangJ , ChuH , GuC , XiaoF , ZhuF , et al. Study of gefitinib and pemetrexed as first‐line treatment in patients with advanced non‐small cell lung cancer harboring EGFR mutation. Pathology and Oncology Research2016;22:763‐8. ">An 2016</a>; <a href="./references#CD006847-bbs2-0003" title="ChenYM , LiuJM , ChouTY , PerngRP , TsaiCM , Whang‐PengJ . Phase II randomized study of daily gefitinib treatment alone or with vinorelbine every 2 weeks in patients with adenocarcinoma of the lung who failed at least 2 regimens of chemotherapy. Cancer2007;109(9):1821‐8. ">Chen 2007</a>; <a href="./references#CD006847-bbs2-0005" title="ChengY , MurakamiH , YangPC , HeJ , NakagawaK , KangJH , et al. Randomized phase II trial of gefitinib with and without pemetrexed as first‐line therapy in patients with advanced nonsquamous non‐small‐cell lung cancer with activating epidermal growth factor receptor mutations. Journal of Clinical Oncology2016;27(20):3258‐66. ">Cheng 2016</a>; <a href="./references#CD006847-bbs2-0006" title="CrinoL , CappuzzoF , ZatloukalP , ReckM , PesekM , ThompsonJC , et al. Gefitinib versus vinorelbine in chemotherapy‐naive elderly patients with advanced non‐small‐cell lung cancer (INVITE): a randomized, phase II study. Journal of Clinical Oncology2008;26(26):4253‐60. ">Crino 2008 INVITE</a>; <a href="./references#CD006847-bbs2-0007" title="CuferT , VrdoljakE , GaafarR , ErensoyI , PembertonK , SIGN study group. Phase II, open‐label, randomized study (SIGN) or single‐agent gefitinib (IRESSA) or docetaxel as second‐line therapy in patients with advanced (stage IIIb or IV) non‐small‐cell lung cancer. Anticancer Drugs2006;17(4):401‐9. ">Cufer 2006 SIGN</a>; <a href="./references#CD006847-bbs2-0008" title="DaiH , XuL , XiaC , ChenW . A randomized clinical study of gefitinib and pemetrexed as second line therapy for advanced non‐squamous non‐small cell lung cancer. Chinese Journal of Lung Cancer2013;16:405‐10. ">Dai 2013</a>; <a href="./references#CD006847-bbs2-0009" title="BaelgaJ , KrisM , YanoS , NataleR , GiacconeG , BrahmerJ , et al. Phase II trials (IDEAL 1 and IDEAL 2) of ZD1839 in advanced or metastatic non‐small cell lung cancer (NSCLC) patient. Annals of Oncology2002;13(Suppl 5):131 Abs 481. DouillardJY , GiacconeG , HoraiT , NodaK , VansteenkisteJF , TakataI , et al. Improvement in disease‐related symptoms and quality of life in patients with advanced non‐small cell lung cancer (NSCLC) treated with ZD1839 ('Iressa') (IDEAL 1) [abstract]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:299a, Abs 1195. DouillardJY , SkarinA , BaselgaJ , NataleR , GiacconeG , MaddoxAM , et al. Improvement in disease‐related symptoms and quality of life (QOL) for advanced non‐small cell lung cancer (NSCLC) patients treated with ZD1839 in IDEAL 1 and IDEAL 2. Annals of Oncology2002;13 Suppl 5:131, Abs 480. FukuokaM , YanoS , GiacconeG , TamuraT , NakagawaK , DouillardJY , et al. Multi‐institutional randomized phase II trial of gefitinib for previously treated patients with advanced non‐small‐cell lung cancer. Journal of Clinical Oncology2003;21(12):2237‐46. FukuokaM , YanoS , GiacconeG , et al. [Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced non‐small cell lung cancer (IDEAL 1) [abstract]]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:298a, Abs 1188. ManegoldC , GatzemeierU , KaukelE . Results from a randomised, double blind phase II trial of ZD1839 (IRESSA) as 2nd/3rd‐line monotherapy in advanced non small cell lung cancer (NSCLC) (IDEAL 1). Journal of Cancer Research &amp; Clinical Oncology2002;128 Suppl 1:S45. NishiwakiY , YanoS , TamuraT , NakagawaK , KudohS , HoraiT , et al. Subset analysis of data in the Japanese patients with NSCLC from IDEAL I study on gefitinib. Gan to Kagaku Ryoho. Cancer &amp; Chemotherapy2004;31(4):567‐73. VansteenkisteJ , NataleR , GiacconeG , et al. Two randomised, double‐blind studies of ZD1839 in 425 patients with pretreated advanced non‐small‐call lung cancer (IDEAL 1 and IDEAL 2) [abstract]. European Respiratory Society Annual Congress. Stockholm, 2002:Abstract 2537. ">Fukuoka 2003 IDEAL I</a>; <a href="./references#CD006847-bbs2-0012" title="GossG , FerryD , WierzibickiR , LaurieSA , ThompsonJ , BiesmaB , et al. Randomized phase II study of gefitinib compared with placebo in chemotherapy‐naive patients with advanced non‐small‐cell lung cancer and poor performance status. Journal of Clinical Oncology2009;27(13):2253‐60. ">Goss 2009 INSTEP</a>; <a href="./references#CD006847-bbs2-0013" title="HanJY , ParkK , KimSW , LeeDH , KimHY , KimHT , et al. First‐SIGNAL: first‐line single‐agent Iressa versus gemcitabine and cisplatin trial in never‐smokers with adenocarcinoma of the lung. Journal of Clinical Oncology2012;30:1122‐8. HanJY , YoonKA , ParkJH , LeeYJ , LeeGK , HanJH , et al. DNA repair gene polymorphisms and benefit from gefitinib in never‐smokers with lung adenocarcinoma. Cancer2011;117(14):3201‐8. ">Han 2012 First SIGNAL</a>; <a href="./references#CD006847-bbs2-0015" title="KellyK , ChanskyK , GasparLE , AlbainKS , JettJ , UngYC , et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non‐small‐cell lung cancer: SWOG S0023. Journal of Clinical Oncology2008;26(15):2450‐6. [SWOG S0023] KellyK , GasparLE , ChanskyK , AlbainKS , CrowleyJ , GandaraDR . Low incidence of pneumonitis on SWOG 0023: A preliminary analysis of an ongoing phase III trial of concurrent chemoradiotherapy followed by consolidation docetaxel and Iressa/placebo maintenance in patients with inoperable stage III non‐small cell lung cancer [abstract]. 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, 13‐17 May, 2005 (Abstract No. 7058). 2005; Vol. 23:634. ">Kelly 2008 SWOG S0023</a>; <a href="./references#CD006847-bbs2-0016" title="DouillardJY , ShephardFA , HirshV , MokT , SocinskiMA , GervaisR , et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non‐small‐cell lung cancer: from the randomized phase III INTEREST Trial. Journal of Clinical Oncology2010;28(5):744‐52. HorganAM , BradburyPA , AmirE , NgR , DouillardJY , KimES , et al. An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second‐/third‐line therapy in advanced non‐small‐cell lung cancer. Annals of Oncology. United Kingdom: Oxford University Press (Great Clarendon Street, Oxford OX2 6DP, United Kingdom), 2011; Vol. 22:1805‐11. HorganAM , ShepherdFA , BradburyPA , NgR , LeighlNB . Preliminary cost‐consequence analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as 2nd line therapy in advanced non‐small cell lung cancer [abstract no. 8110]. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2008;25(15 Suppl Pt 1):451. KimES , HirshV , MokT , SocinskiMA , GervaisR , WuYL , et al. Gefitinib versus docetaxel in previously treated non‐small‐cell lung cancer (INTEREST): a randomized phase III trial. Lancet2008;372:1809‐18. ">Kim 2008 INTEREST</a>; <a href="./references#CD006847-bbs2-0017" title="KimYS , ChoEK , WooHS , HongJ , AhnHK , ParkI , et al. Randomized phase II study of pemetrexed versus gefitinib in previously treated patients with advanced non‐small cell lung cancer. Cancer Research and Treatment2016;48(1):80‐7. ">Kim 2016</a>; <a href="./references#CD006847-bbs2-0018" title="CellaD , HerbstRS , LynchTJ , PragerD , BelaniCP , SchillerJH , et al. Clinically meaningful improvement in symptoms and quality of life for patients with non‐small cell lung cancer receiving gefitinib in a randomized controlled trial. Journal of Clinical Oncology2005;23(13):2946‐54. KrisMG , NataleRB , HerbstRS , et al. A phase II trial of ZD1839 ('Iressa') in advanced non‐small cell lung cancer (NSCLC) patients who had failed platinum‐ and docetaxel‐based regimens (IDEAL 2) [abstract]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:292a Abstract 1166. KrisMG , NataleRB , HerbstRS , LynchTJ , PragerD , BelaniCP , et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non‐small cell lung cancer: a randomized trial. JAMA2003;290(16):2149‐58. NataleRB , SkarinA , MaddoxAM , et al. Improvement in symptoms and quality of life for advanced non‐small cell lung cancer patients receiving ZD1839 ('Iressa') in IDEAL 2 [abstract]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:292a, Abstract 1167. ">Kris 2003 IDEAL II</a>; <a href="./references#CD006847-bbs2-0020" title="LiH , WangX , HuaF . Second‐line treatment with gefitinib or docetaxel for advanced non‐small cell lung cancer. Chinese Journal of Clinical Oncology2010;37:16‐8. ">Li 2010</a>; <a href="./references#CD006847-bbs2-0025" title="FukuokaM , WuYL , ThongprasertS , SunpaweravongP , LeongSS , SriuranpongV , et al. Biomarker analyses and final overall survival results from a phase III, randomized, open‐label, first‐line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non ‐ small‐cell lung cancer in Asia (IPASS). Journal of Clinical Oncology2011;29:2866‐74. MokT , WuY‐L , ThongprasertS , et al. Phase III, randomised, open‐label, first‐line study of gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients (PTS) with advanced non‐small cell lung cancer (NSCLC) (IPASS). Annals of Oncology2008;19 Suppl 8:Viii1. MokTS , WuYL , ThongprasertS , YangCH , ChuDT , SaijoN , et al. Gefitinib or carboplatin‐paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine2009;361(10):947‐57. OheY , IchinoseY , NishiwakiY ,  etal . Phase III, randomized, open‐label, first‐line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in selected patients (pts) with advanced non‐small‐cell lung cancer (NSCLC) (IPASS): Evaluation of recruits in Japan. Journal of Clinical Oncology2009;29(15 Suppl 1):8044. ThongprasertS , DuffieldE , SaijoN , WuYL , YangJC , ChuDT , et al. Health‐related quality‐of‐life in a randomized phase III first‐line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). Journal of Thoracic Oncology2011;6:1872‐80. ThongprasertS , DuffieldE , WuY , et al. Quality of life (QOL) in a randomized phase III first‐line study of gefitinib (G) vs carboplatin/paclitaxel (CP) in clinically selected Asian patients (pts) with advanced NSCLC (IPASS). Journal of Thoracic Oncology2010;5(5 Suppl 1):S80. WuY , ChuD , HanB , LiuX , ZhangL , ZhouC , et al. Phase III, randomized, open‐label, first‐line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non‐small‐cell lung cancer: evaluation of patients recruited from mainland China. Asia‐Pacific Journal of Clinical Oncology2012;8:232‐43. WuY , FukuokaM , MokT S K , SaijoN , ThongprasertS , YangJ C H , et al. Tumour response, skin rash and health‐related quality of life (HRQOL) ‐ Post‐HOC data from the IPASS study. European Multidisciplinary Cancer Congress Stockholm Sweden. Elsevier Ltd, 2011; Vol. 47:S633‐4. WuY , MokT , ChuD , et al. Evaluation of clinically selected patients (pts) with advanced non‐small cell lung cancer (NSCLC) recruited in China in a phase III, randomized, open‐label, first‐line study in Asia of gefitinib (G) versus carboplatin/paclitaxel (C/P) (IPASS). Journal of Clinical Oncology. 2009; Vol. 27 (15 Suppl 1):8041. WuYL , FukuokaM , MokTSK , SaijoN , ThongprasertS , YangJCH , et al. Tumor response and health‐related quality of life in clinically selected patients from Asia with advanced non‐small‐cell lung cancer treated with first‐line gefitinib: post hoc analyses from the IPASS study. Lung Cancer2013;81:280‐7. YangCH , FukuokaM , MokTS , WuYL , ThongprasertS , SaijoN , et al. Final overall survival (OS) results from a phase III, randomised, open‐label, first‐line study of gefitinib (G) v carboplatin/paclitaxel (C/P) in clinically selected patients with advanced nonsmall cell lung cancer (NSCLC) in Asia (IPASS). 35th ESMO Congress Milan Italy. Oxford University Press, 2010; Vol. 21:viii1‐2. YangJ , WuY L , SaijoN , ThongprasertS , ChuD T , ChenY M , et al. Efficacy outcomes in first‐line treatment of advanced NSCLC with gefitinib (G) vs carboplatin/paclitaxel (C/P) by epidermal growth factor receptor (EGFR) gene‐copy number score and by most common EGFR mutation subtypes ‐ Exploratory data from IPASS. 2011 European Multidisciplinary Cancer Congress Stockholm Sweden. Elsevier Ltd, 2011; Vol. 47:S633. YangJ , WuY , ChanV , KurniandaJ , NakagawaK . Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan‐ASia Study (IPASS). Lung Cancer2014;83:174‐81. YangJCH , WuYL , ChanV , KurniandaJ , NakagawaK , SaijoN , et al. Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan‐ASia Study (IPASS). Lung Cancer2014;83:174‐81. ">Mok 2009 IPASS</a>; <a href="./references#CD006847-bbs2-0027" title="SoriaJC , WuYL , NakagawaK , KimSW , YangJJ , AhnMJ , et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR‐mutation‐positive non‐small‐cell lung cancer after progression on first‐line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncology2015;16:990‐8. ">Soria 2015 IMPRESS</a>; <a href="./references#CD006847-bbs2-0028" title="AhnM , SunJ , AhnJS , KimS , MinYJ , YunHJ , et al. Randomized phase III trial of gefitinib or pemetrexed as second‐line treatment in patients with non‐small cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01). ASCO Annual Meeting 2011 Chicago, IL United States. American Society of Clinical Oncology, 2011; Vol. 29. AhnMJ , SunJM , LeeKH , AhnJS , KimSW , MinYJ , et al. Randomized phase III trial of gefitinib or pemetrexed as second‐line treatment in patients with non‐small cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01). 14th World Conference on Lung Cancer Amsterdam Netherlands. International Association for the Study of Lung Cancer, 2011; Vol. 6:S317. SunJM , LeeKH , KimSW , LeeDH , MinYJ , YunHJ , et al. Gefitinib versus pemetrexed as second‐line treatment in patients with nonsmall cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01): an open‐label, phase 3 trial. Cancer2012;118:6234‐42. ">Sun 2012 KCSG‐LU08‐01</a>; <a href="./references#CD006847-bbs2-0033" title="BoyeM , WangX , SrimuninnimitV , KangJH , TsaiCM , OrlandoM , et al. First‐line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian never‐smoker patients with locally advanced or metastatic nonsquamous non‐small cell lung cancer: quality of life results from a randomized phase III trial. Clinical Lung Cancer2016;17(2):150‐60. KangJH , AhnM , KimD , ChoEK , KimJ , ShinSW , et al. Tolerability and outcomes of first‐line pemetrexed‐cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in Korean patients with advanced non‐squamous non‐small cell lung cancer: a post hoc descriptive subgroup analysis of a randomized, phase 3 trial. Cancer Research and Treatment2015;48(2):458‐64. YangJC , KangJH , MokT , AhnM , SrimuninnimitV , LinC , et al. First‐line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non‐squamous non‐small cell lung cancer: a randomised, phase 3 trial. European Journal of Cancer2014;50:2219‐30. YangJC , ParkK , MokTSK , KangJH , SrimuninnimitV , LinCC , et al. A randomized phase 3 study comparing first‐line pemetrexed plus cisplatin followed by gefitinib as maintenance with gefitinib monotherapy in east Asian patients with locally advanced or metastatic nonsquamous non‐small cell lung cancer (NSQNSCLC). 15th World Conference on Lung Cancer Sydney, NSW Australia. International Association for the Study of Lung Cancer, 2013; Vol. 8:S288. YangJC , SrimuninnimitV , AhnM , LinC , KimS , TsaiC , et al. A randomized phase 3 study comparing first‐line pemetrexed plus cisplatin followed by gefitinib maintenance (PC/G) with gefitinib monotherapy (G) in East Asian patients (pts) with locally advanced or metastatic nonsquamous non‐small cell lung cancer (nSqNSCLC): final survival results. Journal of Clinical Oncology2015;15 Suppl:8041. YangJC , SrimunninnimitV , AhnM , LinC , KimS , TsaiC , et al. First‐line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian never‐smoker patients with locally advanced or metastatic nonsquamous non‐small cell lung cancer: final overall survival results from a randomized phase 3 study. Journal of Thoracic Oncology2016;11(3):370‐9. ">Yang 2014</a>; <a href="./references#CD006847-bbs2-0035" title="YangY , MaY , ZhaoY , FangW , HongS , et al. QoL analyses from INFORM study, a phase III study of gefitinib versus placebo as maintenance therapy in advanced NSCLC. Scientific Reports2015;5:11934. ZhangL , MaS , SongX , HanB , ChengY , HuangC , et al. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non‐small‐cell lung cancer (INFORM; C‐TONG 0804): a multicentre, double‐blind randomised phase 3 trial. Lancet Oncology2012;13:466‐75. ZhangL , MaSL , SongXQ , ChengY , HuangC , YangSJ , et al. Pre‐planned subgroup analyses from the phase III, randomised, placebo‐controlled, parallel‐group study of gefitinib (G) as maintenance therapy in patients (pts) with locally advanced or metastatic non‐small‐cell lung cancer (NSCLC) (INFORM; C‐TONG 0804). European Multidisciplinary Cancer Congress Stockholm Sweden. Elsevier Ltd, 2011; Vol. 47:S622‐3. ZhangL , MaSL , SongXQ , HanBH , ChengY , HuangC , et al. Efficacy, tolerability and biomarker analyses from a phase III, randomized, placebo controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non‐small‐cell lung cancer (NSCLC) in China (INFORM) (C‐TONG 0804). 14th World Conference on Lung Cancer Amsterdam Netherlands. International Association for the Study of Lung Cancer, 2011; Vol. 6:S558‐9. ZhangL , ShenglinM , SongX , HanB , ChengY , HuangC , et al. Efficacy, tolerability, and biomarker analyses from a phase III, randomized, placebo‐controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non‐small cell lung cancer (NSCLC; INFORM; C‐TONG 0804). ASCO Annual Meeting 2011 Chicago, IL United States. American Society of Clinical Oncology, 2011; Vol. 29. ZhaoH , FanY , MaS , SongX , HanB , ChengY , et al. Final overall survival results from a phase III, randomized placebo‐controlled, parallel‐group study of gefitinib versus placebo as maintenance therapy in patients with advanced or metastatic non‐small‐cell lung cancer (INFORM; C‐TONG 0804). Journal of Thoracic Oncology2015;10(4):655‐64. ">Zhang 2012 INFORM</a>). </p> </section> </section> <section id="CD006847-sec-0074"> <h3 class="title" id="CD006847-sec-0074">Effects of interventions</h3> <p>See: <a href="./full#CD006847-tbl-0001"><b>Summary of findings for the main comparison</b> Gefitinib compared to chemotherapy for first‐line treatment of advanced NSCLC</a>; <a href="./full#CD006847-tbl-0002"><b>Summary of findings 2</b> Gefitinib compared to chemotherapy for second‐line treatment of advanced NSCLC</a>; <a href="./full#CD006847-tbl-0003"><b>Summary of findings 3</b> Gefitinib compared to chemotherapy for advanced NSCLC ‐ toxicity</a> </p> <p>See: <a href="./full#CD006847-tbl-0001">summary of findings Table for the main comparison</a> ('Gefitinib compared to chemotherapy for first‐line treatment of advanced NSCLC'); <a href="./full#CD006847-tbl-0002">summary of findings Table 2</a> ('Gefitinib compared to chemotherapy for second‐line treatment of advanced NSCLC'); <a href="./full#CD006847-tbl-0003">summary of findings Table 3</a> ('Gefitinib compared to chemotherapy for advanced NSCLC ‐ toxicity'). </p> <section id="CD006847-sec-0075"> <h4 class="title">1. Gefitinib versus placebo or best supportive care</h4> <section id="CD006847-sec-0076"> <h5 class="title">Survival</h5> <p>See <a href="./references#CD006847-fig-0007" title="">Analysis 1.1</a>; <a href="./references#CD006847-fig-0008" title="">Analysis 1.2</a>; <a href="./references#CD006847-fig-0009" title="">Analysis 1.3</a>. </p> <p>Four studies compared gefitinib with placebo in a general population (<a href="./references#CD006847-bbs2-0010" title="GaafarR M , SurmontV , ScagliottiG , VanKlaverenR , PapamichaelD , WelchJ , et al. A double‐blind, randomized, placebo‐controlled phase III intergroup study of gefitinib (G) in patients (pts) with advanced NSCLC, non‐progressing after first‐line platinum‐based chemotherapy (EORTC 08021‐ILCP 01/03). 2010 Annual Meeting of the Americal Society of CLinical Oncology, ASCO, Chicago, IL United States. American Society of Clinical Oncology, 2010; Vol. 28. GaafarRM , SurmontVF , ScagliottiGV , VanKlaverenRJ , PapamichaelD , WelchJJ , et al. A double‐blind, randomised, placebo‐controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non‐progressing after first line platinum‐based chemotherapy (EORTC 08021/ILCP 01/03). European Journal of Cancer2011;47:2331‐40. SurmontVF , GaafarRM , ScagliottiGV , VanKlaverenRJ , PapamichaelD , HasanB , et al. A double‐blind, randomized, placebo‐controlled phase III study of gefitinib (G) versus placebo (P) in patients (pts) with advanced NSCLC, non progressing after first‐line platinum‐based chemotherapy (EORTC 08021‐ ILCP). 35th ESMO Congress Milan Italy. Oxford University Press, 2010; Vol. 21:viii124. ">Gaafar 2011 EORTC08021</a>; <a href="./references#CD006847-bbs2-0012" title="GossG , FerryD , WierzibickiR , LaurieSA , ThompsonJ , BiesmaB , et al. Randomized phase II study of gefitinib compared with placebo in chemotherapy‐naive patients with advanced non‐small‐cell lung cancer and poor performance status. Journal of Clinical Oncology2009;27(13):2253‐60. ">Goss 2009 INSTEP</a>; <a href="./references#CD006847-bbs2-0015" title="KellyK , ChanskyK , GasparLE , AlbainKS , JettJ , UngYC , et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non‐small‐cell lung cancer: SWOG S0023. Journal of Clinical Oncology2008;26(15):2450‐6. [SWOG S0023] KellyK , GasparLE , ChanskyK , AlbainKS , CrowleyJ , GandaraDR . Low incidence of pneumonitis on SWOG 0023: A preliminary analysis of an ongoing phase III trial of concurrent chemoradiotherapy followed by consolidation docetaxel and Iressa/placebo maintenance in patients with inoperable stage III non‐small cell lung cancer [abstract]. 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, 13‐17 May, 2005 (Abstract No. 7058). 2005; Vol. 23:634. ">Kelly 2008 SWOG S0023</a>; <a href="./references#CD006847-bbs2-0030" title="ChangA , ParikhP , ThongprasertS , TanEH , PerngRP , GanzonD , et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non‐small cell lung cancer: subset analysis from the ISEL study. Journal of Thoracic Oncology2006;1(8):847‐55. HirschFR , DziadziuszkoR , ThatcherN , MannH , WatkinsC , ParumsDV , et al. Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo‐controlled study in advanced non small‐cell lung cancer. Cancer2008;112(5):1114‐21. HirschFR , Varella‐GarciaM , Bunn JrPA , FranklinWA , DziadziuszkoR , ThatcherN , et al. Molecular predictors of outcome with gefitinib in a phase III placebo‐controlled study in advanced non‐small cell lung cancer. Journal of Clinical Oncology2006;24(31):5034‐42. ThatcherN , ChangA , ParikhP , Rodrigues PereiraJ , CiuleanuT , vonPawelJ , et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non‐small‐cell lung cancer: results from a randomised, placebo‐controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet2005;366(9496):1527‐37. ">Thatcher 2005 ISEL</a>). The data presented examines the effect of gefitinib compared with placebo in the first‐line, second‐line and maintenance settings. Total pooling of data was not conducted for first‐ or second‐line therapy as only single studies were included. Pooling of data was only possible for maintenance treatment, as two studies were included (<a href="./references#CD006847-bbs2-0010" title="GaafarR M , SurmontV , ScagliottiG , VanKlaverenR , PapamichaelD , WelchJ , et al. A double‐blind, randomized, placebo‐controlled phase III intergroup study of gefitinib (G) in patients (pts) with advanced NSCLC, non‐progressing after first‐line platinum‐based chemotherapy (EORTC 08021‐ILCP 01/03). 2010 Annual Meeting of the Americal Society of CLinical Oncology, ASCO, Chicago, IL United States. American Society of Clinical Oncology, 2010; Vol. 28. GaafarRM , SurmontVF , ScagliottiGV , VanKlaverenRJ , PapamichaelD , WelchJJ , et al. A double‐blind, randomised, placebo‐controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non‐progressing after first line platinum‐based chemotherapy (EORTC 08021/ILCP 01/03). European Journal of Cancer2011;47:2331‐40. SurmontVF , GaafarRM , ScagliottiGV , VanKlaverenRJ , PapamichaelD , HasanB , et al. A double‐blind, randomized, placebo‐controlled phase III study of gefitinib (G) versus placebo (P) in patients (pts) with advanced NSCLC, non progressing after first‐line platinum‐based chemotherapy (EORTC 08021‐ ILCP). 35th ESMO Congress Milan Italy. Oxford University Press, 2010; Vol. 21:viii124. ">Gaafar 2011 EORTC08021</a>; <a href="./references#CD006847-bbs2-0015" title="KellyK , ChanskyK , GasparLE , AlbainKS , JettJ , UngYC , et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non‐small‐cell lung cancer: SWOG S0023. Journal of Clinical Oncology2008;26(15):2450‐6. [SWOG S0023] KellyK , GasparLE , ChanskyK , AlbainKS , CrowleyJ , GandaraDR . Low incidence of pneumonitis on SWOG 0023: A preliminary analysis of an ongoing phase III trial of concurrent chemoradiotherapy followed by consolidation docetaxel and Iressa/placebo maintenance in patients with inoperable stage III non‐small cell lung cancer [abstract]. 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, 13‐17 May, 2005 (Abstract No. 7058). 2005; Vol. 23:634. ">Kelly 2008 SWOG S0023</a>). Gefitinib did not improve overall survival when compared with placebo, either when administered as first‐line (<a href="./references#CD006847-bbs2-0012" title="GossG , FerryD , WierzibickiR , LaurieSA , ThompsonJ , BiesmaB , et al. Randomized phase II study of gefitinib compared with placebo in chemotherapy‐naive patients with advanced non‐small‐cell lung cancer and poor performance status. Journal of Clinical Oncology2009;27(13):2253‐60. ">Goss 2009 INSTEP</a>; hazard ratio (HR) 0.84, 95% confidence interval (CI) 0.62 to 1.14, P = 0.27), second‐line (<a href="./references#CD006847-bbs2-0030" title="ChangA , ParikhP , ThongprasertS , TanEH , PerngRP , GanzonD , et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non‐small cell lung cancer: subset analysis from the ISEL study. Journal of Thoracic Oncology2006;1(8):847‐55. HirschFR , DziadziuszkoR , ThatcherN , MannH , WatkinsC , ParumsDV , et al. Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo‐controlled study in advanced non small‐cell lung cancer. Cancer2008;112(5):1114‐21. HirschFR , Varella‐GarciaM , Bunn JrPA , FranklinWA , DziadziuszkoR , ThatcherN , et al. Molecular predictors of outcome with gefitinib in a phase III placebo‐controlled study in advanced non‐small cell lung cancer. Journal of Clinical Oncology2006;24(31):5034‐42. ThatcherN , ChangA , ParikhP , Rodrigues PereiraJ , CiuleanuT , vonPawelJ , et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non‐small‐cell lung cancer: results from a randomised, placebo‐controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet2005;366(9496):1527‐37. ">Thatcher 2005 ISEL</a>; HR 0.89, 95% CI 0.79 to 1.01, P = 0.06) or maintenance therapy (<a href="./references#CD006847-bbs2-0010" title="GaafarR M , SurmontV , ScagliottiG , VanKlaverenR , PapamichaelD , WelchJ , et al. A double‐blind, randomized, placebo‐controlled phase III intergroup study of gefitinib (G) in patients (pts) with advanced NSCLC, non‐progressing after first‐line platinum‐based chemotherapy (EORTC 08021‐ILCP 01/03). 2010 Annual Meeting of the Americal Society of CLinical Oncology, ASCO, Chicago, IL United States. American Society of Clinical Oncology, 2010; Vol. 28. GaafarRM , SurmontVF , ScagliottiGV , VanKlaverenRJ , PapamichaelD , WelchJJ , et al. A double‐blind, randomised, placebo‐controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non‐progressing after first line platinum‐based chemotherapy (EORTC 08021/ILCP 01/03). European Journal of Cancer2011;47:2331‐40. SurmontVF , GaafarRM , ScagliottiGV , VanKlaverenRJ , PapamichaelD , HasanB , et al. A double‐blind, randomized, placebo‐controlled phase III study of gefitinib (G) versus placebo (P) in patients (pts) with advanced NSCLC, non progressing after first‐line platinum‐based chemotherapy (EORTC 08021‐ ILCP). 35th ESMO Congress Milan Italy. Oxford University Press, 2010; Vol. 21:viii124. ">Gaafar 2011 EORTC08021</a>; <a href="./references#CD006847-bbs2-0015" title="KellyK , ChanskyK , GasparLE , AlbainKS , JettJ , UngYC , et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non‐small‐cell lung cancer: SWOG S0023. Journal of Clinical Oncology2008;26(15):2450‐6. [SWOG S0023] KellyK , GasparLE , ChanskyK , AlbainKS , CrowleyJ , GandaraDR . Low incidence of pneumonitis on SWOG 0023: A preliminary analysis of an ongoing phase III trial of concurrent chemoradiotherapy followed by consolidation docetaxel and Iressa/placebo maintenance in patients with inoperable stage III non‐small cell lung cancer [abstract]. 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, 13‐17 May, 2005 (Abstract No. 7058). 2005; Vol. 23:634. ">Kelly 2008 SWOG S0023</a>; pooled HR 1.14, 95% CI 0.61 to 2.14, P = 0.69, I<sup>2</sup> = 85%, random‐effects model). </p> <p>One‐year survival rates were improved by administration of gefitinib versus placebo as second‐line therapy (risk ratio (RR) 1.28, 95% CI 1.05 to 1.57, P = 0.02), but not as maintenance therapy (RR 0.90, 95% CI 0.78 to 1.04, P = 0.15). Progression‐free survival was not improved when gefitinib was compared with placebo as first‐line therapy and median progression‐free survival was reported as 1.4 months in both groups (HR 0.82, 95% CI 0.60 to 1.12, P = 0.21). Time to treatment failure was improved in favour of gefitinib as second‐line therapy, with a HR of 0.82 (95% CI 0.75 to 0.90, P &lt; 0.0001): median progression‐free survival was 3 months with gefitinib, 2.6 months with placebo. Maintenance use of gefitinib after first‐line treatment improved progression‐free survival (HR 0.70, 95% CI 0.53 to 0.91, P = 0.007, I<sup>2</sup> = 32%). </p> </section> <section id="CD006847-sec-0077"> <h5 class="title">Toxicity</h5> <p>See <a href="./references#CD006847-fig-0010" title="">Analysis 1.4</a>; <a href="./references#CD006847-fig-0012" title="">Analysis 1.6</a>. </p> <p>We have pooled reported toxicity data from three studies in this comparison so as to examine the differences in toxicity between gefitinib and placebo or best supportive care (<a href="./references#CD006847-bbs2-0010" title="GaafarR M , SurmontV , ScagliottiG , VanKlaverenR , PapamichaelD , WelchJ , et al. A double‐blind, randomized, placebo‐controlled phase III intergroup study of gefitinib (G) in patients (pts) with advanced NSCLC, non‐progressing after first‐line platinum‐based chemotherapy (EORTC 08021‐ILCP 01/03). 2010 Annual Meeting of the Americal Society of CLinical Oncology, ASCO, Chicago, IL United States. American Society of Clinical Oncology, 2010; Vol. 28. GaafarRM , SurmontVF , ScagliottiGV , VanKlaverenRJ , PapamichaelD , WelchJJ , et al. A double‐blind, randomised, placebo‐controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non‐progressing after first line platinum‐based chemotherapy (EORTC 08021/ILCP 01/03). European Journal of Cancer2011;47:2331‐40. SurmontVF , GaafarRM , ScagliottiGV , VanKlaverenRJ , PapamichaelD , HasanB , et al. A double‐blind, randomized, placebo‐controlled phase III study of gefitinib (G) versus placebo (P) in patients (pts) with advanced NSCLC, non progressing after first‐line platinum‐based chemotherapy (EORTC 08021‐ ILCP). 35th ESMO Congress Milan Italy. Oxford University Press, 2010; Vol. 21:viii124. ">Gaafar 2011 EORTC08021</a>; <a href="./references#CD006847-bbs2-0012" title="GossG , FerryD , WierzibickiR , LaurieSA , ThompsonJ , BiesmaB , et al. Randomized phase II study of gefitinib compared with placebo in chemotherapy‐naive patients with advanced non‐small‐cell lung cancer and poor performance status. Journal of Clinical Oncology2009;27(13):2253‐60. ">Goss 2009 INSTEP</a>; <a href="./references#CD006847-bbs2-0030" title="ChangA , ParikhP , ThongprasertS , TanEH , PerngRP , GanzonD , et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non‐small cell lung cancer: subset analysis from the ISEL study. Journal of Thoracic Oncology2006;1(8):847‐55. HirschFR , DziadziuszkoR , ThatcherN , MannH , WatkinsC , ParumsDV , et al. Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo‐controlled study in advanced non small‐cell lung cancer. Cancer2008;112(5):1114‐21. HirschFR , Varella‐GarciaM , Bunn JrPA , FranklinWA , DziadziuszkoR , ThatcherN , et al. Molecular predictors of outcome with gefitinib in a phase III placebo‐controlled study in advanced non‐small cell lung cancer. Journal of Clinical Oncology2006;24(31):5034‐42. ThatcherN , ChangA , ParikhP , Rodrigues PereiraJ , CiuleanuT , vonPawelJ , et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non‐small‐cell lung cancer: results from a randomised, placebo‐controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet2005;366(9496):1527‐37. ">Thatcher 2005 ISEL</a>). Administration of gefitinib was significantly associated with Common Toxicity Criteria (CTC) grade 3 to 4 events such as skin rash (RR 7.92, 95% CI 1.46 to 43.03, P = 0.02, I<sup>2</sup> = 0%) and diarrhoea (RR 2.48, 95% CI 1.15 to 5.35, P = 0.02, I<sup>2</sup> = 0%). One study reported a statistically significant increase in alanine aminotransferase (ALT) with gefitinib (RR 9.11, 95% CI 1.18 to 70.32, P = 0.03). The risk of all other adverse events was either not estimable or not significantly different between the two groups. </p> </section> <section id="CD006847-sec-0078"> <h5 class="title">Efficacy</h5> <p>See <a href="./references#CD006847-fig-0028" title="">Analysis 1.22</a>; <a href="./references#CD006847-fig-0029" title="">Analysis 1.23</a>. </p> <p>Response was reported in only three of the four included studies (<a href="./references#CD006847-bbs2-0010" title="GaafarR M , SurmontV , ScagliottiG , VanKlaverenR , PapamichaelD , WelchJ , et al. A double‐blind, randomized, placebo‐controlled phase III intergroup study of gefitinib (G) in patients (pts) with advanced NSCLC, non‐progressing after first‐line platinum‐based chemotherapy (EORTC 08021‐ILCP 01/03). 2010 Annual Meeting of the Americal Society of CLinical Oncology, ASCO, Chicago, IL United States. American Society of Clinical Oncology, 2010; Vol. 28. GaafarRM , SurmontVF , ScagliottiGV , VanKlaverenRJ , PapamichaelD , WelchJJ , et al. A double‐blind, randomised, placebo‐controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non‐progressing after first line platinum‐based chemotherapy (EORTC 08021/ILCP 01/03). European Journal of Cancer2011;47:2331‐40. SurmontVF , GaafarRM , ScagliottiGV , VanKlaverenRJ , PapamichaelD , HasanB , et al. A double‐blind, randomized, placebo‐controlled phase III study of gefitinib (G) versus placebo (P) in patients (pts) with advanced NSCLC, non progressing after first‐line platinum‐based chemotherapy (EORTC 08021‐ ILCP). 35th ESMO Congress Milan Italy. Oxford University Press, 2010; Vol. 21:viii124. ">Gaafar 2011 EORTC08021</a>; <a href="./references#CD006847-bbs2-0012" title="GossG , FerryD , WierzibickiR , LaurieSA , ThompsonJ , BiesmaB , et al. Randomized phase II study of gefitinib compared with placebo in chemotherapy‐naive patients with advanced non‐small‐cell lung cancer and poor performance status. Journal of Clinical Oncology2009;27(13):2253‐60. ">Goss 2009 INSTEP</a>; <a href="./references#CD006847-bbs2-0030" title="ChangA , ParikhP , ThongprasertS , TanEH , PerngRP , GanzonD , et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non‐small cell lung cancer: subset analysis from the ISEL study. Journal of Thoracic Oncology2006;1(8):847‐55. HirschFR , DziadziuszkoR , ThatcherN , MannH , WatkinsC , ParumsDV , et al. Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo‐controlled study in advanced non small‐cell lung cancer. Cancer2008;112(5):1114‐21. HirschFR , Varella‐GarciaM , Bunn JrPA , FranklinWA , DziadziuszkoR , ThatcherN , et al. Molecular predictors of outcome with gefitinib in a phase III placebo‐controlled study in advanced non‐small cell lung cancer. Journal of Clinical Oncology2006;24(31):5034‐42. ThatcherN , ChangA , ParikhP , Rodrigues PereiraJ , CiuleanuT , vonPawelJ , et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non‐small‐cell lung cancer: results from a randomised, placebo‐controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet2005;366(9496):1527‐37. ">Thatcher 2005 ISEL</a>). We did not pool the data as the INSTEP study compared gefitinib with placebo as first‐line therapy, ISEL did so as second‐line therapy and the EORTC08021 trial as maintenance therapy. As first‐line therapy, gefitinib did not improve the overall response rate (RR 6.06, 95% CI 0.74 to 49.43, P = 0.09) or the disease control rate (RR 1.36, 95% CI 0.86 to 2.16, P = 0.19). This was reported as an overall response rate of 6% and 1% in the gefitinib and placebo groups, respectively, and the disease control rate was 31% and 23%, respectively. As second‐line therapy, the overall response rate was higher for gefitinib‐treated cases than for placebo (RR 6.42, 95% CI 2.82 to 14.64, P &lt; 0.00001) and the disease control rate was also significantly higher for gefitinib (RR 1.24, 95% CI 1.06 to 1.44, P = 0.006). The overall response rate was 8% in the gefitinib group and 1% in the placebo group, and the disease control rate was 40% and 32%, respectively. Similarly, gefitinib improved the overall response rate and the disease control rate when used as maintenance therapy (RR 10.12, 95% CI 1.32 to 77.33, P = 0.03; RR 1.21, 95% CI 1.00 to 1.46, P = 0.05, respectively). </p> </section> <section id="CD006847-sec-0079"> <h5 class="title">Quality of life and symptom improvement scores</h5> <p><a href="./references#CD006847-bbs2-0030" title="ChangA , ParikhP , ThongprasertS , TanEH , PerngRP , GanzonD , et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non‐small cell lung cancer: subset analysis from the ISEL study. Journal of Thoracic Oncology2006;1(8):847‐55. HirschFR , DziadziuszkoR , ThatcherN , MannH , WatkinsC , ParumsDV , et al. Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo‐controlled study in advanced non small‐cell lung cancer. Cancer2008;112(5):1114‐21. HirschFR , Varella‐GarciaM , Bunn JrPA , FranklinWA , DziadziuszkoR , ThatcherN , et al. Molecular predictors of outcome with gefitinib in a phase III placebo‐controlled study in advanced non‐small cell lung cancer. Journal of Clinical Oncology2006;24(31):5034‐42. ThatcherN , ChangA , ParikhP , Rodrigues PereiraJ , CiuleanuT , vonPawelJ , et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non‐small‐cell lung cancer: results from a randomised, placebo‐controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet2005;366(9496):1527‐37. ">Thatcher 2005 ISEL</a> reported that the addition of gefitinib to "best supportive care" produced no significant changes in the quality of life subscale of the Functional Assessment of Cancer Therapy‐Lung (FACT‐L) questionnaire when compared with best supportive care alone. Gefitinib was associated with a statistically significant improvement in the symptom score (mean change from baseline ‐0.86 to ‐1.38; P = 0.019), but this did not meet predefined criteria. As described by <a href="./references#CD006847-bbs2-0057" title="CellaD , EtonDT , FaircloughDL , BonomiP , HeyesAE , SilbermanC , et al. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy‐Lung (FACT‐L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. Journal of Clinical Epidemiology2002;55:285‐95. ">Cella 2002</a>, for changes in disease‐related symptoms to be classed as clinically relevant, the score must increase by two points. <a href="./references#CD006847-bbs2-0012" title="GossG , FerryD , WierzibickiR , LaurieSA , ThompsonJ , BiesmaB , et al. Randomized phase II study of gefitinib compared with placebo in chemotherapy‐naive patients with advanced non‐small‐cell lung cancer and poor performance status. Journal of Clinical Oncology2009;27(13):2253‐60. ">Goss 2009 INSTEP</a> reported improvements in FACT‐L quality of life, FACT‐L Trial Outcome Index (TOI), lung cancer subscale (LCS) and Pulmonary Symptom Index (PSI) that were statistically non‐significant. </p> </section> </section> <section id="CD006847-sec-0080"> <h4 class="title">Subgroup analysis: Asian population</h4> <p>See <a href="./references#CD006847-fig-0030" title="">Analysis 2.1</a>; <a href="./references#CD006847-fig-0031" title="">Analysis 2.2</a>; <a href="./references#CD006847-fig-0032" title="">Analysis 2.3</a>; <a href="./references#CD006847-fig-0033" title="">Analysis 2.4</a>. </p> <p>The INFORM study prospectively recruited patients of East Asian ethnic origin without disease progression after first‐line chemotherapy (<a href="./references#CD006847-bbs2-0035" title="YangY , MaY , ZhaoY , FangW , HongS , et al. QoL analyses from INFORM study, a phase III study of gefitinib versus placebo as maintenance therapy in advanced NSCLC. Scientific Reports2015;5:11934. ZhangL , MaS , SongX , HanB , ChengY , HuangC , et al. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non‐small‐cell lung cancer (INFORM; C‐TONG 0804): a multicentre, double‐blind randomised phase 3 trial. Lancet Oncology2012;13:466‐75. ZhangL , MaSL , SongXQ , ChengY , HuangC , YangSJ , et al. Pre‐planned subgroup analyses from the phase III, randomised, placebo‐controlled, parallel‐group study of gefitinib (G) as maintenance therapy in patients (pts) with locally advanced or metastatic non‐small‐cell lung cancer (NSCLC) (INFORM; C‐TONG 0804). European Multidisciplinary Cancer Congress Stockholm Sweden. Elsevier Ltd, 2011; Vol. 47:S622‐3. ZhangL , MaSL , SongXQ , HanBH , ChengY , HuangC , et al. Efficacy, tolerability and biomarker analyses from a phase III, randomized, placebo controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non‐small‐cell lung cancer (NSCLC) in China (INFORM) (C‐TONG 0804). 14th World Conference on Lung Cancer Amsterdam Netherlands. International Association for the Study of Lung Cancer, 2011; Vol. 6:S558‐9. ZhangL , ShenglinM , SongX , HanB , ChengY , HuangC , et al. Efficacy, tolerability, and biomarker analyses from a phase III, randomized, placebo‐controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non‐small cell lung cancer (NSCLC; INFORM; C‐TONG 0804). ASCO Annual Meeting 2011 Chicago, IL United States. American Society of Clinical Oncology, 2011; Vol. 29. ZhaoH , FanY , MaS , SongX , HanB , ChengY , et al. Final overall survival results from a phase III, randomized placebo‐controlled, parallel‐group study of gefitinib versus placebo as maintenance therapy in patients with advanced or metastatic non‐small‐cell lung cancer (INFORM; C‐TONG 0804). Journal of Thoracic Oncology2015;10(4):655‐64. ">Zhang 2012 INFORM</a>). Pre‐planned subgroup analysis in the ISEL trial found marked heterogeneity in survival between patient groups (<a href="./references#CD006847-bbs2-0030" title="ChangA , ParikhP , ThongprasertS , TanEH , PerngRP , GanzonD , et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non‐small cell lung cancer: subset analysis from the ISEL study. Journal of Thoracic Oncology2006;1(8):847‐55. HirschFR , DziadziuszkoR , ThatcherN , MannH , WatkinsC , ParumsDV , et al. Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo‐controlled study in advanced non small‐cell lung cancer. Cancer2008;112(5):1114‐21. HirschFR , Varella‐GarciaM , Bunn JrPA , FranklinWA , DziadziuszkoR , ThatcherN , et al. Molecular predictors of outcome with gefitinib in a phase III placebo‐controlled study in advanced non‐small cell lung cancer. Journal of Clinical Oncology2006;24(31):5034‐42. ThatcherN , ChangA , ParikhP , Rodrigues PereiraJ , CiuleanuT , vonPawelJ , et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non‐small‐cell lung cancer: results from a randomised, placebo‐controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet2005;366(9496):1527‐37. ">Thatcher 2005 ISEL</a>). </p> <p>The ISEL study conducted a subgroup analysis in 342 patients of Asian ethnicity who were enrolled in the ISEL trial. Two hundred and thirty‐five patients received second‐line gefitinib and 107 received placebo. Pre‐planned analysis reported that gefitinib significantly improved overall survival (HR 0.66, 95% CI 0.48 to 0.91, P = 0.01), the one‐year survival rate (RR 1.75, 95% CI 1.20 to 2.55, P = 0.004) and progression‐free survival (HR 0.69, 95% CI 0.52 to 0.91, P = 0.009) compared to placebo. Median overall survival was 9.5 months for gefitinib compared with 5.5 months for placebo. Covariate analysis of demographic subgroups further demonstrated a survival advantage across multiple subgroups. Overall survival in this Asian subgroup of patients was also greater in never‐smokers (HR 0.37, 95% CI 0.21 to 0.64, P = 0.0004) compared with smokers (HR 0.85, 95% CI 0.58 to 1.25, P = 0.40); females (HR 0.46, 95% CI 0.26 to 0.79, P = 0.0045) compared with males (HR 0.80, 95% CI 0.54 to 1.18, P = 0.26); and patients with adenocarcinoma (HR 0.66, 95% CI 0.45 to 0.97, P = 0.04) compared with non‐adenocarcinoma (HR 0.86, 95% CI 0.50 to 1.47, P = 0.58). Objective response rates were higher in Asian patients treated with gefitinib compared with placebo (RR 6.03, 95% CI 1.46 to 24.91, P = 0.01). </p> <p>The INFORM study showed that gefitinib in the maintenance setting did not improve overall survival (HR 0.88, 95% CI 0.68 to 1.14, P = 0.335). However, gefitinib improved progression‐free survival over placebo (HR 0.42, 95% CI 0.33 to 0.54, P &lt; 0.00001), and median progression‐free survival was improved from 2.6 months to 4.8 months. The objective response rate was greater with gefitinib (RR 35.00, 95% CI 4.86 to 252.15, P = 0.0004). There was no difference in reported toxicities. </p> <p>Quality of life improvement rates were higher in those administered gefitinib compared with placebo, as measured by FACT‐L (improvement rates 55% versus 24%, P &lt; 0.001), TOI (51% versus 21%, P &lt; 0.001) and LCS (50% versus 22%, P &lt; 0.001) in the INFORM study (<a href="./references#CD006847-bbs2-0035" title="YangY , MaY , ZhaoY , FangW , HongS , et al. QoL analyses from INFORM study, a phase III study of gefitinib versus placebo as maintenance therapy in advanced NSCLC. Scientific Reports2015;5:11934. ZhangL , MaS , SongX , HanB , ChengY , HuangC , et al. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non‐small‐cell lung cancer (INFORM; C‐TONG 0804): a multicentre, double‐blind randomised phase 3 trial. Lancet Oncology2012;13:466‐75. ZhangL , MaSL , SongXQ , ChengY , HuangC , YangSJ , et al. Pre‐planned subgroup analyses from the phase III, randomised, placebo‐controlled, parallel‐group study of gefitinib (G) as maintenance therapy in patients (pts) with locally advanced or metastatic non‐small‐cell lung cancer (NSCLC) (INFORM; C‐TONG 0804). European Multidisciplinary Cancer Congress Stockholm Sweden. Elsevier Ltd, 2011; Vol. 47:S622‐3. ZhangL , MaSL , SongXQ , HanBH , ChengY , HuangC , et al. Efficacy, tolerability and biomarker analyses from a phase III, randomized, placebo controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non‐small‐cell lung cancer (NSCLC) in China (INFORM) (C‐TONG 0804). 14th World Conference on Lung Cancer Amsterdam Netherlands. International Association for the Study of Lung Cancer, 2011; Vol. 6:S558‐9. ZhangL , ShenglinM , SongX , HanB , ChengY , HuangC , et al. Efficacy, tolerability, and biomarker analyses from a phase III, randomized, placebo‐controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non‐small cell lung cancer (NSCLC; INFORM; C‐TONG 0804). ASCO Annual Meeting 2011 Chicago, IL United States. American Society of Clinical Oncology, 2011; Vol. 29. ZhaoH , FanY , MaS , SongX , HanB , ChengY , et al. Final overall survival results from a phase III, randomized placebo‐controlled, parallel‐group study of gefitinib versus placebo as maintenance therapy in patients with advanced or metastatic non‐small‐cell lung cancer (INFORM; C‐TONG 0804). Journal of Thoracic Oncology2015;10(4):655‐64. ">Zhang 2012 INFORM</a>). Gefitinib also increased the time‐to‐worsening of quality of life when compared with placebo (FACT‐L: 2.8 months versus 1.4 months, P = 0.019; TOI: 3.5 months versus 1.4 months P = 0.006; LCS: 2.8 months versus 1.4 months P = 0.028). The relationship between the change in quality of life score and prognosis was also analysed in the INFORM study. Patients with an improvement in quality of life had significantly longer progression‐free survival and overall survival when compared with those that had a stable or worsened quality of life (FACT‐L: 9.4 months versus 2.8 months versus 2.7 months, P &lt; 0.001 and 25.4 months versus 19.9 months versus 14.4 months, P = 0.003, respectively). </p> </section> <section id="CD006847-sec-0081"> <h4 class="title">Subgroup analysis: biomarker</h4> <p>See <a href="./references#CD006847-fig-0034" title="">Analysis 3.1</a>; <a href="./references#CD006847-fig-0035" title="">Analysis 3.2</a>. </p> <p>Subgroup analysis of patients from the ISEL trial reported that the overall response rate was higher in patients with epidermal growth factor receptor (EGFR) mutations (37.5%; 6 of 16 patients) than those who were EGFR mutation negative (2.6%; 3 of 116 patients). </p> <p>The INFORM study reported improved overall survival in 30 patients with EGFR mutations (HR 0.39, 95% CI 0.15 to 0.98, P = 0.036) with median overall survival improving from 20.97 months to 46.87 months when given gefitinib versus placebo. Whilst this subgroup only contained a very small number of patients, the study was able to show that gefitinib doubled the median overall survival. However, those with no detectable EGFR mutation or an unknown EGFR mutation status did not benefit from gefitinib maintenance therapy (HR 1.27, 95% CI 0.7 to 2.3, P = 0.431; HR 0.92, 95% CI 0.68 to 1.25, P = 0.603, respectively). </p> <p>Progression‐free survival was also improved with gefitinib (HR 0.17, 95% CI 0.07 to 0.41, P &lt; 0.0001) over placebo. Median progression‐free survival improved from 2.8 months to 16.6 months in this subgroup analysis of the INFORM trial. </p> </section> <section id="CD006847-sec-0082"> <h4 class="title"><i>2.</i> Gefitinib versus chemotherapy </h4> <section id="CD006847-sec-0083"> <h5 class="title">Survival</h5> <p>See <a href="./references#CD006847-fig-0036" title="">Analysis 4.1</a>; <a href="./references#CD006847-fig-0037" title="">Analysis 4.2</a>; <a href="./references#CD006847-fig-0038" title="">Analysis 4.3</a>. </p> <section id="CD006847-sec-0084"> <h6 class="title">Gefitinib versus first‐line chemotherapy</h6> <p>As first‐line therapy, only one study reported hazard ratios for survival (<a href="./references#CD006847-bbs2-0006" title="CrinoL , CappuzzoF , ZatloukalP , ReckM , PesekM , ThompsonJC , et al. Gefitinib versus vinorelbine in chemotherapy‐naive elderly patients with advanced non‐small‐cell lung cancer (INVITE): a randomized, phase II study. Journal of Clinical Oncology2008;26(26):4253‐60. ">Crino 2008 INVITE</a>). Gefitinib did not prolong overall survival (HR 0.98, 95% CI 0.66 to 1.46, P = 0.92, moderate quality of evidence) or progression‐free survival (HR 1.19, 95% CI 0.86 to 1.65, P = 0.30, moderate quality of evidence) when compared with vinorelbine in this general population of patients aged at least 70 years. This study selected patients over the age of 70 years old, therefore this limits the applicability of the data to other patients and thus we downgraded the quality of evidence to moderate. </p> <p>Two studies reported selected survival outcomes comparing gefitinib with first‐line chemotherapy (<a href="./references#CD006847-bbs2-0006" title="CrinoL , CappuzzoF , ZatloukalP , ReckM , PesekM , ThompsonJC , et al. Gefitinib versus vinorelbine in chemotherapy‐naive elderly patients with advanced non‐small‐cell lung cancer (INVITE): a randomized, phase II study. Journal of Clinical Oncology2008;26(26):4253‐60. ">Crino 2008 INVITE</a>; <a href="./references#CD006847-bbs2-0026" title="DesGuetzG , LandreT , WesteelV , MilleronB , VayletF , UrbanT , et al. Similar survival rates with first‐line gefitinib, gemcitabine or docetaxel in a randomized phase II trial in elderly patients with advanced non‐small cell lung cancer and a poor performance status (IFCT‐0301). Journal of Geriatric Oncology2015;6:233‐40. MorereJ , WesteelV , MorinF , et al. Randomized phase II trial of first‐line gefitinib,gemcitabine or docetaxel in performance status (PS) 2 or 3 non‐small‐cell lung cancer (NSCLC) patients (IFCT‐0301) [abstract no. 8086]. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2008;26(15 Suppl Pt I):445. MorereJF , BrechotJM , WesteelV , GounantV , LebeauB , VayletF , et al. Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non‐small‐cell lung cancer and a performance status of  2 or 3 (IFCT‐0301 study). Lung Cancer2010;70(1):301‐7. ">Morere 2010 IFCT‐0301</a>). When we pooled data from these two studies there was no difference in one‐year survival rates between gefitinib and first‐line chemotherapy (RR 0.93, 95% CI 0.63 to 1.38, P = 0.73, I<sup>2</sup> = 26%). Median overall survival ranged from 2.2 to 5.9 months and 3.5 to 8 months in the gefitinib and chemotherapy groups, respectively. Median progression‐free survival ranged from 1.9 to 2.7 months and 2.0 to 2.9 months in the gefitinib and chemotherapy groups, respectively. </p> </section> <section id="CD006847-sec-0085"> <h6 class="title">Gefitinib versus second‐line chemotherapy</h6> <p>The SIGN and INTEREST studies compared gefitinib with docetaxel as second‐line therapy (<a href="./references#CD006847-bbs2-0007" title="CuferT , VrdoljakE , GaafarR , ErensoyI , PembertonK , SIGN study group. Phase II, open‐label, randomized study (SIGN) or single‐agent gefitinib (IRESSA) or docetaxel as second‐line therapy in patients with advanced (stage IIIb or IV) non‐small‐cell lung cancer. Anticancer Drugs2006;17(4):401‐9. ">Cufer 2006 SIGN</a>; <a href="./references#CD006847-bbs2-0016" title="DouillardJY , ShephardFA , HirshV , MokT , SocinskiMA , GervaisR , et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non‐small‐cell lung cancer: from the randomized phase III INTEREST Trial. Journal of Clinical Oncology2010;28(5):744‐52. HorganAM , BradburyPA , AmirE , NgR , DouillardJY , KimES , et al. An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second‐/third‐line therapy in advanced non‐small‐cell lung cancer. Annals of Oncology. United Kingdom: Oxford University Press (Great Clarendon Street, Oxford OX2 6DP, United Kingdom), 2011; Vol. 22:1805‐11. HorganAM , ShepherdFA , BradburyPA , NgR , LeighlNB . Preliminary cost‐consequence analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as 2nd line therapy in advanced non‐small cell lung cancer [abstract no. 8110]. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2008;25(15 Suppl Pt 1):451. KimES , HirshV , MokT , SocinskiMA , GervaisR , WuYL , et al. Gefitinib versus docetaxel in previously treated non‐small‐cell lung cancer (INTEREST): a randomized phase III trial. Lancet2008;372:1809‐18. ">Kim 2008 INTEREST</a>). Only <a href="./references#CD006847-bbs2-0016" title="DouillardJY , ShephardFA , HirshV , MokT , SocinskiMA , GervaisR , et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non‐small‐cell lung cancer: from the randomized phase III INTEREST Trial. Journal of Clinical Oncology2010;28(5):744‐52. HorganAM , BradburyPA , AmirE , NgR , DouillardJY , KimES , et al. An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second‐/third‐line therapy in advanced non‐small‐cell lung cancer. Annals of Oncology. United Kingdom: Oxford University Press (Great Clarendon Street, Oxford OX2 6DP, United Kingdom), 2011; Vol. 22:1805‐11. HorganAM , ShepherdFA , BradburyPA , NgR , LeighlNB . Preliminary cost‐consequence analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as 2nd line therapy in advanced non‐small cell lung cancer [abstract no. 8110]. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2008;25(15 Suppl Pt 1):451. KimES , HirshV , MokT , SocinskiMA , GervaisR , WuYL , et al. Gefitinib versus docetaxel in previously treated non‐small‐cell lung cancer (INTEREST): a randomized phase III trial. Lancet2008;372:1809‐18. ">Kim 2008 INTEREST</a> reported survival outcomes and neither overall survival (HR 1.02, 95% CI 0.91 to 1.15, P = 0.74, moderate quality of evidence) nor progression‐free survival (HR 1.04, 95% CI 0.92 to 1.17, P = 0.51, moderate quality of evidence) were prolonged by gefitinib. Median overall survival ranged from 7.5 to 7.6 months and 7.1 to 8 months in the gefitinib and chemotherapy groups, respectively. There was no difference in the one‐year survival rate (RR 0.94, 95% CI 0.82 to 1.09, P = 0.44). Median progression‐free survival in the non‐selected population ranged from 2.2 to 3 months and 2.7 to 3.4 months in the gefitinib and chemotherapy groups, respectively. </p> <p><a href="./references#CD006847-bbs2-0007" title="CuferT , VrdoljakE , GaafarR , ErensoyI , PembertonK , SIGN study group. Phase II, open‐label, randomized study (SIGN) or single‐agent gefitinib (IRESSA) or docetaxel as second‐line therapy in patients with advanced (stage IIIb or IV) non‐small‐cell lung cancer. Anticancer Drugs2006;17(4):401‐9. ">Cufer 2006 SIGN</a> randomised patients to either second‐line gefitinib or docetaxel, however the trial was not formally powered to detect any statistical differences for any endpoint. We judged this to be at risk of serious imprecision and thus downgraded it one level. </p> </section> </section> <section id="CD006847-sec-0086"> <h5 class="title">Toxicity</h5> <p>See <a href="./references#CD006847-fig-0039" title="">Analysis 4.4</a>; <a href="./references#CD006847-fig-0040" title="">Analysis 4.5</a>; <a href="./references#CD006847-fig-0041" title="">Analysis 4.6</a>; <a href="./references#CD006847-fig-0042" title="">Analysis 4.7</a>; <a href="./references#CD006847-fig-0043" title="">Analysis 4.8</a>; <a href="./references#CD006847-fig-0044" title="">Analysis 4.9</a>; <a href="./references#CD006847-fig-0045" title="">Analysis 4.10</a>; <a href="./references#CD006847-fig-0046" title="">Analysis 4.11</a>. </p> <p>We combined data to compare the toxicity profile of gefitinib with chemotherapy for first‐ and second‐line therapy to assess the overall effect in both groups. Data from <a href="./references#CD006847-bbs2-0007" title="CuferT , VrdoljakE , GaafarR , ErensoyI , PembertonK , SIGN study group. Phase II, open‐label, randomized study (SIGN) or single‐agent gefitinib (IRESSA) or docetaxel as second‐line therapy in patients with advanced (stage IIIb or IV) non‐small‐cell lung cancer. Anticancer Drugs2006;17(4):401‐9. ">Cufer 2006 SIGN</a>, <a href="./references#CD006847-bbs2-0006" title="CrinoL , CappuzzoF , ZatloukalP , ReckM , PesekM , ThompsonJC , et al. Gefitinib versus vinorelbine in chemotherapy‐naive elderly patients with advanced non‐small‐cell lung cancer (INVITE): a randomized, phase II study. Journal of Clinical Oncology2008;26(26):4253‐60. ">Crino 2008 INVITE</a>, <a href="./references#CD006847-bbs2-0016" title="DouillardJY , ShephardFA , HirshV , MokT , SocinskiMA , GervaisR , et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non‐small‐cell lung cancer: from the randomized phase III INTEREST Trial. Journal of Clinical Oncology2010;28(5):744‐52. HorganAM , BradburyPA , AmirE , NgR , DouillardJY , KimES , et al. An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second‐/third‐line therapy in advanced non‐small‐cell lung cancer. Annals of Oncology. United Kingdom: Oxford University Press (Great Clarendon Street, Oxford OX2 6DP, United Kingdom), 2011; Vol. 22:1805‐11. HorganAM , ShepherdFA , BradburyPA , NgR , LeighlNB . Preliminary cost‐consequence analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as 2nd line therapy in advanced non‐small cell lung cancer [abstract no. 8110]. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2008;25(15 Suppl Pt 1):451. KimES , HirshV , MokT , SocinskiMA , GervaisR , WuYL , et al. Gefitinib versus docetaxel in previously treated non‐small‐cell lung cancer (INTEREST): a randomized phase III trial. Lancet2008;372:1809‐18. ">Kim 2008 INTEREST</a> and <a href="./references#CD006847-bbs2-0026" title="DesGuetzG , LandreT , WesteelV , MilleronB , VayletF , UrbanT , et al. Similar survival rates with first‐line gefitinib, gemcitabine or docetaxel in a randomized phase II trial in elderly patients with advanced non‐small cell lung cancer and a poor performance status (IFCT‐0301). Journal of Geriatric Oncology2015;6:233‐40. MorereJ , WesteelV , MorinF , et al. Randomized phase II trial of first‐line gefitinib,gemcitabine or docetaxel in performance status (PS) 2 or 3 non‐small‐cell lung cancer (NSCLC) patients (IFCT‐0301) [abstract no. 8086]. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2008;26(15 Suppl Pt I):445. MorereJF , BrechotJM , WesteelV , GounantV , LebeauB , VayletF , et al. Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non‐small‐cell lung cancer and a performance status of  2 or 3 (IFCT‐0301 study). Lung Cancer2010;70(1):301‐7. ">Morere 2010 IFCT‐0301</a> were included. Gefitinib was generally better tolerated than chemotherapy. Gefitinib was associated with an increased risk of skin rash when compared with chemotherapy (RR 2.40, 95% CI 1.08 to 5.31, P = 0.03, I<sup>2</sup> = 4.7%, high quality of evidence). Gefitinib was associated with a decreased risk of constipation (RR 0.41, 95% CI 0.17 to 0.97, P = 0.04, I<sup>2</sup> = 0%, high quality of evidence), fatigue (RR 0.16, 95% CI 0.03 to 0.88, P = 0.04, I<sup>2</sup> = 8.2%, moderate quality of evidence), asthenia (RR 0.51, 95% CI 0.35 to 0.75, P = 0.0007, I<sup>2</sup> = 0%, high quality of evidence), neurotoxicity (RR 0.07, 95% CI 0.01 to 0.34, P = 0.001, I<sup>2</sup> = 0%, high quality of evidence), neutropenia (RR 0.04, 95% CI 0.02 to 0.06, P &lt; 0.00001, I<sup>2</sup> = 43.1%, high quality of evidence), leukopenia (RR 0.03, 95% CI 0.00 to 0.22, P = 0.0005, I<sup>2</sup> = 0%, high quality of evidence) and febrile neutropenia (RR 0.12, 95% CI 0.06 to 0.23, P &lt; 0.00001, I<sup>2</sup> = 0%, high quality of evidence). There were no differences between groups for any other measured adverse side effects including pruritus, diarrhoea, vomiting, anorexia, stomatitis, arthralgia, peripheral oedema, respiratory tract infection, dyspnoea, cough, anaemia, thrombocytopenia, hypokalaemia or pyrexia. </p> <p>We assessed most of the toxicity outcomes as high‐quality evidence. We downgraded one outcome, fatigue, to a moderate quality of evidence as the study by <a href="./references#CD006847-bbs2-0006" title="CrinoL , CappuzzoF , ZatloukalP , ReckM , PesekM , ThompsonJC , et al. Gefitinib versus vinorelbine in chemotherapy‐naive elderly patients with advanced non‐small‐cell lung cancer (INVITE): a randomized, phase II study. Journal of Clinical Oncology2008;26(26):4253‐60. ">Crino 2008 INVITE</a> enrolled only 190 patients who were older than 70 years old, thus there was a risk of serious indirectness. </p> </section> <section id="CD006847-sec-0087"> <h5 class="title">Efficacy</h5> <p>See <a href="./references#CD006847-fig-0061" title="">Analysis 4.26</a>; <a href="./references#CD006847-fig-0062" title="">Analysis 4.27</a>. </p> <p>Only one first‐line study presented data on disease control rates and there was no reported improvement when administering gefitinib versus vinorelbine (RR 0.82, 95% CI 0.61 to 1.10, P = 0.19) (<a href="./references#CD006847-bbs2-0006" title="CrinoL , CappuzzoF , ZatloukalP , ReckM , PesekM , ThompsonJC , et al. Gefitinib versus vinorelbine in chemotherapy‐naive elderly patients with advanced non‐small‐cell lung cancer (INVITE): a randomized, phase II study. Journal of Clinical Oncology2008;26(26):4253‐60. ">Crino 2008 INVITE</a>). Disease control rates were 43.3% and 53.5% for gefitinib and chemotherapy, respectively. Two second‐line studies reported efficacy data (<a href="./references#CD006847-bbs2-0007" title="CuferT , VrdoljakE , GaafarR , ErensoyI , PembertonK , SIGN study group. Phase II, open‐label, randomized study (SIGN) or single‐agent gefitinib (IRESSA) or docetaxel as second‐line therapy in patients with advanced (stage IIIb or IV) non‐small‐cell lung cancer. Anticancer Drugs2006;17(4):401‐9. ">Cufer 2006 SIGN</a>; <a href="./references#CD006847-bbs2-0016" title="DouillardJY , ShephardFA , HirshV , MokT , SocinskiMA , GervaisR , et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non‐small‐cell lung cancer: from the randomized phase III INTEREST Trial. Journal of Clinical Oncology2010;28(5):744‐52. HorganAM , BradburyPA , AmirE , NgR , DouillardJY , KimES , et al. An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second‐/third‐line therapy in advanced non‐small‐cell lung cancer. Annals of Oncology. United Kingdom: Oxford University Press (Great Clarendon Street, Oxford OX2 6DP, United Kingdom), 2011; Vol. 22:1805‐11. HorganAM , ShepherdFA , BradburyPA , NgR , LeighlNB . Preliminary cost‐consequence analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as 2nd line therapy in advanced non‐small cell lung cancer [abstract no. 8110]. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2008;25(15 Suppl Pt 1):451. KimES , HirshV , MokT , SocinskiMA , GervaisR , WuYL , et al. Gefitinib versus docetaxel in previously treated non‐small‐cell lung cancer (INTEREST): a randomized phase III trial. Lancet2008;372:1809‐18. ">Kim 2008 INTEREST</a>). Pooled data showed that there was no improvement in overall response rate when comparing gefitinib and docetaxel as second‐line therapy (RR 1.16, 95% CI 0.85 to 1.59, P = 0.35, I<sup>2</sup> = 0%). Overall response rates were 9% to 13% for both the gefitinib and chemotherapy groups. </p> </section> <section id="CD006847-sec-0088"> <h5 class="title">Quality of life and symptom improvement scores</h5> <p>See <a href="./references#CD006847-fig-0063" title="">Analysis 4.28</a>; <a href="./references#CD006847-fig-0064" title="">Analysis 4.29</a>; <a href="./references#CD006847-fig-0065" title="">Analysis 4.30</a>; <a href="./references#CD006847-fig-0066" title="">Analysis 4.31</a>. </p> <p>We pooled data from the INVITE (<a href="./references#CD006847-bbs2-0006" title="CrinoL , CappuzzoF , ZatloukalP , ReckM , PesekM , ThompsonJC , et al. Gefitinib versus vinorelbine in chemotherapy‐naive elderly patients with advanced non‐small‐cell lung cancer (INVITE): a randomized, phase II study. Journal of Clinical Oncology2008;26(26):4253‐60. ">Crino 2008 INVITE</a>) and INTEREST (<a href="./references#CD006847-bbs2-0016" title="DouillardJY , ShephardFA , HirshV , MokT , SocinskiMA , GervaisR , et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non‐small‐cell lung cancer: from the randomized phase III INTEREST Trial. Journal of Clinical Oncology2010;28(5):744‐52. HorganAM , BradburyPA , AmirE , NgR , DouillardJY , KimES , et al. An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second‐/third‐line therapy in advanced non‐small‐cell lung cancer. Annals of Oncology. United Kingdom: Oxford University Press (Great Clarendon Street, Oxford OX2 6DP, United Kingdom), 2011; Vol. 22:1805‐11. HorganAM , ShepherdFA , BradburyPA , NgR , LeighlNB . Preliminary cost‐consequence analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as 2nd line therapy in advanced non‐small cell lung cancer [abstract no. 8110]. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2008;25(15 Suppl Pt 1):451. KimES , HirshV , MokT , SocinskiMA , GervaisR , WuYL , et al. Gefitinib versus docetaxel in previously treated non‐small‐cell lung cancer (INTEREST): a randomized phase III trial. Lancet2008;372:1809‐18. ">Kim 2008 INTEREST</a>) studies. Patients who received gefitinib reported statistically significant improvements in quality of life as assessed by scores on the FACT‐L (standardised mean difference (SMD) 10.50, 95% CI 9.55 to 11.45, P &lt; 0.00001, I<sup>2</sup> = 21%), LCS (SMD 3.63, 95% CI 3.08 to 4.19, P &lt; 0.00001, I<sup>2</sup> = 0%) and TOI (SMD 9.87, 95% CI 1.26 to 18.48, P = 0.02, I<sup>2</sup> = 59%). One study also described an improvement in PSI scores (SMD 5.60, 95% CI 3.55 to 7.65, P &lt; 0.00001) in patients who received gefitinib (<a href="./references#CD006847-bbs2-0006" title="CrinoL , CappuzzoF , ZatloukalP , ReckM , PesekM , ThompsonJC , et al. Gefitinib versus vinorelbine in chemotherapy‐naive elderly patients with advanced non‐small‐cell lung cancer (INVITE): a randomized, phase II study. Journal of Clinical Oncology2008;26(26):4253‐60. ">Crino 2008 INVITE</a>). </p> </section> </section> <section id="CD006847-sec-0089"> <h4 class="title">Subgroup analysis: Asian population</h4> <section id="CD006847-sec-0090"> <h5 class="title">Survival</h5> <p>See <a href="./references#CD006847-fig-0067" title="">Analysis 5.1</a>; <a href="./references#CD006847-fig-0068" title="">Analysis 5.2</a>; <a href="./references#CD006847-fig-0069" title="">Analysis 5.3</a>; <a href="./references#CD006847-fig-0070" title="">Analysis 5.4</a>; <a href="./references#CD006847-fig-0071" title="">Analysis 5.5</a>; <a href="./references#CD006847-fig-0072" title="">Analysis 5.6</a>; <a href="./references#CD006847-fig-0073" title="">Analysis 5.7</a>. </p> <section id="CD006847-sec-0091"> <h6 class="title">Gefitinib versus first‐line chemotherapy</h6> <p>Five phase III studies compared gefitinib with first‐line platinum doublet chemotherapy (<a href="./references#CD006847-bbs2-0013" title="HanJY , ParkK , KimSW , LeeDH , KimHY , KimHT , et al. First‐SIGNAL: first‐line single‐agent Iressa versus gemcitabine and cisplatin trial in never‐smokers with adenocarcinoma of the lung. Journal of Clinical Oncology2012;30:1122‐8. HanJY , YoonKA , ParkJH , LeeYJ , LeeGK , HanJH , et al. DNA repair gene polymorphisms and benefit from gefitinib in never‐smokers with lung adenocarcinoma. Cancer2011;117(14):3201‐8. ">Han 2012 First SIGNAL</a>; <a href="./references#CD006847-bbs2-0022" title="FukuharaT , MaemondoM , InoueA , KobayashiK , SugawaraS , OizumiS , et al. Factors associated with a poor response to gefitinib in the NEJ002 study: smoking and the L858R mutation. Lung Cancer2015;88:181‐6. InoueA , KobayashiK , MaemondoM , SugawaraS , OizumiS , IsobeH , et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin‐paclitaxel for chemo‐naive non‐small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Annals of Oncology. United Kingdom: Oxford University Press (Great Clarendon Street, Oxford OX2 6DP, United Kingdom), 2013; Vol. 24:54‐9. InoueA , KobayashiK , MaemondoM , et al. A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first‐line treatment of non‐small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 study. European Journal of Cancer. 2009:Abstract 9LBA. MaemondoM , InoueA , KobayashiK , SugawaraS , OizumiS , IsobeH , et al. Gefitinib or chemotherapy for non‐small‐cell lung cancer with mutated EGFR. New England Journal of Medicine2010;362(25):2380‐8. MiyauchiE , InoueA , KobayashiK , MaemondoM , SugawaraS , OizumiS , et al. Efficacy of chemotherapy after first‐line gefitinib therapy in EGFR mutation‐positive advanced non‐small cell lung cancer ‐ data from a randomized phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002). Japanese Journal of Clinical Oncology2015;45(7):670‐6. OizumiS , KobayashiK , InoueA , MaemondoM , SugawaraS , YoshizawaH , et al. Quality of life with gefitinib in patients with EGFR‐mutated non‐small cell lung cancer: quality of life analysis of North East Japan study group 002 trial. Oncologist. United States: AlphaMed Press (318 Blackwell St. Suite 260, Durham NC 27701‐2884, United States), 2012; Vol. 17:863‐70. YoshizawaH , KobayashiK , InoueA , MaemondoM , SugawaraS , OizumiS , et al. QOL analysis from NEJ 002 study comparing gefitinib to chemotherapy for non‐small cell lung cancer with mutated EGFR. 35th ESMO Congress Milan Italy. Oxford University Press, 2010; Vol. 21:viii122. ">Maemondo 2010 NEJ002</a>; <a href="./references#CD006847-bbs2-0024" title="MitsudomiT , MoritaS , YatabeY , NegoroS , OkamotoI , SetoT , et al. Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first‐line treatment for patients with non‐small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR). 2012 Annual Meeting of the American Society of Clinical Oncology, ASCO Chicago, IL United States. American Society of Clinical Oncology, 2012; Vol. 30. MitsudomiT , MoritaS , YatabeY , NegoroS , OkamotoI , TsurutaniJ , et al. Gefitinib versus cisplatin plus docetaxel in patients with non‐small‐cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase III trial. Lancet2010;11:121‐8. TsurutaniJ , MitsudomiT , MoriS , OkamotoI , NozakiK , TadaH , et al. A phase III, first‐line trial of gefitinib versus cisplatin plus docetaxel for patients with advanced or recurrent non‐small cell lung cancer (NSCLC) harboring activating mutation of the epidermal growth factor receptor (EGFR) gene: a preliminary results of WJTOG 3405 [abstract O‐9002]. European Journal of Cancer. 2009; Vol. 7 Suppl:505. ">Mitsudomi 2010 WJTOG3405</a>; <a href="./references#CD006847-bbs2-0025" title="FukuokaM , WuYL , ThongprasertS , SunpaweravongP , LeongSS , SriuranpongV , et al. Biomarker analyses and final overall survival results from a phase III, randomized, open‐label, first‐line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non ‐ small‐cell lung cancer in Asia (IPASS). Journal of Clinical Oncology2011;29:2866‐74. MokT , WuY‐L , ThongprasertS , et al. Phase III, randomised, open‐label, first‐line study of gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients (PTS) with advanced non‐small cell lung cancer (NSCLC) (IPASS). Annals of Oncology2008;19 Suppl 8:Viii1. MokTS , WuYL , ThongprasertS , YangCH , ChuDT , SaijoN , et al. Gefitinib or carboplatin‐paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine2009;361(10):947‐57. OheY , IchinoseY , NishiwakiY ,  etal . Phase III, randomized, open‐label, first‐line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in selected patients (pts) with advanced non‐small‐cell lung cancer (NSCLC) (IPASS): Evaluation of recruits in Japan. Journal of Clinical Oncology2009;29(15 Suppl 1):8044. ThongprasertS , DuffieldE , SaijoN , WuYL , YangJC , ChuDT , et al. Health‐related quality‐of‐life in a randomized phase III first‐line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). Journal of Thoracic Oncology2011;6:1872‐80. ThongprasertS , DuffieldE , WuY , et al. Quality of life (QOL) in a randomized phase III first‐line study of gefitinib (G) vs carboplatin/paclitaxel (CP) in clinically selected Asian patients (pts) with advanced NSCLC (IPASS). Journal of Thoracic Oncology2010;5(5 Suppl 1):S80. WuY , ChuD , HanB , LiuX , ZhangL , ZhouC , et al. Phase III, randomized, open‐label, first‐line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non‐small‐cell lung cancer: evaluation of patients recruited from mainland China. Asia‐Pacific Journal of Clinical Oncology2012;8:232‐43. WuY , FukuokaM , MokT S K , SaijoN , ThongprasertS , YangJ C H , et al. Tumour response, skin rash and health‐related quality of life (HRQOL) ‐ Post‐HOC data from the IPASS study. European Multidisciplinary Cancer Congress Stockholm Sweden. Elsevier Ltd, 2011; Vol. 47:S633‐4. WuY , MokT , ChuD , et al. Evaluation of clinically selected patients (pts) with advanced non‐small cell lung cancer (NSCLC) recruited in China in a phase III, randomized, open‐label, first‐line study in Asia of gefitinib (G) versus carboplatin/paclitaxel (C/P) (IPASS). Journal of Clinical Oncology. 2009; Vol. 27 (15 Suppl 1):8041. WuYL , FukuokaM , MokTSK , SaijoN , ThongprasertS , YangJCH , et al. Tumor response and health‐related quality of life in clinically selected patients from Asia with advanced non‐small‐cell lung cancer treated with first‐line gefitinib: post hoc analyses from the IPASS study. Lung Cancer2013;81:280‐7. YangCH , FukuokaM , MokTS , WuYL , ThongprasertS , SaijoN , et al. Final overall survival (OS) results from a phase III, randomised, open‐label, first‐line study of gefitinib (G) v carboplatin/paclitaxel (C/P) in clinically selected patients with advanced nonsmall cell lung cancer (NSCLC) in Asia (IPASS). 35th ESMO Congress Milan Italy. Oxford University Press, 2010; Vol. 21:viii1‐2. YangJ , WuY L , SaijoN , ThongprasertS , ChuD T , ChenY M , et al. Efficacy outcomes in first‐line treatment of advanced NSCLC with gefitinib (G) vs carboplatin/paclitaxel (C/P) by epidermal growth factor receptor (EGFR) gene‐copy number score and by most common EGFR mutation subtypes ‐ Exploratory data from IPASS. 2011 European Multidisciplinary Cancer Congress Stockholm Sweden. Elsevier Ltd, 2011; Vol. 47:S633. YangJ , WuY , ChanV , KurniandaJ , NakagawaK . Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan‐ASia Study (IPASS). Lung Cancer2014;83:174‐81. YangJCH , WuYL , ChanV , KurniandaJ , NakagawaK , SaijoN , et al. Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan‐ASia Study (IPASS). Lung Cancer2014;83:174‐81. ">Mok 2009 IPASS</a>; <a href="./references#CD006847-bbs2-0033" title="BoyeM , WangX , SrimuninnimitV , KangJH , TsaiCM , OrlandoM , et al. First‐line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian never‐smoker patients with locally advanced or metastatic nonsquamous non‐small cell lung cancer: quality of life results from a randomized phase III trial. Clinical Lung Cancer2016;17(2):150‐60. KangJH , AhnM , KimD , ChoEK , KimJ , ShinSW , et al. Tolerability and outcomes of first‐line pemetrexed‐cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in Korean patients with advanced non‐squamous non‐small cell lung cancer: a post hoc descriptive subgroup analysis of a randomized, phase 3 trial. Cancer Research and Treatment2015;48(2):458‐64. YangJC , KangJH , MokT , AhnM , SrimuninnimitV , LinC , et al. First‐line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non‐squamous non‐small cell lung cancer: a randomised, phase 3 trial. European Journal of Cancer2014;50:2219‐30. YangJC , ParkK , MokTSK , KangJH , SrimuninnimitV , LinCC , et al. A randomized phase 3 study comparing first‐line pemetrexed plus cisplatin followed by gefitinib as maintenance with gefitinib monotherapy in east Asian patients with locally advanced or metastatic nonsquamous non‐small cell lung cancer (NSQNSCLC). 15th World Conference on Lung Cancer Sydney, NSW Australia. International Association for the Study of Lung Cancer, 2013; Vol. 8:S288. YangJC , SrimuninnimitV , AhnM , LinC , KimS , TsaiC , et al. A randomized phase 3 study comparing first‐line pemetrexed plus cisplatin followed by gefitinib maintenance (PC/G) with gefitinib monotherapy (G) in East Asian patients (pts) with locally advanced or metastatic nonsquamous non‐small cell lung cancer (nSqNSCLC): final survival results. Journal of Clinical Oncology2015;15 Suppl:8041. YangJC , SrimunninnimitV , AhnM , LinC , KimS , TsaiC , et al. First‐line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian never‐smoker patients with locally advanced or metastatic nonsquamous non‐small cell lung cancer: final overall survival results from a randomized phase 3 study. Journal of Thoracic Oncology2016;11(3):370‐9. ">Yang 2014</a>). The IPASS (<a href="./references#CD006847-bbs2-0025" title="FukuokaM , WuYL , ThongprasertS , SunpaweravongP , LeongSS , SriuranpongV , et al. Biomarker analyses and final overall survival results from a phase III, randomized, open‐label, first‐line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non ‐ small‐cell lung cancer in Asia (IPASS). Journal of Clinical Oncology2011;29:2866‐74. MokT , WuY‐L , ThongprasertS , et al. Phase III, randomised, open‐label, first‐line study of gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients (PTS) with advanced non‐small cell lung cancer (NSCLC) (IPASS). Annals of Oncology2008;19 Suppl 8:Viii1. MokTS , WuYL , ThongprasertS , YangCH , ChuDT , SaijoN , et al. Gefitinib or carboplatin‐paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine2009;361(10):947‐57. OheY , IchinoseY , NishiwakiY ,  etal . Phase III, randomized, open‐label, first‐line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in selected patients (pts) with advanced non‐small‐cell lung cancer (NSCLC) (IPASS): Evaluation of recruits in Japan. Journal of Clinical Oncology2009;29(15 Suppl 1):8044. ThongprasertS , DuffieldE , SaijoN , WuYL , YangJC , ChuDT , et al. Health‐related quality‐of‐life in a randomized phase III first‐line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). Journal of Thoracic Oncology2011;6:1872‐80. ThongprasertS , DuffieldE , WuY , et al. Quality of life (QOL) in a randomized phase III first‐line study of gefitinib (G) vs carboplatin/paclitaxel (CP) in clinically selected Asian patients (pts) with advanced NSCLC (IPASS). Journal of Thoracic Oncology2010;5(5 Suppl 1):S80. WuY , ChuD , HanB , LiuX , ZhangL , ZhouC , et al. Phase III, randomized, open‐label, first‐line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non‐small‐cell lung cancer: evaluation of patients recruited from mainland China. Asia‐Pacific Journal of Clinical Oncology2012;8:232‐43. WuY , FukuokaM , MokT S K , SaijoN , ThongprasertS , YangJ C H , et al. Tumour response, skin rash and health‐related quality of life (HRQOL) ‐ Post‐HOC data from the IPASS study. European Multidisciplinary Cancer Congress Stockholm Sweden. Elsevier Ltd, 2011; Vol. 47:S633‐4. WuY , MokT , ChuD , et al. Evaluation of clinically selected patients (pts) with advanced non‐small cell lung cancer (NSCLC) recruited in China in a phase III, randomized, open‐label, first‐line study in Asia of gefitinib (G) versus carboplatin/paclitaxel (C/P) (IPASS). Journal of Clinical Oncology. 2009; Vol. 27 (15 Suppl 1):8041. WuYL , FukuokaM , MokTSK , SaijoN , ThongprasertS , YangJCH , et al. Tumor response and health‐related quality of life in clinically selected patients from Asia with advanced non‐small‐cell lung cancer treated with first‐line gefitinib: post hoc analyses from the IPASS study. Lung Cancer2013;81:280‐7. YangCH , FukuokaM , MokTS , WuYL , ThongprasertS , SaijoN , et al. Final overall survival (OS) results from a phase III, randomised, open‐label, first‐line study of gefitinib (G) v carboplatin/paclitaxel (C/P) in clinically selected patients with advanced nonsmall cell lung cancer (NSCLC) in Asia (IPASS). 35th ESMO Congress Milan Italy. Oxford University Press, 2010; Vol. 21:viii1‐2. YangJ , WuY L , SaijoN , ThongprasertS , ChuD T , ChenY M , et al. Efficacy outcomes in first‐line treatment of advanced NSCLC with gefitinib (G) vs carboplatin/paclitaxel (C/P) by epidermal growth factor receptor (EGFR) gene‐copy number score and by most common EGFR mutation subtypes ‐ Exploratory data from IPASS. 2011 European Multidisciplinary Cancer Congress Stockholm Sweden. Elsevier Ltd, 2011; Vol. 47:S633. YangJ , WuY , ChanV , KurniandaJ , NakagawaK . Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan‐ASia Study (IPASS). Lung Cancer2014;83:174‐81. YangJCH , WuYL , ChanV , KurniandaJ , NakagawaK , SaijoN , et al. Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan‐ASia Study (IPASS). Lung Cancer2014;83:174‐81. ">Mok 2009 IPASS</a>) and NEJ002 (<a href="./references#CD006847-bbs2-0022" title="FukuharaT , MaemondoM , InoueA , KobayashiK , SugawaraS , OizumiS , et al. Factors associated with a poor response to gefitinib in the NEJ002 study: smoking and the L858R mutation. Lung Cancer2015;88:181‐6. InoueA , KobayashiK , MaemondoM , SugawaraS , OizumiS , IsobeH , et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin‐paclitaxel for chemo‐naive non‐small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Annals of Oncology. United Kingdom: Oxford University Press (Great Clarendon Street, Oxford OX2 6DP, United Kingdom), 2013; Vol. 24:54‐9. InoueA , KobayashiK , MaemondoM , et al. A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first‐line treatment of non‐small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 study. European Journal of Cancer. 2009:Abstract 9LBA. MaemondoM , InoueA , KobayashiK , SugawaraS , OizumiS , IsobeH , et al. Gefitinib or chemotherapy for non‐small‐cell lung cancer with mutated EGFR. New England Journal of Medicine2010;362(25):2380‐8. MiyauchiE , InoueA , KobayashiK , MaemondoM , SugawaraS , OizumiS , et al. Efficacy of chemotherapy after first‐line gefitinib therapy in EGFR mutation‐positive advanced non‐small cell lung cancer ‐ data from a randomized phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002). Japanese Journal of Clinical Oncology2015;45(7):670‐6. OizumiS , KobayashiK , InoueA , MaemondoM , SugawaraS , YoshizawaH , et al. Quality of life with gefitinib in patients with EGFR‐mutated non‐small cell lung cancer: quality of life analysis of North East Japan study group 002 trial. Oncologist. United States: AlphaMed Press (318 Blackwell St. Suite 260, Durham NC 27701‐2884, United States), 2012; Vol. 17:863‐70. YoshizawaH , KobayashiK , InoueA , MaemondoM , SugawaraS , OizumiS , et al. QOL analysis from NEJ 002 study comparing gefitinib to chemotherapy for non‐small cell lung cancer with mutated EGFR. 35th ESMO Congress Milan Italy. Oxford University Press, 2010; Vol. 21:viii122. ">Maemondo 2010 NEJ002</a>) studies compared gefitinib with carboplatin‐paclitaxel. The WJTOG3405 study compared gefitinib with cisplatin‐docetaxel (<a href="./references#CD006847-bbs2-0024" title="MitsudomiT , MoritaS , YatabeY , NegoroS , OkamotoI , SetoT , et al. Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first‐line treatment for patients with non‐small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR). 2012 Annual Meeting of the American Society of Clinical Oncology, ASCO Chicago, IL United States. American Society of Clinical Oncology, 2012; Vol. 30. MitsudomiT , MoritaS , YatabeY , NegoroS , OkamotoI , TsurutaniJ , et al. Gefitinib versus cisplatin plus docetaxel in patients with non‐small‐cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase III trial. Lancet2010;11:121‐8. TsurutaniJ , MitsudomiT , MoriS , OkamotoI , NozakiK , TadaH , et al. A phase III, first‐line trial of gefitinib versus cisplatin plus docetaxel for patients with advanced or recurrent non‐small cell lung cancer (NSCLC) harboring activating mutation of the epidermal growth factor receptor (EGFR) gene: a preliminary results of WJTOG 3405 [abstract O‐9002]. European Journal of Cancer. 2009; Vol. 7 Suppl:505. ">Mitsudomi 2010 WJTOG3405</a>). The First‐SIGNAL study compared gefitinib with gemcitabine‐cisplatin (<a href="./references#CD006847-bbs2-0013" title="HanJY , ParkK , KimSW , LeeDH , KimHY , KimHT , et al. First‐SIGNAL: first‐line single‐agent Iressa versus gemcitabine and cisplatin trial in never‐smokers with adenocarcinoma of the lung. Journal of Clinical Oncology2012;30:1122‐8. HanJY , YoonKA , ParkJH , LeeYJ , LeeGK , HanJH , et al. DNA repair gene polymorphisms and benefit from gefitinib in never‐smokers with lung adenocarcinoma. Cancer2011;117(14):3201‐8. ">Han 2012 First SIGNAL</a>). The study by <a href="./references#CD006847-bbs2-0033" title="BoyeM , WangX , SrimuninnimitV , KangJH , TsaiCM , OrlandoM , et al. First‐line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian never‐smoker patients with locally advanced or metastatic nonsquamous non‐small cell lung cancer: quality of life results from a randomized phase III trial. Clinical Lung Cancer2016;17(2):150‐60. KangJH , AhnM , KimD , ChoEK , KimJ , ShinSW , et al. Tolerability and outcomes of first‐line pemetrexed‐cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in Korean patients with advanced non‐squamous non‐small cell lung cancer: a post hoc descriptive subgroup analysis of a randomized, phase 3 trial. Cancer Research and Treatment2015;48(2):458‐64. YangJC , KangJH , MokT , AhnM , SrimuninnimitV , LinC , et al. First‐line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non‐squamous non‐small cell lung cancer: a randomised, phase 3 trial. European Journal of Cancer2014;50:2219‐30. YangJC , ParkK , MokTSK , KangJH , SrimuninnimitV , LinCC , et al. A randomized phase 3 study comparing first‐line pemetrexed plus cisplatin followed by gefitinib as maintenance with gefitinib monotherapy in east Asian patients with locally advanced or metastatic nonsquamous non‐small cell lung cancer (NSQNSCLC). 15th World Conference on Lung Cancer Sydney, NSW Australia. International Association for the Study of Lung Cancer, 2013; Vol. 8:S288. YangJC , SrimuninnimitV , AhnM , LinC , KimS , TsaiC , et al. A randomized phase 3 study comparing first‐line pemetrexed plus cisplatin followed by gefitinib maintenance (PC/G) with gefitinib monotherapy (G) in East Asian patients (pts) with locally advanced or metastatic nonsquamous non‐small cell lung cancer (nSqNSCLC): final survival results. Journal of Clinical Oncology2015;15 Suppl:8041. YangJC , SrimunninnimitV , AhnM , LinC , KimS , TsaiC , et al. First‐line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian never‐smoker patients with locally advanced or metastatic nonsquamous non‐small cell lung cancer: final overall survival results from a randomized phase 3 study. Journal of Thoracic Oncology2016;11(3):370‐9. ">Yang 2014</a> compared gefitinib monotherapy with pemetrexed‐cisplatin followed by gefitinib maintenance. </p> <p>Pooled analysis showed that gefitinib did not improve overall survival (HR 0.94, 95% CI 0.82 to 1.06, P = 0.31, I<sup>2</sup> = 0%) or the one‐year survival rate (RR 1.03, 95% C 0.97 to 1.09, P = 0.33, I<sup>2</sup> = 1%). One study reported median overall survival as 22 months in both groups. Progression‐free survival was higher in the gefitinib group than in the chemotherapy group (HR 0.65, 95% CI 0.43 to 0.98, P = 0.04, I<sup>2</sup> = 93%). Median progression‐free survival ranged from 5.5 to 6.4 months with chemotherapy to 5.7 to 10.4 months with gefitinib. Please refer to <a href="#CD006847-fig-0003">Figure 3</a> for the pooled progression‐free survival data from first‐line studies that included Asian patients. </p> <div class="figure" id="CD006847-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Progression‐free survival: Gefitinib versus first‐line chemotherapy in an Asian population (Analysis 5.4)." data-id="CD006847-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Progression‐free survival: Gefitinib versus first‐line chemotherapy in an Asian population (<a href="./references#CD006847-fig-0070" title="">Analysis 5.4</a>). </p> </div> </div> </div> </section> <section id="CD006847-sec-0092"> <h6 class="title">Gefitinib versus second‐line chemotherapy</h6> <p>Two phase III studies compared gefitinib with second‐line docetaxel in patients of Asian ethnicity (<a href="./references#CD006847-bbs2-0019" title="LeeD , KimS , ParkK , et al. A randomized open‐label study of gefitinib versus docetaxel in patients with advanced/metastatic non‐small cell lung cancer (NSCLC) who have previously received platinum‐based chemotherapy [abstract no. 8025]. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2008;26(15 Suppl Pt I):430. LeeDH , ParkK , KimJH , LeeJS , ShinSW , KangJH , et al. Randomized phase III trial of gefitinib versus docetaxel in non‐small‐cell lung cancer patients who have previously received platinum‐based chemotherapy. Clinical Cancer Research2010;16(4):1307‐14. [ISTANA] ">Lee 2010 ISTANA</a>; <a href="./references#CD006847-bbs2-0023" title="LekiR , KawaharaM , WatanabeH , et al. The impact of response evaluation committee in a Phase III study (V‐15‐32) of gefitinib versus docetaxel in Japanese patients with non‐small cell lung cancer [Abstract No. 298P]. Annals of Oncology2009;19 Suppl 8:109‐10. MaruyamaR , NishiwakiY , TamuraT , YamamotoN , TsuboiM , NakagawaK , et al. Phase III study, V‐15‐32, of gefitinib versus docetaxel in previously treated Japanese patients with non‐small‐cell lung cancer. Journal of Clinical Oncology2008;26(26):4245‐52. SekineI , IchinoseY , NishiwakiY , YamamotoN , TsuboiM , NakagawaK , et al. Quality of life and disease‐related symptoms in previously treated Japanese patients with non‐small‐cell lung cancer: results of a randomized phase III study (V‐15‐32) of gefitinib versus docetaxel. Annals of Oncology2009;20(9):1483‐8. YamamotoN , NishiwakiY , NegoroS , JiangH , ItohY , SaijoN , et al. Disease control as a predictor of survival with gefitinib and docetaxel in a phase III study (V‐15‐32) in advanced non‐small‐cell lung cancer patients. Journal of Thoracic Oncology2010;5(7):1042‐7. ">Maruyama 2008 V‐15‐32</a>) and one phase III study compared gefitinib with pemetrexed (<a href="./references#CD006847-bbs2-0028" title="AhnM , SunJ , AhnJS , KimS , MinYJ , YunHJ , et al. Randomized phase III trial of gefitinib or pemetrexed as second‐line treatment in patients with non‐small cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01). ASCO Annual Meeting 2011 Chicago, IL United States. American Society of Clinical Oncology, 2011; Vol. 29. AhnMJ , SunJM , LeeKH , AhnJS , KimSW , MinYJ , et al. Randomized phase III trial of gefitinib or pemetrexed as second‐line treatment in patients with non‐small cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01). 14th World Conference on Lung Cancer Amsterdam Netherlands. International Association for the Study of Lung Cancer, 2011; Vol. 6:S317. SunJM , LeeKH , KimSW , LeeDH , MinYJ , YunHJ , et al. Gefitinib versus pemetrexed as second‐line treatment in patients with nonsmall cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01): an open‐label, phase 3 trial. Cancer2012;118:6234‐42. ">Sun 2012 KCSG‐LU08‐01</a>). In pooled analysis of these three trials, there was no benefit on either overall survival or the one‐year survival rate for gefitinib over second‐line chemotherapy (HR 0.94, 95% CI 0.79 to 1.12, P = 0.50, I<sup>2</sup> = 0%; RR 0.94, 95% CI 0.81 to 1.11, P = 0.48, I<sup>2</sup> = 0%, respectively). Progression‐free survival was prolonged (HR 0.71, 95% CI 0.57 to 0.88, P = 0.002, I<sup>2</sup> = 40%; see <a href="#CD006847-fig-0004">Figure 4</a>) in favour of gefitinib. Median progression‐free survival was 2 to 6.8 months with second‐line chemotherapy, and 2 to 10 months with gefitinib in the second‐line setting. </p> <div class="figure" id="CD006847-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Progression‐free survival: Gefitinib versus second‐line chemotherapy in an Asian population (Analysis 5.5)." data-id="CD006847-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Progression‐free survival: Gefitinib versus second‐line chemotherapy in an Asian population (<a href="./references#CD006847-fig-0071" title="">Analysis 5.5</a>). </p> </div> </div> </div> </section> <section id="CD006847-sec-0093"> <h6 class="title">Gefitinib versus maintenance chemotherapy</h6> <p>Two phase II studies compared maintenance gefitinib with chemotherapy, however only one of them presented survival data (<a href="./references#CD006847-bbs2-0001" title="AhnMJ , YangJCH , LiangJ , KangJH , XiuQ , ChenYM , et al. Randomized phase II trial of first‐line treatment with pemetrexed‐cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never‐smoker patients with advanced non‐small cell lung cancer. Lung Cancer2012;77:346‐52. ">Ahn 2012</a>). There was no difference in overall survival (HR 2.15, 95% CI 0.83 to 5.55, P = 0.11) or progression‐free survival (HR 0.53, 95% CI 0.27 to 1.04, P = 0.06) between the gefitinib and chemotherapy treatment arms. There was an improved one‐year survival rate (RR 0.79, 95% CI 0.65 to 0.98, P = 0.03) with maintenance gefitinib over chemotherapy. </p> </section> </section> <section id="CD006847-sec-0094"> <h5 class="title">Toxicity</h5> <p>See <a href="./references#CD006847-fig-0074" title="">Analysis 5.8</a>; <a href="./references#CD006847-fig-0075" title="">Analysis 5.9</a>; <a href="./references#CD006847-fig-0076" title="">Analysis 5.10</a>; <a href="./references#CD006847-fig-0077" title="">Analysis 5.11</a>; <a href="./references#CD006847-fig-0078" title="">Analysis 5.12</a>; <a href="./references#CD006847-fig-0079" title="">Analysis 5.13</a>; <a href="./references#CD006847-fig-0080" title="">Analysis 5.14</a>; <a href="./references#CD006847-fig-0081" title="">Analysis 5.15</a>; <a href="./references#CD006847-fig-0082" title="">Analysis 5.16</a>; <a href="./references#CD006847-fig-0083" title="">Analysis 5.17</a>; <a href="./references#CD006847-fig-0084" title="">Analysis 5.18</a>; <a href="./references#CD006847-fig-0085" title="">Analysis 5.19</a>; <a href="./references#CD006847-fig-0086" title="">Analysis 5.20</a>; <a href="./references#CD006847-fig-0087" title="">Analysis 5.21</a>; <a href="./references#CD006847-fig-0088" title="">Analysis 5.22</a>; <a href="./references#CD006847-fig-0089" title="">Analysis 5.23</a>. </p> <p>Gefitinib was generally well tolerated in this population. We pooled toxicity data from all studies. Compared to chemotherapy, the gefitinib group reported fewer adverse side effects such as nausea (RR 0.34, 95% CI 0.17 to 0.64, P = 0.001, I<sup>2</sup> = 0%), vomiting (RR 0.19, 95% CI 0.05 to 0.77, P = 0.02, I<sup>2</sup> = 56%, random‐effects model), anorexia (RR 0.36, 95% CI 0.27 to 0.49, P &lt; 0.00001, I<sup>2</sup> = 18%), fatigue (RR 0.32, 95% CI 0.22 to 0.46, P &lt; 0.00001, I<sup>2</sup> = 50%), arthralgia (RR 0.14, 95% CI 0.03 to 0.61, P = 0.009, I<sup>2</sup> = 0%), asthenia (RR 0.22, 95% CI 0.08 to 0.58, P = 0.002, I<sup>2</sup> = 13%), neurotoxicity (RR 0.07, 95% CI 0.02 to 0.24, P &lt; 0.0001, I<sup>2</sup> = 0%), neutropenia (RR 0.11, 95% CI 0.05 to 0.27, P &lt; 0.00001, I<sup>2</sup> = 82%, random‐effects model), anaemia (RR 0.18, 95% CI 0.12 to 0.29, P &lt; 0.00001, I<sup>2</sup> = 4%), leukopenia (RR 0.07, 95% CI 0.02 to 0.23, P &lt; 0.00001, I<sup>2</sup> = 77%, random‐effects model), thrombocytopaenia (RR 0.32, 95% CI 0.14 to 0.72, P = 0.006, I<sup>2</sup> = 22%) and febrile neutropenia (RR 0.09, 95% CI 0.03 to 0.28, P &lt; 0.0001, I<sup>2</sup> = 0%). Other side effects were seen more frequently in the gefitinib group. Skin rash (RR 3.11, 95% CI 1.28 to 7.55, P = 0.01, I<sup>2</sup> = 60%, random‐effects model), diarrhoea (RR 2.79, 95% CI 1.57 to 4.94, P = 0.0005, I<sup>2</sup> = 0%), increased alanine aminotransferase (ALT) (RR 10.03, 95% CI 5.23 to 19.26, P &lt; 0.00001, I<sup>2</sup> = 37%) and increased aspartate transaminase (AST) (RR 7.73, 95% CI 2.78 to 21.46, P &lt; 0.0001, I<sup>2</sup> = 0%) were more frequent in gefitinib‐treated cases. </p> </section> <section id="CD006847-sec-0095"> <h5 class="title">Efficacy</h5> <p>See <a href="./references#CD006847-fig-0090" title="">Analysis 5.24</a>; <a href="./references#CD006847-fig-0091" title="">Analysis 5.25</a>; <a href="./references#CD006847-fig-0092" title="">Analysis 5.26</a>. </p> <p>Objective response rates were higher in the gefitinib group when compared with first‐line chemotherapy (RR 1.43, 95% CI 1.13 to 1.82, P = 0.003, I<sup>2</sup> = 76%, random‐effects model). The overall response rate ranged from 43% to 62.1% in the gefitinib group and 30.7% to 32.2% in the chemotherapy group. There was no effect on the disease control rate (RR 0.99, 95% CI 0.86 to 1.13, P = 0.86, I<sup>2</sup> = 80%, random‐effects model): 73% to 94% and 78% to 81%, respectively. </p> <p>The overall response rate was not significantly improved in the gefitinib group compared with second‐line chemotherapy (RR 1.43, 95% CI 0.92 to 2.22, P = 0.11, I<sup>2</sup> = 46%). Two studies found that overall response rates were poor overall, but the gefitinib group performed better (23% to 28%) than the second‐line chemotherapy group (8% to 13%) (<a href="./references#CD006847-bbs2-0019" title="LeeD , KimS , ParkK , et al. A randomized open‐label study of gefitinib versus docetaxel in patients with advanced/metastatic non‐small cell lung cancer (NSCLC) who have previously received platinum‐based chemotherapy [abstract no. 8025]. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2008;26(15 Suppl Pt I):430. LeeDH , ParkK , KimJH , LeeJS , ShinSW , KangJH , et al. Randomized phase III trial of gefitinib versus docetaxel in non‐small‐cell lung cancer patients who have previously received platinum‐based chemotherapy. Clinical Cancer Research2010;16(4):1307‐14. [ISTANA] ">Lee 2010 ISTANA</a>; <a href="./references#CD006847-bbs2-0023" title="LekiR , KawaharaM , WatanabeH , et al. The impact of response evaluation committee in a Phase III study (V‐15‐32) of gefitinib versus docetaxel in Japanese patients with non‐small cell lung cancer [Abstract No. 298P]. Annals of Oncology2009;19 Suppl 8:109‐10. MaruyamaR , NishiwakiY , TamuraT , YamamotoN , TsuboiM , NakagawaK , et al. Phase III study, V‐15‐32, of gefitinib versus docetaxel in previously treated Japanese patients with non‐small‐cell lung cancer. Journal of Clinical Oncology2008;26(26):4245‐52. SekineI , IchinoseY , NishiwakiY , YamamotoN , TsuboiM , NakagawaK , et al. Quality of life and disease‐related symptoms in previously treated Japanese patients with non‐small‐cell lung cancer: results of a randomized phase III study (V‐15‐32) of gefitinib versus docetaxel. Annals of Oncology2009;20(9):1483‐8. YamamotoN , NishiwakiY , NegoroS , JiangH , ItohY , SaijoN , et al. Disease control as a predictor of survival with gefitinib and docetaxel in a phase III study (V‐15‐32) in advanced non‐small‐cell lung cancer patients. Journal of Thoracic Oncology2010;5(7):1042‐7. ">Maruyama 2008 V‐15‐32</a>). The disease control rate (RR 0.99, 95% CI 0.78 to 1.25, P = 0.92, I<sup>2</sup> = 46%) was statistically similar for both groups (34% and 33%, respectively). </p> <p>Pooled data from two maintenance studies found that gefitinib improved the stable disease rate and the disease control rate (RR 0.64, 95% CI 0.44 to 0.93, P = 0.02; RR 0.65, 95% CI 0.49 to 0.85, P = 0.002, respectively). There was no improvement in the overall response rate with maintenance gefitinib (RR 0.88, 95% CI 0.41 to 1.87, P = 0.06, I<sup>2</sup> = 73%, random‐effects model). </p> </section> <section id="CD006847-sec-0096"> <h5 class="title">Quality of life and symptom improvement scores</h5> <p>Three studies explored the impact of gefitinib versus chemotherapy on quality of life, but unfortunately the data could not be pooled (<a href="./references#CD006847-bbs2-0019" title="LeeD , KimS , ParkK , et al. A randomized open‐label study of gefitinib versus docetaxel in patients with advanced/metastatic non‐small cell lung cancer (NSCLC) who have previously received platinum‐based chemotherapy [abstract no. 8025]. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2008;26(15 Suppl Pt I):430. LeeDH , ParkK , KimJH , LeeJS , ShinSW , KangJH , et al. Randomized phase III trial of gefitinib versus docetaxel in non‐small‐cell lung cancer patients who have previously received platinum‐based chemotherapy. Clinical Cancer Research2010;16(4):1307‐14. [ISTANA] ">Lee 2010 ISTANA</a>; <a href="./references#CD006847-bbs2-0023" title="LekiR , KawaharaM , WatanabeH , et al. The impact of response evaluation committee in a Phase III study (V‐15‐32) of gefitinib versus docetaxel in Japanese patients with non‐small cell lung cancer [Abstract No. 298P]. Annals of Oncology2009;19 Suppl 8:109‐10. MaruyamaR , NishiwakiY , TamuraT , YamamotoN , TsuboiM , NakagawaK , et al. Phase III study, V‐15‐32, of gefitinib versus docetaxel in previously treated Japanese patients with non‐small‐cell lung cancer. Journal of Clinical Oncology2008;26(26):4245‐52. SekineI , IchinoseY , NishiwakiY , YamamotoN , TsuboiM , NakagawaK , et al. Quality of life and disease‐related symptoms in previously treated Japanese patients with non‐small‐cell lung cancer: results of a randomized phase III study (V‐15‐32) of gefitinib versus docetaxel. Annals of Oncology2009;20(9):1483‐8. YamamotoN , NishiwakiY , NegoroS , JiangH , ItohY , SaijoN , et al. Disease control as a predictor of survival with gefitinib and docetaxel in a phase III study (V‐15‐32) in advanced non‐small‐cell lung cancer patients. Journal of Thoracic Oncology2010;5(7):1042‐7. ">Maruyama 2008 V‐15‐32</a>; <a href="./references#CD006847-bbs2-0025" title="FukuokaM , WuYL , ThongprasertS , SunpaweravongP , LeongSS , SriuranpongV , et al. Biomarker analyses and final overall survival results from a phase III, randomized, open‐label, first‐line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non ‐ small‐cell lung cancer in Asia (IPASS). Journal of Clinical Oncology2011;29:2866‐74. MokT , WuY‐L , ThongprasertS , et al. Phase III, randomised, open‐label, first‐line study of gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients (PTS) with advanced non‐small cell lung cancer (NSCLC) (IPASS). Annals of Oncology2008;19 Suppl 8:Viii1. MokTS , WuYL , ThongprasertS , YangCH , ChuDT , SaijoN , et al. Gefitinib or carboplatin‐paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine2009;361(10):947‐57. OheY , IchinoseY , NishiwakiY ,  etal . Phase III, randomized, open‐label, first‐line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in selected patients (pts) with advanced non‐small‐cell lung cancer (NSCLC) (IPASS): Evaluation of recruits in Japan. Journal of Clinical Oncology2009;29(15 Suppl 1):8044. ThongprasertS , DuffieldE , SaijoN , WuYL , YangJC , ChuDT , et al. Health‐related quality‐of‐life in a randomized phase III first‐line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). Journal of Thoracic Oncology2011;6:1872‐80. ThongprasertS , DuffieldE , WuY , et al. Quality of life (QOL) in a randomized phase III first‐line study of gefitinib (G) vs carboplatin/paclitaxel (CP) in clinically selected Asian patients (pts) with advanced NSCLC (IPASS). Journal of Thoracic Oncology2010;5(5 Suppl 1):S80. WuY , ChuD , HanB , LiuX , ZhangL , ZhouC , et al. Phase III, randomized, open‐label, first‐line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non‐small‐cell lung cancer: evaluation of patients recruited from mainland China. Asia‐Pacific Journal of Clinical Oncology2012;8:232‐43. WuY , FukuokaM , MokT S K , SaijoN , ThongprasertS , YangJ C H , et al. Tumour response, skin rash and health‐related quality of life (HRQOL) ‐ Post‐HOC data from the IPASS study. European Multidisciplinary Cancer Congress Stockholm Sweden. Elsevier Ltd, 2011; Vol. 47:S633‐4. WuY , MokT , ChuD , et al. Evaluation of clinically selected patients (pts) with advanced non‐small cell lung cancer (NSCLC) recruited in China in a phase III, randomized, open‐label, first‐line study in Asia of gefitinib (G) versus carboplatin/paclitaxel (C/P) (IPASS). Journal of Clinical Oncology. 2009; Vol. 27 (15 Suppl 1):8041. WuYL , FukuokaM , MokTSK , SaijoN , ThongprasertS , YangJCH , et al. Tumor response and health‐related quality of life in clinically selected patients from Asia with advanced non‐small‐cell lung cancer treated with first‐line gefitinib: post hoc analyses from the IPASS study. Lung Cancer2013;81:280‐7. YangCH , FukuokaM , MokTS , WuYL , ThongprasertS , SaijoN , et al. Final overall survival (OS) results from a phase III, randomised, open‐label, first‐line study of gefitinib (G) v carboplatin/paclitaxel (C/P) in clinically selected patients with advanced nonsmall cell lung cancer (NSCLC) in Asia (IPASS). 35th ESMO Congress Milan Italy. Oxford University Press, 2010; Vol. 21:viii1‐2. YangJ , WuY L , SaijoN , ThongprasertS , ChuD T , ChenY M , et al. Efficacy outcomes in first‐line treatment of advanced NSCLC with gefitinib (G) vs carboplatin/paclitaxel (C/P) by epidermal growth factor receptor (EGFR) gene‐copy number score and by most common EGFR mutation subtypes ‐ Exploratory data from IPASS. 2011 European Multidisciplinary Cancer Congress Stockholm Sweden. Elsevier Ltd, 2011; Vol. 47:S633. YangJ , WuY , ChanV , KurniandaJ , NakagawaK . Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan‐ASia Study (IPASS). Lung Cancer2014;83:174‐81. YangJCH , WuYL , ChanV , KurniandaJ , NakagawaK , SaijoN , et al. Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan‐ASia Study (IPASS). Lung Cancer2014;83:174‐81. ">Mok 2009 IPASS</a>). All three studies reported significantly improved quality of life in patients who received gefitinib as measured by the Trial Outcome Index (TOI). <a href="./references#CD006847-bbs2-0025" title="FukuokaM , WuYL , ThongprasertS , SunpaweravongP , LeongSS , SriuranpongV , et al. Biomarker analyses and final overall survival results from a phase III, randomized, open‐label, first‐line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non ‐ small‐cell lung cancer in Asia (IPASS). Journal of Clinical Oncology2011;29:2866‐74. MokT , WuY‐L , ThongprasertS , et al. Phase III, randomised, open‐label, first‐line study of gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients (PTS) with advanced non‐small cell lung cancer (NSCLC) (IPASS). Annals of Oncology2008;19 Suppl 8:Viii1. MokTS , WuYL , ThongprasertS , YangCH , ChuDT , SaijoN , et al. Gefitinib or carboplatin‐paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine2009;361(10):947‐57. OheY , IchinoseY , NishiwakiY ,  etal . Phase III, randomized, open‐label, first‐line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in selected patients (pts) with advanced non‐small‐cell lung cancer (NSCLC) (IPASS): Evaluation of recruits in Japan. Journal of Clinical Oncology2009;29(15 Suppl 1):8044. ThongprasertS , DuffieldE , SaijoN , WuYL , YangJC , ChuDT , et al. Health‐related quality‐of‐life in a randomized phase III first‐line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). Journal of Thoracic Oncology2011;6:1872‐80. ThongprasertS , DuffieldE , WuY , et al. Quality of life (QOL) in a randomized phase III first‐line study of gefitinib (G) vs carboplatin/paclitaxel (CP) in clinically selected Asian patients (pts) with advanced NSCLC (IPASS). Journal of Thoracic Oncology2010;5(5 Suppl 1):S80. WuY , ChuD , HanB , LiuX , ZhangL , ZhouC , et al. Phase III, randomized, open‐label, first‐line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non‐small‐cell lung cancer: evaluation of patients recruited from mainland China. Asia‐Pacific Journal of Clinical Oncology2012;8:232‐43. WuY , FukuokaM , MokT S K , SaijoN , ThongprasertS , YangJ C H , et al. Tumour response, skin rash and health‐related quality of life (HRQOL) ‐ Post‐HOC data from the IPASS study. European Multidisciplinary Cancer Congress Stockholm Sweden. Elsevier Ltd, 2011; Vol. 47:S633‐4. WuY , MokT , ChuD , et al. Evaluation of clinically selected patients (pts) with advanced non‐small cell lung cancer (NSCLC) recruited in China in a phase III, randomized, open‐label, first‐line study in Asia of gefitinib (G) versus carboplatin/paclitaxel (C/P) (IPASS). Journal of Clinical Oncology. 2009; Vol. 27 (15 Suppl 1):8041. WuYL , FukuokaM , MokTSK , SaijoN , ThongprasertS , YangJCH , et al. Tumor response and health‐related quality of life in clinically selected patients from Asia with advanced non‐small‐cell lung cancer treated with first‐line gefitinib: post hoc analyses from the IPASS study. Lung Cancer2013;81:280‐7. YangCH , FukuokaM , MokTS , WuYL , ThongprasertS , SaijoN , et al. Final overall survival (OS) results from a phase III, randomised, open‐label, first‐line study of gefitinib (G) v carboplatin/paclitaxel (C/P) in clinically selected patients with advanced nonsmall cell lung cancer (NSCLC) in Asia (IPASS). 35th ESMO Congress Milan Italy. Oxford University Press, 2010; Vol. 21:viii1‐2. YangJ , WuY L , SaijoN , ThongprasertS , ChuD T , ChenY M , et al. Efficacy outcomes in first‐line treatment of advanced NSCLC with gefitinib (G) vs carboplatin/paclitaxel (C/P) by epidermal growth factor receptor (EGFR) gene‐copy number score and by most common EGFR mutation subtypes ‐ Exploratory data from IPASS. 2011 European Multidisciplinary Cancer Congress Stockholm Sweden. Elsevier Ltd, 2011; Vol. 47:S633. YangJ , WuY , ChanV , KurniandaJ , NakagawaK . Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan‐ASia Study (IPASS). Lung Cancer2014;83:174‐81. YangJCH , WuYL , ChanV , KurniandaJ , NakagawaK , SaijoN , et al. Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan‐ASia Study (IPASS). Lung Cancer2014;83:174‐81. ">Mok 2009 IPASS</a> and <a href="./references#CD006847-bbs2-0023" title="LekiR , KawaharaM , WatanabeH , et al. The impact of response evaluation committee in a Phase III study (V‐15‐32) of gefitinib versus docetaxel in Japanese patients with non‐small cell lung cancer [Abstract No. 298P]. Annals of Oncology2009;19 Suppl 8:109‐10. MaruyamaR , NishiwakiY , TamuraT , YamamotoN , TsuboiM , NakagawaK , et al. Phase III study, V‐15‐32, of gefitinib versus docetaxel in previously treated Japanese patients with non‐small‐cell lung cancer. Journal of Clinical Oncology2008;26(26):4245‐52. SekineI , IchinoseY , NishiwakiY , YamamotoN , TsuboiM , NakagawaK , et al. Quality of life and disease‐related symptoms in previously treated Japanese patients with non‐small‐cell lung cancer: results of a randomized phase III study (V‐15‐32) of gefitinib versus docetaxel. Annals of Oncology2009;20(9):1483‐8. YamamotoN , NishiwakiY , NegoroS , JiangH , ItohY , SaijoN , et al. Disease control as a predictor of survival with gefitinib and docetaxel in a phase III study (V‐15‐32) in advanced non‐small‐cell lung cancer patients. Journal of Thoracic Oncology2010;5(7):1042‐7. ">Maruyama 2008 V‐15‐32</a> stated that improvements as measured by FACT‐L were significant, but none recorded significant improvements on the lung cancer subscale (LCS). </p> </section> </section> <section id="CD006847-sec-0097"> <h4 class="title">Subgroup analysis: EGFR mutation positive population</h4> <section id="CD006847-sec-0098"> <h5 class="title">Survival</h5> <p>See <a href="./references#CD006847-fig-0096" title="">Analysis 6.1</a>; <a href="./references#CD006847-fig-0097" title="">Analysis 6.2</a>; <a href="./references#CD006847-fig-0098" title="">Analysis 6.3</a>; <a href="./references#CD006847-fig-0099" title="">Analysis 6.4</a>. </p> <section id="CD006847-sec-0099"> <h6 class="title">Gefitinib versus first‐line chemotherapy</h6> <p>Five studies compared gefitinib with first‐line chemotherapy. Two of these studies selected patients with EGFR mutations (<a href="./references#CD006847-bbs2-0022" title="FukuharaT , MaemondoM , InoueA , KobayashiK , SugawaraS , OizumiS , et al. Factors associated with a poor response to gefitinib in the NEJ002 study: smoking and the L858R mutation. Lung Cancer2015;88:181‐6. InoueA , KobayashiK , MaemondoM , SugawaraS , OizumiS , IsobeH , et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin‐paclitaxel for chemo‐naive non‐small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Annals of Oncology. United Kingdom: Oxford University Press (Great Clarendon Street, Oxford OX2 6DP, United Kingdom), 2013; Vol. 24:54‐9. InoueA , KobayashiK , MaemondoM , et al. A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first‐line treatment of non‐small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 study. European Journal of Cancer. 2009:Abstract 9LBA. MaemondoM , InoueA , KobayashiK , SugawaraS , OizumiS , IsobeH , et al. Gefitinib or chemotherapy for non‐small‐cell lung cancer with mutated EGFR. New England Journal of Medicine2010;362(25):2380‐8. MiyauchiE , InoueA , KobayashiK , MaemondoM , SugawaraS , OizumiS , et al. Efficacy of chemotherapy after first‐line gefitinib therapy in EGFR mutation‐positive advanced non‐small cell lung cancer ‐ data from a randomized phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002). Japanese Journal of Clinical Oncology2015;45(7):670‐6. OizumiS , KobayashiK , InoueA , MaemondoM , SugawaraS , YoshizawaH , et al. Quality of life with gefitinib in patients with EGFR‐mutated non‐small cell lung cancer: quality of life analysis of North East Japan study group 002 trial. Oncologist. United States: AlphaMed Press (318 Blackwell St. Suite 260, Durham NC 27701‐2884, United States), 2012; Vol. 17:863‐70. YoshizawaH , KobayashiK , InoueA , MaemondoM , SugawaraS , OizumiS , et al. QOL analysis from NEJ 002 study comparing gefitinib to chemotherapy for non‐small cell lung cancer with mutated EGFR. 35th ESMO Congress Milan Italy. Oxford University Press, 2010; Vol. 21:viii122. ">Maemondo 2010 NEJ002</a>; <a href="./references#CD006847-bbs2-0024" title="MitsudomiT , MoritaS , YatabeY , NegoroS , OkamotoI , SetoT , et al. Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first‐line treatment for patients with non‐small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR). 2012 Annual Meeting of the American Society of Clinical Oncology, ASCO Chicago, IL United States. American Society of Clinical Oncology, 2012; Vol. 30. MitsudomiT , MoritaS , YatabeY , NegoroS , OkamotoI , TsurutaniJ , et al. Gefitinib versus cisplatin plus docetaxel in patients with non‐small‐cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase III trial. Lancet2010;11:121‐8. TsurutaniJ , MitsudomiT , MoriS , OkamotoI , NozakiK , TadaH , et al. A phase III, first‐line trial of gefitinib versus cisplatin plus docetaxel for patients with advanced or recurrent non‐small cell lung cancer (NSCLC) harboring activating mutation of the epidermal growth factor receptor (EGFR) gene: a preliminary results of WJTOG 3405 [abstract O‐9002]. European Journal of Cancer. 2009; Vol. 7 Suppl:505. ">Mitsudomi 2010 WJTOG3405</a>), and the others selected patients based on clinical features and conducted subgroup analyses on patients positive for EGFR mutations (<a href="./references#CD006847-bbs2-0013" title="HanJY , ParkK , KimSW , LeeDH , KimHY , KimHT , et al. First‐SIGNAL: first‐line single‐agent Iressa versus gemcitabine and cisplatin trial in never‐smokers with adenocarcinoma of the lung. Journal of Clinical Oncology2012;30:1122‐8. HanJY , YoonKA , ParkJH , LeeYJ , LeeGK , HanJH , et al. DNA repair gene polymorphisms and benefit from gefitinib in never‐smokers with lung adenocarcinoma. Cancer2011;117(14):3201‐8. ">Han 2012 First SIGNAL</a>; <a href="./references#CD006847-bbs2-0025" title="FukuokaM , WuYL , ThongprasertS , SunpaweravongP , LeongSS , SriuranpongV , et al. Biomarker analyses and final overall survival results from a phase III, randomized, open‐label, first‐line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non ‐ small‐cell lung cancer in Asia (IPASS). Journal of Clinical Oncology2011;29:2866‐74. MokT , WuY‐L , ThongprasertS , et al. Phase III, randomised, open‐label, first‐line study of gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients (PTS) with advanced non‐small cell lung cancer (NSCLC) (IPASS). Annals of Oncology2008;19 Suppl 8:Viii1. MokTS , WuYL , ThongprasertS , YangCH , ChuDT , SaijoN , et al. Gefitinib or carboplatin‐paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine2009;361(10):947‐57. OheY , IchinoseY , NishiwakiY ,  etal . Phase III, randomized, open‐label, first‐line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in selected patients (pts) with advanced non‐small‐cell lung cancer (NSCLC) (IPASS): Evaluation of recruits in Japan. Journal of Clinical Oncology2009;29(15 Suppl 1):8044. ThongprasertS , DuffieldE , SaijoN , WuYL , YangJC , ChuDT , et al. Health‐related quality‐of‐life in a randomized phase III first‐line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). Journal of Thoracic Oncology2011;6:1872‐80. ThongprasertS , DuffieldE , WuY , et al. Quality of life (QOL) in a randomized phase III first‐line study of gefitinib (G) vs carboplatin/paclitaxel (CP) in clinically selected Asian patients (pts) with advanced NSCLC (IPASS). Journal of Thoracic Oncology2010;5(5 Suppl 1):S80. WuY , ChuD , HanB , LiuX , ZhangL , ZhouC , et al. Phase III, randomized, open‐label, first‐line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non‐small‐cell lung cancer: evaluation of patients recruited from mainland China. Asia‐Pacific Journal of Clinical Oncology2012;8:232‐43. WuY , FukuokaM , MokT S K , SaijoN , ThongprasertS , YangJ C H , et al. Tumour response, skin rash and health‐related quality of life (HRQOL) ‐ Post‐HOC data from the IPASS study. European Multidisciplinary Cancer Congress Stockholm Sweden. Elsevier Ltd, 2011; Vol. 47:S633‐4. WuY , MokT , ChuD , et al. Evaluation of clinically selected patients (pts) with advanced non‐small cell lung cancer (NSCLC) recruited in China in a phase III, randomized, open‐label, first‐line study in Asia of gefitinib (G) versus carboplatin/paclitaxel (C/P) (IPASS). Journal of Clinical Oncology. 2009; Vol. 27 (15 Suppl 1):8041. WuYL , FukuokaM , MokTSK , SaijoN , ThongprasertS , YangJCH , et al. Tumor response and health‐related quality of life in clinically selected patients from Asia with advanced non‐small‐cell lung cancer treated with first‐line gefitinib: post hoc analyses from the IPASS study. Lung Cancer2013;81:280‐7. YangCH , FukuokaM , MokTS , WuYL , ThongprasertS , SaijoN , et al. Final overall survival (OS) results from a phase III, randomised, open‐label, first‐line study of gefitinib (G) v carboplatin/paclitaxel (C/P) in clinically selected patients with advanced nonsmall cell lung cancer (NSCLC) in Asia (IPASS). 35th ESMO Congress Milan Italy. Oxford University Press, 2010; Vol. 21:viii1‐2. YangJ , WuY L , SaijoN , ThongprasertS , ChuD T , ChenY M , et al. Efficacy outcomes in first‐line treatment of advanced NSCLC with gefitinib (G) vs carboplatin/paclitaxel (C/P) by epidermal growth factor receptor (EGFR) gene‐copy number score and by most common EGFR mutation subtypes ‐ Exploratory data from IPASS. 2011 European Multidisciplinary Cancer Congress Stockholm Sweden. Elsevier Ltd, 2011; Vol. 47:S633. YangJ , WuY , ChanV , KurniandaJ , NakagawaK . Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan‐ASia Study (IPASS). Lung Cancer2014;83:174‐81. YangJCH , WuYL , ChanV , KurniandaJ , NakagawaK , SaijoN , et al. Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan‐ASia Study (IPASS). Lung Cancer2014;83:174‐81. ">Mok 2009 IPASS</a>; <a href="./references#CD006847-bbs2-0033" title="BoyeM , WangX , SrimuninnimitV , KangJH , TsaiCM , OrlandoM , et al. First‐line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian never‐smoker patients with locally advanced or metastatic nonsquamous non‐small cell lung cancer: quality of life results from a randomized phase III trial. Clinical Lung Cancer2016;17(2):150‐60. KangJH , AhnM , KimD , ChoEK , KimJ , ShinSW , et al. Tolerability and outcomes of first‐line pemetrexed‐cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in Korean patients with advanced non‐squamous non‐small cell lung cancer: a post hoc descriptive subgroup analysis of a randomized, phase 3 trial. Cancer Research and Treatment2015;48(2):458‐64. YangJC , KangJH , MokT , AhnM , SrimuninnimitV , LinC , et al. First‐line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non‐squamous non‐small cell lung cancer: a randomised, phase 3 trial. European Journal of Cancer2014;50:2219‐30. YangJC , ParkK , MokTSK , KangJH , SrimuninnimitV , LinCC , et al. A randomized phase 3 study comparing first‐line pemetrexed plus cisplatin followed by gefitinib as maintenance with gefitinib monotherapy in east Asian patients with locally advanced or metastatic nonsquamous non‐small cell lung cancer (NSQNSCLC). 15th World Conference on Lung Cancer Sydney, NSW Australia. International Association for the Study of Lung Cancer, 2013; Vol. 8:S288. YangJC , SrimuninnimitV , AhnM , LinC , KimS , TsaiC , et al. A randomized phase 3 study comparing first‐line pemetrexed plus cisplatin followed by gefitinib maintenance (PC/G) with gefitinib monotherapy (G) in East Asian patients (pts) with locally advanced or metastatic nonsquamous non‐small cell lung cancer (nSqNSCLC): final survival results. Journal of Clinical Oncology2015;15 Suppl:8041. YangJC , SrimunninnimitV , AhnM , LinC , KimS , TsaiC , et al. First‐line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian never‐smoker patients with locally advanced or metastatic nonsquamous non‐small cell lung cancer: final overall survival results from a randomized phase 3 study. Journal of Thoracic Oncology2016;11(3):370‐9. ">Yang 2014</a>). We have separately analysed studies that selected EGFR mutants and those that selected patients based on clinical features then conducted subgroup analyses and progression‐free survival results are presented in <a href="#CD006847-fig-0005">Figure 5</a>. </p> <div class="figure" id="CD006847-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Progression‐free survival: Gefitinib versus first‐line chemotherapy in an EGFR mutation positive population (Analysis 6.3)." data-id="CD006847-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Progression‐free survival: Gefitinib versus first‐line chemotherapy in an EGFR mutation positive population (<a href="./references#CD006847-fig-0098" title="">Analysis 6.3</a>). </p> </div> </div> </div> <p>The two biomarker driven studies did not show any improvement in overall survival (HR 0.98, 95% CI 0.72 to 1.33, P = 0.90, I<sup>2</sup> = 54%). Progression‐free survival was significantly increased with gefitinib compared with first‐line chemotherapy (HR 0.39, 95% CI 0.26 to 0.59, P &lt; 0.00001, I<sup>2</sup> = 66%, random‐effects model). </p> <p>Three phase III studies conducted subgroup analyses in EGFR mutation positive patients. There was no improvement in overall survival (HR 0.95, 95% CI 0.68 to 1.33, P = 0.75, I<sup>2</sup> = 20%). However, there was a statistically significant improvement in progression‐free survival (HR 0.53, 95% CI 0.41 to 0.70, P &lt; 0.00001, I<sup>2</sup> = 9%). </p> <p>Pooled analysis of all first‐line studies that examined EGFR mutation positive patients showed that there was no difference in overall survival (HR 0.97, 95% CI 0.77 to 1.21, P = 0.76, I<sup>2</sup> = 15%). However, pooled data from these five studies showed that gefitinib was able to prolong progression‐free survival when compared with first‐line chemotherapy (HR 0.47, 95% CI 0.36 to 0.61, P &lt; 0.00001, I<sup>2</sup> = 53%, random‐effects model), with median progression‐free survival improving from 5.5 to 6.3 months in the chemotherapy group to 9.2 to 10.4 months in the gefitinib group. </p> </section> <section id="CD006847-sec-0100"> <h6 class="title">Gefitinib versus second‐line chemotherapy</h6> <p>When comparing gefitinib with second‐line chemotherapy, data were available from two studies (<a href="./references#CD006847-bbs2-0016" title="DouillardJY , ShephardFA , HirshV , MokT , SocinskiMA , GervaisR , et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non‐small‐cell lung cancer: from the randomized phase III INTEREST Trial. Journal of Clinical Oncology2010;28(5):744‐52. HorganAM , BradburyPA , AmirE , NgR , DouillardJY , KimES , et al. An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second‐/third‐line therapy in advanced non‐small‐cell lung cancer. Annals of Oncology. United Kingdom: Oxford University Press (Great Clarendon Street, Oxford OX2 6DP, United Kingdom), 2011; Vol. 22:1805‐11. HorganAM , ShepherdFA , BradburyPA , NgR , LeighlNB . Preliminary cost‐consequence analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as 2nd line therapy in advanced non‐small cell lung cancer [abstract no. 8110]. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2008;25(15 Suppl Pt 1):451. KimES , HirshV , MokT , SocinskiMA , GervaisR , WuYL , et al. Gefitinib versus docetaxel in previously treated non‐small‐cell lung cancer (INTEREST): a randomized phase III trial. Lancet2008;372:1809‐18. ">Kim 2008 INTEREST</a>; <a href="./references#CD006847-bbs2-0028" title="AhnM , SunJ , AhnJS , KimS , MinYJ , YunHJ , et al. Randomized phase III trial of gefitinib or pemetrexed as second‐line treatment in patients with non‐small cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01). ASCO Annual Meeting 2011 Chicago, IL United States. American Society of Clinical Oncology, 2011; Vol. 29. AhnMJ , SunJM , LeeKH , AhnJS , KimSW , MinYJ , et al. Randomized phase III trial of gefitinib or pemetrexed as second‐line treatment in patients with non‐small cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01). 14th World Conference on Lung Cancer Amsterdam Netherlands. International Association for the Study of Lung Cancer, 2011; Vol. 6:S317. SunJM , LeeKH , KimSW , LeeDH , MinYJ , YunHJ , et al. Gefitinib versus pemetrexed as second‐line treatment in patients with nonsmall cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01): an open‐label, phase 3 trial. Cancer2012;118:6234‐42. ">Sun 2012 KCSG‐LU08‐01</a>). This showed that gefitinib did not improve overall survival (HR 0.83, 95% CI 0.41 to 1.66, P = 0.60). There was a statistically significant improvement in progression‐free survival (HR 0.24, 95% CI 0.12 to 0.47, P &lt; 0.0001, I<sup>2</sup> = 0%) in EGFR mutation positive patients. Progression‐free survival for this analysis is presented in <a href="#CD006847-fig-0006">Figure 6</a>. </p> <div class="figure" id="CD006847-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Progression‐free survival: Gefitinib versus second‐line chemotherapy in an EGFR mutation positive population (Analysis 6.4)." data-id="CD006847-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Progression‐free survival: Gefitinib versus second‐line chemotherapy in an EGFR mutation positive population (<a href="./references#CD006847-fig-0099" title="">Analysis 6.4</a>). </p> </div> </div> </div> </section> </section> <section id="CD006847-sec-0101"> <h5 class="title">Efficacy</h5> <p>See <a href="./references#CD006847-fig-0100" title="">Analysis 6.5</a>; <a href="./references#CD006847-fig-0101" title="">Analysis 6.6</a>; <a href="./references#CD006847-fig-0102" title="">Analysis 6.7</a>. </p> <section id="CD006847-sec-0102"> <h6 class="title">Gefitinib versus first‐line chemotherapy</h6> <p>Pooled analysis comparing first‐line gefitinib with chemotherapy showed that the overall response rate was significantly improved in favour of gefitinib. The two studies that selected patients with EGFR mutations (<a href="./references#CD006847-bbs2-0022" title="FukuharaT , MaemondoM , InoueA , KobayashiK , SugawaraS , OizumiS , et al. Factors associated with a poor response to gefitinib in the NEJ002 study: smoking and the L858R mutation. Lung Cancer2015;88:181‐6. InoueA , KobayashiK , MaemondoM , SugawaraS , OizumiS , IsobeH , et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin‐paclitaxel for chemo‐naive non‐small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Annals of Oncology. United Kingdom: Oxford University Press (Great Clarendon Street, Oxford OX2 6DP, United Kingdom), 2013; Vol. 24:54‐9. InoueA , KobayashiK , MaemondoM , et al. A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first‐line treatment of non‐small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 study. European Journal of Cancer. 2009:Abstract 9LBA. MaemondoM , InoueA , KobayashiK , SugawaraS , OizumiS , IsobeH , et al. Gefitinib or chemotherapy for non‐small‐cell lung cancer with mutated EGFR. New England Journal of Medicine2010;362(25):2380‐8. MiyauchiE , InoueA , KobayashiK , MaemondoM , SugawaraS , OizumiS , et al. Efficacy of chemotherapy after first‐line gefitinib therapy in EGFR mutation‐positive advanced non‐small cell lung cancer ‐ data from a randomized phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002). Japanese Journal of Clinical Oncology2015;45(7):670‐6. OizumiS , KobayashiK , InoueA , MaemondoM , SugawaraS , YoshizawaH , et al. Quality of life with gefitinib in patients with EGFR‐mutated non‐small cell lung cancer: quality of life analysis of North East Japan study group 002 trial. Oncologist. United States: AlphaMed Press (318 Blackwell St. Suite 260, Durham NC 27701‐2884, United States), 2012; Vol. 17:863‐70. YoshizawaH , KobayashiK , InoueA , MaemondoM , SugawaraS , OizumiS , et al. QOL analysis from NEJ 002 study comparing gefitinib to chemotherapy for non‐small cell lung cancer with mutated EGFR. 35th ESMO Congress Milan Italy. Oxford University Press, 2010; Vol. 21:viii122. ">Maemondo 2010 NEJ002</a>; <a href="./references#CD006847-bbs2-0024" title="MitsudomiT , MoritaS , YatabeY , NegoroS , OkamotoI , SetoT , et al. Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first‐line treatment for patients with non‐small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR). 2012 Annual Meeting of the American Society of Clinical Oncology, ASCO Chicago, IL United States. American Society of Clinical Oncology, 2012; Vol. 30. MitsudomiT , MoritaS , YatabeY , NegoroS , OkamotoI , TsurutaniJ , et al. Gefitinib versus cisplatin plus docetaxel in patients with non‐small‐cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase III trial. Lancet2010;11:121‐8. TsurutaniJ , MitsudomiT , MoriS , OkamotoI , NozakiK , TadaH , et al. A phase III, first‐line trial of gefitinib versus cisplatin plus docetaxel for patients with advanced or recurrent non‐small cell lung cancer (NSCLC) harboring activating mutation of the epidermal growth factor receptor (EGFR) gene: a preliminary results of WJTOG 3405 [abstract O‐9002]. European Journal of Cancer. 2009; Vol. 7 Suppl:505. ">Mitsudomi 2010 WJTOG3405</a>), as well as the phase III studies that conducted subgroup analyses on EGFR mutation positive patients found significant improvements in overall response rate (RR 2.23, 95% CI 1.75 to 2.85, P &lt; 0.00001, I<sup>2</sup> = 0% and RR 1.45, 95% CI 1.05 to 1.99, P = 0.02, I<sup>2</sup> = 53%, random‐effects model, respectively). Pooled analysis of all studies showed that first‐line gefitinib improved the overall response rate over chemotherapy (RR 1.73, 95% CI 1.29 to 2.31, P = 0.002, I<sup>2</sup> = 70%, random‐effects model) and overall response rates ranged from 62% to 76% in the gefitinib group, compared with 31% to 47% in the first‐line chemotherapy group. The stable disease rate was improved in favour of first‐line chemotherapy (RR 0.52, 95% CI 0.28 to 0.97, P = 0.04, I<sup>2</sup> = 66%, random‐effects model) but there was no difference in the disease control rate (RR 1.06, 95% CI 0.91 to 1.22, P = 0.46, I<sup>2</sup> = 82%, random‐effects model). </p> </section> <section id="CD006847-sec-0103"> <h6 class="title">Gefitinib versus second‐line chemotherapy</h6> <p>Gefitinib as second‐line therapy did not result in a significant difference in overall response rate (RR 1.65, 95% CI 0.88 to 3.09, P = 0.12). Overall response rates were reported as 67% in the gefitinib group and 46% in the chemotherapy group. </p> </section> </section> </section> <section id="CD006847-sec-0104"> <h4 class="title">3. Gefitinib at a specific dose versus gefitinib at a different dose</h4> <section id="CD006847-sec-0105"> <h5 class="title">Survival</h5> <p>See <a href="./references#CD006847-fig-0103" title="">Analysis 7.1</a>. </p> <p>Two multicentre, randomised, double‐blind, phase II studies evaluated differing doses of gefitinib (250 mg and 500 mg) in the second‐line setting (<a href="./references#CD006847-bbs2-0009" title="BaelgaJ , KrisM , YanoS , NataleR , GiacconeG , BrahmerJ , et al. Phase II trials (IDEAL 1 and IDEAL 2) of ZD1839 in advanced or metastatic non‐small cell lung cancer (NSCLC) patient. Annals of Oncology2002;13(Suppl 5):131 Abs 481. DouillardJY , GiacconeG , HoraiT , NodaK , VansteenkisteJF , TakataI , et al. Improvement in disease‐related symptoms and quality of life in patients with advanced non‐small cell lung cancer (NSCLC) treated with ZD1839 ('Iressa') (IDEAL 1) [abstract]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:299a, Abs 1195. DouillardJY , SkarinA , BaselgaJ , NataleR , GiacconeG , MaddoxAM , et al. Improvement in disease‐related symptoms and quality of life (QOL) for advanced non‐small cell lung cancer (NSCLC) patients treated with ZD1839 in IDEAL 1 and IDEAL 2. Annals of Oncology2002;13 Suppl 5:131, Abs 480. FukuokaM , YanoS , GiacconeG , TamuraT , NakagawaK , DouillardJY , et al. Multi‐institutional randomized phase II trial of gefitinib for previously treated patients with advanced non‐small‐cell lung cancer. Journal of Clinical Oncology2003;21(12):2237‐46. FukuokaM , YanoS , GiacconeG , et al. [Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced non‐small cell lung cancer (IDEAL 1) [abstract]]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:298a, Abs 1188. ManegoldC , GatzemeierU , KaukelE . Results from a randomised, double blind phase II trial of ZD1839 (IRESSA) as 2nd/3rd‐line monotherapy in advanced non small cell lung cancer (NSCLC) (IDEAL 1). Journal of Cancer Research &amp; Clinical Oncology2002;128 Suppl 1:S45. NishiwakiY , YanoS , TamuraT , NakagawaK , KudohS , HoraiT , et al. Subset analysis of data in the Japanese patients with NSCLC from IDEAL I study on gefitinib. Gan to Kagaku Ryoho. Cancer &amp; Chemotherapy2004;31(4):567‐73. VansteenkisteJ , NataleR , GiacconeG , et al. Two randomised, double‐blind studies of ZD1839 in 425 patients with pretreated advanced non‐small‐call lung cancer (IDEAL 1 and IDEAL 2) [abstract]. European Respiratory Society Annual Congress. Stockholm, 2002:Abstract 2537. ">Fukuoka 2003 IDEAL I</a>; <a href="./references#CD006847-bbs2-0018" title="CellaD , HerbstRS , LynchTJ , PragerD , BelaniCP , SchillerJH , et al. Clinically meaningful improvement in symptoms and quality of life for patients with non‐small cell lung cancer receiving gefitinib in a randomized controlled trial. Journal of Clinical Oncology2005;23(13):2946‐54. KrisMG , NataleRB , HerbstRS , et al. A phase II trial of ZD1839 ('Iressa') in advanced non‐small cell lung cancer (NSCLC) patients who had failed platinum‐ and docetaxel‐based regimens (IDEAL 2) [abstract]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:292a Abstract 1166. KrisMG , NataleRB , HerbstRS , LynchTJ , PragerD , BelaniCP , et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non‐small cell lung cancer: a randomized trial. JAMA2003;290(16):2149‐58. NataleRB , SkarinA , MaddoxAM , et al. Improvement in symptoms and quality of life for advanced non‐small cell lung cancer patients receiving ZD1839 ('Iressa') in IDEAL 2 [abstract]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:292a, Abstract 1167. ">Kris 2003 IDEAL II</a>). There was no significant effect on one‐year survival (RR 0.83, 95% CI 0.61 to 1.11, P = 0.21, I<sup>2</sup> = 0%). HRs were not available for meta‐analysis. Median overall survival ranged from 7 to 7.6 months in patients given 250 mg, and 6 to 8 months in those given 500 mg of gefitinib. Median progression‐free survival ranged from 2.7 to 7 months and from 2.8 to 6 months in patients given 250 mg and 500 mg, respectively. </p> <p>One study examined the effect of a higher dose of gefitinib in patients that had been stable after one month of 250 mg/day dosing of gefitinib (<a href="./references#CD006847-bbs2-0032" title="XueC , HongS , LiN , FengW , JiaJ , PengJ , et al. Randomized, multicenter study of gefitinib dose‐escalation in advanced non‐small‐cell lung cancer patients achieved stable disease after one‐month gefitinib treatment. Scientific Reports2015;5:10648. ZhangL , XueC , LiN , FengW , JiaJ , PengJ , et al. Randomized, open‐label, multi‐center study of gefitinib dose‐escalation (500mg/d versus 250mg/d) in advanced NSCLC patient achieved stable disease (SD) after one‐month gefitinib treatment. 15th World Conference on Lung Cancer Sydney, NSW Australia. International Association for the Study of Lung Cancer, 2013; Vol. 8:S1185. ">Xue 2015</a>). In this study, there was no difference in progression‐free or overall survival with a higher dose of gefitinib (500 mg/day versus 250 mg/day: median progression‐free survival 5.30 months versus 6.23 months, P = 0.167; median overall survival 13.70 months versus 18.87 months, P = 0.156). </p> </section> <section id="CD006847-sec-0106"> <h5 class="title">Toxicity</h5> <p>See <a href="./references#CD006847-fig-0104" title="">Analysis 7.2</a>; <a href="./references#CD006847-fig-0105" title="">Analysis 7.3</a>; <a href="./references#CD006847-fig-0106" title="">Analysis 7.4</a>; <a href="./references#CD006847-fig-0107" title="">Analysis 7.5</a>; <a href="./references#CD006847-fig-0108" title="">Analysis 7.6</a>; <a href="./references#CD006847-fig-0109" title="">Analysis 7.7</a>; <a href="./references#CD006847-fig-0110" title="">Analysis 7.8</a>; <a href="./references#CD006847-fig-0111" title="">Analysis 7.9</a>. </p> <p>Data from all three studies were available for pooling (<a href="./references#CD006847-bbs2-0009" title="BaelgaJ , KrisM , YanoS , NataleR , GiacconeG , BrahmerJ , et al. Phase II trials (IDEAL 1 and IDEAL 2) of ZD1839 in advanced or metastatic non‐small cell lung cancer (NSCLC) patient. Annals of Oncology2002;13(Suppl 5):131 Abs 481. DouillardJY , GiacconeG , HoraiT , NodaK , VansteenkisteJF , TakataI , et al. Improvement in disease‐related symptoms and quality of life in patients with advanced non‐small cell lung cancer (NSCLC) treated with ZD1839 ('Iressa') (IDEAL 1) [abstract]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:299a, Abs 1195. DouillardJY , SkarinA , BaselgaJ , NataleR , GiacconeG , MaddoxAM , et al. Improvement in disease‐related symptoms and quality of life (QOL) for advanced non‐small cell lung cancer (NSCLC) patients treated with ZD1839 in IDEAL 1 and IDEAL 2. Annals of Oncology2002;13 Suppl 5:131, Abs 480. FukuokaM , YanoS , GiacconeG , TamuraT , NakagawaK , DouillardJY , et al. Multi‐institutional randomized phase II trial of gefitinib for previously treated patients with advanced non‐small‐cell lung cancer. Journal of Clinical Oncology2003;21(12):2237‐46. FukuokaM , YanoS , GiacconeG , et al. [Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced non‐small cell lung cancer (IDEAL 1) [abstract]]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:298a, Abs 1188. ManegoldC , GatzemeierU , KaukelE . Results from a randomised, double blind phase II trial of ZD1839 (IRESSA) as 2nd/3rd‐line monotherapy in advanced non small cell lung cancer (NSCLC) (IDEAL 1). Journal of Cancer Research &amp; Clinical Oncology2002;128 Suppl 1:S45. NishiwakiY , YanoS , TamuraT , NakagawaK , KudohS , HoraiT , et al. Subset analysis of data in the Japanese patients with NSCLC from IDEAL I study on gefitinib. Gan to Kagaku Ryoho. Cancer &amp; Chemotherapy2004;31(4):567‐73. VansteenkisteJ , NataleR , GiacconeG , et al. Two randomised, double‐blind studies of ZD1839 in 425 patients with pretreated advanced non‐small‐call lung cancer (IDEAL 1 and IDEAL 2) [abstract]. European Respiratory Society Annual Congress. Stockholm, 2002:Abstract 2537. ">Fukuoka 2003 IDEAL I</a>; <a href="./references#CD006847-bbs2-0018" title="CellaD , HerbstRS , LynchTJ , PragerD , BelaniCP , SchillerJH , et al. Clinically meaningful improvement in symptoms and quality of life for patients with non‐small cell lung cancer receiving gefitinib in a randomized controlled trial. Journal of Clinical Oncology2005;23(13):2946‐54. KrisMG , NataleRB , HerbstRS , et al. A phase II trial of ZD1839 ('Iressa') in advanced non‐small cell lung cancer (NSCLC) patients who had failed platinum‐ and docetaxel‐based regimens (IDEAL 2) [abstract]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:292a Abstract 1166. KrisMG , NataleRB , HerbstRS , LynchTJ , PragerD , BelaniCP , et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non‐small cell lung cancer: a randomized trial. JAMA2003;290(16):2149‐58. NataleRB , SkarinA , MaddoxAM , et al. Improvement in symptoms and quality of life for advanced non‐small cell lung cancer patients receiving ZD1839 ('Iressa') in IDEAL 2 [abstract]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:292a, Abstract 1167. ">Kris 2003 IDEAL II</a>; <a href="./references#CD006847-bbs2-0032" title="XueC , HongS , LiN , FengW , JiaJ , PengJ , et al. Randomized, multicenter study of gefitinib dose‐escalation in advanced non‐small‐cell lung cancer patients achieved stable disease after one‐month gefitinib treatment. Scientific Reports2015;5:10648. ZhangL , XueC , LiN , FengW , JiaJ , PengJ , et al. Randomized, open‐label, multi‐center study of gefitinib dose‐escalation (500mg/d versus 250mg/d) in advanced NSCLC patient achieved stable disease (SD) after one‐month gefitinib treatment. 15th World Conference on Lung Cancer Sydney, NSW Australia. International Association for the Study of Lung Cancer, 2013; Vol. 8:S1185. ">Xue 2015</a>). A gefitinib dose of 500 mg had a marginally worse toxicity profile when compared with the lower dose of 250 mg. This higher dose was associated with an increased rate of diarrhoea (RR 8.36, 95% CI 1.58 to 44.34, P = 0.01, I<sup>2</sup> = 0%) and skin rash (RR 8.13, 95% CI 1.51 to 43.72, P = 0.01, I<sup>2</sup> = 0%). Other reported side effects such as pruritus, acne, vomiting, anorexia, asthenia, neutropenia, leukopenia and dyspnoea were not significantly different between doses. </p> </section> <section id="CD006847-sec-0107"> <h5 class="title">Efficacy</h5> <p>See <a href="./references#CD006847-fig-0112" title="">Analysis 7.10</a>; <a href="./references#CD006847-fig-0113" title="">Analysis 7.11</a>. </p> <p>Pooled analysis of two studies found no significant difference in overall response rate (RR 0.92, 95% CI 0.58 to 1.46, P = 0.72, I<sup>2</sup> = 0%) between doses (<a href="./references#CD006847-bbs2-0009" title="BaelgaJ , KrisM , YanoS , NataleR , GiacconeG , BrahmerJ , et al. Phase II trials (IDEAL 1 and IDEAL 2) of ZD1839 in advanced or metastatic non‐small cell lung cancer (NSCLC) patient. Annals of Oncology2002;13(Suppl 5):131 Abs 481. DouillardJY , GiacconeG , HoraiT , NodaK , VansteenkisteJF , TakataI , et al. Improvement in disease‐related symptoms and quality of life in patients with advanced non‐small cell lung cancer (NSCLC) treated with ZD1839 ('Iressa') (IDEAL 1) [abstract]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:299a, Abs 1195. DouillardJY , SkarinA , BaselgaJ , NataleR , GiacconeG , MaddoxAM , et al. Improvement in disease‐related symptoms and quality of life (QOL) for advanced non‐small cell lung cancer (NSCLC) patients treated with ZD1839 in IDEAL 1 and IDEAL 2. Annals of Oncology2002;13 Suppl 5:131, Abs 480. FukuokaM , YanoS , GiacconeG , TamuraT , NakagawaK , DouillardJY , et al. Multi‐institutional randomized phase II trial of gefitinib for previously treated patients with advanced non‐small‐cell lung cancer. Journal of Clinical Oncology2003;21(12):2237‐46. FukuokaM , YanoS , GiacconeG , et al. [Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced non‐small cell lung cancer (IDEAL 1) [abstract]]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:298a, Abs 1188. ManegoldC , GatzemeierU , KaukelE . Results from a randomised, double blind phase II trial of ZD1839 (IRESSA) as 2nd/3rd‐line monotherapy in advanced non small cell lung cancer (NSCLC) (IDEAL 1). Journal of Cancer Research &amp; Clinical Oncology2002;128 Suppl 1:S45. NishiwakiY , YanoS , TamuraT , NakagawaK , KudohS , HoraiT , et al. Subset analysis of data in the Japanese patients with NSCLC from IDEAL I study on gefitinib. Gan to Kagaku Ryoho. Cancer &amp; Chemotherapy2004;31(4):567‐73. VansteenkisteJ , NataleR , GiacconeG , et al. Two randomised, double‐blind studies of ZD1839 in 425 patients with pretreated advanced non‐small‐call lung cancer (IDEAL 1 and IDEAL 2) [abstract]. European Respiratory Society Annual Congress. Stockholm, 2002:Abstract 2537. ">Fukuoka 2003 IDEAL I</a>; <a href="./references#CD006847-bbs2-0018" title="CellaD , HerbstRS , LynchTJ , PragerD , BelaniCP , SchillerJH , et al. Clinically meaningful improvement in symptoms and quality of life for patients with non‐small cell lung cancer receiving gefitinib in a randomized controlled trial. Journal of Clinical Oncology2005;23(13):2946‐54. KrisMG , NataleRB , HerbstRS , et al. A phase II trial of ZD1839 ('Iressa') in advanced non‐small cell lung cancer (NSCLC) patients who had failed platinum‐ and docetaxel‐based regimens (IDEAL 2) [abstract]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:292a Abstract 1166. KrisMG , NataleRB , HerbstRS , LynchTJ , PragerD , BelaniCP , et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non‐small cell lung cancer: a randomized trial. JAMA2003;290(16):2149‐58. NataleRB , SkarinA , MaddoxAM , et al. Improvement in symptoms and quality of life for advanced non‐small cell lung cancer patients receiving ZD1839 ('Iressa') in IDEAL 2 [abstract]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:292a, Abstract 1167. ">Kris 2003 IDEAL II</a>). Overall response rates in the 250mg arm were reported as 18% and 12% in the IDEAL I and IDEAL II trials respectively, compared with ORR rates of 19% and 9% respectively, in patients receiving 500mg of gefitinib. Complete and partial response rates were only reported individually in the IDEAL I paper, and were 10% and 18.1%, respectively. </p> <p>A higher dose of gefitinib as maintenance treatment did not improve the overall response rate (12.5% versus 12.5%, P = 1) (<a href="./references#CD006847-bbs2-0032" title="XueC , HongS , LiN , FengW , JiaJ , PengJ , et al. Randomized, multicenter study of gefitinib dose‐escalation in advanced non‐small‐cell lung cancer patients achieved stable disease after one‐month gefitinib treatment. Scientific Reports2015;5:10648. ZhangL , XueC , LiN , FengW , JiaJ , PengJ , et al. Randomized, open‐label, multi‐center study of gefitinib dose‐escalation (500mg/d versus 250mg/d) in advanced NSCLC patient achieved stable disease (SD) after one‐month gefitinib treatment. 15th World Conference on Lung Cancer Sydney, NSW Australia. International Association for the Study of Lung Cancer, 2013; Vol. 8:S1185. ">Xue 2015</a>). </p> </section> <section id="CD006847-sec-0108"> <h5 class="title">Quality of life and symptom improvement scores</h5> <p>See <a href="./references#CD006847-fig-0114" title="">Analysis 7.12</a>; <a href="./references#CD006847-fig-0115" title="">Analysis 7.13</a>. </p> <p>Two studies reported changes in quality of life and symptom improvement scores (<a href="./references#CD006847-bbs2-0009" title="BaelgaJ , KrisM , YanoS , NataleR , GiacconeG , BrahmerJ , et al. Phase II trials (IDEAL 1 and IDEAL 2) of ZD1839 in advanced or metastatic non‐small cell lung cancer (NSCLC) patient. Annals of Oncology2002;13(Suppl 5):131 Abs 481. DouillardJY , GiacconeG , HoraiT , NodaK , VansteenkisteJF , TakataI , et al. Improvement in disease‐related symptoms and quality of life in patients with advanced non‐small cell lung cancer (NSCLC) treated with ZD1839 ('Iressa') (IDEAL 1) [abstract]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:299a, Abs 1195. DouillardJY , SkarinA , BaselgaJ , NataleR , GiacconeG , MaddoxAM , et al. Improvement in disease‐related symptoms and quality of life (QOL) for advanced non‐small cell lung cancer (NSCLC) patients treated with ZD1839 in IDEAL 1 and IDEAL 2. Annals of Oncology2002;13 Suppl 5:131, Abs 480. FukuokaM , YanoS , GiacconeG , TamuraT , NakagawaK , DouillardJY , et al. Multi‐institutional randomized phase II trial of gefitinib for previously treated patients with advanced non‐small‐cell lung cancer. Journal of Clinical Oncology2003;21(12):2237‐46. FukuokaM , YanoS , GiacconeG , et al. [Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced non‐small cell lung cancer (IDEAL 1) [abstract]]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:298a, Abs 1188. ManegoldC , GatzemeierU , KaukelE . Results from a randomised, double blind phase II trial of ZD1839 (IRESSA) as 2nd/3rd‐line monotherapy in advanced non small cell lung cancer (NSCLC) (IDEAL 1). Journal of Cancer Research &amp; Clinical Oncology2002;128 Suppl 1:S45. NishiwakiY , YanoS , TamuraT , NakagawaK , KudohS , HoraiT , et al. Subset analysis of data in the Japanese patients with NSCLC from IDEAL I study on gefitinib. Gan to Kagaku Ryoho. Cancer &amp; Chemotherapy2004;31(4):567‐73. VansteenkisteJ , NataleR , GiacconeG , et al. Two randomised, double‐blind studies of ZD1839 in 425 patients with pretreated advanced non‐small‐call lung cancer (IDEAL 1 and IDEAL 2) [abstract]. European Respiratory Society Annual Congress. Stockholm, 2002:Abstract 2537. ">Fukuoka 2003 IDEAL I</a>; <a href="./references#CD006847-bbs2-0018" title="CellaD , HerbstRS , LynchTJ , PragerD , BelaniCP , SchillerJH , et al. Clinically meaningful improvement in symptoms and quality of life for patients with non‐small cell lung cancer receiving gefitinib in a randomized controlled trial. Journal of Clinical Oncology2005;23(13):2946‐54. KrisMG , NataleRB , HerbstRS , et al. A phase II trial of ZD1839 ('Iressa') in advanced non‐small cell lung cancer (NSCLC) patients who had failed platinum‐ and docetaxel‐based regimens (IDEAL 2) [abstract]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:292a Abstract 1166. KrisMG , NataleRB , HerbstRS , LynchTJ , PragerD , BelaniCP , et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non‐small cell lung cancer: a randomized trial. JAMA2003;290(16):2149‐58. NataleRB , SkarinA , MaddoxAM , et al. Improvement in symptoms and quality of life for advanced non‐small cell lung cancer patients receiving ZD1839 ('Iressa') in IDEAL 2 [abstract]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:292a, Abstract 1167. ">Kris 2003 IDEAL II</a>). </p> <p>Quality of life improvements were also measured using the Trial Outcome Index (TOI), a summary score of the physical and functional domains of FACT‐L and the lung cancer subscale (a validated subscale of the FACT‐L questionnaire). No statistically significant difference was found between 250 mg and 500 mg of gefitinib in the rate of change of the FACT‐L and TOI scales (SMD 3.70, 95% CI ‐7.28 to 14.69; P = 0.51, I<sup>2</sup> = 0% and SMD 7.38, 95% CI ‐2.30 to 17.05; P = 0.14, I<sup>2</sup> = 0%, respectively). Unfortunately, extractable data from the published papers were inconsistently reported and thus not all data were pooled for analysis. </p> <p>Data from the IDEAL II study further correlated symptom improvement with objective response and survival. When given a dose of 250 mg of gefitinib, all patients who experienced a partial response also experienced symptom improvement. Patients with stable or progressive disease who experienced symptom improvement also had a longer median survival time compared to those in the same tumour progression category without symptom improvement. </p> </section> </section> <section id="CD006847-sec-0109"> <h4 class="title">Subgroup analysis</h4> <p>Both studies performed subgroup analyses.</p> <p><a href="./references#CD006847-bbs2-0009" title="BaelgaJ , KrisM , YanoS , NataleR , GiacconeG , BrahmerJ , et al. Phase II trials (IDEAL 1 and IDEAL 2) of ZD1839 in advanced or metastatic non‐small cell lung cancer (NSCLC) patient. Annals of Oncology2002;13(Suppl 5):131 Abs 481. DouillardJY , GiacconeG , HoraiT , NodaK , VansteenkisteJF , TakataI , et al. Improvement in disease‐related symptoms and quality of life in patients with advanced non‐small cell lung cancer (NSCLC) treated with ZD1839 ('Iressa') (IDEAL 1) [abstract]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:299a, Abs 1195. DouillardJY , SkarinA , BaselgaJ , NataleR , GiacconeG , MaddoxAM , et al. Improvement in disease‐related symptoms and quality of life (QOL) for advanced non‐small cell lung cancer (NSCLC) patients treated with ZD1839 in IDEAL 1 and IDEAL 2. Annals of Oncology2002;13 Suppl 5:131, Abs 480. FukuokaM , YanoS , GiacconeG , TamuraT , NakagawaK , DouillardJY , et al. Multi‐institutional randomized phase II trial of gefitinib for previously treated patients with advanced non‐small‐cell lung cancer. Journal of Clinical Oncology2003;21(12):2237‐46. FukuokaM , YanoS , GiacconeG , et al. [Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced non‐small cell lung cancer (IDEAL 1) [abstract]]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:298a, Abs 1188. ManegoldC , GatzemeierU , KaukelE . Results from a randomised, double blind phase II trial of ZD1839 (IRESSA) as 2nd/3rd‐line monotherapy in advanced non small cell lung cancer (NSCLC) (IDEAL 1). Journal of Cancer Research &amp; Clinical Oncology2002;128 Suppl 1:S45. NishiwakiY , YanoS , TamuraT , NakagawaK , KudohS , HoraiT , et al. Subset analysis of data in the Japanese patients with NSCLC from IDEAL I study on gefitinib. Gan to Kagaku Ryoho. Cancer &amp; Chemotherapy2004;31(4):567‐73. VansteenkisteJ , NataleR , GiacconeG , et al. Two randomised, double‐blind studies of ZD1839 in 425 patients with pretreated advanced non‐small‐call lung cancer (IDEAL 1 and IDEAL 2) [abstract]. European Respiratory Society Annual Congress. Stockholm, 2002:Abstract 2537. ">Fukuoka 2003 IDEAL I</a> found that the objective tumour response rate was higher for Japanese patients versus non‐Japanese patients (27.5% versus 10.4%; odds ratio (OR) 3.27; P = 0.0023). A planned subgroup multivariate analysis revealed seven factors that predicted response in Japanese patients: baseline lung cancer subscale, body mass index, performance status, prior radiotherapy, histology, prior immuno/hormonal therapy and gender. After accounting for all the baseline imbalances, the odds ratio indicated that Japanese patients had response rates 1.64 times that of non‐Japanese patients, but this was not considered statistically significant. </p> <p><a href="./references#CD006847-bbs2-0018" title="CellaD , HerbstRS , LynchTJ , PragerD , BelaniCP , SchillerJH , et al. Clinically meaningful improvement in symptoms and quality of life for patients with non‐small cell lung cancer receiving gefitinib in a randomized controlled trial. Journal of Clinical Oncology2005;23(13):2946‐54. KrisMG , NataleRB , HerbstRS , et al. A phase II trial of ZD1839 ('Iressa') in advanced non‐small cell lung cancer (NSCLC) patients who had failed platinum‐ and docetaxel‐based regimens (IDEAL 2) [abstract]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:292a Abstract 1166. KrisMG , NataleRB , HerbstRS , LynchTJ , PragerD , BelaniCP , et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non‐small cell lung cancer: a randomized trial. JAMA2003;290(16):2149‐58. NataleRB , SkarinA , MaddoxAM , et al. Improvement in symptoms and quality of life for advanced non‐small cell lung cancer patients receiving ZD1839 ('Iressa') in IDEAL 2 [abstract]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:292a, Abstract 1167. ">Kris 2003 IDEAL II</a> reported observation of symptom improvement and radiographic responses in all patient subgroups. Multivariate analysis identified female gender to be predictive of both symptom improvement and radiographic responses. </p> <p>Symptom improvement was rapid, with a median time to onset of less than two weeks: 10 days in the 250 mg group (95% CI 8 to 22 days) and 9 days (95% CI 9 to 16 days) in the 500 mg group. </p> <p>It was also reported that patients receiving third‐, fourth‐ and fifth‐line and above therapy had similar rates of symptom improvement both for 250 mg and 500 mg doses of gefitinib. Post‐hoc analysis showed that RRs for symptom improvement for the subgroup of patients who had previously received a platinum and taxane were 24% at 250 mg and 28% at 500 mg and for patients who had previously received platinum and docetaxel, 24% and 26% for the 250 mg and 500 mg groups, respectively.  </p> </section> <section id="CD006847-sec-0110"> <h4 class="title">4. Gefitinib versus gefitinib plus chemotherapy</h4> <section id="CD006847-sec-0111"> <h5 class="title">Survival </h5> <p>See <a href="./references#CD006847-fig-0116" title="">Analysis 8.1</a>; <a href="./references#CD006847-fig-0117" title="">Analysis 8.2</a>; <a href="./references#CD006847-fig-0118" title="">Analysis 8.3</a>. </p> <p>In the first‐line setting, two studies compared gefitinib alone with gefitinib plus pemetrexed (<a href="./references#CD006847-bbs2-0002" title="AnC , ZhangJ , ChuH , GuC , XiaoF , ZhuF , et al. Study of gefitinib and pemetrexed as first‐line treatment in patients with advanced non‐small cell lung cancer harboring EGFR mutation. Pathology and Oncology Research2016;22:763‐8. ">An 2016</a>; <a href="./references#CD006847-bbs2-0005" title="ChengY , MurakamiH , YangPC , HeJ , NakagawaK , KangJH , et al. Randomized phase II trial of gefitinib with and without pemetrexed as first‐line therapy in patients with advanced nonsquamous non‐small‐cell lung cancer with activating epidermal growth factor receptor mutations. Journal of Clinical Oncology2016;27(20):3258‐66. ">Cheng 2016</a>). One study reported no difference in median survival between the gefitinib and gefitinib plus chemotherapy group (32 months versus 34 months respectively) (<a href="./references#CD006847-bbs2-0002" title="AnC , ZhangJ , ChuH , GuC , XiaoF , ZhuF , et al. Study of gefitinib and pemetrexed as first‐line treatment in patients with advanced non‐small cell lung cancer harboring EGFR mutation. Pathology and Oncology Research2016;22:763‐8. ">An 2016</a>). The other study did not present survival data (<a href="./references#CD006847-bbs2-0005" title="ChengY , MurakamiH , YangPC , HeJ , NakagawaK , KangJH , et al. Randomized phase II trial of gefitinib with and without pemetrexed as first‐line therapy in patients with advanced nonsquamous non‐small‐cell lung cancer with activating epidermal growth factor receptor mutations. Journal of Clinical Oncology2016;27(20):3258‐66. ">Cheng 2016</a>). There was, however, a statistically significant improvement in progression‐free survival in favour of gefitinib plus chemotherapy over gefitinib alone (HR 0.69, 95% CI 0.49 to 0.96; P = 0.03; median progression‐free survival 12.6 months versus 18.3 months) (<a href="./references#CD006847-bbs2-0005" title="ChengY , MurakamiH , YangPC , HeJ , NakagawaK , KangJH , et al. Randomized phase II trial of gefitinib with and without pemetrexed as first‐line therapy in patients with advanced nonsquamous non‐small‐cell lung cancer with activating epidermal growth factor receptor mutations. Journal of Clinical Oncology2016;27(20):3258‐66. ">Cheng 2016</a>). </p> <p>In the second‐line or greater setting, median overall survival improved from 13.3 months (<a href="./references#CD006847-bbs2-0003" title="ChenYM , LiuJM , ChouTY , PerngRP , TsaiCM , Whang‐PengJ . Phase II randomized study of daily gefitinib treatment alone or with vinorelbine every 2 weeks in patients with adenocarcinoma of the lung who failed at least 2 regimens of chemotherapy. Cancer2007;109(9):1821‐8. ">Chen 2007</a>) and 18.3 months (<a href="./references#CD006847-bbs2-0004" title="ChenYM , FanWC , TsaiCM , LiuSH , ShihJF , ChouTY , et al. A phase II randomized trial of gefitinib alone or with Tegafur/uracil treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy. Journal of Thoracic Oncology2011;6:1110‐6. ">Chen 2011</a>) to 23.4 months and 23.6 months, respectively. This improvement was not statistically significant. Combining gefitinib with either vinorelbine or tegafur/uracil did not improve the one‐year survival rate (RR 1.15, 95% CI 0.92 to 1.43; P = 0.22; I<sup>2</sup> = 43%). Gefitinib plus chemotherapy improved one‐year progression‐free survival (RR 2.29, 95% CI 1.38 to 3.80; P = 0.001). However, the HR for progression‐free survival was only presented in <a href="./references#CD006847-bbs2-0004" title="ChenYM , FanWC , TsaiCM , LiuSH , ShihJF , ChouTY , et al. A phase II randomized trial of gefitinib alone or with Tegafur/uracil treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy. Journal of Thoracic Oncology2011;6:1110‐6. ">Chen 2011</a> (HR 0.65, 95% CI 0.43 to 0.97; P = 0.04: median progression‐free survival improved from 7.1 months (<a href="./references#CD006847-bbs2-0003" title="ChenYM , LiuJM , ChouTY , PerngRP , TsaiCM , Whang‐PengJ . Phase II randomized study of daily gefitinib treatment alone or with vinorelbine every 2 weeks in patients with adenocarcinoma of the lung who failed at least 2 regimens of chemotherapy. Cancer2007;109(9):1821‐8. ">Chen 2007</a>) and 5.3 months (<a href="./references#CD006847-bbs2-0004" title="ChenYM , FanWC , TsaiCM , LiuSH , ShihJF , ChouTY , et al. A phase II randomized trial of gefitinib alone or with Tegafur/uracil treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy. Journal of Thoracic Oncology2011;6:1110‐6. ">Chen 2011</a>) to 12.8 months and 8.3 months, respectively). </p> </section> <section id="CD006847-sec-0112"> <h5 class="title">Toxicity</h5> <p>See <a href="./references#CD006847-fig-0119" title="">Analysis 8.4</a>; <a href="./references#CD006847-fig-0120" title="">Analysis 8.5</a>; <a href="./references#CD006847-fig-0121" title="">Analysis 8.6</a>; <a href="./references#CD006847-fig-0122" title="">Analysis 8.7</a>; <a href="./references#CD006847-fig-0123" title="">Analysis 8.8</a>; <a href="./references#CD006847-fig-0124" title="">Analysis 8.9</a>; <a href="./references#CD006847-fig-0125" title="">Analysis 8.10</a>; <a href="./references#CD006847-fig-0126" title="">Analysis 8.11</a>; <a href="./references#CD006847-fig-0127" title="">Analysis 8.12</a>; <a href="./references#CD006847-fig-0128" title="">Analysis 8.13</a>; <a href="./references#CD006847-fig-0129" title="">Analysis 8.14</a>; <a href="./references#CD006847-fig-0130" title="">Analysis 8.15</a>. </p> <p>We pooled toxicity data from three studies (<a href="./references#CD006847-bbs2-0002" title="AnC , ZhangJ , ChuH , GuC , XiaoF , ZhuF , et al. Study of gefitinib and pemetrexed as first‐line treatment in patients with advanced non‐small cell lung cancer harboring EGFR mutation. Pathology and Oncology Research2016;22:763‐8. ">An 2016</a>; <a href="./references#CD006847-bbs2-0003" title="ChenYM , LiuJM , ChouTY , PerngRP , TsaiCM , Whang‐PengJ . Phase II randomized study of daily gefitinib treatment alone or with vinorelbine every 2 weeks in patients with adenocarcinoma of the lung who failed at least 2 regimens of chemotherapy. Cancer2007;109(9):1821‐8. ">Chen 2007</a>; <a href="./references#CD006847-bbs2-0005" title="ChengY , MurakamiH , YangPC , HeJ , NakagawaK , KangJH , et al. Randomized phase II trial of gefitinib with and without pemetrexed as first‐line therapy in patients with advanced nonsquamous non‐small‐cell lung cancer with activating epidermal growth factor receptor mutations. Journal of Clinical Oncology2016;27(20):3258‐66. ">Cheng 2016</a>). Both regimens were well tolerated with no significant difference in rates of skin rash, diarrhoea, constipation, fatigue, blood counts, nausea or vomiting. </p> <p>Pooled data from both first‐line studies did show that the addition of pemetrexed chemotherapy to gefitinib resulted in higher rates of raised ALT (RR 2.57, 95% CI 1.09 to 6.04; P = 0.03; I<sup>2</sup> = 63%) but not AST (RR 1.47, 95% CI 0.56 to 3.88; P = 0.44; I<sup>2</sup> = 0%). </p> </section> <section id="CD006847-sec-0113"> <h5 class="title">Efficacy</h5> <p>See <a href="./references#CD006847-fig-0131" title="">Analysis 8.16</a>; <a href="./references#CD006847-fig-0132" title="">Analysis 8.17</a>; <a href="./references#CD006847-fig-0133" title="">Analysis 8.18</a>. </p> <p>When comparing gefitinib alone to gefitinib plus chemotherapy as first‐line therapy, there was no improvement in overall response rate (RR 1.02, 95% CI 0.89 to 1.17; P = 0.73; I<sup>2</sup> = 26%) or rate of stable disease (RR 0.67, 95% CI 0.39 to 1.16; P = 0.16; I<sup>2</sup> = 0%). </p> <p>In the second‐line setting, the addition of chemotherapy to gefitinib did not result in an improvement in either partial radiological response (RR 1.02, 95% CI 0.71 to 1.47; P = 0.92; I<sup>2</sup> = 0%) or stable disease (RR 1.30, 95% CI 0.84 to 2.03; P = 0.24; I<sup>2</sup> = 16%). </p> </section> </section> <section id="CD006847-sec-0114"> <h4 class="title">5. Gefitinib plus chemotherapy versus chemotherapy</h4> <section id="CD006847-sec-0115"> <h5 class="title">Survival</h5> <p>See <a href="./references#CD006847-fig-0134" title="">Analysis 9.1</a>; <a href="./references#CD006847-fig-0135" title="">Analysis 9.2</a>; <a href="./references#CD006847-fig-0136" title="">Analysis 9.3</a>. </p> <p>Meta‐analysis of two phase II, first‐line trials examining 1411 patients showed that the addition of gefitinib (250 mg/day) to a chemotherapy regimen in chemotherapy‐naive patients did not change the one‐year survival rate (RR 0.95, 95% CI 0.84 to 1.08, P = 0.44, I<sup>2</sup> = 0%) (<a href="./references#CD006847-bbs2-0011" title="BellDW , LynchTJ , MaserlatSM , HarrisPL , OkimotoFA , BranniganBW , et al. Epidermal growth factor receptor mutations and gene amplification in non‐small‐cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. Journal of Clinical Oncology2005;23(31):8081‐92. GiacconeG , HerbstRS , ManegoldC , ScagliottiG , RosellR , MillerV , et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non‐small cell lung cancer: a phase III trial ‐ INTACT I. Journal of Clinical Oncology2004;22(5):777‐84. GiacconeG , JohnsonDH , ManegoldC , et al. A phase III clinical trial of ZD1839 ('Iressa') in combination with gemcitabine and cisplatin in chemotherapy‐naive patients with advanced non‐small cell lung cancer (INTACT 1). Annals of Oncology2002;13 Suppl 5:2, Abstract 4. ">Giaccone 2004 INTACT I</a>; <a href="./references#CD006847-bbs2-0014" title="HerbstRS , GiacconeG , SchillerJH , NataleRB , MillerV , ManegoldC , et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non‐small cell lung cancer: a phase III trial ‐ INTACT 2. Journal of Clinical Oncology2004;22(5):785‐94. JohnsonDH , HerbstR , GiacconeG , et al. ZD1839 ('Iressa') in combination with paclitaxel &amp; carboplatin in chemotherapy‐naive patients with advanced non‐small cell lung cancer (NSCLC): results from a phase III clinical trial (INTACT 2). Annals of Oncology2002;13 Suppl 5:127, Abstract 468. ">Herbst 2004 INTACT II</a>). </p> <p>Two trials compared the addition of first‐line gefitinib to chemotherapy with chemotherapy alone in Asian patients only (<a href="./references#CD006847-bbs2-0029" title="OkamotoI , HidaT , KashiiT , et al. Randomized phase III study of platinum‐doublet chemotherapy followed by gefitinib versus continued platinum‐doublet chemotherapy in patients (pts) with advanced non‐small cell lung cancer (NSCLC): Results of West Japan Thoracic Oncology Group Trial (WJTOG0203) [Abstract No. 2 33PD]. Annals of Oncology2008;19 Suppl 8:91. TakedaK , HidaT , SatoT , AndoM , SetoT , SatouchiM , et al. Randomized phase III trial of platinum‐doublet chemotherapy followed by gefitinib comparted with continued platinum‐doublet chemotherapy in Japanese patients with advanced non‐small cell lung cancer: results of a West Japan Thoracic Oncology Group Trial (WJTOG0203). Journal of Clinical Oncology2010;28(5):753‐60. ">Takeda 2010 WJTOG0203</a>; <a href="./references#CD006847-bbs2-0034" title="YuH , ZhangJ , WuX , LuoZ , WangH , SunS , et al. A phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non‐squamous non‐small cell lung cancer. Cancer Biology and Therapy2014;15(7):832‐9. ">Yu 2014</a>). There was no improvement in overall survival (HR 0.86, 95% CI 0.72 to 1.02, P = 0.08, I<sup>2</sup> = 0%), however there was a statistically significant improvement in progression‐free survival (HR 0.69, 95% CI 0.62 to 0.77, P &lt; 0.00001, I<sup>2</sup> = 18%). </p> <p>A single phase III trial recruited only EGFR mutation positive patients who had failed prior first‐line gefitinib, and the addition of gefitinib to chemotherapy did not improve progression‐free survival (HR 0.86, 95% CI 0.65 to 1.13, P = 0.28) (<a href="./references#CD006847-bbs2-0027" title="SoriaJC , WuYL , NakagawaK , KimSW , YangJJ , AhnMJ , et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR‐mutation‐positive non‐small‐cell lung cancer after progression on first‐line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncology2015;16:990‐8. ">Soria 2015 IMPRESS</a>). Overall survival appeared to be better in the chemotherapy alone group (HR 1.62, 95% CI 1.05 to 2.50, P = 0.03). </p> </section> <section id="CD006847-sec-0116"> <h5 class="title">Toxicity</h5> <p>See <a href="./references#CD006847-fig-0137" title="">Analysis 9.4</a>; <a href="./references#CD006847-fig-0138" title="">Analysis 9.5</a>; <a href="./references#CD006847-fig-0139" title="">Analysis 9.6</a>. </p> <p>Pooled data from all five trials showed that the addition of gefitinib to a chemotherapeutic regimen resulted in increased rates of skin rash (RR 2.98, 95% CI 1.54 to 5.77, P = 0.001, I<sup>2</sup> = 28%), acne (RR 4.95, 95% CI 1.09 to 22.51, P = 0.04, I<sup>2</sup> = 0%) and diarrhoea (RR 2.04, 95% CI 1.17 to 3.58, P = 0.01, I<sup>2</sup> = 17%). Other measured side effects such as pruritus, vomiting, nausea, anorexia, asthenia, dyspnoea, anaemia, neutropenia and leukopenia were not significantly increased. </p> </section> <section id="CD006847-sec-0117"> <h5 class="title">Efficacy</h5> <p>See <a href="./references#CD006847-fig-0149" title="">Analysis 9.16</a>. </p> <p>In the first‐line setting, the addition of gefitinib to chemotherapy did not effect the overall response rate in either the unselected population (RR 1.07, 95% CI 0.94 to 1.22, P = 0.28, I<sup>2</sup> = 0%) or the Asian population (RR 1.14, 95% CI 0.93 to 1.40, P = 0.20, I<sup>2</sup> = 0%). The overall response rate ranged from 30% to 51% in the gefitinib plus chemotherapy group and 29% to 50% in the chemotherapy group. </p> <p>There was also no improvement in the overall response rate in the second‐line setting (RR 0.93, 95% CI 0.66 to 1.31, P = 0.66, I<sup>2</sup> = 0%), and the overall response rate was 32% in the gefitinib plus chemotherapy group and 34% in the chemotherapy alone group. </p> </section> <section id="CD006847-sec-0118"> <h5 class="title">Quality of life and symptom improvement scores</h5> <p>In the first‐line setting, the WJTOG0203 study reported a disease‐related symptoms assessment (<a href="./references#CD006847-bbs2-0029" title="OkamotoI , HidaT , KashiiT , et al. Randomized phase III study of platinum‐doublet chemotherapy followed by gefitinib versus continued platinum‐doublet chemotherapy in patients (pts) with advanced non‐small cell lung cancer (NSCLC): Results of West Japan Thoracic Oncology Group Trial (WJTOG0203) [Abstract No. 2 33PD]. Annals of Oncology2008;19 Suppl 8:91. TakedaK , HidaT , SatoT , AndoM , SetoT , SatouchiM , et al. Randomized phase III trial of platinum‐doublet chemotherapy followed by gefitinib comparted with continued platinum‐doublet chemotherapy in Japanese patients with advanced non‐small cell lung cancer: results of a West Japan Thoracic Oncology Group Trial (WJTOG0203). Journal of Clinical Oncology2010;28(5):753‐60. ">Takeda 2010 WJTOG0203</a>). Sequential administration of gefitinib was reported to provide better symptom control, however these differences were not statistically significant. The adjusted mean of initial summed scores of the lung cancer subscale were 20.3 for Arm A and 20.6 for Arm B. The adjusted lung cancer subscale scores at 12 and 18 weeks were 21 and 20.9 for Arm A and 21.8 and 21.2 for Arm B, respectively. </p> <p>In the second‐line setting, the IMPRESS study reported that the improvements in quality of life were no different when gefitinib plus chemotherapy was compared to placebo plus chemotherapy as measured by the Trial Outcome Index (TOI) (29% versus 30.2%, respectively), FACT‐L (35.5% versus 38%, respectively) or lung cancer subscale (43.5% versus 42.6%, respectively) (<a href="./references#CD006847-bbs2-0027" title="SoriaJC , WuYL , NakagawaK , KimSW , YangJJ , AhnMJ , et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR‐mutation‐positive non‐small‐cell lung cancer after progression on first‐line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncology2015;16:990‐8. ">Soria 2015 IMPRESS</a>). There was also no difference in the time to worsening of health‐related quality of life as measured by the TOI, FACT‐L and lung cancer subscale. </p> <p>These data could not be pooled for meta‐analysis.</p> </section> </section> <section id="CD006847-sec-0119"> <h4 class="title">Subgroup analysis</h4> <p>A planned exploratory subgroup analysis in Japanese patients of overall survival by histological group reported that patients with adenocarcinoma that were given sequential gefitinib had better outcomes than patients given chemotherapy alone (n = 467; progression‐free survival: HR 0.79, 95% CI 0.65 to 0.98, P = 0.03; overall survival: HR 0.60, 95% CI 0.50 to 0.73, P &lt; 0.001) (<a href="./references#CD006847-bbs2-0029" title="OkamotoI , HidaT , KashiiT , et al. Randomized phase III study of platinum‐doublet chemotherapy followed by gefitinib versus continued platinum‐doublet chemotherapy in patients (pts) with advanced non‐small cell lung cancer (NSCLC): Results of West Japan Thoracic Oncology Group Trial (WJTOG0203) [Abstract No. 2 33PD]. Annals of Oncology2008;19 Suppl 8:91. TakedaK , HidaT , SatoT , AndoM , SetoT , SatouchiM , et al. Randomized phase III trial of platinum‐doublet chemotherapy followed by gefitinib comparted with continued platinum‐doublet chemotherapy in Japanese patients with advanced non‐small cell lung cancer: results of a West Japan Thoracic Oncology Group Trial (WJTOG0203). Journal of Clinical Oncology2010;28(5):753‐60. ">Takeda 2010 WJTOG0203</a>). There was no difference in overall survival or progression‐free survival in those with non‐adenocarcinoma (overall survival: HR 1.24, 95% CI 0.85 to 1.79, P = 0.25 and progression‐free survival: HR 1.14, 95% CI 0.80 to 1.62, P = 0.47). This study also reported that smokers also experienced improved survival with sequential gefitinib (HR 0.79, 95% CI 0.64 to 0.98), as opposed to non‐smokers (HR 0.94, 95% CI 0.66 to 1.33), however P values were not published. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD006847-sec-0120" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006847-sec-0120">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006847-sec-0158">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD006847-sec-0120"></div> <p>This meta‐analysis examined published data on the effectiveness and safety of gefitinib in patients with non‐small cell lung cancer (NSCLC). We performed an extensive search of electronic databases and carried out handsearching, and 35 randomised studies fulfilled the inclusion criteria. Some were phase II, open‐label design trials and limited pooling of data was possible due to methodological differences between studies. </p> <section id="CD006847-sec-0121"> <h3 class="title" id="CD006847-sec-0121">Summary of main results</h3> <p>A total of 35 studies were included in this review.</p> <p>Five studies compared gefitinib with placebo: one study in the first‐line, one study in the second‐line and three studies in the maintenance setting. Gefitinib did not improve survival in the first‐line setting in a general population of NSCLC patients. The ISEL study found that gefitinib as a second‐line therapy was able to reduce the risk of disease progression by 18%, and improve the objective response rate from 1% to 6% when compared to placebo (<a href="./references#CD006847-bbs2-0030" title="ChangA , ParikhP , ThongprasertS , TanEH , PerngRP , GanzonD , et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non‐small cell lung cancer: subset analysis from the ISEL study. Journal of Thoracic Oncology2006;1(8):847‐55. HirschFR , DziadziuszkoR , ThatcherN , MannH , WatkinsC , ParumsDV , et al. Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo‐controlled study in advanced non small‐cell lung cancer. Cancer2008;112(5):1114‐21. HirschFR , Varella‐GarciaM , Bunn JrPA , FranklinWA , DziadziuszkoR , ThatcherN , et al. Molecular predictors of outcome with gefitinib in a phase III placebo‐controlled study in advanced non‐small cell lung cancer. Journal of Clinical Oncology2006;24(31):5034‐42. ThatcherN , ChangA , ParikhP , Rodrigues PereiraJ , CiuleanuT , vonPawelJ , et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non‐small‐cell lung cancer: results from a randomised, placebo‐controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet2005;366(9496):1527‐37. ">Thatcher 2005 ISEL</a>). Three studies compared gefitinib with placebo in the maintenance setting. Gefitinib reduced the risk of disease progression by 31%. </p> <p>In patients of Asian ethnicity, preplanned subgroup analysis in the ISEL study found that second‐line gefitinib improved overall and progression‐free survival by 34% and 31%, respectively (<a href="./references#CD006847-bbs2-0059" title="ChangA , ParikhP , ThongprasertS , TanEH , PerngRP , GanzonD , et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non‐small‐cell lung cancer: Subset analysis from the ISEL study. Journal of Thoracic Oncology2006;1(8):847‐55. ">Chang 2006</a>). The INFORM study compared gefitinib with placebo in the maintenance setting and selected patients of Asian ethnicity (<a href="./references#CD006847-bbs2-0035" title="YangY , MaY , ZhaoY , FangW , HongS , et al. QoL analyses from INFORM study, a phase III study of gefitinib versus placebo as maintenance therapy in advanced NSCLC. Scientific Reports2015;5:11934. ZhangL , MaS , SongX , HanB , ChengY , HuangC , et al. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non‐small‐cell lung cancer (INFORM; C‐TONG 0804): a multicentre, double‐blind randomised phase 3 trial. Lancet Oncology2012;13:466‐75. ZhangL , MaSL , SongXQ , ChengY , HuangC , YangSJ , et al. Pre‐planned subgroup analyses from the phase III, randomised, placebo‐controlled, parallel‐group study of gefitinib (G) as maintenance therapy in patients (pts) with locally advanced or metastatic non‐small‐cell lung cancer (NSCLC) (INFORM; C‐TONG 0804). European Multidisciplinary Cancer Congress Stockholm Sweden. Elsevier Ltd, 2011; Vol. 47:S622‐3. ZhangL , MaSL , SongXQ , HanBH , ChengY , HuangC , et al. Efficacy, tolerability and biomarker analyses from a phase III, randomized, placebo controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non‐small‐cell lung cancer (NSCLC) in China (INFORM) (C‐TONG 0804). 14th World Conference on Lung Cancer Amsterdam Netherlands. International Association for the Study of Lung Cancer, 2011; Vol. 6:S558‐9. ZhangL , ShenglinM , SongX , HanB , ChengY , HuangC , et al. Efficacy, tolerability, and biomarker analyses from a phase III, randomized, placebo‐controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non‐small cell lung cancer (NSCLC; INFORM; C‐TONG 0804). ASCO Annual Meeting 2011 Chicago, IL United States. American Society of Clinical Oncology, 2011; Vol. 29. ZhaoH , FanY , MaS , SongX , HanB , ChengY , et al. Final overall survival results from a phase III, randomized placebo‐controlled, parallel‐group study of gefitinib versus placebo as maintenance therapy in patients with advanced or metastatic non‐small‐cell lung cancer (INFORM; C‐TONG 0804). Journal of Thoracic Oncology2015;10(4):655‐64. ">Zhang 2012 INFORM</a>). This study found that gefitinib prolonged progression‐free survival by 58% and the overall response rate improved from 1% to 24%. Quality of life analysis from the INFORM study also showed that improvement rates as measured by the Functional Assessment of Cancer Therapy‐Lung (FACT‐L), Trial Outcome Index (TOI) and lung cancer subscale were higher in the patients who were given gefitinib as maintenance therapy. These patients also experienced a longer time‐to‐worsening of quality of life scores. </p> <p>In patients positive for an epidermal growth factor receptor (EGFR) mutation, subgroup analysis of the INFORM study showed an improvement in median overall survival from 21 months to 47 months and maintenance gefitinib reduced the risk of death by 61% (<a href="./references#CD006847-bbs2-0035" title="YangY , MaY , ZhaoY , FangW , HongS , et al. QoL analyses from INFORM study, a phase III study of gefitinib versus placebo as maintenance therapy in advanced NSCLC. Scientific Reports2015;5:11934. ZhangL , MaS , SongX , HanB , ChengY , HuangC , et al. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non‐small‐cell lung cancer (INFORM; C‐TONG 0804): a multicentre, double‐blind randomised phase 3 trial. Lancet Oncology2012;13:466‐75. ZhangL , MaSL , SongXQ , ChengY , HuangC , YangSJ , et al. Pre‐planned subgroup analyses from the phase III, randomised, placebo‐controlled, parallel‐group study of gefitinib (G) as maintenance therapy in patients (pts) with locally advanced or metastatic non‐small‐cell lung cancer (NSCLC) (INFORM; C‐TONG 0804). European Multidisciplinary Cancer Congress Stockholm Sweden. Elsevier Ltd, 2011; Vol. 47:S622‐3. ZhangL , MaSL , SongXQ , HanBH , ChengY , HuangC , et al. Efficacy, tolerability and biomarker analyses from a phase III, randomized, placebo controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non‐small‐cell lung cancer (NSCLC) in China (INFORM) (C‐TONG 0804). 14th World Conference on Lung Cancer Amsterdam Netherlands. International Association for the Study of Lung Cancer, 2011; Vol. 6:S558‐9. ZhangL , ShenglinM , SongX , HanB , ChengY , HuangC , et al. Efficacy, tolerability, and biomarker analyses from a phase III, randomized, placebo‐controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non‐small cell lung cancer (NSCLC; INFORM; C‐TONG 0804). ASCO Annual Meeting 2011 Chicago, IL United States. American Society of Clinical Oncology, 2011; Vol. 29. ZhaoH , FanY , MaS , SongX , HanB , ChengY , et al. Final overall survival results from a phase III, randomized placebo‐controlled, parallel‐group study of gefitinib versus placebo as maintenance therapy in patients with advanced or metastatic non‐small‐cell lung cancer (INFORM; C‐TONG 0804). Journal of Thoracic Oncology2015;10(4):655‐64. ">Zhang 2012 INFORM</a>). Maintenance gefitinib also improved progression‐free survival from 2.8 months to 16.6 months. </p> <p>Several phase II and III studies compared gefitinib with chemotherapy. Eighteen randomised studies have examined the effectiveness of gefitinib compared with recommended chemotherapy regimes. Meta‐analysis of four studies failed to demonstrate any benefit for survival or response rate in a general population (moderate quality of evidence). (Please refer to <a href="./full#CD006847-tbl-0001">summary of findings Table for the main comparison</a> and <a href="./full#CD006847-tbl-0002">summary of findings Table 2</a>). Quality of life was significantly better for patients on gefitinib than for those having chemotherapy, and gefitinib was significantly less toxic and generally well tolerated when compared with chemotherapy (high quality of evidence), in keeping with results from other studies. Skin rash, diarrhoea and increased liver transaminases were more frequent in the gefitinib group, but other significant side effects such as neutropenia, anaemia, leukopenia and febrile neutropenia were less frequent. (Please refer to <a href="./full#CD006847-tbl-0003">summary of findings Table 3</a>). </p> <p>Fourteen trials included patients exclusively of Asian ethnicity, with some additionally selecting by EGFR mutation status or clinical criteria that are likely to have enriched EGFR mutations. Gefitinib improved the overall response rate by 43% and progression‐free survival by 35% when compared with first‐line chemotherapy, but this did not translate into an improvement in overall survival. Comparing gefitinib with second‐line chemotherapy found that progression‐free survival was improved by 29%, but there was no effect on overall survival or overall response rate. The effect of Asian ethnicity is complicated, and may be confounded by higher rates of EGFR mutation and the biologically plausible predictive biomarker characteristic of EGFR mutations. Two trials compared maintenance gefitinib with maintenance chemotherapy. There was no difference in either progression‐free survival or overall survival, but gefitinib was able to improve the one‐year survival rate by 21% and the disease control rate by 35%. Skin rash, diarrhoea and elevated liver transaminases were more common in those treated with gefitinib, however severe adverse side effects such as haematological derangements, neurotoxicity, nausea, anorexia, fatigue and arthralgia were much more common in the chemotherapy group. </p> <p>Eight studies either selected patients with tumours expressing EGFR mutations for comparison or conducted subgroup analyses in these patients. Use of gefitinib in the first‐line setting improved progression‐free survival over platinum‐doublet chemotherapy. Studies that selected patients with EGFR mutations exclusively were able to show a 61% improvement in progression‐free survival over first‐line chemotherapy. Two studies recruited patients with clinical features likely to respond favourably to gefitinib, and showed a 51% improvement in progression‐free survival after subgroup analysis of EGFR mutation positive patients. Gefitinib also improved the overall response rate by 73% over first‐line chemotherapy. However, none were able to demonstrate an improvement in overall survival, arguably due to high rates of cross‐over. When comparing gefitinib with second‐line chemotherapy, a similar improvement in progression‐free survival of 76% was seen. There was no impact on overall survival or overall response rate. </p> <p>Increasing the dose of gefitinib from 250 mg/day to 500 mg/day yielded no additional benefit in survival or response rate in three phase II trials. This increased dose, however, was associated with greater toxicity. </p> <p>Two phase II studies compared pemetrexed plus gefitinib with gefitinib alone as first‐line treatment. Progression‐free survival was improved by 31% with a median improvement from 12.6 months to 18.3 months. There were, however, increased rates of raised ALT in this treatment arm. All other toxicities were similar. The two studies comparing gefitinib plus chemotherapy with gefitinib alone in the second‐line setting showed improved one‐year progression‐free survival when chemotherapy was added to gefitinib. </p> <p>Five studies showed that the addition of gefitinib to a chemotherapy regimen compared to chemotherapy alone did not confer any survival benefit. In patients of Asian ethnicity, two studies showed that first‐line gefitinib plus chemotherapy improved progression‐free survival by 31% compared to chemotherapy alone. One phase III study compared gefitinib plus chemotherapy to chemotherapy alone and found that survival was improved in favour of chemotherapy alone. All patients in this study were EGFR mutation positive, but had failed prior first‐line therapy with gefitinib. </p> <p>A summary of the efficacy results is presented in <a href="#CD006847-tbl-0005">Table 2</a>. </p> </section> <section id="CD006847-sec-0122"> <h3 class="title" id="CD006847-sec-0122">Overall completeness and applicability of evidence</h3> <p>Much of the data analysed in this review has predated the routine assessment of EGFR mutation status in NSCLC. This testing is now done routinely in many countries before starting treatment, and the status of EGFR mutation now guides the therapeutic options. Gefitinib has already been registered in occidental countries for treatment of NSCLC with EGFR activating mutations. The treatment options for patients with advanced NSCLC continue to evolve rapidly and although some of the data in this review may be considered historical, it still provides a foundation upon which ongoing studies examining the relationship between the effectiveness of gefitinib and the timing of its use with other treatment modalities can be built. </p> <p>The inclusion criteria for selecting patients for these studies may have adversely affected their ability to provide statistically significant results. For example, some studies selected patients with highly refractory disease who may have been less likely to respond to any additional therapy. Some studies selected chemotherapy‐naive patients for inclusion (<a href="./references#CD006847-bbs2-0011" title="BellDW , LynchTJ , MaserlatSM , HarrisPL , OkimotoFA , BranniganBW , et al. Epidermal growth factor receptor mutations and gene amplification in non‐small‐cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. Journal of Clinical Oncology2005;23(31):8081‐92. GiacconeG , HerbstRS , ManegoldC , ScagliottiG , RosellR , MillerV , et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non‐small cell lung cancer: a phase III trial ‐ INTACT I. Journal of Clinical Oncology2004;22(5):777‐84. GiacconeG , JohnsonDH , ManegoldC , et al. A phase III clinical trial of ZD1839 ('Iressa') in combination with gemcitabine and cisplatin in chemotherapy‐naive patients with advanced non‐small cell lung cancer (INTACT 1). Annals of Oncology2002;13 Suppl 5:2, Abstract 4. ">Giaccone 2004 INTACT I</a>; <a href="./references#CD006847-bbs2-0014" title="HerbstRS , GiacconeG , SchillerJH , NataleRB , MillerV , ManegoldC , et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non‐small cell lung cancer: a phase III trial ‐ INTACT 2. Journal of Clinical Oncology2004;22(5):785‐94. JohnsonDH , HerbstR , GiacconeG , et al. ZD1839 ('Iressa') in combination with paclitaxel &amp; carboplatin in chemotherapy‐naive patients with advanced non‐small cell lung cancer (NSCLC): results from a phase III clinical trial (INTACT 2). Annals of Oncology2002;13 Suppl 5:127, Abstract 468. ">Herbst 2004 INTACT II</a>), whereas others included patients who had received at least one prior platinum‐containing chemotherapy regimen (<a href="./references#CD006847-bbs2-0018" title="CellaD , HerbstRS , LynchTJ , PragerD , BelaniCP , SchillerJH , et al. Clinically meaningful improvement in symptoms and quality of life for patients with non‐small cell lung cancer receiving gefitinib in a randomized controlled trial. Journal of Clinical Oncology2005;23(13):2946‐54. KrisMG , NataleRB , HerbstRS , et al. A phase II trial of ZD1839 ('Iressa') in advanced non‐small cell lung cancer (NSCLC) patients who had failed platinum‐ and docetaxel‐based regimens (IDEAL 2) [abstract]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:292a Abstract 1166. KrisMG , NataleRB , HerbstRS , LynchTJ , PragerD , BelaniCP , et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non‐small cell lung cancer: a randomized trial. JAMA2003;290(16):2149‐58. NataleRB , SkarinA , MaddoxAM , et al. Improvement in symptoms and quality of life for advanced non‐small cell lung cancer patients receiving ZD1839 ('Iressa') in IDEAL 2 [abstract]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:292a, Abstract 1167. ">Kris 2003 IDEAL II</a>; <a href="./references#CD006847-bbs2-0009" title="BaelgaJ , KrisM , YanoS , NataleR , GiacconeG , BrahmerJ , et al. Phase II trials (IDEAL 1 and IDEAL 2) of ZD1839 in advanced or metastatic non‐small cell lung cancer (NSCLC) patient. Annals of Oncology2002;13(Suppl 5):131 Abs 481. DouillardJY , GiacconeG , HoraiT , NodaK , VansteenkisteJF , TakataI , et al. Improvement in disease‐related symptoms and quality of life in patients with advanced non‐small cell lung cancer (NSCLC) treated with ZD1839 ('Iressa') (IDEAL 1) [abstract]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:299a, Abs 1195. DouillardJY , SkarinA , BaselgaJ , NataleR , GiacconeG , MaddoxAM , et al. Improvement in disease‐related symptoms and quality of life (QOL) for advanced non‐small cell lung cancer (NSCLC) patients treated with ZD1839 in IDEAL 1 and IDEAL 2. Annals of Oncology2002;13 Suppl 5:131, Abs 480. FukuokaM , YanoS , GiacconeG , TamuraT , NakagawaK , DouillardJY , et al. Multi‐institutional randomized phase II trial of gefitinib for previously treated patients with advanced non‐small‐cell lung cancer. Journal of Clinical Oncology2003;21(12):2237‐46. FukuokaM , YanoS , GiacconeG , et al. [Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced non‐small cell lung cancer (IDEAL 1) [abstract]]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:298a, Abs 1188. ManegoldC , GatzemeierU , KaukelE . Results from a randomised, double blind phase II trial of ZD1839 (IRESSA) as 2nd/3rd‐line monotherapy in advanced non small cell lung cancer (NSCLC) (IDEAL 1). Journal of Cancer Research &amp; Clinical Oncology2002;128 Suppl 1:S45. NishiwakiY , YanoS , TamuraT , NakagawaK , KudohS , HoraiT , et al. Subset analysis of data in the Japanese patients with NSCLC from IDEAL I study on gefitinib. Gan to Kagaku Ryoho. Cancer &amp; Chemotherapy2004;31(4):567‐73. VansteenkisteJ , NataleR , GiacconeG , et al. Two randomised, double‐blind studies of ZD1839 in 425 patients with pretreated advanced non‐small‐call lung cancer (IDEAL 1 and IDEAL 2) [abstract]. European Respiratory Society Annual Congress. Stockholm, 2002:Abstract 2537. ">Fukuoka 2003 IDEAL I</a>). <a href="./references#CD006847-bbs2-0030" title="ChangA , ParikhP , ThongprasertS , TanEH , PerngRP , GanzonD , et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non‐small cell lung cancer: subset analysis from the ISEL study. Journal of Thoracic Oncology2006;1(8):847‐55. HirschFR , DziadziuszkoR , ThatcherN , MannH , WatkinsC , ParumsDV , et al. Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo‐controlled study in advanced non small‐cell lung cancer. Cancer2008;112(5):1114‐21. HirschFR , Varella‐GarciaM , Bunn JrPA , FranklinWA , DziadziuszkoR , ThatcherN , et al. Molecular predictors of outcome with gefitinib in a phase III placebo‐controlled study in advanced non‐small cell lung cancer. Journal of Clinical Oncology2006;24(31):5034‐42. ThatcherN , ChangA , ParikhP , Rodrigues PereiraJ , CiuleanuT , vonPawelJ , et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non‐small‐cell lung cancer: results from a randomised, placebo‐controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet2005;366(9496):1527‐37. ">Thatcher 2005 ISEL</a> selected patients who had recurrence or progressive disease during treatment or within 90 days of the last dose of chemotherapy. </p> <p>In some studies, patients who progressed on a certain treatment were allowed the opportunity to switch to the comparison arm. This was reported in some studies (e.g. <a href="./references#CD006847-bbs2-0025" title="FukuokaM , WuYL , ThongprasertS , SunpaweravongP , LeongSS , SriuranpongV , et al. Biomarker analyses and final overall survival results from a phase III, randomized, open‐label, first‐line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non ‐ small‐cell lung cancer in Asia (IPASS). Journal of Clinical Oncology2011;29:2866‐74. MokT , WuY‐L , ThongprasertS , et al. Phase III, randomised, open‐label, first‐line study of gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients (PTS) with advanced non‐small cell lung cancer (NSCLC) (IPASS). Annals of Oncology2008;19 Suppl 8:Viii1. MokTS , WuYL , ThongprasertS , YangCH , ChuDT , SaijoN , et al. Gefitinib or carboplatin‐paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine2009;361(10):947‐57. OheY , IchinoseY , NishiwakiY ,  etal . Phase III, randomized, open‐label, first‐line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in selected patients (pts) with advanced non‐small‐cell lung cancer (NSCLC) (IPASS): Evaluation of recruits in Japan. Journal of Clinical Oncology2009;29(15 Suppl 1):8044. ThongprasertS , DuffieldE , SaijoN , WuYL , YangJC , ChuDT , et al. Health‐related quality‐of‐life in a randomized phase III first‐line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). Journal of Thoracic Oncology2011;6:1872‐80. ThongprasertS , DuffieldE , WuY , et al. Quality of life (QOL) in a randomized phase III first‐line study of gefitinib (G) vs carboplatin/paclitaxel (CP) in clinically selected Asian patients (pts) with advanced NSCLC (IPASS). Journal of Thoracic Oncology2010;5(5 Suppl 1):S80. WuY , ChuD , HanB , LiuX , ZhangL , ZhouC , et al. Phase III, randomized, open‐label, first‐line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non‐small‐cell lung cancer: evaluation of patients recruited from mainland China. Asia‐Pacific Journal of Clinical Oncology2012;8:232‐43. WuY , FukuokaM , MokT S K , SaijoN , ThongprasertS , YangJ C H , et al. Tumour response, skin rash and health‐related quality of life (HRQOL) ‐ Post‐HOC data from the IPASS study. European Multidisciplinary Cancer Congress Stockholm Sweden. Elsevier Ltd, 2011; Vol. 47:S633‐4. WuY , MokT , ChuD , et al. Evaluation of clinically selected patients (pts) with advanced non‐small cell lung cancer (NSCLC) recruited in China in a phase III, randomized, open‐label, first‐line study in Asia of gefitinib (G) versus carboplatin/paclitaxel (C/P) (IPASS). Journal of Clinical Oncology. 2009; Vol. 27 (15 Suppl 1):8041. WuYL , FukuokaM , MokTSK , SaijoN , ThongprasertS , YangJCH , et al. Tumor response and health‐related quality of life in clinically selected patients from Asia with advanced non‐small‐cell lung cancer treated with first‐line gefitinib: post hoc analyses from the IPASS study. Lung Cancer2013;81:280‐7. YangCH , FukuokaM , MokTS , WuYL , ThongprasertS , SaijoN , et al. Final overall survival (OS) results from a phase III, randomised, open‐label, first‐line study of gefitinib (G) v carboplatin/paclitaxel (C/P) in clinically selected patients with advanced nonsmall cell lung cancer (NSCLC) in Asia (IPASS). 35th ESMO Congress Milan Italy. Oxford University Press, 2010; Vol. 21:viii1‐2. YangJ , WuY L , SaijoN , ThongprasertS , ChuD T , ChenY M , et al. Efficacy outcomes in first‐line treatment of advanced NSCLC with gefitinib (G) vs carboplatin/paclitaxel (C/P) by epidermal growth factor receptor (EGFR) gene‐copy number score and by most common EGFR mutation subtypes ‐ Exploratory data from IPASS. 2011 European Multidisciplinary Cancer Congress Stockholm Sweden. Elsevier Ltd, 2011; Vol. 47:S633. YangJ , WuY , ChanV , KurniandaJ , NakagawaK . Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan‐ASia Study (IPASS). Lung Cancer2014;83:174‐81. YangJCH , WuYL , ChanV , KurniandaJ , NakagawaK , SaijoN , et al. Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan‐ASia Study (IPASS). Lung Cancer2014;83:174‐81. ">Mok 2009 IPASS</a>) and in some data were censored accordingly (e.g. <a href="./references#CD006847-bbs2-0024" title="MitsudomiT , MoritaS , YatabeY , NegoroS , OkamotoI , SetoT , et al. Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first‐line treatment for patients with non‐small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR). 2012 Annual Meeting of the American Society of Clinical Oncology, ASCO Chicago, IL United States. American Society of Clinical Oncology, 2012; Vol. 30. MitsudomiT , MoritaS , YatabeY , NegoroS , OkamotoI , TsurutaniJ , et al. Gefitinib versus cisplatin plus docetaxel in patients with non‐small‐cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase III trial. Lancet2010;11:121‐8. TsurutaniJ , MitsudomiT , MoriS , OkamotoI , NozakiK , TadaH , et al. A phase III, first‐line trial of gefitinib versus cisplatin plus docetaxel for patients with advanced or recurrent non‐small cell lung cancer (NSCLC) harboring activating mutation of the epidermal growth factor receptor (EGFR) gene: a preliminary results of WJTOG 3405 [abstract O‐9002]. European Journal of Cancer. 2009; Vol. 7 Suppl:505. ">Mitsudomi 2010 WJTOG3405</a>). The impact of this cross‐over is difficult to analyse and may contribute to a lack of survival benefit seen in these large phase III studies. </p> <p>We analysed EGFR mutation positive patients in this review, finding that gefitinib improved progression‐free survival over first‐ and second‐line chemotherapy and over placebo in the maintenance setting. However, patients with EGFR wild type NSCLC were not formally included in this meta‐analysis. Studies such as <a href="./references#CD006847-bbs2-0044" title="YangJ , ChengY , ZhaoM , ZhouQ , YanHH , ZhangL , et al. A phase II trial comparing pemetrexed with gefitinib as the second‐line treatment of nonsquamous NSCLC patients with wild‐type EGFR (CTONG0806). 2013 Annual Meeting of the American Society of Clinical Oncology, ASCO Chicago, IL United States. American Society of Clinical Oncology, 2013; Vol. 31. ZhouQ , ChengY , YangJJ , ZhaoMF , ZhangL , ZhangXC , et al. Pemetrexed versus gefitinib as second‐line treatment in advanced non‐squamous nonsmall‐cell lung cancer patients harbouring wild‐type EGFR (CTONG 0806): a multicenter randomized trial. Annals of Oncology2014;25(12):2385‐91. ZhouQ , ChengY , ZhaoMF , YangJJ , YanH H , ZhangL , et al. Final results of CTONG 0806: a phase II trial comparing pemetrexed with gefitinib as second‐line treatment of advanced non‐squamous NSCLC patients with wild‐type EGFR. 15th World Conference on Lung Cancer Sydney, NSW Australia. International Association for the Study of Lung Cancer, 2013; Vol. 8:S194‐5. ">Zhou 2014 CTONG 0806</a> were excluded from this meta‐analysis as they selected only EGFR wild type NSCLC. This study showed that second‐line pemetrexed chemotherapy was superior to gefitinib in terms of progression‐free survival but a trend towards improved overall survival was also seen. Thus, this highlights the importance of determining the EGFR mutation status in patients with advanced NSCLC, as this result will guide further management decisions. </p> <p>Patients with progressive NSCLC who have failed to respond to first‐line chemotherapy have an extremely poor prognosis and often exhibit severe symptoms. One difficulty with meta‐analyses of quality of life data is that outcomes are not consistently reported in the published papers, limiting the pooling of data. Some studies reported changes in FACT‐L and the lung cancer subscale that reached the pre‐defined criteria for clinical significance (<a href="./references#CD006847-bbs2-0058" title="CellaD , HerbstRS , LynchTJ , PragerD , BelaniCP , SchillerJH , et al. Clinically meaningful improvement in symptoms and quality of life for patients with non‐small cell lung cancer receiving gefitinib in a randomized controlled trial. Journal of Clinical Oncology2005;23(13):2946‐54. ">Cella 2005</a>; <a href="./references#CD006847-bbs2-0018" title="CellaD , HerbstRS , LynchTJ , PragerD , BelaniCP , SchillerJH , et al. Clinically meaningful improvement in symptoms and quality of life for patients with non‐small cell lung cancer receiving gefitinib in a randomized controlled trial. Journal of Clinical Oncology2005;23(13):2946‐54. KrisMG , NataleRB , HerbstRS , et al. A phase II trial of ZD1839 ('Iressa') in advanced non‐small cell lung cancer (NSCLC) patients who had failed platinum‐ and docetaxel‐based regimens (IDEAL 2) [abstract]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:292a Abstract 1166. KrisMG , NataleRB , HerbstRS , LynchTJ , PragerD , BelaniCP , et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non‐small cell lung cancer: a randomized trial. JAMA2003;290(16):2149‐58. NataleRB , SkarinA , MaddoxAM , et al. Improvement in symptoms and quality of life for advanced non‐small cell lung cancer patients receiving ZD1839 ('Iressa') in IDEAL 2 [abstract]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:292a, Abstract 1167. ">Kris 2003 IDEAL II</a>), whereas others failed to show any improvement (<a href="./references#CD006847-bbs2-0009" title="BaelgaJ , KrisM , YanoS , NataleR , GiacconeG , BrahmerJ , et al. Phase II trials (IDEAL 1 and IDEAL 2) of ZD1839 in advanced or metastatic non‐small cell lung cancer (NSCLC) patient. Annals of Oncology2002;13(Suppl 5):131 Abs 481. DouillardJY , GiacconeG , HoraiT , NodaK , VansteenkisteJF , TakataI , et al. Improvement in disease‐related symptoms and quality of life in patients with advanced non‐small cell lung cancer (NSCLC) treated with ZD1839 ('Iressa') (IDEAL 1) [abstract]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:299a, Abs 1195. DouillardJY , SkarinA , BaselgaJ , NataleR , GiacconeG , MaddoxAM , et al. Improvement in disease‐related symptoms and quality of life (QOL) for advanced non‐small cell lung cancer (NSCLC) patients treated with ZD1839 in IDEAL 1 and IDEAL 2. Annals of Oncology2002;13 Suppl 5:131, Abs 480. FukuokaM , YanoS , GiacconeG , TamuraT , NakagawaK , DouillardJY , et al. Multi‐institutional randomized phase II trial of gefitinib for previously treated patients with advanced non‐small‐cell lung cancer. Journal of Clinical Oncology2003;21(12):2237‐46. FukuokaM , YanoS , GiacconeG , et al. [Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced non‐small cell lung cancer (IDEAL 1) [abstract]]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:298a, Abs 1188. ManegoldC , GatzemeierU , KaukelE . Results from a randomised, double blind phase II trial of ZD1839 (IRESSA) as 2nd/3rd‐line monotherapy in advanced non small cell lung cancer (NSCLC) (IDEAL 1). Journal of Cancer Research &amp; Clinical Oncology2002;128 Suppl 1:S45. NishiwakiY , YanoS , TamuraT , NakagawaK , KudohS , HoraiT , et al. Subset analysis of data in the Japanese patients with NSCLC from IDEAL I study on gefitinib. Gan to Kagaku Ryoho. Cancer &amp; Chemotherapy2004;31(4):567‐73. VansteenkisteJ , NataleR , GiacconeG , et al. Two randomised, double‐blind studies of ZD1839 in 425 patients with pretreated advanced non‐small‐call lung cancer (IDEAL 1 and IDEAL 2) [abstract]. European Respiratory Society Annual Congress. Stockholm, 2002:Abstract 2537. ">Fukuoka 2003 IDEAL I</a>; <a href="./references#CD006847-bbs2-0030" title="ChangA , ParikhP , ThongprasertS , TanEH , PerngRP , GanzonD , et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non‐small cell lung cancer: subset analysis from the ISEL study. Journal of Thoracic Oncology2006;1(8):847‐55. HirschFR , DziadziuszkoR , ThatcherN , MannH , WatkinsC , ParumsDV , et al. Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo‐controlled study in advanced non small‐cell lung cancer. Cancer2008;112(5):1114‐21. HirschFR , Varella‐GarciaM , Bunn JrPA , FranklinWA , DziadziuszkoR , ThatcherN , et al. Molecular predictors of outcome with gefitinib in a phase III placebo‐controlled study in advanced non‐small cell lung cancer. Journal of Clinical Oncology2006;24(31):5034‐42. ThatcherN , ChangA , ParikhP , Rodrigues PereiraJ , CiuleanuT , vonPawelJ , et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non‐small‐cell lung cancer: results from a randomised, placebo‐controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet2005;366(9496):1527‐37. ">Thatcher 2005 ISEL</a>). <a href="./references#CD006847-bbs2-0058" title="CellaD , HerbstRS , LynchTJ , PragerD , BelaniCP , SchillerJH , et al. Clinically meaningful improvement in symptoms and quality of life for patients with non‐small cell lung cancer receiving gefitinib in a randomized controlled trial. Journal of Clinical Oncology2005;23(13):2946‐54. ">Cella 2005</a> reported a correlation between symptom improvement, objective response and survival, and found that 30% of patients showed a quality of life improvement that was correlated with tumour response. <a href="./references#CD006847-bbs2-0018" title="CellaD , HerbstRS , LynchTJ , PragerD , BelaniCP , SchillerJH , et al. Clinically meaningful improvement in symptoms and quality of life for patients with non‐small cell lung cancer receiving gefitinib in a randomized controlled trial. Journal of Clinical Oncology2005;23(13):2946‐54. KrisMG , NataleRB , HerbstRS , et al. A phase II trial of ZD1839 ('Iressa') in advanced non‐small cell lung cancer (NSCLC) patients who had failed platinum‐ and docetaxel‐based regimens (IDEAL 2) [abstract]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:292a Abstract 1166. KrisMG , NataleRB , HerbstRS , LynchTJ , PragerD , BelaniCP , et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non‐small cell lung cancer: a randomized trial. JAMA2003;290(16):2149‐58. NataleRB , SkarinA , MaddoxAM , et al. Improvement in symptoms and quality of life for advanced non‐small cell lung cancer patients receiving ZD1839 ('Iressa') in IDEAL 2 [abstract]. 38th Annual Meeting of the American Society of Clinical Oncology; 18‐21 May 2002; Orlando, Florida, USA. 2002; Vol. 21 Pt 1:292a, Abstract 1167. ">Kris 2003 IDEAL II</a> reported that symptoms improved in 96% of patients with partial radiographic responses. Pre‐planned subgroup analysis in <a href="./references#CD006847-bbs2-0030" title="ChangA , ParikhP , ThongprasertS , TanEH , PerngRP , GanzonD , et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non‐small cell lung cancer: subset analysis from the ISEL study. Journal of Thoracic Oncology2006;1(8):847‐55. HirschFR , DziadziuszkoR , ThatcherN , MannH , WatkinsC , ParumsDV , et al. Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo‐controlled study in advanced non small‐cell lung cancer. Cancer2008;112(5):1114‐21. HirschFR , Varella‐GarciaM , Bunn JrPA , FranklinWA , DziadziuszkoR , ThatcherN , et al. Molecular predictors of outcome with gefitinib in a phase III placebo‐controlled study in advanced non‐small cell lung cancer. Journal of Clinical Oncology2006;24(31):5034‐42. ThatcherN , ChangA , ParikhP , Rodrigues PereiraJ , CiuleanuT , vonPawelJ , et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non‐small‐cell lung cancer: results from a randomised, placebo‐controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet2005;366(9496):1527‐37. ">Thatcher 2005 ISEL</a> found that gefitinib was associated with a significant improvement in symptom score compared with placebo in never‐smokers and patients of Asian origin. </p> </section> <section id="CD006847-sec-0123"> <h3 class="title" id="CD006847-sec-0123">Quality of the evidence</h3> <p>The 'Risk of bias' tables have enabled a methodical and thorough assessment of the quality of evidence. We included a total of 35 randomised controlled trials (RCTs) randomising 12,089 patients in this review. (Please refer to <a href="#CD006847-fig-0002">Figure 2</a>). Trials included in this meta‐analysis generally had a low risk of selection and attrition bias. Unfortunately, differences in reporting of outcomes, such as survival times, and a lack of survival curves, meant that only extractable data could be included in the analyses. The duration of gefitinib treatment and duration of follow‐up may also have affected outcomes in these RCTs. Despite these limitations, the included RCTs were generally consistent with their findings. </p> <p>For studies that compared gefitinib with first‐line chemotherapy, we judged the quality of evidence as moderate. One study enrolled elderly patients (over 70 years old) and thus we downgraded the quality of evidence as this may be at serious risk of indirectness (<a href="./references#CD006847-bbs2-0006" title="CrinoL , CappuzzoF , ZatloukalP , ReckM , PesekM , ThompsonJC , et al. Gefitinib versus vinorelbine in chemotherapy‐naive elderly patients with advanced non‐small‐cell lung cancer (INVITE): a randomized, phase II study. Journal of Clinical Oncology2008;26(26):4253‐60. ">Crino 2008 INVITE</a>). When comparing gefitinib with second‐line chemotherapy, we also judged the quality of evidence as moderate as one study was not statistically powered to detect differences in any endpoint and was thus at serious risk of imprecision (<a href="./references#CD006847-bbs2-0007" title="CuferT , VrdoljakE , GaafarR , ErensoyI , PembertonK , SIGN study group. Phase II, open‐label, randomized study (SIGN) or single‐agent gefitinib (IRESSA) or docetaxel as second‐line therapy in patients with advanced (stage IIIb or IV) non‐small‐cell lung cancer. Anticancer Drugs2006;17(4):401‐9. ">Cufer 2006 SIGN</a>). When considering toxicity outcomes, generally the quality of data was high, except for fatigue, which we judged as moderate quality of evidence. We downgraded this outcome one level, as we judged one study as having a serious risk of indirectness for enrolling only patients over the age of 70 years old (<a href="./references#CD006847-bbs2-0006" title="CrinoL , CappuzzoF , ZatloukalP , ReckM , PesekM , ThompsonJC , et al. Gefitinib versus vinorelbine in chemotherapy‐naive elderly patients with advanced non‐small‐cell lung cancer (INVITE): a randomized, phase II study. Journal of Clinical Oncology2008;26(26):4253‐60. ">Crino 2008 INVITE</a>). </p> </section> <section id="CD006847-sec-0124"> <h3 class="title" id="CD006847-sec-0124">Agreements and disagreements with other studies or reviews</h3> <p>Two published meta‐analyses also examined the effect of gefitinib in NSCLC. The first by <a href="./references#CD006847-bbs2-0066" title="IbrahimEM . Frontline gefitinib in advanced non‐small cell lung cancer: meta‐analysis of published randomized trials. Annals of Thoracic Medicine2010;5(3):153‐60. ">Ibrahim 2010</a> reported on seven studies that included chemotherapy‐naive patients (<a href="./references#CD006847-bbs2-0006" title="CrinoL , CappuzzoF , ZatloukalP , ReckM , PesekM , ThompsonJC , et al. Gefitinib versus vinorelbine in chemotherapy‐naive elderly patients with advanced non‐small‐cell lung cancer (INVITE): a randomized, phase II study. Journal of Clinical Oncology2008;26(26):4253‐60. ">Crino 2008 INVITE</a>; <a href="./references#CD006847-bbs2-0011" title="BellDW , LynchTJ , MaserlatSM , HarrisPL , OkimotoFA , BranniganBW , et al. Epidermal growth factor receptor mutations and gene amplification in non‐small‐cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. Journal of Clinical Oncology2005;23(31):8081‐92. GiacconeG , HerbstRS , ManegoldC , ScagliottiG , RosellR , MillerV , et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non‐small cell lung cancer: a phase III trial ‐ INTACT I. Journal of Clinical Oncology2004;22(5):777‐84. GiacconeG , JohnsonDH , ManegoldC , et al. A phase III clinical trial of ZD1839 ('Iressa') in combination with gemcitabine and cisplatin in chemotherapy‐naive patients with advanced non‐small cell lung cancer (INTACT 1). Annals of Oncology2002;13 Suppl 5:2, Abstract 4. ">Giaccone 2004 INTACT I</a>; <a href="./references#CD006847-bbs2-0012" title="GossG , FerryD , WierzibickiR , LaurieSA , ThompsonJ , BiesmaB , et al. Randomized phase II study of gefitinib compared with placebo in chemotherapy‐naive patients with advanced non‐small‐cell lung cancer and poor performance status. Journal of Clinical Oncology2009;27(13):2253‐60. ">Goss 2009 INSTEP</a>; <a href="./references#CD006847-bbs2-0014" title="HerbstRS , GiacconeG , SchillerJH , NataleRB , MillerV , ManegoldC , et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non‐small cell lung cancer: a phase III trial ‐ INTACT 2. Journal of Clinical Oncology2004;22(5):785‐94. JohnsonDH , HerbstR , GiacconeG , et al. ZD1839 ('Iressa') in combination with paclitaxel &amp; carboplatin in chemotherapy‐naive patients with advanced non‐small cell lung cancer (NSCLC): results from a phase III clinical trial (INTACT 2). Annals of Oncology2002;13 Suppl 5:127, Abstract 468. ">Herbst 2004 INTACT II</a>; <a href="./references#CD006847-bbs2-0015" title="KellyK , ChanskyK , GasparLE , AlbainKS , JettJ , UngYC , et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non‐small‐cell lung cancer: SWOG S0023. Journal of Clinical Oncology2008;26(15):2450‐6. [SWOG S0023] KellyK , GasparLE , ChanskyK , AlbainKS , CrowleyJ , GandaraDR . Low incidence of pneumonitis on SWOG 0023: A preliminary analysis of an ongoing phase III trial of concurrent chemoradiotherapy followed by consolidation docetaxel and Iressa/placebo maintenance in patients with inoperable stage III non‐small cell lung cancer [abstract]. 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, 13‐17 May, 2005 (Abstract No. 7058). 2005; Vol. 23:634. ">Kelly 2008 SWOG S0023</a>; <a href="./references#CD006847-bbs2-0025" title="FukuokaM , WuYL , ThongprasertS , SunpaweravongP , LeongSS , SriuranpongV , et al. Biomarker analyses and final overall survival results from a phase III, randomized, open‐label, first‐line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non ‐ small‐cell lung cancer in Asia (IPASS). Journal of Clinical Oncology2011;29:2866‐74. MokT , WuY‐L , ThongprasertS , et al. Phase III, randomised, open‐label, first‐line study of gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients (PTS) with advanced non‐small cell lung cancer (NSCLC) (IPASS). Annals of Oncology2008;19 Suppl 8:Viii1. MokTS , WuYL , ThongprasertS , YangCH , ChuDT , SaijoN , et al. Gefitinib or carboplatin‐paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine2009;361(10):947‐57. OheY , IchinoseY , NishiwakiY ,  etal . Phase III, randomized, open‐label, first‐line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in selected patients (pts) with advanced non‐small‐cell lung cancer (NSCLC) (IPASS): Evaluation of recruits in Japan. Journal of Clinical Oncology2009;29(15 Suppl 1):8044. ThongprasertS , DuffieldE , SaijoN , WuYL , YangJC , ChuDT , et al. Health‐related quality‐of‐life in a randomized phase III first‐line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). Journal of Thoracic Oncology2011;6:1872‐80. ThongprasertS , DuffieldE , WuY , et al. Quality of life (QOL) in a randomized phase III first‐line study of gefitinib (G) vs carboplatin/paclitaxel (CP) in clinically selected Asian patients (pts) with advanced NSCLC (IPASS). Journal of Thoracic Oncology2010;5(5 Suppl 1):S80. WuY , ChuD , HanB , LiuX , ZhangL , ZhouC , et al. Phase III, randomized, open‐label, first‐line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non‐small‐cell lung cancer: evaluation of patients recruited from mainland China. Asia‐Pacific Journal of Clinical Oncology2012;8:232‐43. WuY , FukuokaM , MokT S K , SaijoN , ThongprasertS , YangJ C H , et al. Tumour response, skin rash and health‐related quality of life (HRQOL) ‐ Post‐HOC data from the IPASS study. European Multidisciplinary Cancer Congress Stockholm Sweden. Elsevier Ltd, 2011; Vol. 47:S633‐4. WuY , MokT , ChuD , et al. Evaluation of clinically selected patients (pts) with advanced non‐small cell lung cancer (NSCLC) recruited in China in a phase III, randomized, open‐label, first‐line study in Asia of gefitinib (G) versus carboplatin/paclitaxel (C/P) (IPASS). Journal of Clinical Oncology. 2009; Vol. 27 (15 Suppl 1):8041. WuYL , FukuokaM , MokTSK , SaijoN , ThongprasertS , YangJCH , et al. Tumor response and health‐related quality of life in clinically selected patients from Asia with advanced non‐small‐cell lung cancer treated with first‐line gefitinib: post hoc analyses from the IPASS study. Lung Cancer2013;81:280‐7. YangCH , FukuokaM , MokTS , WuYL , ThongprasertS , SaijoN , et al. Final overall survival (OS) results from a phase III, randomised, open‐label, first‐line study of gefitinib (G) v carboplatin/paclitaxel (C/P) in clinically selected patients with advanced nonsmall cell lung cancer (NSCLC) in Asia (IPASS). 35th ESMO Congress Milan Italy. Oxford University Press, 2010; Vol. 21:viii1‐2. YangJ , WuY L , SaijoN , ThongprasertS , ChuD T , ChenY M , et al. Efficacy outcomes in first‐line treatment of advanced NSCLC with gefitinib (G) vs carboplatin/paclitaxel (C/P) by epidermal growth factor receptor (EGFR) gene‐copy number score and by most common EGFR mutation subtypes ‐ Exploratory data from IPASS. 2011 European Multidisciplinary Cancer Congress Stockholm Sweden. Elsevier Ltd, 2011; Vol. 47:S633. YangJ , WuY , ChanV , KurniandaJ , NakagawaK . Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan‐ASia Study (IPASS). Lung Cancer2014;83:174‐81. YangJCH , WuYL , ChanV , KurniandaJ , NakagawaK , SaijoN , et al. Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan‐ASia Study (IPASS). Lung Cancer2014;83:174‐81. ">Mok 2009 IPASS</a>; <a href="./references#CD006847-bbs2-0029" title="OkamotoI , HidaT , KashiiT , et al. Randomized phase III study of platinum‐doublet chemotherapy followed by gefitinib versus continued platinum‐doublet chemotherapy in patients (pts) with advanced non‐small cell lung cancer (NSCLC): Results of West Japan Thoracic Oncology Group Trial (WJTOG0203) [Abstract No. 2 33PD]. Annals of Oncology2008;19 Suppl 8:91. TakedaK , HidaT , SatoT , AndoM , SetoT , SatouchiM , et al. Randomized phase III trial of platinum‐doublet chemotherapy followed by gefitinib comparted with continued platinum‐doublet chemotherapy in Japanese patients with advanced non‐small cell lung cancer: results of a West Japan Thoracic Oncology Group Trial (WJTOG0203). Journal of Clinical Oncology2010;28(5):753‐60. ">Takeda 2010 WJTOG0203</a>), analysing a total of 2545 and 1939 patients in the gefitinib and control arms. The same seven studies also fulfilled the inclusion criteria for this review; however our review included a further 17 studies that analysed the use of gefitinib as second‐ or third‐line and maintenance therapy. The authors were not able to show any benefit in objective response rate, progression‐free survival or overall survival in this general population. In a small subset of patients with EGFR mutations, gefitinib was shown to significantly improve the overall response rate (odds ratio (OR) 2.81, 95% CI 1.71 to 4.62, P &lt; 0.0001). This benefit was not associated with a progression‐free or overall survival advantage in that group. Only three of the included seven studies reported on quality of life, showing a measurable and statistically significant improvement as measured by FACT‐L. </p> <p>The second meta‐analysis by <a href="./references#CD006847-bbs2-0068" title="JiangJ , HuangL , LiangX , ZhouX , HuangR , ChuZ , et al. Gefitinib versus docetaxel in previously treated advanced non‐small‐cell lung cancer: a meta‐analysis of randomized controlled trials. Acta Oncologica2011;50(4):582‐8. ">Jiang 2011</a> compared gefitinib with docetaxel as second‐line therapy. Four studies were included, all of which were also included in this review (<a href="./references#CD006847-bbs2-0007" title="CuferT , VrdoljakE , GaafarR , ErensoyI , PembertonK , SIGN study group. Phase II, open‐label, randomized study (SIGN) or single‐agent gefitinib (IRESSA) or docetaxel as second‐line therapy in patients with advanced (stage IIIb or IV) non‐small‐cell lung cancer. Anticancer Drugs2006;17(4):401‐9. ">Cufer 2006 SIGN</a>; <a href="./references#CD006847-bbs2-0016" title="DouillardJY , ShephardFA , HirshV , MokT , SocinskiMA , GervaisR , et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non‐small‐cell lung cancer: from the randomized phase III INTEREST Trial. Journal of Clinical Oncology2010;28(5):744‐52. HorganAM , BradburyPA , AmirE , NgR , DouillardJY , KimES , et al. An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second‐/third‐line therapy in advanced non‐small‐cell lung cancer. Annals of Oncology. United Kingdom: Oxford University Press (Great Clarendon Street, Oxford OX2 6DP, United Kingdom), 2011; Vol. 22:1805‐11. HorganAM , ShepherdFA , BradburyPA , NgR , LeighlNB . Preliminary cost‐consequence analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as 2nd line therapy in advanced non‐small cell lung cancer [abstract no. 8110]. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2008;25(15 Suppl Pt 1):451. KimES , HirshV , MokT , SocinskiMA , GervaisR , WuYL , et al. Gefitinib versus docetaxel in previously treated non‐small‐cell lung cancer (INTEREST): a randomized phase III trial. Lancet2008;372:1809‐18. ">Kim 2008 INTEREST</a>; <a href="./references#CD006847-bbs2-0019" title="LeeD , KimS , ParkK , et al. A randomized open‐label study of gefitinib versus docetaxel in patients with advanced/metastatic non‐small cell lung cancer (NSCLC) who have previously received platinum‐based chemotherapy [abstract no. 8025]. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2008;26(15 Suppl Pt I):430. LeeDH , ParkK , KimJH , LeeJS , ShinSW , KangJH , et al. Randomized phase III trial of gefitinib versus docetaxel in non‐small‐cell lung cancer patients who have previously received platinum‐based chemotherapy. Clinical Cancer Research2010;16(4):1307‐14. [ISTANA] ">Lee 2010 ISTANA</a>; <a href="./references#CD006847-bbs2-0023" title="LekiR , KawaharaM , WatanabeH , et al. The impact of response evaluation committee in a Phase III study (V‐15‐32) of gefitinib versus docetaxel in Japanese patients with non‐small cell lung cancer [Abstract No. 298P]. Annals of Oncology2009;19 Suppl 8:109‐10. MaruyamaR , NishiwakiY , TamuraT , YamamotoN , TsuboiM , NakagawaK , et al. Phase III study, V‐15‐32, of gefitinib versus docetaxel in previously treated Japanese patients with non‐small‐cell lung cancer. Journal of Clinical Oncology2008;26(26):4245‐52. SekineI , IchinoseY , NishiwakiY , YamamotoN , TsuboiM , NakagawaK , et al. Quality of life and disease‐related symptoms in previously treated Japanese patients with non‐small‐cell lung cancer: results of a randomized phase III study (V‐15‐32) of gefitinib versus docetaxel. Annals of Oncology2009;20(9):1483‐8. YamamotoN , NishiwakiY , NegoroS , JiangH , ItohY , SaijoN , et al. Disease control as a predictor of survival with gefitinib and docetaxel in a phase III study (V‐15‐32) in advanced non‐small‐cell lung cancer patients. Journal of Thoracic Oncology2010;5(7):1042‐7. ">Maruyama 2008 V‐15‐32</a>). A total of 2247 patients received either gefitinib or docetaxel as second‐line therapy. Similar results were also found in this meta‐analysis. There was an improved overall response rate with gefitinib compared with docetaxel (risk ratio (RR) 1.58, 95% CI 1.02 to 2.45, P = 0.04) and quality of life as measured with the FACT‐L and TOI questionnaires (RR 1.55, 95% CI 1.27 to 1.88, P &lt; 0.001; RR 1.86, 95% 1.43 to 2.42, P &lt; 0.001, respectively). There was no benefit in overall survival or progression‐free survival.  </p> <p>Both of these systematic reviews reported results similar to those of this meta‐analysis.</p> <p>Patients with tumours bearing EGFR mutations derive benefit from gefitinib treatment. It has been shown that in patients of Asian ethnicity with tumours with EGFR mutations, progression‐free survival and overall response rate were significantly improved by the use of gefitinib as first‐line therapy; however there was no effect on overall survival, perhaps because of cross‐over between study interventions. </p> <p>An interaction between ethnicity, EGFR mutation status and other clinical features is likely to confound a straightforward analysis of factors predictive of a gefitinib response. Patients of Asian descent, who are non‐smokers or with adenocarcinoma histology are also more likely to have tumours harbouring EGFR mutations. </p> <p>There is increasing evidence to justify the use of molecular markers in clinical practice and the EGFR mutation status appears to be a significant predictor of benefit in terms of progression‐free survival and response to gefitinib. Other markers of EGFR status such as EGFR protein expression and EGFR gene copy number appear to be related to EGFR mutations, but interpretation criteria still need to be established. Further research into optimal sampling, mutation testing methods and the precise spectrum of predictive EGFR mutations is required. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD006847-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram for searches 1966‐2017.(EGFR: epidermal growth factor receptor)" data-id="CD006847-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram for searches 1966‐2017.</p> <p>(EGFR: epidermal growth factor receptor)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/full#CD006847-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD006847-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/full#CD006847-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Progression‐free survival: Gefitinib versus first‐line chemotherapy in an Asian population (Analysis 5.4)." data-id="CD006847-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Progression‐free survival: Gefitinib versus first‐line chemotherapy in an Asian population (<a href="./references#CD006847-fig-0070" title="">Analysis 5.4</a>). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/full#CD006847-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Progression‐free survival: Gefitinib versus second‐line chemotherapy in an Asian population (Analysis 5.5)." data-id="CD006847-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Progression‐free survival: Gefitinib versus second‐line chemotherapy in an Asian population (<a href="./references#CD006847-fig-0071" title="">Analysis 5.5</a>). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/full#CD006847-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Progression‐free survival: Gefitinib versus first‐line chemotherapy in an EGFR mutation positive population (Analysis 6.3)." data-id="CD006847-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Progression‐free survival: Gefitinib versus first‐line chemotherapy in an EGFR mutation positive population (<a href="./references#CD006847-fig-0098" title="">Analysis 6.3</a>). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/full#CD006847-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Progression‐free survival: Gefitinib versus second‐line chemotherapy in an EGFR mutation positive population (Analysis 6.4)." data-id="CD006847-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Progression‐free survival: Gefitinib versus second‐line chemotherapy in an EGFR mutation positive population (<a href="./references#CD006847-fig-0099" title="">Analysis 6.4</a>). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/full#CD006847-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Gefitinib versus placebo, Outcome 1 HR Overall survival." data-id="CD006847-fig-0007" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Gefitinib versus placebo, Outcome 1 HR Overall survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Gefitinib versus placebo, Outcome 2 HR Progression‐free survival." data-id="CD006847-fig-0008" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Gefitinib versus placebo, Outcome 2 HR Progression‐free survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Gefitinib versus placebo, Outcome 3 1‐year survival rate." data-id="CD006847-fig-0009" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Gefitinib versus placebo, Outcome 3 1‐year survival rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Gefitinib versus placebo, Outcome 4 Skin rash." data-id="CD006847-fig-0010" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Gefitinib versus placebo, Outcome 4 Skin rash.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Gefitinib versus placebo, Outcome 5 Pruritus." data-id="CD006847-fig-0011" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Gefitinib versus placebo, Outcome 5 Pruritus.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Gefitinib versus placebo, Outcome 6 Diarrhoea." data-id="CD006847-fig-0012" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Gefitinib versus placebo, Outcome 6 Diarrhoea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Gefitinib versus placebo, Outcome 7 Constipation." data-id="CD006847-fig-0013" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Gefitinib versus placebo, Outcome 7 Constipation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Gefitinib versus placebo, Outcome 8 Nausea." data-id="CD006847-fig-0014" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Gefitinib versus placebo, Outcome 8 Nausea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Gefitinib versus placebo, Outcome 9 Vomiting." data-id="CD006847-fig-0015" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Gefitinib versus placebo, Outcome 9 Vomiting.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Gefitinib versus placebo, Outcome 10 Anorexia." data-id="CD006847-fig-0016" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Gefitinib versus placebo, Outcome 10 Anorexia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Gefitinib versus placebo, Outcome 11 Fatigue." data-id="CD006847-fig-0017" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Gefitinib versus placebo, Outcome 11 Fatigue.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Gefitinib versus placebo, Outcome 12 Asthenia." data-id="CD006847-fig-0018" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Gefitinib versus placebo, Outcome 12 Asthenia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Gefitinib versus placebo, Outcome 13 Respiratory tract infection." data-id="CD006847-fig-0019" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Gefitinib versus placebo, Outcome 13 Respiratory tract infection.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Gefitinib versus placebo, Outcome 14 Dyspnoea." data-id="CD006847-fig-0020" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Gefitinib versus placebo, Outcome 14 Dyspnoea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Gefitinib versus placebo, Outcome 15 Anaemia." data-id="CD006847-fig-0021" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Gefitinib versus placebo, Outcome 15 Anaemia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Gefitinib versus placebo, Outcome 16 Abdominal pain." data-id="CD006847-fig-0022" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Gefitinib versus placebo, Outcome 16 Abdominal pain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Gefitinib versus placebo, Outcome 17 Increased ALT." data-id="CD006847-fig-0023" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Gefitinib versus placebo, Outcome 17 Increased ALT.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Gefitinib versus placebo, Outcome 18 Increased AST." data-id="CD006847-fig-0024" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 Gefitinib versus placebo, Outcome 18 Increased AST.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Gefitinib versus placebo, Outcome 19 Neutropenia." data-id="CD006847-fig-0025" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 Gefitinib versus placebo, Outcome 19 Neutropenia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-001-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-001-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Gefitinib versus placebo, Outcome 20 Anaemia." data-id="CD006847-fig-0026" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-001-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1 Gefitinib versus placebo, Outcome 20 Anaemia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-001-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-001-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-001-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Gefitinib versus placebo, Outcome 21 Thrombocytopaenia." data-id="CD006847-fig-0027" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-001-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1 Gefitinib versus placebo, Outcome 21 Thrombocytopaenia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-001-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-001-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-001-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Gefitinib versus placebo, Outcome 22 Overall response rate." data-id="CD006847-fig-0028" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-001-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1 Gefitinib versus placebo, Outcome 22 Overall response rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-001-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-001-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-001-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Gefitinib versus placebo, Outcome 23 Disease control rate." data-id="CD006847-fig-0029" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-001-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1 Gefitinib versus placebo, Outcome 23 Disease control rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-001-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Gefitinib versus placebo (Asian subgroup), Outcome 1 HR Overall survival." data-id="CD006847-fig-0030" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Gefitinib versus placebo (Asian subgroup), Outcome 1 HR Overall survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Gefitinib versus placebo (Asian subgroup), Outcome 2 HR Progression‐free survival." data-id="CD006847-fig-0031" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Gefitinib versus placebo (Asian subgroup), Outcome 2 HR Progression‐free survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Gefitinib versus placebo (Asian subgroup), Outcome 3 1‐year survival rate." data-id="CD006847-fig-0032" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Gefitinib versus placebo (Asian subgroup), Outcome 3 1‐year survival rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Gefitinib versus placebo (Asian subgroup), Outcome 4 Overall response rate." data-id="CD006847-fig-0033" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Gefitinib versus placebo (Asian subgroup), Outcome 4 Overall response rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Gefitinib versus placebo (biomarker subgroup), Outcome 1 HR Overall survival." data-id="CD006847-fig-0034" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Gefitinib versus placebo (biomarker subgroup), Outcome 1 HR Overall survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Gefitinib versus placebo (biomarker subgroup), Outcome 2 HR Progression‐free survival." data-id="CD006847-fig-0035" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Gefitinib versus placebo (biomarker subgroup), Outcome 2 HR Progression‐free survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Gefitinib versus chemotherapy, Outcome 1 HR Overall survival." data-id="CD006847-fig-0036" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Gefitinib versus chemotherapy, Outcome 1 HR Overall survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Gefitinib versus chemotherapy, Outcome 2 HR Progression‐free survival." data-id="CD006847-fig-0037" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Gefitinib versus chemotherapy, Outcome 2 HR Progression‐free survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Gefitinib versus chemotherapy, Outcome 3 1‐year survival rate." data-id="CD006847-fig-0038" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Gefitinib versus chemotherapy, Outcome 3 1‐year survival rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Gefitinib versus chemotherapy, Outcome 4 Skin rash." data-id="CD006847-fig-0039" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Gefitinib versus chemotherapy, Outcome 4 Skin rash.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Gefitinib versus chemotherapy, Outcome 5 Constipation." data-id="CD006847-fig-0040" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Gefitinib versus chemotherapy, Outcome 5 Constipation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Gefitinib versus chemotherapy, Outcome 6 Fatigue." data-id="CD006847-fig-0041" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Gefitinib versus chemotherapy, Outcome 6 Fatigue.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Gefitinib versus chemotherapy, Outcome 7 Asthenia." data-id="CD006847-fig-0042" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Gefitinib versus chemotherapy, Outcome 7 Asthenia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-004-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Gefitinib versus chemotherapy, Outcome 8 Neurotoxicity." data-id="CD006847-fig-0043" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 Gefitinib versus chemotherapy, Outcome 8 Neurotoxicity.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-004-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-004-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Gefitinib versus chemotherapy, Outcome 9 Neutropenia." data-id="CD006847-fig-0044" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4 Gefitinib versus chemotherapy, Outcome 9 Neutropenia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-004-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-004-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Gefitinib versus chemotherapy, Outcome 10 Leukopenia." data-id="CD006847-fig-0045" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4 Gefitinib versus chemotherapy, Outcome 10 Leukopenia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-004-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-004-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Gefitinib versus chemotherapy, Outcome 11 Febrile neutropenia." data-id="CD006847-fig-0046" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.11</div> <div class="figure-caption"> <p>Comparison 4 Gefitinib versus chemotherapy, Outcome 11 Febrile neutropenia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-004-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-004-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Gefitinib versus chemotherapy, Outcome 12 Pruritus." data-id="CD006847-fig-0047" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.12</div> <div class="figure-caption"> <p>Comparison 4 Gefitinib versus chemotherapy, Outcome 12 Pruritus.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-004-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-004-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Gefitinib versus chemotherapy, Outcome 13 Diarrhoea." data-id="CD006847-fig-0048" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.13</div> <div class="figure-caption"> <p>Comparison 4 Gefitinib versus chemotherapy, Outcome 13 Diarrhoea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-004-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-004-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Gefitinib versus chemotherapy, Outcome 14 Vomiting." data-id="CD006847-fig-0049" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.14</div> <div class="figure-caption"> <p>Comparison 4 Gefitinib versus chemotherapy, Outcome 14 Vomiting.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-004-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-004-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Gefitinib versus chemotherapy, Outcome 15 Anorexia." data-id="CD006847-fig-0050" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.15</div> <div class="figure-caption"> <p>Comparison 4 Gefitinib versus chemotherapy, Outcome 15 Anorexia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-004-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-004-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Gefitinib versus chemotherapy, Outcome 16 Stomatitis." data-id="CD006847-fig-0051" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.16</div> <div class="figure-caption"> <p>Comparison 4 Gefitinib versus chemotherapy, Outcome 16 Stomatitis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-004-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-004-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Gefitinib versus chemotherapy, Outcome 17 Arthralgia/myalgia." data-id="CD006847-fig-0052" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.17</div> <div class="figure-caption"> <p>Comparison 4 Gefitinib versus chemotherapy, Outcome 17 Arthralgia/myalgia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-004-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-004-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Gefitinib versus chemotherapy, Outcome 18 Peripheral oedema." data-id="CD006847-fig-0053" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.18</div> <div class="figure-caption"> <p>Comparison 4 Gefitinib versus chemotherapy, Outcome 18 Peripheral oedema.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-004-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-004-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Gefitinib versus chemotherapy, Outcome 19 Respiratory tract infection." data-id="CD006847-fig-0054" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.19</div> <div class="figure-caption"> <p>Comparison 4 Gefitinib versus chemotherapy, Outcome 19 Respiratory tract infection.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-004-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-004-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Gefitinib versus chemotherapy, Outcome 20 Dyspnoea." data-id="CD006847-fig-0055" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.20</div> <div class="figure-caption"> <p>Comparison 4 Gefitinib versus chemotherapy, Outcome 20 Dyspnoea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-004-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-004-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Gefitinib versus chemotherapy, Outcome 21 Cough." data-id="CD006847-fig-0056" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.21</div> <div class="figure-caption"> <p>Comparison 4 Gefitinib versus chemotherapy, Outcome 21 Cough.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-004-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-004-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Gefitinib versus chemotherapy, Outcome 22 Anaemia." data-id="CD006847-fig-0057" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.22</div> <div class="figure-caption"> <p>Comparison 4 Gefitinib versus chemotherapy, Outcome 22 Anaemia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-004-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-004-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Gefitinib versus chemotherapy, Outcome 23 Thrombocytopenia." data-id="CD006847-fig-0058" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.23</div> <div class="figure-caption"> <p>Comparison 4 Gefitinib versus chemotherapy, Outcome 23 Thrombocytopenia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-004-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-004-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Gefitinib versus chemotherapy, Outcome 24 Hypokalaemia." data-id="CD006847-fig-0059" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.24</div> <div class="figure-caption"> <p>Comparison 4 Gefitinib versus chemotherapy, Outcome 24 Hypokalaemia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-004-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-004-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Gefitinib versus chemotherapy, Outcome 25 Pyrexia." data-id="CD006847-fig-0060" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.25</div> <div class="figure-caption"> <p>Comparison 4 Gefitinib versus chemotherapy, Outcome 25 Pyrexia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-004-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-004-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Gefitinib versus chemotherapy, Outcome 26 Overall response rate." data-id="CD006847-fig-0061" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.26</div> <div class="figure-caption"> <p>Comparison 4 Gefitinib versus chemotherapy, Outcome 26 Overall response rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-004-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-004-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Gefitinib versus chemotherapy, Outcome 27 Disease control rate." data-id="CD006847-fig-0062" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.27</div> <div class="figure-caption"> <p>Comparison 4 Gefitinib versus chemotherapy, Outcome 27 Disease control rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-004-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-004-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Gefitinib versus chemotherapy, Outcome 28 FACT‐L QOL improvement rate." data-id="CD006847-fig-0063" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.28</div> <div class="figure-caption"> <p>Comparison 4 Gefitinib versus chemotherapy, Outcome 28 FACT‐L QOL improvement rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-004-29" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-004-29.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Gefitinib versus chemotherapy, Outcome 29 LCS QOL improvement rate." data-id="CD006847-fig-0064" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-29.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.29</div> <div class="figure-caption"> <p>Comparison 4 Gefitinib versus chemotherapy, Outcome 29 LCS QOL improvement rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-29.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-004-30" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-004-30.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Gefitinib versus chemotherapy, Outcome 30 TOI QOL improvement rate." data-id="CD006847-fig-0065" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-30.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.30</div> <div class="figure-caption"> <p>Comparison 4 Gefitinib versus chemotherapy, Outcome 30 TOI QOL improvement rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-30.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-004-31" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-004-31.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Gefitinib versus chemotherapy, Outcome 31 PSI QOL improvement rate." data-id="CD006847-fig-0066" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-31.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.31</div> <div class="figure-caption"> <p>Comparison 4 Gefitinib versus chemotherapy, Outcome 31 PSI QOL improvement rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-004-31.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 1 HR Overall survival = 1st line." data-id="CD006847-fig-0067" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 1 HR Overall survival = 1st line. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 2 HR Overall survival = 2nd line." data-id="CD006847-fig-0068" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 2 HR Overall survival = 2nd line. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 3 HR Overall survival = Maintenance." data-id="CD006847-fig-0069" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 3 HR Overall survival = Maintenance. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-005-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 4 HR Progression‐free survival = 1st line." data-id="CD006847-fig-0070" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 4 HR Progression‐free survival = 1st line. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-005-05.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 5 HR Progression‐free survival = 2nd line." data-id="CD006847-fig-0071" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 5 HR Progression‐free survival = 2nd line. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 6 HR Progression‐free survival = Maintenance." data-id="CD006847-fig-0072" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 6 HR Progression‐free survival = Maintenance. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-005-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-005-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 7 1‐year survival rate." data-id="CD006847-fig-0073" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 7 1‐year survival rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-005-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-005-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 8 Nausea." data-id="CD006847-fig-0074" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 8 Nausea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-005-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-005-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 9 Vomiting." data-id="CD006847-fig-0075" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.9</div> <div class="figure-caption"> <p>Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 9 Vomiting.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-005-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-005-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 10 Anorexia." data-id="CD006847-fig-0076" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.10</div> <div class="figure-caption"> <p>Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 10 Anorexia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-005-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-005-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 11 Fatigue." data-id="CD006847-fig-0077" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.11</div> <div class="figure-caption"> <p>Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 11 Fatigue.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-005-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-005-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 12 Arthralgia/myalgia." data-id="CD006847-fig-0078" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.12</div> <div class="figure-caption"> <p>Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 12 Arthralgia/myalgia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-005-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-005-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 13 Asthenia." data-id="CD006847-fig-0079" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.13</div> <div class="figure-caption"> <p>Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 13 Asthenia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-005-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-005-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 14 Neurotoxicity." data-id="CD006847-fig-0080" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.14</div> <div class="figure-caption"> <p>Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 14 Neurotoxicity.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-005-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-005-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 15 Neutropenia." data-id="CD006847-fig-0081" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.15</div> <div class="figure-caption"> <p>Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 15 Neutropenia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-005-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-005-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 16 Anaemia." data-id="CD006847-fig-0082" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.16</div> <div class="figure-caption"> <p>Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 16 Anaemia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-005-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-005-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 17 Leukopenia." data-id="CD006847-fig-0083" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.17</div> <div class="figure-caption"> <p>Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 17 Leukopenia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-005-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-005-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 18 Thrombocytopenia." data-id="CD006847-fig-0084" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.18</div> <div class="figure-caption"> <p>Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 18 Thrombocytopenia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-005-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-005-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 19 Febrile neutropenia." data-id="CD006847-fig-0085" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.19</div> <div class="figure-caption"> <p>Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 19 Febrile neutropenia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-005-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-005-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 20 Skin rash." data-id="CD006847-fig-0086" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.20</div> <div class="figure-caption"> <p>Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 20 Skin rash.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-005-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-005-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 21 Diarrhoea." data-id="CD006847-fig-0087" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.21</div> <div class="figure-caption"> <p>Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 21 Diarrhoea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-005-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-005-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 22 Increased ALT." data-id="CD006847-fig-0088" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.22</div> <div class="figure-caption"> <p>Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 22 Increased ALT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-005-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-005-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 23 Increased AST." data-id="CD006847-fig-0089" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.23</div> <div class="figure-caption"> <p>Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 23 Increased AST. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-005-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-005-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 24 Overall response rate." data-id="CD006847-fig-0090" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.24</div> <div class="figure-caption"> <p>Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 24 Overall response rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-005-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-005-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 25 Stable disease." data-id="CD006847-fig-0091" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.25</div> <div class="figure-caption"> <p>Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 25 Stable disease.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-005-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-005-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 26 Disease control rate." data-id="CD006847-fig-0092" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.26</div> <div class="figure-caption"> <p>Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 26 Disease control rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-005-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-005-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 27 FACT‐L QOL improvement rate." data-id="CD006847-fig-0093" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.27</div> <div class="figure-caption"> <p>Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 27 FACT‐L QOL improvement rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-005-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-005-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 28 LCS QOL improvement rate." data-id="CD006847-fig-0094" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.28</div> <div class="figure-caption"> <p>Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 28 LCS QOL improvement rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-005-29" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-005-29.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 29 TOI QOL improvement rate." data-id="CD006847-fig-0095" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-29.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.29</div> <div class="figure-caption"> <p>Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 29 TOI QOL improvement rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-005-29.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Gefitinib versus chemotherapy (EGFR mutation), Outcome 1 HR Overall survival = 1st line." data-id="CD006847-fig-0096" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Gefitinib versus chemotherapy (EGFR mutation), Outcome 1 HR Overall survival = 1st line. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0097"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Gefitinib versus chemotherapy (EGFR mutation), Outcome 2 HR Overall survival = 2nd line." data-id="CD006847-fig-0097" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Gefitinib versus chemotherapy (EGFR mutation), Outcome 2 HR Overall survival = 2nd line. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0097">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0098"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-006-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Gefitinib versus chemotherapy (EGFR mutation), Outcome 3 HR Progression‐free survival = 1st line." data-id="CD006847-fig-0098" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Gefitinib versus chemotherapy (EGFR mutation), Outcome 3 HR Progression‐free survival = 1st line. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0098">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0099"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-006-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Gefitinib versus chemotherapy (EGFR mutation), Outcome 4 HR Progression‐free survival = 2nd line." data-id="CD006847-fig-0099" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Gefitinib versus chemotherapy (EGFR mutation), Outcome 4 HR Progression‐free survival = 2nd line. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0099">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0100"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-006-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-006-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Gefitinib versus chemotherapy (EGFR mutation), Outcome 5 Overall response rate." data-id="CD006847-fig-0100" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-006-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 Gefitinib versus chemotherapy (EGFR mutation), Outcome 5 Overall response rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0100">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-006-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-006-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-006-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Gefitinib versus chemotherapy (EGFR mutation), Outcome 6 Stable disease." data-id="CD006847-fig-0101" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-006-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6 Gefitinib versus chemotherapy (EGFR mutation), Outcome 6 Stable disease.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-006-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-006-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-006-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Gefitinib versus chemotherapy (EGFR mutation), Outcome 7 Disease control rate." data-id="CD006847-fig-0102" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-006-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6 Gefitinib versus chemotherapy (EGFR mutation), Outcome 7 Disease control rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-006-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Gefitinib 250 mg versus gefitinib 500 mg, Outcome 1 1‐year survival rate." data-id="CD006847-fig-0103" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Gefitinib 250 mg versus gefitinib 500 mg, Outcome 1 1‐year survival rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Gefitinib 250 mg versus gefitinib 500 mg, Outcome 2 Skin rash." data-id="CD006847-fig-0104" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Gefitinib 250 mg versus gefitinib 500 mg, Outcome 2 Skin rash.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0105"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-007-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-007-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Gefitinib 250 mg versus gefitinib 500 mg, Outcome 3 Acne." data-id="CD006847-fig-0105" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-007-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 Gefitinib 250 mg versus gefitinib 500 mg, Outcome 3 Acne.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0105">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-007-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0106"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-007-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-007-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Gefitinib 250 mg versus gefitinib 500 mg, Outcome 4 Pruritus." data-id="CD006847-fig-0106" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-007-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7 Gefitinib 250 mg versus gefitinib 500 mg, Outcome 4 Pruritus.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0106">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-007-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0107"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-007-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-007-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Gefitinib 250 mg versus gefitinib 500 mg, Outcome 5 Diarrhoea." data-id="CD006847-fig-0107" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-007-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7 Gefitinib 250 mg versus gefitinib 500 mg, Outcome 5 Diarrhoea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0107">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-007-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0108"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-007-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-007-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Gefitinib 250 mg versus gefitinib 500 mg, Outcome 6 Nausea." data-id="CD006847-fig-0108" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-007-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.6</div> <div class="figure-caption"> <p>Comparison 7 Gefitinib 250 mg versus gefitinib 500 mg, Outcome 6 Nausea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0108">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-007-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0109"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-007-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-007-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Gefitinib 250 mg versus gefitinib 500 mg, Outcome 7 Vomiting." data-id="CD006847-fig-0109" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-007-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.7</div> <div class="figure-caption"> <p>Comparison 7 Gefitinib 250 mg versus gefitinib 500 mg, Outcome 7 Vomiting.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0109">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-007-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0110"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-007-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-007-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Gefitinib 250 mg versus gefitinib 500 mg, Outcome 8 Anorexia." data-id="CD006847-fig-0110" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-007-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.8</div> <div class="figure-caption"> <p>Comparison 7 Gefitinib 250 mg versus gefitinib 500 mg, Outcome 8 Anorexia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0110">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-007-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0111"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-007-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-007-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Gefitinib 250 mg versus gefitinib 500 mg, Outcome 9 Asthenia." data-id="CD006847-fig-0111" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-007-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.9</div> <div class="figure-caption"> <p>Comparison 7 Gefitinib 250 mg versus gefitinib 500 mg, Outcome 9 Asthenia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0111">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-007-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0112"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-007-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-007-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Gefitinib 250 mg versus gefitinib 500 mg, Outcome 10 Overall response rate." data-id="CD006847-fig-0112" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-007-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.10</div> <div class="figure-caption"> <p>Comparison 7 Gefitinib 250 mg versus gefitinib 500 mg, Outcome 10 Overall response rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0112">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-007-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0113"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-007-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-007-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Gefitinib 250 mg versus gefitinib 500 mg, Outcome 11 Partial response." data-id="CD006847-fig-0113" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-007-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.11</div> <div class="figure-caption"> <p>Comparison 7 Gefitinib 250 mg versus gefitinib 500 mg, Outcome 11 Partial response.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0113">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-007-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0114"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-007-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-007-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Gefitinib 250 mg versus gefitinib 500 mg, Outcome 12 FACT‐L Symptom improvement rate." data-id="CD006847-fig-0114" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-007-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.12</div> <div class="figure-caption"> <p>Comparison 7 Gefitinib 250 mg versus gefitinib 500 mg, Outcome 12 FACT‐L Symptom improvement rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0114">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-007-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0115"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-007-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-007-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Gefitinib 250 mg versus gefitinib 500 mg, Outcome 13 TOI QOL improvement rate." data-id="CD006847-fig-0115" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-007-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.13</div> <div class="figure-caption"> <p>Comparison 7 Gefitinib 250 mg versus gefitinib 500 mg, Outcome 13 TOI QOL improvement rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0115">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-007-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0116"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 1 HR Progression‐free survival." data-id="CD006847-fig-0116" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 1 HR Progression‐free survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0116">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0117"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 2 1‐year survival rate." data-id="CD006847-fig-0117" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 2 1‐year survival rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0117">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0118"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-008-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-008-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 3 1‐year progression‐free survival." data-id="CD006847-fig-0118" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-008-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 3 1‐year progression‐free survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0118">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-008-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0119"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-008-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-008-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 4 Skin rash." data-id="CD006847-fig-0119" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-008-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 4 Skin rash.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0119">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-008-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0120"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-008-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-008-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 5 Diarrhoea." data-id="CD006847-fig-0120" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-008-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 5 Diarrhoea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0120">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-008-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0121"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-008-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-008-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 6 Constipation." data-id="CD006847-fig-0121" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-008-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.6</div> <div class="figure-caption"> <p>Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 6 Constipation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0121">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-008-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0122"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-008-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-008-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 7 Fatigue." data-id="CD006847-fig-0122" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-008-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.7</div> <div class="figure-caption"> <p>Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 7 Fatigue.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0122">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-008-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0123"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-008-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-008-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 8 Leukopenia." data-id="CD006847-fig-0123" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-008-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.8</div> <div class="figure-caption"> <p>Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 8 Leukopenia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0123">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-008-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0124"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-008-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-008-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 9 Anaemia." data-id="CD006847-fig-0124" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-008-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.9</div> <div class="figure-caption"> <p>Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 9 Anaemia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0124">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-008-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0125"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-008-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-008-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 10 Thrombocytopenia." data-id="CD006847-fig-0125" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-008-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.10</div> <div class="figure-caption"> <p>Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 10 Thrombocytopenia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0125">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-008-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0126"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-008-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-008-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 11 Neutropenia." data-id="CD006847-fig-0126" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-008-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.11</div> <div class="figure-caption"> <p>Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 11 Neutropenia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0126">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-008-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0127"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-008-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-008-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 12 Increased ALT." data-id="CD006847-fig-0127" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-008-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.12</div> <div class="figure-caption"> <p>Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 12 Increased ALT.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0127">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-008-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0128"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-008-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-008-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 13 Increased AST." data-id="CD006847-fig-0128" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-008-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.13</div> <div class="figure-caption"> <p>Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 13 Increased AST.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0128">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-008-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0129"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-008-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-008-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 14 Vomiting." data-id="CD006847-fig-0129" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-008-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.14</div> <div class="figure-caption"> <p>Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 14 Vomiting.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0129">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-008-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0130"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-008-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-008-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 15 Nausea." data-id="CD006847-fig-0130" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-008-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.15</div> <div class="figure-caption"> <p>Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 15 Nausea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0130">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-008-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0131"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-008-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-008-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 16 Overall response rate." data-id="CD006847-fig-0131" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-008-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.16</div> <div class="figure-caption"> <p>Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 16 Overall response rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0131">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-008-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0132"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-008-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-008-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 17 Partial response." data-id="CD006847-fig-0132" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-008-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.17</div> <div class="figure-caption"> <p>Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 17 Partial response.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0132">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-008-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0133"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-008-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-008-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 18 Stable disease." data-id="CD006847-fig-0133" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-008-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.18</div> <div class="figure-caption"> <p>Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 18 Stable disease.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0133">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-008-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0134"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 1 HR Overall survival." data-id="CD006847-fig-0134" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 1 HR Overall survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0134">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0135"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-009-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-009-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 2 HR Progression‐free survival." data-id="CD006847-fig-0135" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-009-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 2 HR Progression‐free survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0135">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-009-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0136"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-009-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-009-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 3 1‐year survival rate." data-id="CD006847-fig-0136" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-009-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 3 1‐year survival rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0136">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-009-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0137"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-009-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-009-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 4 Skin rash." data-id="CD006847-fig-0137" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-009-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.4</div> <div class="figure-caption"> <p>Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 4 Skin rash.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0137">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-009-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0138"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-009-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-009-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 5 Acne." data-id="CD006847-fig-0138" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-009-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.5</div> <div class="figure-caption"> <p>Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 5 Acne.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0138">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-009-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0139"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-009-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-009-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 6 Diarrhoea." data-id="CD006847-fig-0139" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-009-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.6</div> <div class="figure-caption"> <p>Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 6 Diarrhoea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0139">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-009-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0140"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-009-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-009-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 7 Pruritus." data-id="CD006847-fig-0140" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-009-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.7</div> <div class="figure-caption"> <p>Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 7 Pruritus.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0140">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-009-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0141"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-009-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-009-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 8 Vomiting." data-id="CD006847-fig-0141" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-009-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.8</div> <div class="figure-caption"> <p>Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 8 Vomiting.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0141">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-009-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0142"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-009-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-009-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 9 Nausea." data-id="CD006847-fig-0142" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-009-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.9</div> <div class="figure-caption"> <p>Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 9 Nausea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0142">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-009-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0143"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-009-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-009-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 10 Anorexia." data-id="CD006847-fig-0143" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-009-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.10</div> <div class="figure-caption"> <p>Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 10 Anorexia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0143">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-009-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0144"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-009-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-009-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 11 Asthenia." data-id="CD006847-fig-0144" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-009-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.11</div> <div class="figure-caption"> <p>Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 11 Asthenia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0144">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-009-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0145"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-009-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-009-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 12 Dyspnoea." data-id="CD006847-fig-0145" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-009-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.12</div> <div class="figure-caption"> <p>Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 12 Dyspnoea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0145">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-009-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0146"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-009-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-009-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 13 Anaemia." data-id="CD006847-fig-0146" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-009-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.13</div> <div class="figure-caption"> <p>Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 13 Anaemia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0146">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-009-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0147"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-009-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-009-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 14 Neutropenia." data-id="CD006847-fig-0147" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-009-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.14</div> <div class="figure-caption"> <p>Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 14 Neutropenia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0147">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-009-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0148"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-009-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-009-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 15 Leukopenia." data-id="CD006847-fig-0148" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-009-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.15</div> <div class="figure-caption"> <p>Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 15 Leukopenia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0148">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-009-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006847-fig-0149"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/urn:x-wiley:14651858:media:CD006847:CD006847-CMP-009-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_t/tCD006847-CMP-009-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 16 Overall response rate." data-id="CD006847-fig-0149" src="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-009-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.16</div> <div class="figure-caption"> <p>Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 16 Overall response rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-fig-0149">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/media/CDSR/CD006847/image_n/nCD006847-CMP-009-16.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD006847-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Gefitinib compared to chemotherapy for first‐line treatment of advanced NSCLC</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Gefitinib compared to chemotherapy for first‐line treatment of advanced NSCLC</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> advanced NSCLC<br/> <b>Settings:</b> first‐line treatment<br/> <b>Intervention:</b> gefitinib<br/> <b>Comparison:</b> chemotherapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Chemotherapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall survival (OS)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean OS ranged across control groups from <b>3.5 to 8</b> months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean OS in the intervention group ranged from <b>2.2 to 5.9</b> months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.98</b> (0.91 to 1.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>275<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OS similar in the Asian (HR 0.94, 0.82 to 1.06) and EGFR mutation positive subgroups (HR 0.97, 0.77 to 1.21) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progression‐free survival (PFS)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The PFS ranged across control groups from <b>2 to 2.9</b> months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean PFS in the intervention group ranged from <b>1.9 to 2.7</b> months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 1.19</b> (0.86 to 1.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>275<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PFS improved with gefitinib in the Asian subgroup (HR 0.65, 0.43 to 0.98) and the EGFR mutation positive subgroup (HR 0.47, 0.36 to 0.61) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>EGFR:</b> epidermal growth factor receptor; <b>HR:</b> hazard ratio; <b>NSCLC:</b> non‐small cell lung cancer; <b>OS:</b> overall survival; <b>PFS:</b> progression‐free survival; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>We downgraded the quality of evidence by one level because of serious indirectness as one study included only elderly patients (&gt; 70 years old). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Gefitinib compared to chemotherapy for first‐line treatment of advanced NSCLC</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/full#CD006847-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006847-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Gefitinib compared to chemotherapy for second‐line treatment of advanced NSCLC</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Gefitinib compared to chemotherapy for second‐line treatment of advanced NSCLC</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> advanced NSCLC<br/> <b>Settings:</b> second‐line therapy<br/> <b>Intervention:</b> gefitinib<br/> <b>Comparison:</b> chemotherapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Chemotherapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall survival (OS)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean OS ranged across control groups from <b>7.1 to 8</b> months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean OS in the intervention group ranged from <b>7.5 to 7.6</b> months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 1.02</b> (0.91 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1607<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OS similar in Asian patients (HR 0.94, 0.79 to 1.12) and EGFR mutation positive patients (HR 0.83, 0.41 to 1.66). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progression‐free survival (PFS)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean PFS ranged across control groups from <b>2.7 to 3.4</b> months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean PFS in the intervention group ranged from <b>2.2 to 3</b> months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 1.04</b> (0.92 to 1.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1607<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PFS significantly improved in Asian patients (HR 0.71, 0.57 to 0.88) and in patients positive for EGFR mutation (HR 0.24, 0.12 to 0.47) (ranged from 2.7 to 4.1 months versus 4.5 to 7 months). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>EGFR:</b> epidermal growth factor receptor; <b>HR:</b> hazard ratio; <b>NSCLC:</b> non‐small cell lung cancer; <b>OS:</b> overall survival; <b>PFS:</b> progression‐free survival; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>We downgraded the quality of evidence by one level because of imprecision based on the wide confidence interval. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Gefitinib compared to chemotherapy for second‐line treatment of advanced NSCLC</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/full#CD006847-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006847-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Gefitinib compared to chemotherapy for advanced NSCLC ‐ toxicity</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Gefitinib compared to chemotherapy for advanced NSCLC</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> advanced NSCLC<br/> <b>Settings:</b> first‐line and second‐line therapy<br/> <b>Intervention:</b> gefitinib<br/> <b>Comparison:</b> chemotherapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Chemotherapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Skin rash</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.40<br/> (1.08 to 5.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1858<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000<br/> (9 to 46) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Constipation</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.41<br/> (0.17 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1719<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 1000<br/> (3 to 18) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Fatigue</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.16<br/> (0.03 to 0.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>275<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>65 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000<br/> (2 to 57) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Asthenia</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.51<br/> (0.35 to 0.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1773<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>79 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40 per 1000<br/> (28 to 60) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Neurotoxicity</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.07<br/> (0.01 to 0.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1529<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/> (0 to 10) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Neutropenia</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.04<br/> (0.02 to 0.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1857<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>505 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000<br/> (10 to 30) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Febrile neutropenia</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.12<br/> (0.06 to 0.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1768<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>92 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000<br/> (6 to 21) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>We downgraded the quality of evidence by one level because of serious indirectness as one study included only elderly patients (&gt; 70 years old). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Gefitinib compared to chemotherapy for advanced NSCLC ‐ toxicity</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/full#CD006847-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006847-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Included studies</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Author/Year</b> </p> <p><b>(Study name)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Journal</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparison</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inclusion criteria</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Phase</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Asian</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>EGFR mutation</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Line?</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p><b>1. Gefitinib versus placebo</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Goss 2009 (INSTEP)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JCO 27(13):2253‐2260</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>201</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Poor PS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subgroup</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1st line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thatcher 2005 (ISEL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lancet 366:1527‐37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1692</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subset (Chang)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subgroup (Hirsch)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2nd line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gaafar 2011 (EORTC08021)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eur J Cancer (47):2331‐2340</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>173</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maintenance</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maintenance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kelly 2008 (SWOGS0023)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JCO 26(15):2450‐2456</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>243</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Consolidation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maintenance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zhang 2012 (INFORM)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lancet Oncology 13:466‐475</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>296</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maintenance</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subgroup</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maintenance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p><b>2. Gefitinib versus chemotherapy</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Crino 2008 (INVITE)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JCO 26(26):4253‐4260</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>196</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vinorelbine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Elderly patients</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subgroup</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1st line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lou 2014</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Natl Med J China 94(30): 2337‐2341</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin + paclitaxel</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asian</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1st line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Morere 2010 (IFCT0301)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lung Cancer 70:301‐307</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Docetaxel</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Poor PS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1st line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Han 2013 (First‐SIGNAL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JCO 30(10): 1122‐1128</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>313</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gemcitabine + cisplatin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Planned Subgroup</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1st line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mok 2009 (IPASS)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NEJM 361(10):947‐957</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1217</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin + paclitaxel</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asian, adenocarcinomas</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subgroup</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1st line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maemondo 2010 (NEJ002)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NEJM 362(25):2580‐2588</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>230</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin + paclitaxel</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asian, EGFR mutation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1st line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mitsudomi 2010 (WJTOG3405)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lancet Oncol 11:121‐128</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>177</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cisplatin + docetaxel</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asian, EGFR mutation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1st line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yang 2014</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eur J Cancer 50:2219‐2230</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>236</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pemetrexed + cisplatin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asian</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subgroup</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1st line + maintenance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cufer 2006 (SIGN)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐cancer Drugs 14:401‐409</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Docetaxel</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open‐label</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2nd line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dai 2013</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chin J Lung Cancer 16(8):405‐410</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pemetrexed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asian</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2nd line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kim 2016</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cancer Res Treat 48(1):80‐87</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pemetrexed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asian</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2nd/3rd line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Li 2010</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chinese J Clin Onc 37:16‐18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Docetaxel</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asian</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2nd line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kim 2008 (INTEREST)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lancet 372:1809‐1818</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1466</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Docetaxel</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subgroup (Doulliard)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2nd line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lee 2010 (ISTANA)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clin Cancer Res 16(4):1307‐1314</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>161</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Docetaxel</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asian</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2nd/3rd line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maruyama 2008 (V‐15‐32)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JCO 26(26):4244‐4252</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>489</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Docetaxel</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asian</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subgroup</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2nd/3rd line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sun 2012 (KSCG‐LU08‐01)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cancer 118:6234‐6242</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pemetrexed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adenocarcinoma, non‐smoker</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subgroup</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2nd line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ahn 2012</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lung Cancer 77:346‐352</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pemetrexed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asian, never‐smokers</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maintenance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xu 2015</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Int J Clin Exp Med 8(4):6242‐6246</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>188</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pemetrexed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asian</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maintenance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p><b>3. Gefitinib 250 mg versus gefitinib 500 mg</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fukuoka 2003 (IDEAL I)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JCO 21(12):2237‐2246</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>210</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G250 versus G500</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2rd/3rd line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kris 2003 (IDEAL II)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JAMA 290(16):2149‐2158</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>216</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G250 versus G500</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3rd line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xue 2015</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Int J Clin Exp Med 8(4):6242‐6246</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>188</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G250 versus G500</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asian</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maintenance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p><b>4. Gefitinib versus gefitinib + chemotherapy</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An 2016</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pathol Oncol Res 22:763‐768</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gefitinib + Pemetrexed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asian, EGFR mutation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1st line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cheng 2016</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JCO 34(27): 3258‐3266</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>191</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gefitinib + Pemetrexed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asian, EGFR mutation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1st line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chen 2007</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cancer 109:1821‐8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gefitinib + Vinorelbine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adenocarcinoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subgroup</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3rd line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chen 2011</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>J Thor Oncol 6:1110‐1116</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gefitinib + Tegafur</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adenocarcinoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subgroup</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2nd/3rd line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p><b>5. Gefitinib + chemotherapy versus chemotherapy</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Giaccone 2004 (INTACT I)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JCO 22(5):777‐784</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1093</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gemcitabine + Cisplatin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1st line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Herbst 2004</p> <p>(INTACT II)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JCO 22(5):785‐794</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1037</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin + paclitaxel</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1st line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Takeda 2010 (WTOG0203)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JCO 28(5):753‐760</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>604</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Platinum doublet</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1st line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yu 2014</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cancer Biology &amp; Therapy 15:832‐839</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pemetrexed + platinum</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asian</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1st line</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Soria 2015 (IMPRESS)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lancet Oncology 16:990‐98</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>265</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pemetrexed + cisplatin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EGFR mutation positive</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2nd line</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>EGFR: epidermal growth factor receptor<br/> N: number of patients included<br/> PS: performance status </p> <p>Journals:</p> <p>Cancer Res Treat: <i>Cancer Research and Treatment</i> <br/> Chin J Lung Cancer: <i>Chinese Journal of Lung Cancer</i> <br/> Chinese J Clin Onc: <i>Chinese Journal of Clinical Oncology</i> <br/> Clin Cancer Res: <i>Clinical Cancer Research</i> <br/> Eur J Cancer: <i>European Journal of Cancer</i> <br/> Int J Clin Exp Med: <i>International Journal of Clinical and Experimental Medicine</i> <br/> J Thor Oncol: <i>Journal of Thoracic Oncology</i> <br/> JCO: <i>Journal of Clinical Oncology</i> <br/> Natl Med J China: <i>National Medical Journal of China</i> <br/> NMEJ: <i>New England Journal of Medicine</i> <br/> Pathol Oncol Res: <i>Pathology and Oncology Research</i> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/full#CD006847-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006847-tbl-0005"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Efficacy and survival data</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>ORR (%)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>PFS (months)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>OS (months)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1. Gefitinib versus placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p><b>1st line</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Goss 2009</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.43</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p><b>2nd line</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thatcher 2005 ISEL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0006</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.087</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p><b>Maintenance therapy</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kelly 2008 SWOGS0023</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.013</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gaafar 2011 EORTC08021</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.004</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0015</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2. Gefitinib versus placebo (Asian population)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chang 2006 ISEL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.008</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zhang 2012 INFORM</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.0001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3. Gefitinib versus placebo (EGFR mutation positive)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zhang 2012 INFORM</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0063</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.87</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.97</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.036</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p><b>Gefitinib vs chemotherapy</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4. General population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chemo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chemo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chemo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p><b>versus 1st line chemotherapy</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Crino 2008 INVITE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Morere 2010 IFCT0301</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.078</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.088</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Morere 2010 IFCT0301 (Adenocarcinoma)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.272</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p><b>versus 2nd line chemotherapy</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cufer 2006 SIGN</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kim 2008 INTEREST</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kim 2008 INTEREST</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5. Asian population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chemo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chemo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chemo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p><b>versus 1st line chemotherapy</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lou 2014</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maemondo 2010 (EGFR mutation positive)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mitsudomi 2010 WJTOG (EGFR mutation positive)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.0001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.0001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mok 2009 IPASS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Han 2012 First‐SIGNAL (adenocarcinoma)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yang 2014 (Asian)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.63</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.38</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>versus 2nd line chemotherapy</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dai 2013</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kim 2016</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Li 2010</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kim 2008 INTEREST (subgroup)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lee 2010 ISTANA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0007</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maruyama 2008 V‐15‐32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.009</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sun 2012 KCSG‐LU08‐01 (adenocarcinoma, subgroup)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0006</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p><b>versus maintenance therapy</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ahn 2012 (Asian)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.95</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.83</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xu 2015 (Asian)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>6. EGFR mutation positive</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chemo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chemo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chemo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p><b>versus 1st line chemotherapy</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maemondo 2010 (EGFR mutation positive)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mitsudomi 2010 WJTOG (EGFR mutation positive)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.0001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.0001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mok 2009 IPASS (subgroup)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Han 2012 First‐SIGNAL (subgroup)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.002</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yang 2014 (subgroup)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.62</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.91</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.255</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p><b>versus 2nd line chemotherapy</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>INTEREST Doulliard 2010 (subgroup)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.04</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maruyama 2008 (subgroup)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sun 2012 KCSG‐LU08‐01 (subgroup)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.005</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>7. Gefitinib 250 mg versus gefitinib 500 mg</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>250 mg</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>500 mg</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>250 mg</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>500 mg</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>250 mg</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>500 mg</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p><b>2nd+ line</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fukuoka 2003</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kris 2004</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p><b>Maintenance therapy</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xue 2015 (Asian)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>8. Gefitinib versus gefitinib + chemotherapy</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>G + Chemo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>G + Chemo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gefitinib</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>G + Chemo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p><b>1st line</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An 2016</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73.33</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.05</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cheng 2016</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.014</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p><b>2nd+ line</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chen 2007(Asian, adenocarcinoma)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chen 2011(Asian, adenocarcinoma)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.04</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chen 2011 (EGFR mutation positive subgroup)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0061</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>9. Gefitinib + chemotherapy versus chemotherapy</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>250 mg + Chemo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chemo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>250 mg + Chemo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chemo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>250 mg + Chemo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chemo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1st line</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Giaccone 2004</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Herbst 2004</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Takeda 2010 (Asian)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yu 2014 (Asian)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2nd line</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Soria 2015 IMPRESS (EGFR mutation positive)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>Chemo: chemotherapy<br/> G: gefitinib<br/> NS: non‐significant<br/> ORR: overall response rate<br/> OS: overall survival<br/> PFS: progression‐free survival </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Efficacy and survival data</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/full#CD006847-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006847-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Gefitinib versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 HR Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 G(250) vs P = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.62, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 G(250) vs P = 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.79, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 G(500) vs P = Maintenance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.61, 2.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 HR Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 G(250) vs P = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.60, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 G(250) vs P = 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.75, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 G(500) vs P = Maintenance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.53, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 1‐year survival rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 G(250) vs P = 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1439</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [1.05, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 G(500) vs P = Maintenance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>243</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.78, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Skin rash <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2060</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.92 [1.46, 43.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 G(250) vs P = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 G(250) vs P = 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1688</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.98 [1.20, 67.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 G(250) vs P = Maintenance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.06 [0.25, 103.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Pruritus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1889</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [0.22, 17.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 G(250) vs P = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 G(250) vs P = 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1688</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [0.22, 17.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2060</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.48 [1.15, 5.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 G(250) vs P = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.21, 4.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 G(250) vs P = 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1688</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.09 [1.21, 7.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 G(250) vs P = Maintenance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.03 [0.13, 73.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Constipation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.06, 15.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 G(250) vs P = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.06, 15.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1889</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.03, 12.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 G(250) vs P = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.01, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 G(250) vs P = 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1688</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.25 [0.49, 10.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1859</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.21 [0.83, 12.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 G(250) vs P = 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1688</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.24 [0.73, 14.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 G(250) vs P = Maintenance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.03 [0.13, 73.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Anorexia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2060</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.64, 2.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 G(250) vs P = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.05 [0.25, 103.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 G(250) vs P = 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1688</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.59, 2.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 G(250) vs P = Maintenance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Fatigue <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 G(250) vs P = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.27, 2.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 G(250) vs P = Maintenance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.05 [0.46, 35.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Asthenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 G(250) vs P = 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1688</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.66, 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Respiratory tract infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1889</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.07, 3.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 G(250) vs P = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.01, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 G(250) vs P = 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1688</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.54, 1.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Dyspnoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2060</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.59, 1.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 G(250) vs P = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.85 [0.71, 4.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 G(250) vs P = 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1688</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.49, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3 G(250) vs P = Maintenance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.20, 2.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Anaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.07 [0.37, 135.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 G(250) vs P = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.07 [0.37, 135.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Abdominal pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.05, 5.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 G(250) vs P = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.05, 5.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Increased ALT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.11 [1.18, 70.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 G(250) vs P = Maintenance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.11 [1.18, 70.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Increased AST <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.08 [0.89, 56.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 G(250) vs P = Maintenance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.08 [0.89, 56.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Neutropenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.03 [0.13, 73.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 G(250) vs P = Maintenance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.03 [0.13, 73.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Anaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 4.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 G(250) vs P = Maintenance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 4.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Thrombocytopaenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.03 [0.13, 73.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 G(250) vs P = Maintenance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.03 [0.13, 73.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Overall response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 G(250) vs P = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.06 [0.74, 49.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2 G(250) vs P= 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1439</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.42 [2.82, 14.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.3 G(250) vs P = Maintenance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>173</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.12 [1.32, 77.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Disease control rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1 G(250) vs P = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.86, 2.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.2 G(250) vs P = 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1439</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [1.06, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.3 G(250) vs P = Maintenance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>173</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [1.00, 1.46]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Gefitinib versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006847-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Gefitinib versus placebo (Asian subgroup)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 HR Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 G(250) vs P = 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.48, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 G(250) vs P = Maintenance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.68, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 HR Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 G(250) vs P = 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.52, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 G(250) vs P = Maintenance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.33, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 1‐year survival rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 G(250) vs P = 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.75 [1.20, 2.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Overall response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 G(250) vs P = 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.03 [1.46, 24.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 G(250) vs P = Maintenance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>35.00 [4.86, 252.15]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Gefitinib versus placebo (Asian subgroup)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006847-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Gefitinib versus placebo (biomarker subgroup)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 HR Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 G(250) vs P = Maintenance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.15, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 HR Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 G(250) vs P = Maintenance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.07, 0.41]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Gefitinib versus placebo (biomarker subgroup)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006847-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Gefitinib versus chemotherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 HR Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 G vs vinorelbine = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.66, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 G vs docetaxel = 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.91, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 HR Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 G vs vinorelbine = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.86, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 G vs docetaxel = 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.92, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 1‐year survival rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1741</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.82, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 G vs vinorelbine = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.69, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 G vs docetaxel = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.08, 1.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 G vs docetaxel = 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1466</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.82, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Skin rash <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1858</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.40 [1.08, 5.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 G vs vinorelbine = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.11 [0.25, 104.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 G vs docetaxel = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.05, 5.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 G vs docetaxel = 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.82 [1.11, 7.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Constipation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1719</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.17, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 G vs vinorelbine = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 4.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 G vs docetaxel = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 G vs docetaxel = 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1444</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.17, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Fatigue <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>275</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.03, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 G vs vinorelbine = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.00, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 G vs docetaxel = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.05, 5.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Asthenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1773</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.35, 0.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 G vs vinorelbine = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.01, 2.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 G vs docetaxel = 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.36, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Neurotoxicity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1529</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.01, 0.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 G vs docetaxel = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.01, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 G vs docetaxel = 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1444</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.01, 0.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Neutropenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1857</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [0.02, 0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 G vs vinorelbine = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [0.00, 0.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 G vs docetaxel = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.04, 0.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 G vs docetaxel = 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1582</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [0.02, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Leukopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [0.00, 0.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 G vs vinorelbine = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.00, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 G vs docetaxel = 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [0.00, 0.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Febrile neutropenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1768</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.06, 0.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 G vs vinorelbine = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.00, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 G vs docetaxel = 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1578</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.06, 0.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Pruritus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.22 [0.26, 106.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 G vs docetaxel = 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.22 [0.26, 106.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1858</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.48, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 G vs vinorelbine = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.26, 3.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 G vs docetaxel = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.14, 6.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 G vs docetaxel = 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.43, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.19, 1.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 G vs docetaxel = 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.19, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Anorexia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1719</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.61, 3.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 G vs vinorelbine = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.15, 7.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 G vs docetaxel = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3 G vs docetaxel = 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1444</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [0.60, 3.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Stomatitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1444</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.01, 2.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 G vs docetaxel = 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1444</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.01, 2.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Arthralgia/myalgia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1529</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.03, 2.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 G vs docetaxel = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 G vs docetaxel = 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1444</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.03, 2.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Peripheral oedema <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1634</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.00, 1.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 G vs vinorelbine = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 G vs docetaxel = 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1444</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.00, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Respiratory tract infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1444</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.52, 1.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 G vs docetaxel = 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1444</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.52, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Dyspnoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1773</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.57, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 G vs vinorelbine = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.03, 2.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 G vs docetaxel = 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.59, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Cough <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.36, 3.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 G vs docetaxel = 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.36, 3.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Anaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1853</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.36, 1.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 G vs vinorelbine = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2 G vs docetaxel = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.01, 2.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.3 G vs docetaxel = 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1578</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.42, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Thrombocytopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.12, 72.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1 G vs docetaxel = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.2 G vs docetaxel = 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.12, 72.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Hypokalaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.06, 16.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 G vs vinorelbine = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.06, 16.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Pyrexia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1773</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.14, 2.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1 G vs vinorelbine = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.06, 16.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.2 G vs docetaxel = 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.09, 2.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 Overall response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1 G vs docetaxel = 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1607</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.85, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 Disease control rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.1 G vs docetaxel = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.61, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.2 G vs docetaxel = 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.82, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 FACT‐L QOL improvement rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1656</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.50 [9.55, 11.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.1 G vs vinorelbine = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.4 [8.25, 18.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.2 G vs docetaxel = 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1466</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.40 [9.43, 11.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29 LCS QOL improvement rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1656</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.63 [3.08, 4.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.1 G vs vinorelbine = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.80 [2.42, 5.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.2 G vs docetaxel = 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1466</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.60 [2.99, 4.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30 TOI QOL improvement rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1656</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.87 [1.26, 18.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.1 G vs vinorelbine = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>16.60 [4.61, 28.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.2 G vs docetaxel = 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1466</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.0 [5.97, 8.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">31 PSI QOL improvement rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.60 [3.55, 7.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.1 G vs vinorelbine = 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.60 [3.55, 7.65]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Gefitinib versus chemotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006847-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Gefitinib versus chemotherapy (Asian subgroup)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 HR Overall survival = 1st line <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.82, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 G vs carboplatin + paclitaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.64, 1.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 G vs gemcitabine + cisplatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.72, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 G vs pemetrexed + cisplatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.68, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 HR Overall survival = 2nd line <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.79, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 G vs docetaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.80, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 G vs pemetrexed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.50, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 HR Overall survival = Maintenance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.15 [0.83, 5.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 G vs pemetrexed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.15 [0.83, 5.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 HR Progression‐free survival = 1st line <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.43, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 G vs carboplatin + paclitaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.20, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 G vs cisplatin + docetaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.34, 0.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 G vs gemcitabine + cisplatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.95, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 G vs pemetrexed + cisplatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.64, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 HR Progression‐free survival = 2nd line <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.57, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 G vs docetaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.65, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 G vs pemetrexed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.37, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 HR Progression‐free survival = Maintenance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.27, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 G vs pemetrexed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.27, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 1‐year survival rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1754</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.97, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>681</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.81, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Maintenance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.65, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2898</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.17, 0.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1912</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.06, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>916</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.22, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Maintenance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.09, 2.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2447</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.05, 0.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1737</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.02, 0.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.30, 5.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Maintenance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.02, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Anorexia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2950</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.27, 0.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1964</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.23, 0.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>916</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.27, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Maintenance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.05, 12.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Fatigue <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1960</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.22, 0.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>943</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.17, 0.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>759</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.06, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 Maintenance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.41, 2.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Arthralgia/myalgia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2063</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.03, 0.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1423</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.03, 0.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Asthenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1755</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.08, 0.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1598</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.07, 0.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.03, 2.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Neurotoxicity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1797</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.02, 0.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1505</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.02, 0.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Neutropenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3061</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.05, 0.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [0.03, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>664</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.08, 0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3 Maintenance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.49, 2.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Anaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2538</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.12, 0.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.10, 0.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.02, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 Maintenance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.24, 7.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Leukopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2086</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.02, 0.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1603</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [0.02, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.09, 0.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Thrombocytopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1070</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.14, 0.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.04, 0.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>276</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.03, 2.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3 Maintenance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.63 [0.42, 31.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Febrile neutropenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1679</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.03, 0.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.01, 0.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.03, 0.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Skin rash <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.11 [1.28, 7.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.09 [2.21, 11.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>775</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.54 [0.46, 13.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.3 Maintenance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.24, 3.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3055</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.79 [1.57, 4.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.74 [1.43, 5.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>916</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.93 [0.88, 9.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Increased ALT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1542</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.03 [5.23, 19.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>943</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.66 [5.13, 26.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>529</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.22 [3.18, 54.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.3 Maintenance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.01, 6.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Increased AST <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>762</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.73 [2.78, 21.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>716</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.73 [2.78, 21.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.2 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Overall response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [1.13, 1.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.2 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>921</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.92, 2.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.3 Maintenance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.41, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Stable disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>941</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.34, 0.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.2 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.64, 1.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.3 Maintenance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.44, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 Disease control rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1848</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.86, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.2 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>528</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.78, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.3 Maintenance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.49, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 FACT‐L QOL improvement rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1670</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.50 [7.95, 11.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.2 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>519</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.50 [7.95, 11.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 LCS QOL improvement rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1748</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.30 [1.53, 3.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.2 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>597</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.30 [1.53, 3.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29 TOI QOL improvement rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1670</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.8 [9.17, 14.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.2 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>519</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.8 [9.17, 14.43]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Gefitinib versus chemotherapy (Asian subgroup)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006847-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Gefitinib versus chemotherapy (EGFR mutation)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 HR Overall survival = 1st line <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.77, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Biomarker driven selection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.72, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Clinical feature driven selection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.68, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 HR Overall survival = 2nd line <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.41, 1.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 G vs docetaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.41, 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 HR Progression‐free survival = 1st line <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.36, 0.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Biomarker driven selection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.26, 0.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Clinical feature driven selection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.41, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 HR Progression‐free survival = 2nd line <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.12, 0.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 G vs docetaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.05, 0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 G vs pemetrexed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.13, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Overall response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>758</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [1.34, 2.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 First‐line biomarker driven selection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>347</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.23 [1.75, 2.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 First‐line, clinical feature driven selection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>353</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [1.05, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [0.88, 3.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Stable disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>397</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.28, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 First‐line, biomarker driven selection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>347</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.22, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 First‐line, clinical feature driven selection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.26, 2.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Disease control rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.93, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 First‐line, biomarker driven selection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>347</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [1.05, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 First‐line, clinical feature driven selection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.87, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Second‐line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>387</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.77, 1.36]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Gefitinib versus chemotherapy (EGFR mutation)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006847-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Gefitinib 250 mg versus gefitinib 500 mg</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 1‐year survival rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>424</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.61, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>424</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.61, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Skin rash <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.13 [1.51, 43.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.80 [0.85, 54.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Maintenance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.41 [0.61, 176.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Acne <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.86 [0.24, 100.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.86 [0.24, 100.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Pruritus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.92 [0.12, 70.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.92 [0.12, 70.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.36 [1.58, 44.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.36 [1.58, 44.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.06, 15.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.06, 15.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Anorexia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.92 [0.12, 70.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.92 [0.12, 70.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Asthenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.92 [0.12, 70.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.92 [0.12, 70.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Overall response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>424</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.58, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Maintenance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.35, 2.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Partial response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.34, 1.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.34, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 FACT‐L Symptom improvement rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.70 [‐7.28, 14.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.70 [‐7.28, 14.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 TOI QOL improvement rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>424</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.38 [‐2.30, 17.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>424</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.38 [‐2.30, 17.05]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Gefitinib 250 mg versus gefitinib 500 mg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006847-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Gefitinib versus gefitinib + chemotherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 HR Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.49, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.43, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 1‐year survival rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.92, 1.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.92, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 1‐year progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.29 [1.38, 3.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.29 [1.38, 3.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Skin rash <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.39, 4.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.23, 4.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.57 [0.25, 26.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.21, 6.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.21, 6.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Constipation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.02, 9.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.02, 9.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Fatigue <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.68 [0.60, 11.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.68 [0.60, 11.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Leukopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.48, 4.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.36, 4.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.82 [0.16, 89.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Anaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.22 [0.66, 15.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.06 [0.49, 19.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.82 [0.16, 89.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Thrombocytopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Neutropenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.71, 3.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.65, 2.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.82 [0.16, 89.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Increased ALT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.57 [1.09, 6.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.57 [1.09, 6.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Increased AST <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.56, 3.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.56, 3.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [0.06, 37.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [0.06, 37.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [0.06, 37.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [0.06, 37.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Overall response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.89, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.89, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Partial response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>444</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.88, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.88, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.71, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Stable disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>444</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.69, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.39, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 2nd line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.84, 2.03]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Gefitinib versus gefitinib + chemotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006847-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Gefitinib + chemotherapy versus chemotherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 HR Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 1st line [Asian]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.72, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 2nd line [EGFRm]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [1.05, 2.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 HR Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 1st line [Asian]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.62, 0.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 2nd line [EGFRm]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.65, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 1‐year survival rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1411</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.84, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1411</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.84, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Skin rash <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2379</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.98 [1.54, 5.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.64 [1.23, 5.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 1st line [Asian]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>715</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.23 [1.08, 16.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 2nd line [EGFRm]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Acne <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1664</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.95 [1.09, 22.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.59 [0.99, 31.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 2nd line [EGFRm]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.12, 72.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2379</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.04 [1.17, 3.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.44 [1.17, 5.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 1st line [Asian]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>715</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.32, 2.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 2nd line [EGFRm]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.32, 28.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Pruritus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.99 [0.18, 21.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.99 [0.18, 21.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2379</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.81, 1.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.53, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 1st line [Asian]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>715</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.70, 2.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 2nd line [EGFRm]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.51, 7.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2379</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.58, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.51, 2.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 1st line [Asian]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>715</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.48, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 2nd line [EGFRm]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.26, 2.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Anorexia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2379</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.55, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [0.36, 10.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 1st line [Asian]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>715</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.53, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 2nd line [EGFRm]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.04, 3.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Asthenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1664</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.21, 2.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.10, 7.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 2nd line [EGFRm]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [0.09, 2.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Dyspnoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>947</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.25, 3.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>683</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.99 [0.18, 21.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 2nd line [EGFRm]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.11, 3.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Anaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>979</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.53, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 1st line [Asian]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>715</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.44, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 2nd line [EGFRm]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.2 [0.79, 6.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Neutropenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2379</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.87, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.77, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 1st line [Asian]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>715</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.84, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3 2nd line [EGFRm]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.49, 3.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Leukopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.89, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.61, 2.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 1st line [Asian]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>598</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.87, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3 2nd line [EGFRm]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.21, 4.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Overall response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.97, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 1st line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.94, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 1st line [Asian]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>706</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.93, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 2nd line [EGFRm]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.66, 1.31]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Gefitinib + chemotherapy versus chemotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006847.pub2/references#CD006847-tbl-0014">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD006847.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD006847-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD006847-note-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="ja#CD006847-note-0003">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD006847-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD006847-note-0004">Polski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD006847-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006847\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006847\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006847\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006847\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006847\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006847\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006847\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006847\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006847\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006847\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006847\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006847\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006847\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006847\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006847\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006847\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006847\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006847\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jxlIh5Me&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006847.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006847.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD006847.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD006847.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006847.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729693660"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006847.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729693664"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006847.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ee31cfd679377',t:'MTc0MDcyOTY5NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 